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ABSTRACT 
 
Background: The natural history of Acute Kidney Injury (AKI) in hospitalized patients is 
poorly characterized in the literature. Its relationship to the development of de novo 
chronic kidney disease (CKD) and the progression of known CKD is unclear particularly 
in patients outside of the intensive care setting. This study was designed to explore 
the natural history of AKI in the general hospital population to better characterize its 
relationship to CKD. 
 
Methods: This is a single centre prospective observational study. Subjects were 
recruited over 17 months from Nov. 2009 to April 2011 from unselected admissions to 
Queen Alexandra Hospital Portsmouth, a large UK general hospital. Follow up was 
scheduled at 6 months post-discharge to assess the primary outcomes of recovery of 
renal function and mortality. Additional follow up was carried out at 12 months to 
assess mortality. The study consisted of three groups: Group 1 with previous 
baseline eGFR ! 60 mls/min who developed an AKI, Group 2 with a background of CKD 
(defined by at least two eGFRs < 60 mls/min) who developed an AKI, and Group 3 a 
control group consisting of those with previous CKD who did not sustain an AKI. 
Baseline function was derived from records over the previous year while AKI was 
defined by the AKIN criteria. Extensive baseline data was recorded on each patient. To 
explore the impact of different definitions of loss of function: failure to recover 
function after six months was defined as a fall in eGFR of 5mls/min, a fall of 
10mls/min and as a fall of 25% of eGFR from baseline. 
 
Results: 401 patients were recruited. 375 patients were recruited with AKI (Group 1 
n=190, Group 2 n=185) with 26 CKD controls in Group 3. Mean age was 67 in Group 1 
and 77 in Group 2. At 6 months mortality in the AKI group was 12.6% while in the 
AKI/CKD group it was 24.3%. After 12 months mortality in the AKI group was 16.3% 
while in the AKI/CKD group it was 30.2%. 20.8% of the AKI group and 14.8% of the 
AKI/CKD group demonstrated a fall in eGFR of at least 25% from baseline after 6 
months. During the 6 months after discharge 40% of the AKI group and 43% of the 
AKI/CKD group were readmitted and of these 12.1% and 19.8% experienced another 
AKI.  
 
Conclusions: AKI in hospitalised patients carries a poor prognosis in the long-term. 
AKI is contributing to the incident CKD population and to the progression of known 
CKD. At least some patients with AKI are characterised by recurrent episodes and this 
may represent an important factor in CKD progression in the general population. In 
this study the AKIN definition performed poorly at predicting the key outcomes.       
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Chapter 1: Introduction 
 
Acute Kidney injury (AKI) is a complex heterogeneous condition. It involves the rapid 
loss of renal function over hours to days secondary to a pathological process causing 
damage to the kidney. It can arise in isolated forms due to a single cause but is most 
commonly seen in the setting of other acute conditions where it forms a part of the 
‘syndrome’ of acute illness. Until recently, AKI was recognised as an important marker 
of the gravity of the underlying disease but was not felt to be directly responsible for 
the outcomes 
1-3. Recent publications have highlighted the high incidence of AKI. They 
have demonstrated many important independent effects of AKI on clinical outcomes 
and health care resource use. As a result, AKI has become an area of increasing 
importance for research and public health policy making.  
 
The increased focus on AKI has paralleled a growing interest in Chronic Kidney Disease 
(CKD). CKD is now well established as a major public health concern. Whilst in some 
cases CKD can progress to End Stage Kidney Disease the primary absolute risk 
associated with CKD is an increase in cardiovascular morbidity and mortality 
4,5. The 
Health Survey for England 2010 reported a CKD prevalence of 6% in adults. The 
prevalence rises significantly with age and evidence from the US suggests that it is 
increasing 
6,7. This has been linked to rises in the prevalence of some of its underlying 
determinants such as diabetes, hypertension and obesity. Changes in demographics 
due to the aging population may also be contributing 
7. A key question in this area is 
whether or not AKI is contributing to the incidence of CKD. 
 
1.1 AKI is common and its incidence is rising 
 
The descriptive epidemiology of AKI is unclear from the literature. The principal reason 
for this is due to the marked heterogeneity of published studies. Until very recently 
there has been no consensus definition of AKI. This has made extrapolation and 
comparison of published work difficult. This will be discussed further in Chapter 2. 
However, it is known that AKI is common with estimates of its frequency in 
hospitalised patients ranging from 7 – 10% in the developed world 
8,9. AKI is particularly 
important in the intensive care population where studies show its incidence to be over 
30% 
10-12. The incidence of AKI appears to be rising. For example, Xue et al described an 
increase of up to 11% per year between 1992 and 2001 in US Medicare beneficiaries 
13. 
The authors suggest this may in part be due to an increased recognition of the 
condition and a change in coding practices. However, it has also been found in several 
different study populations in the US and was also recognised by Bagshaw et al in  Mark Uniacke    Chapter 1     
        2 
Australian intensive care units 
8,13-17. The rising incidence is more likely due to the 
increased use of complex interventions in increasingly older and sicker comorbid 
patients. This has included a greater use of drugs and contrast agents that are toxic to 
the kidney 
15.  
 
1.2 AKI is associated with significant morbidity and 
mortality 
 
It has been recognised for decades that AKI is associated with significantly increased 
mortality in the hospital population 
18-21. Mortality figures vary in the literature 
depending on the definition of AKI used and the population studied. Contemporary 
work using a new consensus definition has shown it to be around 15% in hospitalised 
patients 
22-24. Mortality varies with AKI severity and the severity of the underlying illness 
such that in the intensive care setting mortality rates over 70% have been reported 
25. A 
high mortality is maintained even with adjustment for the severity of underlying illness 
and comorbidities. In addition it has been shown to extend well beyond the acute 
illness and even small acute changes in kidney function have been associated with an 
increase in mortality in various settings 
26,27.  
Notwithstanding the influence of confounding factors, AKI appears to be an 
independent risk factor for adverse outcomes. The reason for this is unclear. It has 
been postulated that the effects of the fluid and metabolic disturbances associated 
with the AKI may be impairing the immune system and organ function 
28,29. This topic 
will be revisited in Chapter 2. 
 
In addition to its effects on mortality, survivors of AKI have been shown to have an 
increased length of hospital stay compared to those without AKI 
24,30-32. Furthermore, 
there is evidence that those who do survive hospitalisation with AKI are more likely to 
be discharged to a rehabilitation or nursing home facility rather than to their own 
homes. In some populations studied there appears to be an increased risk of 
rehospitalisation 
16,17,24,33,34. In addition to the cost in terms of patient morbidity and 
mortality, AKI is placing an increasing burden on the healthcare economy. 
 
1.3 AKI is preventable and management is suboptimal 
 
There is emerging evidence that AKI itself is managed poorly and may be preventable.  
In 2002, Stevens et al reported findings from East Kent where they found that 37.5% of 
cases of AKI were iatrogenic and may have been preventable. They found that the 
initial assessment of these patients was often suboptimal, and key steps in Mark Uniacke    Chapter 1     
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investigation and initial management were lacking 
35. The National Confidential Enquiry 
into Patient Outcomes and Deaths (NCEPOD) examined these findings further in 2009 
and published a report highlighting the process of care of patients who died in 
hospital with a primary diagnosis of AKI. Only 50% of patients included in this enquiry 
were felt to have had a standard of care that was considered ‘good’ by the Advisory 
Panel 
36. More recently, a study using information from Hospital Episode Statistics (HES) 
in England and Wales found that patients with AKI presenting to hospitals without 
nephrology cover had a higher mortality 
37.  
 
1.4 AKI is now a research priority 
 
In 2002 the Acute Dialysis Quality Initiative (ADQI) Group proposed a graded 
classification system for AKI known as the RIFLE criteria in an attempt to standardise 
the definition of AKI and facilitate research 
38. Following this, the Acute Kidney Injury 
Network (AKIN) was formed in 2004 with a mandate ‘to facilitate international, 
interdisciplinary, and inter-societal collaborations to ensure progress in the field of AKI 
and obtain the best outcomes for patients with or at risk for AKI’. They proposed the 
AKIN definition for AKI 
39. 
 
In 2005 the American Society of Nephrology Renal Research Report recognised 
significant gaps in knowledge relating to AKI. The natural history and spectrum of AKI 
were unclear, knowledge of the risk factors for AKI was limited, and the causes were 
not defined. In addition, it was recognised that data on the long-term outcomes of AKI 
and its influence on Chronic Kidney Disease was particularly limited 
40. In the same 
year, Chertow et al published a landmark study identifying the increased mortality, 
length of stay and costs associated with AKI. They called for the prevention and 
effective treatment of AKI to be made a national priority in the United States 
32.  
 
The recognition of AKI has not been restricted to nephrology and intensive care circles. 
In 2008 the Centre for Disease Control (CDC) published a report on the hospitalisation 
and discharge diagnoses for kidney diseases in the USA between 1984 and 2005. They 
found that much of the observed change in reported kidney disease was the result of 
increases in hospitalisation for AKI. They highlighted a need for research to determine 
the causes for this and to examine the risk for CKD and ESRD associated with AKI 
41.   
 
1.5 AKI and its relationship to CKD 
 
Considerable interest has developed recently regarding the relationship between AKI 
and the development and progression of CKD. CKD is recognised as an important risk Mark Uniacke    Chapter 1     
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factor for AKI. Studies have consistently shown that up to a third of AKI patients had 
evidence of pre-existing CKD 
30,42-44. However, the relationship between AKI and 
subsequent CKD is unclear. Although it has long been appreciated that AKI may lead to 
permanent renal damage 
49, the clinical perception has been that recovery from AKI, 
when it occurs, has no important long-term sequelae. This may be because many of 
the studies examining renal recovery after AKI used independence from dialysis as an 
endpoint and once this was achieved it was felt to be ‘adequate’ 
45,46. Despite this 
perception there are now concerns that AKI may be contributing to the development 
and progression of CKD.  In 2008 AKIN rated investigating the relationship between 
AKI and CKD as one of the top three research priorities in the field 
47. More recently, 
the Kidney Disease Improving Global Outcomes (KDIGO) consortium has published AKI 
Guidelines and highlighted the need for ‘research with follow up beyond discharge to 
better understand the clinical consequences of AKI in patients with and without 
underlying CKD’ 
48.  
 
1.6 The purpose of this research 
 
It has been known for over 60 years that recovery of kidney function is not complete 
after an episode of severe AKI 
49. Despite extensive research in recent years, the 
relationship between milder episodes of AKI and CKD in the general hospital 
population remains unclear 
50. In addition, studies in this area to date have been 
retrospective in nature. They have lacked baseline clinical data and have been subject 
to many methodological flaws. As a result, the natural history of AKI remains poorly 
characterized.  
 
The aim of this research was to explore the natural history of AKI and in particular its 
relationship to CKD in the general hospital population. The study was designed around 
the hypothesis that AKI can cause CKD in those with previously normal function and 
may worsen pre-existing CKD. This hypothesis was tested by conducting a prospective 
observational study of general hospitalised patients who sustained an AKI. The aim 
was to have an adequate follow up period to assess the impact of the AKI on baseline 
kidney function. The prospective design allowed for the collection of extensive 
baseline data in order to explore the risk factors for the outcomes in question.  
 
This study contributes to the existing literature in the field in several ways. Judging 
from the available published data, this is the only prospective study completed to date 
specifically designed to explore AKI and its medium–term (6 months) effects on renal 
function. It has been undertaken in the general hospital setting and is not restricted to 
the intensive care population. The use of the AKIN definition allows for the exploration Mark Uniacke    Chapter 1     
        5 
of the effects of milder degrees of AKI. The methods used and the findings will 
contribute to future AKI research design.  
 
1.7 Outline of the thesis 
 
This thesis begins with a thorough review of the current knowledge of the natural 
history of AKI in Chapter 2. This is followed by a literature review of the outcomes of 
kidney function after an AKI episode in Chapter 3. The study design and methods are 
presented in Chapter 4 followed by results and analysis in Chapters 5, 6 and 7. Finally, 
Chapter 8 contains a discussion of the findings together with the strengths and 
limitations of the study and future research directions.  
 
1.8 Literature sources 
 
It is important to note that the recent surge of interest in AKI has resulted in a 
dramatic expansion of the literature. The present study was undertaken between 2009 
and 2011 and during this period the number of new AKI articles exceeded 2,500 per 
year 
51. As a result a single systematic search of the literature for the purpose of the 
reviews contained in Chapters 2 and 3 would rapidly have become out-dated. The 
literature reviewed was therefore compiled from multiple Medline searches undertaken 
during the course of the study. This was consolidated by undertaking a broad 
systematic search of the Medline and Embase databases in January 2012. The search 
strategy used is outlined in Appendix 1. It was developed using an iterative process 
with keywords relevant to the natural history of AKI and spanned the period 1990 to 
2011. The references within the articles reviewed were also consulted for any relevant 
studies prior to this period. In addition to this more formal search, regular email alerts 
from the major critical care and nephrology journals were used to identify newly 
published articles. Using these methods a database of over 150 cohort studies in AKI 
was built. The reviews in Chapters 2 and 3 are as comprehensive as possible 
accounting for the rapidly changing literature base in AKI.  Mark Uniacke    Chapter 2     
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Chapter 2: Background 
 
2.1 Basic Structure and Functions of the kidney 
 
2.1.1 Kidney Anatomy  
 
The functioning unit of the kidney is the nephron and there are over a million in each 
kidney. The nephron is made up of a glomerulus and a tubule system. The glomerulus 
consists of a tuft of capillaries that receive blood from the systemic circulation through 
the afferent arteriole and drain through the efferent arteriole. Blood is filtered across 
the glomerular basement membrane into the space in Bowman’s Capsule to form an 
ultrafiltrate of plasma. This is the early stage of urine formation. The ultrafiltrate 
passes through the tubules before leaving the kidney through the collecting tubule 
which drains into the ureter. During its passage through the tubules the ultrafiltrate is 
subjected to selective secretion and reabsorption of electrolytes and other solutes by 
the cells lining the tubules. Through this regulated process the kidney is able to 
maintain water, electrolyte and acid/base balance. The final urine that is produced is 
concentrated according to the prevailing physiological conditions and is excreted 
along with the metabolic waste it contains through the ureter into the bladder. 
 
2.1.2 Functions of the Kidney 
 
The kidneys are an important regulator of body homeostasis. The five principle 
functions of the kidney are outlined in Figure 2.1. The kidney primarily regulates fluid 
and electrolyte balance, acid/base balance, and excretes metabolic waste products. 
These include urea and creatinine which are the surrogates currently used to measure 
kidney function in clinical practice. In addition to the functions directly related to the 
filtration of blood, the kidney also produces a number of important hormones and has 
some metabolic functions for example the metabolism of insulin. In the context of an 
AKI, the most important impact is on the ability of the kidney to filter blood to excrete 
metabolic waste and maintain fluid and electrolyte balance.  
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Figure 2.1 Principle functions of the kidney. 
   
Functions of the Kidney   
1. Maintenance of body fluid balance.   
2. Maintenance of electrolyte balance.   
3. Maintenance of Acid/Base balance.   
4. Elimination of metabolic waste products.   
5. Endocrine functions:   
                                       - production of Erythropoetin   
                                       - production of Renin   
                                       - production of Calcitriol  (Vitamin D)   
   
 
 
 
2.2 Measurement of Kidney Function 
 
2.2.1 Glomerular Filtration Rate (GFR) 
 
The most important measure of kidney function is the Glomerular Filtration Rate (GFR). 
The GFR is the rate in unit time at which fluid is filtered by the glomerulus and is 
widely accepted as the best overall index of kidney function 
52. The driving force for 
filtration is the glomerular capillary hydrostatic pressure. This ultimately depends on 
cardiac output and an effective circulating volume. The oncotic pressure due to plasma 
proteins within the filtered blood and the hydrostatic pressure in Bowman’s space 
oppose this pressure. The difference between the opposing pressures is the net 
filtration pressure. In addition to the net filtration pressure the GFR is also determined 
by the glomerular filtration coefficient which reflects the permeability and the surface 
area of the basement membrane across which the fluid is filtered. In men the GFR 
averages 125mls/min or 180L/day while in women it averages 110mls/min or 
160L/day 
53. Any of the determinants of GFR mentioned above may be altered in 
disease states. In particular, approximately 25% of cardiac output is used to drive 
filtration. The kidneys are therefore very ‘vascular’ organs which is why they are 
susceptible to conditions that change haemodynamics. The level of GFR and its 
magnitude of change over time are vital to the detection of kidney disease, 
understanding its severity, and for making decisions about diagnosis, prognosis, and 
treatment 
52. In AKI the GFR is generally decreased and the ability of the kidney to carry 
out the functions outlined above is compromised.  
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2.2.2 Measurement of GFR 
 
The glomerular filtration rate can be expressed in terms of the renal clearance. The 
renal clearance of a substance is the volume of plasma from which all the substance is 
removed and excreted into the urine in unit time 
54. This can be measured by using a 
substance as a filtration marker and by calculating the rate at which it is excreted in 
the urine and dividing this by the plasma concentration according to the following 
formula: 
 
C
X = U
XV/P
X 
 
where U
X is the urine concentration of the substance, V the urine flow rate, and P
X the 
plasma concentration of the substance. In order to measure GFR in this way the 
substance must be cleared from the plasma solely by glomerular filtration. It should 
not be metabolised, synthesised, or stored by the kidneys and neither should it be 
reabsorbed or secreted by the renal tubules. In addition, it should not be bound to 
plasma proteins that might hinder its filtration 
53. The polysaccharide inulin is 
classically recognised as the ideal filtration marker and its use is considered the ‘gold 
standard’ for measuring GFR. After an intravenous infusion, the plasma inulin 
concentration can be measured together with its concentration in a timed urine 
sample. The use of inulin as a filtration marker can give an accurate measurement of 
the GFR. However, the need for an intravenous infusion and a difficult chemical assay 
makes it impractical for use in clinical practice 
55.  
 
As an alternative to inulin, several radioactive isotopes have been developed and used 
as filtration markers. All can be given as a single injection and thus avoid the need for 
a continuous infusion. These include 
125I-Iotholamate, 
51Cr-EDTA and 
99mTc-DTPA.  
125I-
Iothalamate is known to be comparable to inulin as a filtration marker and can be 
assayed accurately and precisely in a laboratory. For this reason it has been used in 
clinical trials assessing progression of renal disease 
56. Iotholamate and Iohexol are 
also available as nonradioactive filtration markers and levels are measured by X-ray 
fluorescence assay or high performance liquid chromatography.  
 
While the methods described above are the most accurate available for measuring GFR 
they are invasive and time consuming. In everyday clinical practice, measurement of 
serum urea and creatinine remain the mainstay for determining changes in renal 
function. Serum creatinine together with a urine collection can be used to estimate GFR 
by measuring creatinine clearance while several equations have been developed to 
estimate GFR based on serum creatinine alone. The use of creatinine as a marker of Mark Uniacke    Chapter 2     
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renal function and subsequent employment in estimating equations is subject to 
limitations that are discussed below. 
 
2.2.3 Urea as a filtration marker 
 
Urea is a nitrogenous waste product excreted by the kidneys and can serve as a crude 
marker of filtration. It is the main by-product of the oxidation of amino acids in protein 
catabolism. An elevated plasma urea level suggests impairment of renal function 
54. Its 
use as a marker is limited by significant variation that can occur in its levels on a day-
to-day basis. Protein intake and levels of hydration can affect urea levels. It may also 
be elevated in other situations such as an upper gastrointestinal bleed owing to the 
absorption of degraded blood products from the gastrointestinal tract. As a result of 
these limitations it is not generally used in the setting of acute kidney injury. In 
addition it is not used in any of the GFR estimating equations in current use.  
 
2.2.4 Creatinine as a filtration marker 
 
Despite numerous limitations serum creatinine remains the mainstay for assessing 
renal function in clinical practice and is widely employed in estimating equations to 
determine GFR. Creatinine has been in use as a filtration marker since endogenous 
levels were first measured in the 1930’s 
55. The obvious advantage of using an 
endogenous filtration marker is that it does not require the administration of a test 
compound 
57. 
 
Creatinine is a cyclic anhydride of creatine and is the metabolic end product of creatine 
metabolism in muscle. Creatine is produced primarily in the liver and transported to 
muscle cells where it is phosphoralated to creatine phosphate that then acts as a 
storage depot for muscle energy 
57. Creatinine possesses many of the attributes of a 
perfect filtration marker described above. It is freely filtered and not protein bound. In 
addition, it is not metabolised by the kidney and it is physiologically inert 
55. However, 
there are a number of issues that limit creatinines ability to reflect GFR accurately 
which are related to its production, its renal handling and its measurement. These 
issues need to be kept in mind when interpreting renal function expressed in terms of 
creatinine excretion and are of great importance in AKI. They follow the same 
principles of biological and analytical variation of any analyte.  
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2.2.4 (i) Creatinine Production 
 
In the steady state the production of creatinine from creatine occurs at a constant rate 
58. It stems from this that influences on the size of the creatine pool will lead to 
proportionate changes in creatinine production. Muscle mass is the most important 
determinant of the size of the creatine pool and so age and sex have dominant effects 
on creatinine production because of their effects on muscle mass 
55. Muscle mass 
decreases with age and hence creatinine production falls 
59. Muscle mass in women is 
lower than it is in men and so creatinine production and excretion is lower in women 
60. Racial differences have also been identified. African Americans have been shown to 
have higher serum creatinine levels for any given GFR than non-African Americans 
61. In 
addition, creatinine production will be lower in individuals with muscle wasting 
conditions such as mytonic dystrophy or in those who have had an amputation. In 
these situations serum creatinine and its associated clearance are unlikely to be an 
accurate reflection of GFR.  
 
Serum creatinine can also be influenced by dietary intake of meat. Reducing or 
eliminating the meat content of the diet reduces creatinine excretion by 10-30%. It has 
been shown that serum creatinine levels are lower in vegetarians
 62. After a meal of 
cooked meat, serum creatinine levels rise substantially and peak within the first two 
hours after the meal. Normal levels are not regained until between 12 and 24 hours 
after the meat load 
63-65.   
 
Trauma and exercise have also been shown to increase serum creatinine levels 
55. In 
animal models it has been recently demonstrated that creatinine production is reduced 
in the setting of sepsis 
66. There have been additional reports of a diurnal variation in 
serum creatinine concentration with levels being higher in the afternoon 
67. 
 
2.2.4 (ii) Renal handling of creatinine 
 
Although creatinine is freely filtered it does not pass through the renal tubules 
unaltered. In 1935 Shannon demonstrated that at low plasma concentrations of 
creatinine the creatinine clearance is 30 to 45% higher than the inulin clearance in 
healthy volunteers. The active secretion of creatinine by tubular cells accounts for this 
difference
 68.  
 
Shamesh et al took these findings further in 1985 by demonstrating that there is 
progressive fractional hypersecretion of creatinine by renal tubules in glomerular 
disease and that this hypersecretion increases as the glomerular disease worsens 
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the setting of low urine flow rates some reabsorption of creatinine may also occur due 
to its passive back-diffusion from the lumen to the blood 
55.  
 
In addition to the secretion and reabsorption of creatinine by the renal tubules the 
handling of creatinine is further complicated by extrarenal metabolism. This is 
undetectable in normal subjects. However, in those with chronic kidney disease it has 
been shown that creatinine production exceeds the rate of accumulation of serum 
creatinine and its excretion in the urine. This 'creatinine deficit’ is eliminated via 
extrarenal routes. This is thought to mainly involve its release into the gut where it is 
degraded by bacterial flora in a similar manner to urea and uric acid 
70. 
 
The direct relationship between serum creatinine concentration and the GFR is also an 
important consideration. At near normal levels of renal function, large changes in GFR 
correspond to small changes in serum creatinine concentration. Enger et al and others 
demonstrated that patients with up to a 50% fall in GFR may still have serum creatinine 
concentrations in the near normal range 
57,71.  
 
In pregnancy creatinine generation remains unchanged however there is up to a 50% 
increase in GFR from the first trimester onwards which leads to decreases in the 
concentration of serum creatinine 
55. The implication of this in the setting of AKI is that 
a serum creatinine considered normal in the nonpregnant state may in fact represent 
significant renal injury. 
 
2.2.4 (iii) Creatinine measurement 
 
Creatinine is easily measured in serum, plasma or urine. The standard method used is 
the Jaffe reaction. Creatinine reacts directly with picrate ion under alkaline conditions 
to form an equimolar complex whose orange-red colour is detected and quantified. 
This method has been modified over the years to separate ‘true creatinine’ from 
noncreatinine chromogens which accounted for up to 20% of the colour reaction. 
Several enzymatic methods are now available in addition to a kinetic alkaline picrate 
method. Elevated serum bilirubin levels have been shown to interfere with these 
techniques and result in a reduced serum creatinine concentration 
72.   
 
Like any biochemical test these methods are associated with a degree of 
intraindividual analytical variation that can be expressed as a coefficient of variation. 
Data from the NHANES 3 study showed that the analytical variation for creatinine was 
1%. However, when the biological variation described above was also taken into 
account the total coefficient of variation for an individual was 6.9% 
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In addition to intraindividual variation, variation can also occur between laboratories. 
This may be due to differences in calibration of the analyser or due to different 
analysis techniques. This has implications for comparing results from different 
laboratories particularly in clinical trials. In recent years efforts have been made to 
standardise the reporting of results by calibrating to a single standardized serum 
creatinine based on gold standard methods. The primary reference is assigned values 
based on isotope dilution mass spectrometry (IDMS). IDMS traceable creatinine 
measurements have been in use in the UK since April 2006 
74. Prior to the introduction 
of IDMS calibrated creatinine measurements quite large differences were observed in 
results between different laboratories 
75. 
 
2.2.4 (iv) Drug influences on creatinine measurement 
 
Numerous drugs influence renal handling of creatinine and its serum concentration. In 
renal insufficiency, tubular secretion of creatinine can account for as much as 60% of 
the total amount of creatinine excreted. Complete inhibition of this pathway could 
result in a doubling of the serum creatinine concentration 
55. Cimetidine is known to be 
potent inhibitor of creatinine secretion by the tubules and is used for this purpose 
experimentally 
76. Probenecid, trimethoprim and calcitriol have also been described in 
this manner and can result in increases in serum creatinine concentration in the 
absence of renal damage.  
 
Volume depletion due to diuretic treatment can lead to an increase in serum creatinine 
concentration. Certain drugs can also influence renal haemodynamics such as RAS-
blockers and NSAIDS both of which reduce renal blood flow. 
 
2.2.4 (v) Creatinine Clearance 
 
Carrying out a timed urine collection and applying the clearance formula (C
X = U
XV/P
X) 
described above can measure the clearance of creatinine. However, creatinine 
clearance is subject to the same limitations associated with serum creatinine. It has 
been shown to overestimate ‘true’ GFR measured by inulin clearance 
69. Timed urine 
collections are inconvenient for patients and frequently inaccurate. Inaccuracies can 
result from incomplete bladder emptying and failure to collect the entire specimen 
55. 
This method was commonly used in clinical practice however it has been replaced by 
estimated GFR over the past decade.  A recent report by Kagoma et al showed a 23.5% 
reduction in the use of creatinine clearance since the introduction of eGFR reporting 
77. 
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2.2.5 Cystatin C as a marker of renal function 
 
Due to the many limitations with the use of creatinine as a marker of renal function 
there have been efforts to find better alternatives. Cystatin C is one such alternative 
that has been extensively studied.  
 
Cystatin C is a non-glycosylated polypeptide and is part of the cystatin superfamily. 
These proteins inhibit cysteine proteinases and play a key role in protection against 
tissue injury during the course of an insult. It is released from all nucleated cells. In 
addition to its role as a cysteine proteinase inhibitor it also has properties that 
modulate the immune system and it has antibacterial and antiviral effects. Cystatin C is 
almost completely filtered by the glomerulus. It is then taken up by proximal tubular 
cells which catabolise virtually all of it. It can be found in all body fluids. Elevations in 
its serum levels occur almost exclusively in the setting of a reduced GFR and this drew 
attention to it as a potential filtration marker. Its levels can be measured by 
immunoassay with rabbit antibodies against human cystatin C and a fully automated 
particle-enhanced nephelometric immunoassay (PENIA) is now available 
78.  
 
Cystatin C possesses properties that in theory would make it a better filtration marker 
than creatinine. Age, sex, and race have been shown to have less influence on it 
52. In 
addition, it appears to be unaffected by dietary protein intake and muscle mass 
79-80. 
Two meta-analyses in the past decade have suggested that cystatin C is superior to 
creatinine as a marker of kidney function 
81,82. However, there is evidence that its 
measurement is influenced by other factors such as body mass index, the presence of 
diabetes and inflammation 
52. Cystatin C alone has been incorporated into GFR 
estimating equations but these have not been show to be superior to those based on 
serum creatinine. More recently, the two have been combined together and have 
shown more promise at estimating renal function 
80,83. At present Cystatin C is 
considered a possible alternative to creatinine however it is not widely used. It is costly 
to measure and in the absence of evidence that it significantly improves outcomes 
these costs are difficult to justify 
84.  
 
2.2.6 GFR estimating equations 
 
There are several reasons why an estimation of GFR is useful in clinical practice. Firstly, 
it allows adjustment of drug doses in patients with impaired renal function. Secondly, 
it enables physicians to establish the presence of and monitor CKD. It has gained 
additional importance over the past decade with the recognition that CKD increases 
the risk of cardiovascular mortality in addition to being a precursor to ESRD 
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GFR estimating equations are derived from regression analysis in which the level of 
measured GFR is related to the serum concentration of an endogenous filtration 
marker. It is also related to observed clinical and demographic variables that serve as 
surrogates for the non-GFR determinants of the serum concentration 
85. At present, 
serum creatinine based equations are the mainstay in clinical practice.  
 
As discussed above, age, sex, race, and body weight are surrogates that can influence 
creatinine generation from muscle. These can be adjusted for in estimating equations 
and so they can provide a more accurate estimate of measured GFR than serum 
creatinine alone. In addition, the estimates are provided in the same units as GFR 
which simplifies clinical decision making 
85. However, like serum creatinine from which 
they are derived, the estimating equations are subject to variation and bias. A key 
assumption in their development is that renal function is in the steady state 
55. 
Therefore they cannot be used in the setting of AKI where creatinine may be acutely 
rising or falling. The equations only capture the average relationships between the 
marker and its non-GFR determinants and this relationship may vary over time 
86. 
Another key issue to take into consideration is the population from which the 
equations are derived. This can influence their generalizability and can account for 
bias in their interpretation. For example, the MDRD equation was developed in a 
population with CKD and has been found to perform less well at higher levels of GFR in 
those without CKD 
87.  
  
The first widely accepted estimating equations was proposed by Cockcroft and Gault in 
1976 
60. This equation was derived from investigation of 249 patients, mainly men, 
who had no history of renal disease and is an estimate of creatinine clearance rather 
than GFR itself. It accounts for age and weight in its calculation and required a 
correction for use in women: 
 
C
cr   =  [140 – age ] x weight / 7.2 x serum creatinine (mg/L) 
 
The CG formula has seen widespread use but has several limitations. It has been 
shown to underestimate clearance at higher levels of GFR and to overestimate 
clearance at lower levels 
88.  
 
2.2.6 (i) MDRD eGFR 
 
Levey et al presented the Modification of Diet in Renal Disease equation in 1999 
89. 
This was developed using data from the MDRD study in which GFR was measured 
using 
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some of the limitations of the equation. In the original paper describing its 
development, the MDRD eGFR was found to be more accurate at measuring GFR than 
measured creatinine clearance or the CG equation. An advantage of the MDRD 
equation is that it does not need a weight measurement and so can be readily 
calculated by a laboratory. The equation has since been modified including an 
adjustment for use with creatinine values standardised to IDMS: 
 
GFR = 175 x Serum Creatinine
-1.154 x age
-0.203 x 1.212(if black) x 0.742(if female). 
 
In addition adjustment needs to be made for racial differences. It was discussed earlier 
that serum creatinine values have been found to be higher in blacks and so adjustment 
is now made for those of black Afro-Caribbean origin.  
 
Since its introduction the MDRD formula has been applied in more diverse populations 
in a number of studies where it has demonstrated reasonably good performance at 
levels of GFR < 60mls/min. However at higher levels its performance was poor and it 
was found to underestimate GFR. In one study the overall performance of the equation 
expressed as P
30  was found to be 83% 
90. This means that 83% of measurements are 
within 30% of the measured GFR. Another study by Botev et al comprising mainly 
European Caucasian subjects found that the equation had an overall P
30  accuracy of 
70% and that approximately 60% of the study population was correctly defined by the 
K/DOQI-CKD classification. Despite these limitations in accuracy it has been deemed 
acceptable for routine decision-making in clinical practice. As a result the MDRD 
equation has been widely adopted as the means to estimate GFR 
74,91.  
 
A key issue with the MDRD equation is its ability to monitor progression of renal 
disease in the individual. This is relevant to the study described in this thesis. Despite 
its inaccuracy in terms of estimating true GFR its ability to identify relative changes in 
function is important in longitudinal studies. Tent et al described the renal function 
outcomes in 253 consecutive living kidney donors who had GFR measured with 
125I-
Iotholamate four months before and two months after donation. This was compared 
with the MDRD eGFR, CG estimation of creatinine clearance, and the CKD –EPI eGFR 
discussed below. All three equations significantly underestimated true GFR at both 
time points prompting the authors to caution the use of estimating equations in 
healthy individuals. However, while the equations underestimated the absolute 
measured eGFR decline the percentage decrease of MDRD and CKD-EPI were 
proportionally equal to the change in measured GFR 
92. In terms of the coefficient of 
variation (CV) within an individual, the CV for MDRD eGFR was reported as 6.7% 
93. 
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however in terms of relative change it appears to mirror changes in the true GFR with 
less than 10% intraindividual variation.  
 
2.2.6 (ii) CKD – EPI eGFR 
 
The CKD – EPI equation to estimate GFR was introduced by the Chronic Kidney Disease 
Epidemiology Collaboration in 2009 
94. This equation was developed to improve on the 
performance of the MDRD equation particularly at higher levels of GFR. With CKD –EPI 
adjustments are made leading to higher eGFR at lower creatinine levels. In addition, 
the relationship between GFR and sex varies according to the level of serum creatinine 
whereas in the MDRD equation it was constant. Concordance of estimated and 
measured GFR stages was 69% for the CKD –EPI equation versus 64% for the MDRD 
equation. When applied to the NHANES study data the CKD –EPI equation led to a 
reduction in the estimated prevalence of CKD from 13.1% to 11.5% primarily due to a 
lower prevalence of Stage 3 CKD. The authors concluded that while precision remains a 
problem, the CKD –EPI equation has lower bias than the MDRD eGFR at higher levels of 
GFR 
94. Compared to the MDRD formula, CKD-EPI improves bias substantially in those 
under 65 years of age. However there is little change in performance for those older 
than 65 years of age 
95. The elderly make up a substantial proportion of the CKD 
population and so further evaluation of this formula is required before it is widely 
adopted. Nevertheless, some authors have recommended that it should replace the 
MDRD equation in routine practice 
95.  
 
2.2.6 (iii) GFR measurement and AKI 
 
Estimating equations for GFR are not valid in AKI as they are derived under the 
assumption that the patient is in a steady state without acute changes in serum 
creatinine. Despite its many limitations there is still a consensus that serum creatinine 
together with urine output if available should form the basis of all diagnostic criteria in 
AKI 
48. Urine output has been included in diagnostic criteria because it is known that 
decreases in urine output often herald renal dysfunction before serum creatinine 
increases 
39. However, its precise role in the diagnosis of AKI is poorly characterised. 
Considerable renal injury may be present in certain conditions such as 
glomerulonephritis in the absence of any changes in urine output 
48.  
 
It is of particular relevance to AKI that up to 50% of GFR may be lost before the 
creatinine level begins to rise. Measurements of serum creatinine are therefore of little 
value in determining the degree of renal impairment in AKI. Simulation studies by 
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the concentration of serum creatinine continues to rise or fall until new steady state 
levels are reached. The time required to reach the new steady state is dependent on 
the half-life of serum creatinine. This in turn is dependent on clearance, so a longer 
period of time will be needed to reach steady state when the GFR is falling rather than 
rising 
57. The delay in reaching steady state has such an effect that it is possible for the 
creatinine level to continue to rise even after the GFR has started to recover 
55.  
 The limitations associated with using serum creatinine for diagnosing AKI have been 
the driving force behind the quest to develop new biomarkers that can more accurately 
reflect the timing and extent of injury during AKI. These biomarkers will be discussed 
further later in the chapter.   
 
2.3 Defining AKI 
 
In the past decade two widely accepted definitions and classification systems of AKI 
have been developed. Firstly, the RIFLE criteria which were introduced in 2004 by the 
Acute Dialysis Quality Initiative Group (ADQI Group) and secondly, the AKIN criteria 
introduced by the Acute Kidney Injury Network in 2007 
39,96. In order to fully 
understand these definitions and their limitations it is necessary to discuss why 
defining AKI is considered so important. In addition, it is important to discuss the 
reasoning behind any definition of AKI. 
 
2.3.1 Acute Renal Failure becomes AKI 
 
Bellomo et al were the first to put the concept of kidney ‘injury’ forward in 2001. While 
acknowledging that this was a matter of semantics they felt that the term ‘injury’ was 
more useful to describe the initial phase of kidney malfunction 
97. The Acute Kidney 
Injury Network (AKIN) has adopted the term Acute Kidney Injury. There were several 
reasons for this: firstly, the recognition that relatively modest changes in serum 
creatinine were associated with adverse outcomes suggested that the syndrome should 
encompass more than just outright kidney failure. Secondly, it was felt that the term 
‘injury’ more accurately conveyed the associated pathophysiology than the term 
‘failure’. Finally, it was recognised that the word ‘kidney’ was more accessible than the 
Latin derived ‘renal’ by the general public 
98.  
 
2.3.2 The need to define and classify AKI 
 
It has been recognised that there are significant gaps in the understanding of the 
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Renal research report identified a number of important areas in clinical AKI that 
needed further work 
40: 
 
-  The incidence and prevalence were unknown 
-  The natural history and spectrum of AKI was unknown 
-  The causes of AKI were not defined 
-  The variations in processes of care were unknown 
-  There was no data on long-term outcomes, particularly progression to CKD 
-  Information was required to inform the design and conduct of multicentre 
interventional studies 
-  Benchmarks for disease patterns and their management were needed 
 
One of the principal barriers to progress in these areas was recognised as the lack of a 
consensus definition and classification system for AKI 
38,97. This problem had been 
apparent in the literature for many years. In a 1991 study on the immediate and long-
term prognosis in acute renal failure in the elderly, Gentric et al found comparison with 
other studies difficult because of the use of different creatinine values as the cut-off to 
define AKI 
19.  In 1994 Novis et al attempted to perform a systematic review of 26 
studies published between 1965 and 1989 in order to examine preoperative risk 
factors for postoperative renal failure. No two studies used the same definition for 
acute renal failure and the authors concluded that the literature was not adequate to 
support a comprehensive quantitative review 
99.  
 
In a 2002 review Kellum et al referred to more than 35 different quantitative 
definitions of AKI and concluded that a standardised classification system was 
mandatory for the advancement of clinical research in the prevention and treatment of 
AKI 
38.  In 2001, Bellomo et al highlighted that there were too many essentially 
arbitrary biochemical “cut-off values” for serum creatinine in the definition of AKI 
leaving one unable to come to any conclusions when comparing clinical research 
97. 
Observational research relevant to this current study carried out between 1990 and 
2011 revealed 42 different definitions of AKI and these are outlined in Appendix 2. 
Some of these definitions were similar in terms of the creatinine cut-off used but they 
then differed in other areas such as the cut-off for baseline renal function. It is notable 
that some used an absolute increase in creatinine, for example a rise > 0.3mg/dl, 
while others used a relative increase such as a rise of 30%. This potentially has 
important implications when the level of baseline kidney function is considered. In 
addition, some studies even used a fall in estimated GFR to define AKI 
124.  
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2.3.3 Considerations when defining AKI 
 
A number of factors needed to be taken into account when defining AKI and these 
ultimately determine the usefulness of any definition. These factors are illustrated in 
the diagram in Figure 2.2. The first and most important consideration is to establish 
what marker should be used to measure kidney function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There are only two physiological functions that are unique to the kidney that can be 
easily measured in clinical practice and these are the production of urine and renal 
solute clearance. Renal solute clearance reflects glomerular filtration rate and serum 
creatinine remains the most useful measure of this function despite its many 
limitations. While no single creatinine value corresponds to a given GFR across all 
patients, changes in creatinine levels are clinically and physiologically useful in 
determining the presence of AKI 
128. For these reasons the current definition and 
classification systems of AKI are based on serum creatinine as the main marker of 
renal function.  
Baseline 
Timing 
Duration 
Threshold 
Staging/ 
Classification 
of severity. 
Marker 
Acute rise in a marker 
from baseline to indicate 
AKI:   
AKI 
Figure 2. 2 Diagram illustrating the various factors that need to be 
accounted for in any definition of AKI. A marker of kidney function (in 
yellow) begins at a baseline level and peaks across a threshold level to 
indicate an AKI has occurred.  Mark Uniacke    Chapter 2     
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Urine output has also been included as a marker in the current definitions and has 
some advantages over biochemical markers. However, it also has notable limitations. It 
is more sensitive to changes in haemodynamics than biochemical markers such as 
serum creatinine because changes in urine output can become apparent long before 
biochemical markers change. However, it is far less specific. Severe cases of AKI can 
exist despite maintaining normal urine output 
128. Measurement of urine output in 
practice is an additional problem. Accurate measurement requires a urinary catheter 
and this is not always available in cases of AKI particularly the milder ones.  
 
The next consideration in any definition is the baseline from which the AKI is 
measured. This is not only important from the point of view of outcomes such as 
recovery of function but will also influence how the threshold to define AKI is defined 
and interpreted. Many patients with AKI will have pre-existing CKD. The implication of 
this is that the absolute decrease in renal function required to reach a level consistent 
with the diagnosis of AKI will be less than that of a patient without pre-existing kidney 
disease. To overcome this problem, developers of the current definitions included 
relative changes in creatinine rather than an absolute change 
38. An additional 
important concern is that many patients with AKI will not have a known baseline on 
record.  
 
Another consideration is the choice of threshold for the marker beyond which AKI is 
defined. This is largely arbitrary but needs to be set so that it is sensitive enough to 
detect milder cases of AKI. The issues surrounding the importance of sensitivity and 
specificity to any definition of AKI were recognised in the development of the current 
definitions 
38,96. In proposing the RIFLE definition, the ADQI Group advocated using a 
multilevel classification system to separate mild (or early) and severe (or late) cases. 
This allowed the classification to detect those whose renal function was mildly affected 
(high sensitivity but limited specificity) and those whose function was severely affected 
(high specificity but limited sensitivity).  
 
A final consideration in any definition is the timing and duration of the injury. These 
will also influence the sensitivity and specificity of the definition when it is applied in 
practice 
38. For example, if a sudden decline in function is defined as less than 48 
hours this will be far less sensitive at detecting AKI than say a 7 day time frame.  
All of the above factors need to be considered in the development of a suitable 
definition of AKI.  However, it is widely recognised that no consensus definition will 
ever be perfect 
38. 
 
 Mark Uniacke    Chapter 2     
        21 
2.3.4 The RIFLE Classification 
 
The Rifle Classification was introduced by the ADQI Group in 2004 and is illustrated in 
its original format in Figure 2.3 
96.  
 
 
The RIFLE classification uses two separate markers of renal dysfunction. Firstly, renal 
excretory capacity measured by either serum creatinine or GFR and secondly, urine 
output. Either or both of these markers may be used to place the patient in the worst 
classification possible. Changes in excretory capacity are measured from baseline and 
when this was unknown the ADQI group suggested using an estimate of baseline 
function by back calculating from an assumed eGFR of 75mls/min. The definition uses 
a multilevel staging system with three stages of dysfunction; risk, injury and failure, 
and two outcomes; loss and end stage renal disease. It was proposed that when the 
Risk 
Injury 
Failure 
Loss 
ESRD 
Increased creatinine x 1.5 
or 
GFR decrease > 25% 
Increased creatinine x 2 or 
GFR decrease > 50% 
Increased creatinine x 3 or 
GFR decrease > 75% or 
creatinine ! 4mg/dl. 
(Acute rise ! 0.5mg/dl) 
Urine Output < 0.5 ml/kg/hr 
X 6 hrs 
Urine Output < 0.5 ml/kg/hr 
X 12 hrs 
Urine Output < 0.3 
ml/kg/hr X 24 hrs or 
Anuria x 12 hrs 
Persistent ARF = complete loss of 
renal function for > 4 weeks 
 
         End Stage Renal Disease 
GFR criteria  Urine output 
High  
Sensitivity 
High  
Specificity 
Oliguria 
Figure 2. 3. The Rifle Classification 
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failure stage is reached and there is a background of CKD then this stage should be 
designated RIFLE-Fc with the ‘c’ indicating CKD. In a similar manner, if the failure stage 
is reached and the urine output criteria have been used then this should be designated 
RIFLE – Fo. The overall classification was presented as an inverted pyramid to indicate 
the larger numbers of patients that would be included in the milder stages owing to 
greater sensitivity 
96. In 2008 Ricci et al concluded that RIFLE was a simple and useful 
clinical tool for detecting and stratifying the severity of AKI. In addition, it also 
appeared to predict outcomes with a stepwise increase in relative risk for death with 
each of the three stages Risk, Injury, and Failure 
129.  
 
The RIFLE criteria have a number of limitations. Firstly, it is largely based on changes 
in serum creatinine and the limitations of this are well-recognised 
130-132. It included a 
fall in GFR in addition to changes in serum creatinine and as discussed earlier this is 
not valid in the setting of acutely changing renal function 
131,132. Secondly,  urine output 
is not available in all settings. It is not reliable in retrospective studies and these have 
made up the bulk of AKI research to date. In a pooled analysis of the studies reviewed 
by Ricci et al only 12% of patients had the urine output criteria applied to them. The 
authors also found that the relative risk for death among studies that used both 
creatinine and urine output was lower than in those using the creatinine criteria alone 
129. This finding suggests that there is an imbalance between the creatinine and urine 
output criteria 
131. A third limitation of the criteria is the need to use a baseline 
creatinine or GFR level that in many cases will not be available. The ADQI group 
suggested using an estimate of the baseline but this has been heavily criticised and 
will be discussed further in section 2.3.7. A fourth issue raised by some authors is that 
the criteria do not take into account the nature and site of the injury bearing in mind 
the heterogeneous nature of AKI 
130-132. Finally, around the time that the RIFLE 
classification was being introduced evidence was emerging that even small increments 
in serum creatinine were associated with adverse outcomes 
32,133-135. These increments 
were much smaller than would be picked up by the Risk category of RIFLE which 
requires a 50% increase in serum creatinine. In 2007 Coca et al carried out a meta-
analysis to look specifically at the prognostic importance of a small decrement in 
kidney function. They found that even very small increases in serum creatinine, of the 
order of 10% to 24% or 0.3 to 0.4 mg/dl (26 to 35μmol/l) were associated with 
approximately a 2-fold risk of short-term death 
27.  
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2.3.5 The AKIN Definition  
 
In 2007 the Acute Kidney Injury Network put forward the AKIN definition of AKI 
39. This 
represented a modification of the RIFLE criteria and an effort to solve some of the 
problems with RIFLE outlined above. The AKIN definition is illustrated in Figure 2.4. 
 
 
Figure 2. 4 AKIN Definition and staging system 
39. 
 
Stage 
 
Serum Creatinine Criteria 
 
 
Urine Output Criteria 
 
1 
Increase in Creat. of ! 0.3mg/dl 
(!26.4μmol/l) or increase to ! 150% 
to 200% (1.5 fold to 2 fold) from 
baseline.  
 
      < 0.5ml/kg/hr for more   
      than 6 hours 
2  Increase in Creat. to > 200% to 
300% (>2 to 3 fold) from baseline 
 
      < 0.5mls/kg/hr for more 
      than 12 hours  
3  Increase in Creat. to > 300% (>3 
fold) from baseline or a Creat. of 
!4.0mg/dl (!354μmol/l) with an 
acute increase of at least o.5mg/dl 
(44μmol/l). 
      < 0.3mls/kg/hr for 24  
      hours or anuria for 12  
      hours  
 
 
The AKIN definition was designed to account for smaller increments in serum 
creatinine and hence the first stage includes an increase of 0.3mg/dl or 26.4μmol/l. 
The original proposal stipulated that a 48 hour time frame should be applied for the 
acute rise in serum creatinine. AKIN proposed that this would ensure the process was 
acute and representative of a clinically relevant time period. In addition, it was 
proposed that the diagnostic criteria should only be applied after an optimal state of 
hydration was achieved. This was to account for the influence of volume status on 
serum creatinine levels. However, there was no proposal on how this might be 
achieved. The group retained the use of urine output criteria but with recognition of 
the limitations of this as a marker of renal dysfunction. The group did not include any 
stipulation regarding pre-existing renal impairment or CKD but recognised that the 
criterion for elevation of creatinine of 0.3mg/dl would need to be validated in this 
population. 
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AKIN retained the multilevel classification approach used in RIFLE and divided AKI into 
three stages that could be used to classify AKI over a 7 day period. The Loss and ESRD 
categories were removed as these were considered outcomes of AKI and not relevant 
to the definition itself. They stipulated that anyone requiring renal replacement 
therapy should automatically fall into Stage 3 and this would account for the variation 
in practices regarding the timing of RRT start up. The GFR criteria used in RIFLE were 
also eliminated to avoid its incorrect use in AKI 
39. 
 
The AKIN definition partially addressed some of the limitations associated with RIFLE 
however issues still remain 
131. Firstly, while efforts were made to exclude easily 
reversible causes of creatinine elevation such as volume depletion the definition still 
does not account for the nature of the renal injury 
24.  Application of the volume 
repletion component of the definition has proved problematic particularly in 
retrospective studies. In one of the first validation studies of the AKIN definition in an 
intensive care population, Barrantes et al found that only 123 of 213 patients had 
complete information on a fluid challenge at the time of their AKI although all had met 
the criteria of a rise in creatinine of 0.3mg/dl 
136. Barrantes et al defined a fluid 
challenge as having received at least 500mls of fluid at the time of the creatinine rise 
and whether or not this actually represents volume repletion is open to question. 
Secondly, the AKIN definition remains dependent on rises in serum creatinine. At 
present there is no way around this issue. A third problem with the AKIN definition has 
been the 48 hour timeframe. In another study by Barrantes et al in a general hospital 
population, 209 cases out of 6033 were excluded because of an unspecified timeframe 
or one beyond 48 hours despite meeting the creatinine criteria. These cases were 
analysed separately and were found to have outcomes similar to the AKI cases 
included in the study 
24. This suggests that this aspect of the definition may miss 
clinically relevant cases of AKI. Ostermann et al also noted problems with the 
timeframe when applying the definition to a large cohort of intensive care patients. 
The authors expressed concern that such a narrow time window would miss cases with 
a slower rise in creatinine that may be clinically relevant 
137. The original proposal for 
the AKIN definition also stated that at least two creatinine measurements were 
required in the 48 hour timeframe in order to make the diagnosis of AKI – it was hoped 
that this would reduce the need for a baseline creatinine which was shown to be a 
problem with the RIFLE criteria. This poses difficulties for diagnosing AKI at the time of 
admission to hospital. However the AKIN definition did state that the criteria should be 
used in the context of the clinical presentation.  
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2.3.6 RIFLE compared to AKIN  
 
Following the introduction of the AKIN definition, a key question was whether or not it 
offered any improvement on the RIFLE classification of AKI. Since its introduction over 
a dozen publications have appeared in the literature conducting some form of 
comparison between the two definitions in adult populations. These publications are 
summarised in Appendix 3. The general consensus in the literature is that the AKIN 
criteria offer no clear advantage over the RIFLE criteria 
150. The key difference is that 
more patients are diagnosed in the milder Stage 1 of AKIN than its counterpart Risk in 
the RIFLE classification. This increased sensitivity at the milder end of the AKI spectrum 
is not surprising as it was the intention of the AKIN group to do this by including a 
lower threshold for the diagnosis of AKI 
39.  
 
The interpretation of the rules attached to the AKIN definition and their application 
have led to a few notable problems. These relate mainly to the 48 hour timeframe used 
in the AKIN definition. For example, Ando et al in their study on AKI after stem cell 
transplantation found contrary to other studies, that RIFLE appeared to be more 
sensitive than AKIN at detecting AKI. In their study, RIFLE diagnosed 52.6% with AKI as 
opposed to 46.6% diagnosed by AKIN. The reason for this difference was that many 
patients in the study did not have more than one blood sample taken in a 48 hour 
period and so by rigidly applying the need to have two serum creatinine measurements 
in 48 hours many cases of AKI could not be classified 
147.  
 
It was the intention of the AKIN group that by requiring two creatinine measurements 
within 48 hours it would negate the need to have a known baseline. Engleberger et al 
clearly demonstrated the problems with this approach. In their study looking at AKI 
after cardiac surgery it was found that 9.6% of patients classified as AKIN stage 1 had 
no AKI according to RIFLE. It was found that these patients actually had a fall in serum 
creatinine post-operatively due to fluid therapy however the rise in creatinine was 
taken from this new nadir level during the 48 hour window. In fact none of these 
patients had a rise of > 0.3mg/dl if the pre-operative creatinine was used. Strict 
application of the AKIN rules can therefore potentially over diagnose AKI 
146.  
 
Haase et al noted some differences between the two definitions in how they assigned 
cases to various stages of AKI. They noted that 13 patients were classified as AKIN 
stage 1 but went beyond this to the Injury Class in RIFLE 
143. This disparity again comes 
down to how the definition is interpreted. They stuck rigidly to the 48 hour timeframe 
and those who were assigned to AKIN stage 1 remained in that group. However their 
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being assigned a higher RIFLE class. This is an error in interpretation of the definition 
because AKIN did not intend for the 48 timeframe to be a limit for the staging of the 
AKI and clearly stated, albeit in small print, that the staging could take place over the 
course of 7 days.   
 
Joannidis et al also found similar problems. In their study, RIFLE classified close to 7% 
more patients as having AKI. These were mainly patients who presented with 
significantly increased creatinine values compared to the estimated baselines and so 
were classified by RIFLE. However, they did not progress any further during the 48 
hour window of observation and so did not strictly meet AKIN criteria 
140. 
 
Strict application of the AKIN 48 hour rule would make it virtually impossible to 
diagnose adequately community acquired AKI which is evident on admission to 
hospital. In addition, using the first serum creatinine in the 48 hour period as 
representative of baseline function will not always be accurate as was demonstrated by 
Engleberger above. It is notable that outside of the comparison studies summarised in 
Appendix 3 many of the observational studies which have used the AKIN definition 
have used an adapted version.  
 
During the course of this research 33 observational studies applying the AKIN criteria 
were reviewed and are summarised in Appendix 4. All but four of these studies were 
retrospective in nature. Direct application of the AKIN definition was carried out in 16 
studies (48%). In the others, the definition was either adapted or the precise methods 
were unclear. As an example of this approach, Kramer et al used the definition of a 
rise in serum creatinine by 0.3mg/dl or a 50% rise from a pre-operative stable baseline 
to any creatinine taken up to the point of discharge from hospital. There was no 
timeframe specified nor was there any form of staging used 
161. 15 studies defined a 
time point from which to measure a stable baseline level of kidney function. There was 
considerable variation in the definitions of baseline used and this will be discussed 
further in the next section. Just four studies formally applied the urine output criteria 
to define AKI. Only one study in an ITU population by Mandelbaum et al managed to 
record urine output on all patients 
170. Bucovic et al and Fonseca et al had urine outputs 
on 58.9% and 57.5% of patients respectively 
166,177. Finally, only one study by Minejima 
et al attempted to insure the patients were adequately hydrated at the time of the AKI. 
They defined dehydration by a rapid decline in the patients weight or if the serum 
creatinine or urea normalized within 48 hours following administration of fluids. It was 
found that 18 patients were excluded by applying this definition of dehydration, which 
compares to 43 patients actually recruited as cases of AKI 
176. However, the validity of 
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that adverse outcomes occur even with this type of transient azotemia 
180. This will be 
discussed in more detail later.  
 
In summary, the AKIN definition has been widely adopted. However, it has not been 
precisely applied in any study. There appears to be considerable variation in its 
application particularly in relation to the 48 hour timeframe. Many studies have 
attempted to define a stable baseline from which the rise in creatinine can be 
measured but these also show much variation.  
 
2.3.7 Defining the baseline level of kidney function 
 
There has been considerable inconsistency in the literature on what determines 
baseline kidney function. 146 observational studies were reviewed during the course 
of this research using the search strategy outlined in Appendix 1. 30 different 
definitions for baseline kidney function were found in use during the past decade and 
are summarised in Appendix 5. In addition to this, 56 studies had not clearly specified 
what baseline if any was used. 
 
Baseline kidney function is important for a number of reasons and is arguably more 
important than the arbitrary thresholds of serum creatinine used as a cut off to 
determine the presence of an AKI. Any threshold chosen for AKI must be determined 
relative to some baseline (see Figure 2.3). A patient presenting for the first time with a 
raised serum creatinine may have CKD or it could be an AKI and the only way of 
knowing this is to use a baseline as reference. Without a reasonably accurate baseline, 
cases of CKD could be misclassified as AKI. This would in turn lead to bias in reported 
incidences and outcomes.  CKD has been recognised as an important risk factor for 
AKI for many years and close to a third of patients with AKI in contemporary studies 
have evidence of CKD prior to the AKI. 
42,43.  
 
The ADQI group attempted to address the problem of baseline function when they 
introduced the RIFLE classification. They recognised that any definition of AKI should 
consider a change from baseline and it should include classifications for CKD. They 
also recognised that many patients may present with acute renal dysfunction but 
without any baseline measure of kidney function. They suggested that one option to 
circumvent this would be to calculate a theoretical baseline serum creatinine value 
assuming a given normal GFR 
96. From this arose the practice of back estimating serum 
creatinine for a given eGFR of 75mls/min using the MDRD formula. This approach that 
can be found in many publications in the literature (see Appendix 5).  
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The Acute Kidney Injury Network did not make any specific recommendations 
regarding the assessment of baseline kidney function. In fact it could be argued that 
the AKIN approach was a step backwards. The AKIN definition requires two serum 
creatinine measurements within 48 hours with which to diagnose AKI and it was hoped 
that this would reduce the need for a baseline creatinine 
39. This aspect of the 
definition has proved problematic as discussed above and cannot be reasonably 
applied to a patient presenting with an acute illness and a raised serum creatinine. For 
this reason many studies have adapted the definition and devised their own definition 
of baseline function or simply used the back estimation previously recommended by 
the ADQI group.  
 
Several studies have been conducted to assess the impact of various definitions of 
baseline kidney function 
196-200. In 2009 Bagshaw et al published a study comparing the 
use of a known pre-morbid baseline creatinine level with a back estimation derived by 
solving the MDRD equation for an eGFR of 75mls/min. The authors found that by using 
a back estimation 18.8% of patients were classified as having an AKI when they had 
not. These false positives were primarily due to patients with CKD being classified as 
AKI. The authors concluded that back estimation should not be used in those with 
suspected CKD 
196. This however is very difficult to assess especially in older patients.  
 
Siew et al reviewed 4863 adult patients with a known outpatient creatinine in the year 
prior to the index admission that served as a reference baseline. They studied the 
effects of using several different surrogates for baseline function including back 
estimation, the minimum serum creatinine available during the first seven days of 
hospitalisation, and the first serum creatinine available on admission. The overall 
incidence of AKI using the known baseline as a reference was 25.5%. This was 
considerably higher when an estimated baseline or when the minimum inpatient level 
was used reaching 38.3% and 35.9% respectively. In the case of using the first 
admission serum creatinine the incidence fell to 13.7%. The use of different methods 
also resulted in different mortality rates. For example, the higher incidence rate 
associated with the imputed baseline resulted in a lower mortality. This would be 
expected to have a significant impact in populations enriched with CKD such as the 
elderly or those with diabetes 
199.  
 
One option in observational studies would be to classify only those who had a known 
baseline serum creatinine although this would exclude an important and selective 
group with no prior results. The question then is what kind of time frame should be 
used for obtaining this serum creatinine from the patient records. La France et al 
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with a creatinine on admission with a period extending back 3months, 6 months and 
12 months. Extending the baseline assessment period back to twelve months resulted 
in an incremental increase in the cumulative incidence of AKI from 12.5% to 18.3%. The 
cases added tended to be milder and have a lower mortality. The authors highlighted 
that differences in baseline assessment periods had the potential to severely bias 
results 
197.  
 
A notable feature of some studies listed in Appendix 5 is that they used more than one 
definition of baseline function and even in one study by Hoste et al there were three. 
The most common approach was to use a known baseline when available and to back 
estimate the rest. For example, Cruz et al used a known pre-morbid baseline creatinine 
from an unspecified period prior to the index admission and when this was not 
available an estimate using an eGFR of 75mls/min was used. 22% of patients had an 
estimated baseline 
186. The problem with this approach is that these two essentially 
separate cohorts were analysed together adding to any potential bias in the results.  
 
In summary, progress has been made in trying to achieve a consensus definition of AKI 
and most studies in the literature are now using either the RIFLE definition or some 
form of the AKIN definition. However, this is a process that is still in evolution. There is 
still a lack of consensus on other aspects of AKI such as the definition of baseline 
function that are contributing to study heterogeneity.  
 
2.3.8 KDIGO 2012 
 
In March 2012 KDIGO (Kidney Disease: Improving Global Outcomes) released a clinical 
practice guideline for AKI. They recognised that two similar definitions of AKI are in 
use in the literature namely the RIFLE classification and the AKIN definition and stated 
that there was a need for a single definition for practice, research and public health. 
KDIGO also recognised that there is the potential for a bidirectional misclassification of 
AKI cases between the RIFLE and AKIN definitions and that cases that were missed by 
either definition also had poor outcomes. For this reason they felt that there was 
strong rational for the use of both RIFLE and AKIN criteria to identify patients with AKI. 
A new hybrid definition of AKI has therefore been proposed which has some minor 
modifications and possesses features of both definitions and is shown in Figure 2.5 
48. 
In figure 2.5 it can be seen that the new KDIGO definition includes the 0.3mg/dl rise in 
48 hours seen in AKIN but also the 50% rise over 7 days seen in RIFLE. For clarity, 
KDIGO specified that to reach Stage 3 by a serum creatinine > 4.0mg/dl, it should be 
required that this is reached by a rise of !0.3mg/dl within 48 hours rather than a rise 
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Figure 2. 5  The 2012 KDIGO definition and staging of AKI which combines 
features of both the RIFLE and AKIN definitions 
48. 
 
AKI is defined as any of the following: 
 
An increase in serum creatinine by !0.3mg/dl (!26.5μmol/l) within 48 hours  
or 
An increase in serum creatinine to !1.5 times baseline, which is known or 
presumed to have occurred within the prior 7 days 
or 
A urine volume < 0.5ml/kg/hr for 6 hours 
 
 
 
Stage 
 
 
Serum Creatinine 
 
Urine Output 
1  1.5-1.9 times baseline or 
!0.3mg/dl (!26.5μmol/l) 
increase 
<0.5ml/kg/hr for 6-12 hours 
2  2.0 -2.9 times baseline  <0.5 ml/kg/hr for !12 hours 
3  3.0 times baseline or an 
increase in serum creatinine 
to !4.0mg/dl (!353.6μmol/l) 
or initiation of RRT 
<0.3ml/kg/hr for !24 hours 
or anuria for ! 12 hours. 
 
The combination of the RIFLE and AKIN thresholds seems to be a logical evolution in 
the definition of AKI but there remain some issues regarding baseline function.  
There will be some cases where a baseline is not known and in this instance a back 
estimate as described earlier may be used provided there is no evidence of CKD. In 
doing this however, there is still the risk of misclassifying patients. KDIGO felt that by 
using all available clinical data it should be possible to arrive at an accurate estimate of 
baseline. This type of dynamic interpretation can occur in clinical practice but may be 
difficult to apply in the research setting. In addition, as mentioned earlier, the time 
period from which a known pre-morbid level of function is taken may also influence 
outcomes. This aspect of function was not addressed by KDIGO. KDIGO has stressed 
that clinical judgement must be used in applying the definition of AKI.  
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2.3.9 New Biomarkers for AKI 
 
As interest in the definition and natural history of AKI has grown, there has been 
increasing interest in the development of new biomarkers for AKI. The limitations of 
serum creatinine and urine output for the detection of AKI have been discussed. More 
sensitive and specific markers of renal injury and dysfunction could offer several 
advantages: 
 
1.  They could allow the diagnosis of AKI before a rise in creatinine is detected. 
2.  Better stratification for severity may be possible. 
3.  They may provide prognostic indicators. 
 
In 2005 the ASN Renal Research Report cited these points as reasons to prioritise the 
development of new biomarkers 
40. Earlier diagnosis of AKI could offer several 
advantages. Chief among them would be the ability to offer targeted therapy at an 
earlier stage 
48. It is well recognised in the literature that several agents that showed 
promise for the treatment of AKI in animal models failed in human trials 
201. Most 
notable is Anaratide, a synthetic analogue of Atrial Natriuetic Peptide, that was shown 
to improve renal function and renal histopathology in laboratory animals but later 
failed to show an improvement in the overall rate of dialysis-free survival in critically ill 
patients with acute tubular necrosis 
202.   
 
One of the reasons put forward for the failure of therapeutic trials in humans is the 
fact that we rely on serum creatinine as a marker of renal dysfunction. Renal injury is 
already well established by the time a rise in serum creatinine is detected and hence 
any treatment may be too late 
40,201,203.  
 
Over 20 different candidate biomarkers can be found in the literature and the area 
continues to grow as a result of new technologies such as functional genomics and 
proteomics 
201,204,205. These markers are illustrated in Figure 2.6. Urinary NGAL is one of 
the markers which is showing great promise but for the present none of these markers 
can be recommended for routine clinical use 
48,205. Given the heterogeneous nature of 
AKI it is unlikely that any one marker would suffice on its own for the detection of AKI 
and so a panel of markers may well be needed.  
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Figure 2.6 Candidate biomarkers which have been used for the early diagnosis 
and assessment of AKI. 
 
Candidate biomarkers for AKI 
 
 
Abbreviation 
Cystatin C   
Prohormone of atrial natriuretic peptide                               ProANP(1-98) 
Neutrophil Gelatinase Associated Lipocalin          NGAL 
Neutrophil CD11b                   
Interleukin 18           IL-18 
Interleukin-6            IL-6 
Interleukin-8             IL-8 
Interleukin-10             IL-10 
Kidney Injury Molecule – 1            KIM-1 
N-acetyl-β- D-glucosaminidase           NAG 
Matrix Metalloproteinase – 9           MMP-9 
Glutathione-S-transferase             GST 
!-GST                                   
α-GST   
γ-Glutamyl Transpeptidase              γ-GT 
Alkaline Phosphatase                  AP 
Lactate Dehydrogenase               LDH 
α-Microglobulin                     
Retinol Binding Protein     RBP 
β-2-Microglobulin   
MicroRNA – 210      miRNA-210 
Monocyte chemoattractant protein -1    MCP-1 
L type fatty acid binging protein  
 
L-FABP 
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2.4 Epidemiology of AKI 
 
The epidemiology of AKI remains difficult to ascertain from the literature 
48. The table 
in Appendix 6 contains a list of the observational studies carried out on AKI that were 
reviewed during this research. There are considerable differences in the definitions of 
AKI, the majority are from single centres or derived from databases, and the 
populations studied are diverse.  
 
A review of the data summarised in Appendix 6 indicates that AKI is more common in 
the elderly with an average age of 66 years in the studies reviewed. There is also a 
male predominance with an average of 63% in these cohorts.  
 
2.4.1 Incidence 
 
Marked differences are found in the incidences reported for similar populations 
depending on whether or not cases with baseline CKD were included. Few studies have 
calculated population based incidence rates so at best the incidence of AKI can be 
expressed in terms of crude risk or cumulative incidence. 
 
In studies using the RIFLE or AKIN definitions the incidences range between 3 and 18% 
and so interpreted together the overall incidence of AKI is probably somewhere in the 
region of 10% of hospitalised patients depending on the population studied with up to 
1% requiring renal replacement therapy. 
 
Appendix 7 contains summary tables of contemporary observational studies with AKI 
incidences for the overall general population including hospital and community 
acquired cases (Table A7.1), critical care (Table A7.2), and specific critical care groups 
(Table A7.3). The incidence in studies using coded data ranges from 0.7 to 3.1% and 
this is much less than that reported from studies using a formal definition of AKI 
42,224,230. Coded discharge summaries use ICD-9 codes and are known to have a poor 
sensitivity and so will under report the incidence of AKI 
15. Ali et al reported an 
incidence rate of 2147 per million population per year in northern Scotland using the 
RIFLE classification 
187. Bedford et al reported an annual incidence of 7007 per million 
population in the Kent region using the AKIN definition 
238. This marked difference 
between these incidence rates is due mainly to the inclusion of milder cases of AKI 
using the AKIN definition.   
 
Many studies have been undertaken applying the RIFLE or AKIN definitions in the 
critical care setting and relevant studies are summarised in Table A7.2 (Appendix 7). Mark Uniacke    Chapter 2     
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The incidence of AKI in critical care has a broad range between 10.8 and 67%. 
Averaging the available figures gives an incidence in the region of 40% with up to 30% 
of AKI cases requiring renal replacement therapy depending on the population studied. 
The broad range in incidence in the critical care setting can be accounted for by local 
admission policies but in addition the patient mix is likely to have a significant effect. 
Table A7.3 (Appendix 7) summarises contemporary studies where the incidences 
reflect specific patient groups within critical care. It can be seen that there is a broad 
range reflecting the underlying illness. Licker et al reported an incidence of just 6.8% 
in patients undergoing lung surgery while an incidence as high as 78% was reported by 
Lin et al in patients receiving extracorporeal membrane oxygenation (ECMO) 
211,234. 
 
Finally, there is evidence in the literature that the incidence of AKI is increasing. In 
2002 Nash et al conducted a single centre study of hospital acquired AKI in the US and 
reported an incidence of 7.2%. This study was carried out in 1996 and mirrored exactly 
a study carried out in the same hospital in 1979 that reported an incidence of 4.9% 
8,239. 
Xue et al reported on the incidence and mortality of AKI in Medicare beneficiaries in 
the US between 1992 and 2001 and found that the incidence rates were increasing by 
approximately 11% per year. They felt that the increase in admission for sepsis could 
partly account for this 
13. However, in addition to this, multiple new drugs have been 
introduced that can affect renal function, new surgical procedures have been 
introduced, and there has been a change in the pattern of use of radiographic contrast 
media as was demonstrated by Nash et al in their cohort 
8. It is not possible to assess 
the influence of changes in the age profile of patients in the study by Nash et al as this 
data was not provided in the original study conducted by Hou et al. In the study by Xue 
et al the increased incidence during the 1992 to 2001 period was confirmed after 
adjustment for age, gender and race 
13.  
 
2.4.2 Hospital compared to Community Acquired AKI 
 
In terms of epidemiology, some authors have divided AKI into community acquired 
AKI, hospital acquired AKI, and AKI occurring in critical care settings 
48,240. The division 
between community and hospital acquired AKI is an important distinction to make, as 
evidence exists that the causes and outcomes may differ 
107,110,206,241. In 2004 Sesso et al 
reported on a population of elderly patients with AKI and found that hospital acquired 
cases were more likely to be due to prerenal causes and have a significantly higher 
mortality 
110. However, very few studies have looked at these specific populations 
8,23,107,174,190,206. Community acquired AKI is usually defined as AKI that occurs in the 
community and is evident at the point of admission to hospital 
206. The key insult or 
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where the insults occur at some point during the hospital stay. Some studies 
purporting to be community based have in fact included hospital acquired cases in 
their final cohorts 
20,101. In the case of studies looking specifically at hospital acquired 
cases there have been differences in how this has been defined. Kwon et al defined 
hospital acquired AKI as that occurring during hospitalisation and excluded those 
presenting in the first 48 hours of admission 
190. Broce et al calculated hospital 
acquired cases from rises in creatinine from the nadir level in the first three days of 
hospitalisation 
23.  
 
There is evidence that community acquired cases are in the majority 
107,110,168. Obialo et 
al compared the incidences of the two in a population of African Americans and found 
community acquired cases were 3.5 times more common 
107. Pannu et al in a broader 
population based study reported that 60% of cases of AKI had achieved their highest 
serum creatinine within 48 hours of admission 
168. Finally, Murugan et al recently 
reported on non-severe community acquired pneumonia and found that two thirds of 
patients with AKI had already developed it at the time of hospital admission 
31. Overall, 
while there are clear differences between the two types of AKI in the literature it is 
difficult to clearly distinguish between the two from an epidemiological point of view. 
As can be seen in Appendix 6 the majority of hospital- based studies have included 
community cases. 
 
2.4.3 AKI around the world 
 
Appendix 6 also illustrates that the majority of AKI studies in the English speaking 
literature are from Europe or North America. South America, Asia, and Australasia are 
also represented but to a lesser extent. There is very little information available on AKI 
in Africa. The aetiology of AKI in Africa is considerably different from that in developed 
countries, infections such as Malaria and HIV, nephrotoxins, obstetric and surgical 
complications predominate. AKI appears to be a considerable burden on resources in 
African countries but little if anything is known about its epidemiology 
242.  
 
2.5 Causes, Risk Factors and pathophysiology of AKI 
 
AKI is a syndrome rather than a single disease entity and its aetiological pathway is 
complex. It can consist of an interaction between risk factors that make an individual 
susceptible to developing an AKI and the definitive insult that causes the AKI. Often 
more than one insult may occur in the same patient particularly in the elderly 
18,106,243,244. 
In some cases the distinction between being a susceptibility factor and a causative 
insult is unclear. For example, dehydration could be considered a risk or susceptibility Mark Uniacke    Chapter 2     
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factor in some settings whereas in others it may be the definitive cause if severe 
enough.  In this section those factors traditionally considered insults will be discussed 
under ‘causes of AKI’ while susceptibility factors will be discussed under the heading 
of ‘risk factors’. It should nonetheless be remembered that there is some overlap. The 
interaction between cause and risk is difficult to decipher from the literature because 
the risk factors for AKI are incompletely understood and very few studies have 
thoroughly explored the cause of AKI 
48,245,246. 
 
2.5.1 Causes of AKI 
 
The many causes of AKI are traditionally divided into Prerenal, Intrinsic and Postrenal 
causes. This is outlined in Appendix 8 
48,244.  Prerenal is defined as a functional decline 
in glomerular filtration associated with renal hypoperfusion. Renal hypoperfusion is 
generally described to occur in the context of a loss of effective circulating or arterial 
volume. Intrinsic refers to causes that lead to structural damage to the kidney that 
includes the many causes of acute nephritis. Postrenal refers to obstruction of urine 
outflow from the kidney and urinary tract and is sometimes simply called Obstructive 
renal failure 
244,247. It is important to note that while this division is useful during the 
initial assessment of patients with AKI there is often overlap between these divisions.  
 
It is not possible to precisely describe the contribution of the many causes of AKI listed 
in Appendix 8 to its epidemiology. There are a number of reasons for this. The first 
relates to the description and classification of the causes. For example, acute tubular 
necrosis figures prominently as a cause of AKI in most observational studies that 
report aetiology. It is generally classified as intrinsic but for the most part it is 
predominantly due to prolonged ischaemic injury and so represents the severe end of 
the prerenal spectrum. The problem with this diagnosis is that it is usually based on 
clinical grounds and so there is subjectivity in classification. The distinction often 
comes down to whether the AKI is volume responsive or not volume responsive 
20,226. 
However, this distinction between functional AKI due to prerenal causes and structural 
ATN is known to be difficult to make 
248. The methods used to describe them in the 
literature differ considerably. Some authors have preferred to retain the concept of 
‘Prerenal AKI’ while others have avoided it completely and used terms such as 
hypovolaemia, hypotension, ischaemic  or hypoxic 
44,186,247,249.  Coupled with this 
problem are other issues surrounding classification that have evolved in recent years. 
AKI associated with sepsis has traditionally been linked with reduced renal perfusion 
and so has been included in the prerenal causes. In more severe cases it has been 
classified as Septic ATN in some studies 
20,45. However, there is now evidence that the 
pathophysiological mechanisms involved in septic AKI are far more complex and there Mark Uniacke    Chapter 2     
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may even be increased renal perfusion in some cases. This has led some authors to 
separate sepsis as an aetiology 
248. Current literature is therefore confused and difficult 
to compare. Authors have attempted their own classification of aetiology that has lead 
to widely differing reporting 
8,44,106,108,186,190,208,226,235,236,250-252.  
 
A second reason for the difficulty in describing the cause of AKI is due to the small 
number of studies that have attempted to report on it in detail. In recent years 
observational studies on AKI have been dominated by retrospective reviews of hospital 
records and databases. While this approach offers large patient numbers the baseline 
clinical data are incomplete or even absent and therefore potential aetiological factors 
cannot be accurately described. Of 128 observational studies carried out between 
2000 and 2011 that were reviewed just 22 were prospective in nature. Only 13 of 
these studies attempted to describe the distribution of causes. The remaining studies 
either did not report aetiology or the focus was on a particular cause of AKI such as 
sepsis, the use of contrast or post-surgery. Therefore an overall picture of AKI 
aetiology could not be given 
25,117,216. The studies that did attempt to report aetiology 
came from diverse populations and no two of them used the same method for 
describing and reporting the aetiology as described above.  
 
Finally, the aetiology of AKI is probably multifactorial in many cases. Many of the 
causes outlined in Appendix 8 overlap with each other in the same patient making 
accurate description of aetiology very difficult. In the Madrid Acute Renal Failure Study 
Liano et al found that more than one aetiology could be attributed to the overall cause 
in 16% of patients 
20. In a study of elderly patients with AKI, Kohli et al found 31 
different combinations of causes in their cohort 
106. Metcalfe et al reported up to three 
insults in each patient in a cohort with AKI who required renal replacement therapy 
236. 
It is also likely that the definition of AKI used in these studies will have influenced the 
reporting of aetiology. For example, the AKIN definition will detect much milder cases 
of AKI and this may alter the reporting of aetiology.   
 
AKI aetiology is poorly described and understood. The syndrome of AKI is used as an 
umbrella term for a wide variety of overlapping causes and there is a lack of consensus 
on how these should be described. Appendix 9 contains a summary of thirteen 
prospective studies reviewed which attempted to describe the causes of AKI in various 
cohorts. It can be clearly seen that it would not be possible to cross tabulate these 
reports for comparison owing to the differences in classification and reporting.  
However, some deductions can be made from these data. Postrenal obstructive causes 
of AKI make up a very small proportion of AKI in all settings. In the intensive care 
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population it is likely to be somewhere in the region of 2-10% depending on the 
population studied. The distinction between prerenal and intrinsic causes are less clear 
but it can be deduced that the spectrum of prerenal failure due to reduced renal 
perfusion extending to ischaemic ATN makes up the large majority of cases of AKI. 
Using the figures provided in Appendix 9 it is likely to be around 85%. These overlap 
with other causes. Sepsis appears to contribute in over 50% of cases in all settings 
while medications, radiocontrast and post surgery are also important contributors. In 
the case of most of these contributors the pathophysiological mechanisms appear to 
be similar and related to renal ischaemia. However, their contribution will depend on 
the population studied. Kohli et al reported that medications contributed in 66% of 
cases in an elderly population while Nash et al found medications contributed in just 
16% of a general hospital population 
8,106. Primary intrinsic diseases such as acute 
glomerulonephritis and interstitial nephritis are very uncommon. Using the figures 
provided by Nash and Liano for general hospital populations they are likely to make up 
< 5% of cases 
8,20.   
 
There is also evidence that the aetiology of AKI has changed in the past 50 years. A 
publication by KG Lowe in the Lancet in 1952 illustrates the very different causes 
attributed to renal failure in that era. Figure 2.7 outlines the causes listed by Lowe for 
his series of 14 patients from the Hammersmith Hospital in London 
49. 36% of the cases 
are obstetric related while a further 29% are related to haemolytic transfusion 
reactions. With modern medical care the latter cause is now virtually unheard of. 
Turney et al conducted an extensive review of cases of AKI in Leeds between 1956 and 
1988. They found that obstetric causes made up 20-30% of cases between 1956 and 
1970 but by the 1980s this cause had become rare however it remained an important 
cause in the young. In addition, they found that the incidence of trauma related AKI 
had fallen from 11.3% in the 1960s to 2.8% in the 1980s. The authors attributed these 
findings to improved medical care. There was a marked increase in general medical 
cases of AKI which could be attributed to the aging population and increased use of 
medications toxic to the kidney together with more advanced medical and surgical 
procedures 
253. These have already been used to account for the rising incidence in AKI 
noted in the past decade. While the aetiology of AKI has changed in the western world 
as a result of improvements in medical management over the past fifty years some of 
the causes that were prominent in the 1950s remain a problem in the developing 
world. A recent publication from Pakistan by Ali et al reported that obstetric-related 
AKI continues to make up 9-11% of their AKI series 
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Figure 2.7  List of causes of AKI, more specifically ATN, by KG Lowe in the Lancet 
1952. The causes are described exactly as they were in the original article and 
demonstrate the different aetiologies in that era 
49.  
 
Case 
 
 
Age 
 
Cause of ATN 
1  38  Post abortion 
2  27  Post abortion 
3  24  Post abortion 
4  27  Post abortion 
5  38  Unexplained episode of intravascular haemolysis following 
delivery of anencephalic monster 
6  24  Haemolytic transfusion reaction 
7  42  Haemolytic transfusion reaction 
8  23  Haemolytic transfusion reaction 
9  41  Haemolytic transfusion reaction 
10  30  Anuria, following concealed accidental haemorrhage 
11  21  Mercury poisoning 
12  39  Posthaemorrhagic shock 
13  19  Posthaemorrhagic shock 
14  54  Myanesin poisoning 
  
 
2.5.2 Prerenal AKI and Acute Tubular Necrosis (ATN) 
 
2.5.2(i) Defining Prerenal AKI and ATN 
 
Prerenal AKI (also referred to as Prerenal azotemia) is classically defined as a decrease 
in GFR resulting from renal hypoperfusion, which is rapidly reversible when the 
underlying cause is corrected 
98. The body can adapt to reduced renal blood flow to a 
certain extent, but if the ischaemia is prolonged, adaptive mechanisms fail and cellular 
injury ensues 
247. This has been referred to as the stage of renal decompensation 
254. 
With established cellular injury the AKI is no longer rapidly reversible and at this point 
ATN is said to be present.  ATN describes the clinical situation in which there is 
adequate renal perfusion but GFR is not maintained 
48,255. Based on animal models the 
transition from Prerenal to ATN appears to be at least in part dependent on the 
duration of ischaemia, with increasing cellular damage seen with greater duration of 
hypoperfusion 
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practice and underscores the need to view Prerenal and ATN as part of the same 
continuum 
256,257.  
 
2.5.2(ii) Pathophysiology of Prerenal AKI and ATN 
 
Current understanding of the mechanisms involved in prerenal AKI and its evolution to 
ATN are largely based on animal models, chiefly the rat. Although widely quoted in the 
literature these pathological processes need to be interpreted with caution in the 
context of human AKI. Human AKI is poorly depicted by most animal models 
249. The 
rat kidney possesses fundamental differences to its human counterpart. It has a well-
developed medullary outer strip, which is not the case in humans, and in addition the 
vascular bundle in the inner strip is more complex 
255. Several rat models have been 
utilized in basic science research, particularly the warm ischaemia-reflow model, but 
none have any direct resemblance to the findings in human AKI. In the warm 
ischaemia-reflow model extensive tubular destruction is seen particularly in the 
proximal tubules. This is not the case in human AKI 
255. In fact, in human AKI, overt 
tissue injury is more focal and limited. It tends to be concentrated in distal medullary 
tubule segments and the inflammatory component is not prominent 
249. The limited 
nature of the damage seen histologically in human AKI is not accurately reflected in 
animal models and the term acute tubular necrosis is in some ways a misnomer. Part 
of the problem may be that in animal models hypoxic ischaemic damage is simulated 
by total cessation of blood flow to the kidney. However, in clinical practice most cases 
of ‘hypoxic’ AKI are characterized by compromised renal microcirculation and 
oxygenation that is related to systemic haemodynamic disturbance, sustained critical 
hypoxaemia, or to various nephrotoxins that cause renal dysfunction by disrupting 
oxygenation. The latter includes radiocontrast agents and NSAIDS. In these settings, in 
contrast to the animal models, renal blood flow never ceases completely, and oxygen 
consumption for residual tubular transport persists 
249. Despite their limitations, animal 
models have nevertheless provided some basis for understanding the processes 
involved 
255.  
 
In response to reduced effective circulating volume several neurohumural processes 
come into play in order to compensate for the disturbance. There is an increase in 
activity of the renin-angiotensin-aldosterone system. Angiotensin II increases both 
afferent and efferent arteriole vascular resistance through vasoconstriction and in the 
early stages this is concentrated on the efferent arteriole. This has the effect of 
increasing glomerular capillary pressure and so maintains GFR. In addition there is 
increased adrenergic activity which appears to have its effects through Angiotensin II 
and there is also increased release of Antidiuretic hormone 
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effects of Angiotensin II and adrenergic nerve stimulation are buffered by vasodilation 
promoted by Nitric Oxide and Prostaglandins 
254. All of these mechanisms serve to 
retain salt and water and maintain an effective circulating volume. In later stages 
Angiotensin II causes severe vasoconstriction of both the afferent and efferent 
arterioles. This leads to a reduction in nephron plasma flow and hence a reduction in 
GFR.  
 
Another mechanism which comes into play in the early stages of the prerenal injury is 
tubuloglomerular feedback. Reduced proximal tubular reabsorption owing to injury 
leads to an increase in the delivery of sodium chloride to the macula densa cells of the 
nephron which cause a feedback to increase afferent vasoconstriction and hence 
reduce GFR even further 
254. It is thought by some that the reduction in GFR that is seen 
in these early stages of AKI may actually be an adaptive response to protect the 
kidney. The renal medulla is known to operate at low oxygen tensions and is sensitive 
to reductions in oxygen supply. By reducing GFR the kidney reduces the demands on 
the medullary tubule cells for transport activity and hence their oxygen requirements 
249. This has led some to suggest that efforts to increase GFR in this setting may 
actually put the kidney at more risk 
249,257.  
 
It is clear from the description above that prerenal AKI does not involve a simple 
ischaemic injury. Nevertheless, the most widely accepted cause for the more advanced 
stages of renal damage in this setting involves the reduction of oxygen supply to cells 
which leads to a depletion of cellular ATP. ATP is vital for essential cellular processes 
258. The cells most susceptible to this process are tubular epithelial cells. They have a 
high oxygen and ATP demand in order to carry out transport functions and they 
operate in an environment with already low oxygen tension. In addition they are 
vulnerable to higher concentrations of toxic substances as these are transported into 
the urine 
259. Liberthal et al have demonstrated that the extent of ATP reduction 
determines the fate of the cells affected. With moderate reductions cells undergo 
apoptosis while with more severe reduction necrosis of cells occurs 
260. This difference 
in the outcome of cells may explain why in animal models where ischaemia tends to be 
more complete, necrosis predominates, whereas in human AKI necrosis is limited. 
Indeed, apoptosis is now considered to be one of the most important mechanisms in 
human AKI. Oxidative stress leads to the release of reactive oxygen species from 
mitochondria which can activate apoptotic pathways and also lead to direct cellular 
damage. In addition, renal tubular cells also express cell surface receptors of the 
tumor necrosis factor (TNF) superfamily that also induce apoptosis. This is part of the 
basis for the theory that removal of circulating cytokines such as TNF-α, particularly in 
the setting of sepsis, could preserve organ function. Apoptosis is known to promote Mark Uniacke    Chapter 2     
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fibrosis and this could account for some of the long-term sequelae of AKI including its 
possible progression to CKD 
258.In addition to the direct ischaemic damage described 
above, cell death leads to desquamation of cells into the tubular lumen where they can 
form casts and cause obstruction.  
In summary, the processes involved in prerenal AKI and ATN are complex and 
incompletely understood. They lead to epithelial and endothelial cell death, 
intratubular obstruction, changes in local blood flow and immunological responses. 
The relative contribution of each of these processes to the injury is unclear but may 
depend on the type and severity of the injury along with individual susceptibility 
258. 
Why some patients with prerenal AKI appear to reverse quickly and others do not and 
progress to ATN is an important question but at present the answer is unclear. It is 
likely to be at least partly due to the severity and the duration of the injury but in 
addition patients may possess predisposing factors. Intensified medullary hypoxia has 
been demonstrated in various settings that may increase the risk of cellular damage. 
These include patients taking NSAIDS, those after radiocontrast administration, in 
diabetes, and in those with CKD 
249.  
 
2.5.2(iii) Differentiating Prerenal AKI from ATN 
 
There is no universal definition of when Prerenal AKI should be considered to have 
progressed to ATN but it is generally considered to have occurred if the AKI does not 
reverse within 24 to 72 hours 
180,261. Distinguishing between reversible prerenal AKI and 
established ATN is important in clinical practice. Prerenal AKI is generally reversed 
using fluid resuscitation. However, in the setting of ATN when GFR is not maintained, 
continued fluid resuscitation can be detrimental and lead to fluid overload and 
potentially increased mortality 
262. Apart from the initial response to a volume 
challenge a number of additional methods have been explored in order to differentiate 
between prerenal and ATN. The fractional excretion of sodium (FeNa) has been shown 
at least in some settings to be useful. This is the percentage of sodium filtered by the 
kidney that is excreted in the urine 
263. In prerenal AKI sodium handling by the kidney 
is preserved, as opposed to ATN where it is impaired and associated with increased 
sodium losses in the urine. A fractional excretion of sodium < 1% has been shown to 
indicate the presence of prerenal AKI and hence the potential for reversibility 
263. 
However, the usefulness of FeNa is reduced in certain settings particularly in patients 
who have been administered diuretics, diabetics with glucosuria, advanced CKD, and in 
sepsis 
261,264. These have limited its use in clinical practice. Urine microscopy may also 
be a useful tool in determining the presence of ATN. As outlined above ATN is 
associated with the release of tubular cells and casts into the urine. A recent study by 
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renal tubular epithelial cells had a strong positive predictive value for a final diagnosis 
of ATN 
265. Finally, there is some evidence that the use of Doppler ultrasound may be 
useful in detecting the presence of ATN although this has little support in clinical 
practice and requires more investigation 
266,267. 
 
2.5.3 Septic AKI 
 
Sepsis is one of the most important contributing factors to AKI. It has traditionally 
been viewed that AKI in the setting of sepsis is due to impaired renal perfusion and is 
part of the prerenal/ATN spectrum. While some of the mechanisms of cellular injury 
discussed in relation to ischaemic AKI may take place in the setting of sepsis, the 
evidence base to support any firm conclusion about the processes involved is lacking. 
Bellomo et al have pointed out that the understanding of septic AKI is limited and that 
the knowledge of the pathophysiological mechanisms are based on animal models 
subjected to ischaemia or toxins and not to sepsis itself 
248,268. Evidence has been 
emerging that septic AKI may not fit the ischaemia model. Langenberg et al conducted 
experiments using female Merino sheep as animal models of septic AKI and found that 
at least in hyperdynamic sepsis there was marked renal vasodilation and a marked 
increase in renal blood flow 
269. This is contrary to what one would expect with the 
prerenal/ATN model. Indeed there is evidence from post-mortem studies that ATN may 
not be the pathological endpoint of septic AKI. Over 90% of one series of septic 
patients were found to have normal renal histology 
248. Another recent study by Benes 
et al using a porcine animal model demonstrated that in some animals there was an 
increase in renal vascular resistance associated with AKI. These were predominately 
animals with normodynamic haemodynamics and not the hyperdynamic circulation 
seen in Langenberg’s study. However, AKI was preceded by an early and marked 
inflammatory response with oxidative stress suggesting that more complex 
mechanisms may be in play 
270. In summary, septic AKI appears to share some of the 
pathophysiological mechanisms associated with ischaemic AKI however it is 
incompletely understood and inflammatory mechanisms may also play an important 
role. This supports the approach taken by some authors to separate sepsis as an 
individual cause of AKI. Nevertheless the reduced renal perfusion model should not be 
completely ignored in sepsis. Despite the findings that in some septic patients the 
renal blood flow is increased there is still strong evidence in the literature that early 
goal directed resuscitation of septic patients to restore haemodynamics reduces the 
risk of AKI 
195.   
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2.5.4 Risk factors for developing AKI 
 
There is a complex interaction between known insults and risk factors in the 
development of AKI. As is the case with the causes of AKI, the risk factors for AKI are 
also incompletely understood 
246. KDIGO have recently put forward the need for better 
delineation of risk for hospital- and community- acquired AKI as a research 
recommendation. KDIGO have referred to them as susceptibility factors and Figure 2.8 
lists these factors according to the 2012 KDIGO Clinical Practice Guideline for Acute 
Kidney Injury 
48.  
Figure 2.8 AKI Susceptibilities according to KDIGO 2012 
48. 
 
AKI Susceptibilities  
 
Dehydration or volume depletion   
Advanced age   
Female gender   
Black Race   
CKD   
Chronic Diseases  (heart, lung, liver)   
Diabetes Mellitus   
Cancer   
Anaemia   
  
AKI risk factors have not been extensively studied and few studies have conducted an 
adjusted analysis to thoroughly explore them. Many of the studies that have reviewed 
risk factors in any detail have been limited to specific populations such as cardiac 
surgery and therefore it is difficult to extrapolate their findings 
222,223. Appendix 10 
contains a summary of 14 studies from the past decade from various populations that 
conducted an analysis of the risk factors for AKI adjusted for potential confounders 
such as age, sex, and comorbidities. It is evident that increased age and the presence 
of baseline CKD are consistent risk factors in most of the populations studied. The 
presence of comorbid illnesses and in particular diabetes, hypertension and vascular 
disease are also important. There appears to be little to support including female sex 
as a susceptibility factor as KDIGO has done. Of the fourteen studies shown in table 
2.9 only four have found a sex association following adjusted analysis and three of 
these favoured male sex as a risk factor rather than female. In addition there is 
evidence from animal models that male hormones may exacerbate the effects of renal 
ischaemia/reperfusion injury 
272. With regard to CKD there is evidence that the 
association with AKI is a graded one. Hsu et al demonstrated that even with a baseline 
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        45 
of AKI and this risk then increased sharply for increasing severity of baseline kidney 
disease 
271. There is also recent evidence that those with albuminuria have an increased 
risk of AKI. This is likely to be linked to the risks associated with CKD 
30,231,273. A study 
by Grams et al demonstrated that an eGFR of 60mls/min had adjusted relative hazards 
for AKI nearly twice as high as those with eGFR 75mls/min. This is a stronger and 
earlier signal for an adverse outcome than that seen in studies of eGFR with death or 
cardiovascular disease 
274. 
 
2.5.5 AKI and the elderly 
 
Epidemiological studies show that AKI is more common in the elderly and that 
increasing age is an important risk factor for AKI. The reason for this strong link 
between age and the development of AKI is complex and not completely understood 
275. There are a number of likely overlapping factors that make elderly people 
vulnerable to developing an AKI. Firstly, there is a general loss of function with age. 
Secondly, there is impaired sodium and water handling which makes elderly people 
vulnerable to dehydration. Finally, there is an increased prevalence of comorbidities 
with age and these bring with them increased exposure to potentially nephrotoxic 
medications and procedures 
245. In addition to these factors, age-related changes in 
cardiovascular haemodynamics can lead to a reduction in cardiac output and hence 
renal perfusion 
276. Renal atherosclerosis is also likely to play a role.  
 
The loss of function that occurs with age has been known for decades and is illustrated 
in Figure 2.9. How much of this is actually due to senescence and how much of it is 
due to other factors such as accumulated vascular disease remains unclear. There is 
good evidence of specific age-related changes within the kidney. For example, in 
experimental animals collagen accumulates in the kidney with age and has been linked 
with increased gene transcription 
277. One of the hallmarks of the aging kidney is 
considered to be increasing glomerulosclerosis and as much as 30% of glomeruli have 
been found to be sclerosed in apparently healthy elderly patients. This compares to 
less than 10% that would be expected in those under 40 years of age 
278,279. However, 
the association between age and glomerulosclerosis is not clear-cut and Kasiske 
showed that atherosclerosis is also likely to play an important role 
280. Along similar 
lines, in 1950 Davies and Shock published a widely cited paper on the decline in GFR 
that occurs with age and this has become part of nephrology dogma. They reported a 
gradual reduction in GFR from the third decade onwards such that by the ninth decade 
the GFR has fallen by nearly 50%.  They were initially careful to exclude patients with 
hypertension, coronary artery disease and known renal disease. However, examination 
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categories had a history of atherosclerosis suggesting their results may have been 
confounded 
281,282. Facts such as these have led some to conclude that age-related 
glomerulosclerosis is indicative of subclinical renal injury from comorbid conditions 
leading to atherosclerosis and is not entirely due to increasing aging per se 
281.  
 
Figure 2. 9 GFR measured by inulin clearance plotted as a function of age in 164 
healthy individuals. Reprinted by permission from Macmillan Publishers Ltd:[Kidney 
International]
425,Copyright 2003. 
 
 
 
 
In addition to the fall in GFR with aging other factors have been recognised including a 
reduction in renal blood flow, increased glomerular basement membrane permeability 
and a reduction in renal mass 
276. There also appear to be changes in the activity 
and/or responsiveness to vasoactive mediators. There is an impaired ability to 
autoregulate renal blood flow and this can lead to a fall in GFR even when the 
magnitude of the acquired renal insult is relatively modest 
276,281. Elderly patients will 
also have increased sensitivity to medications that can affect renal blood flow such as 
NSAIDS and RAS-blockers 
244. The former inhibit the vasodilatory effects of 
prostaglandins while the latter inhibit angiotensin II mediated efferent arteriole 
vasoconstriction and so reduce glomerular capillary pressure and hence GFR. It is not 
uncommon that such medications are used together in the elderly and they may also 
be combined with diuretic use and so the effects are potentiated.  Finally, renal salt 
and water handling is altered with age. The elderly are characterised by a reduced 
ability to concentrate and dilute urine and so their ability to conserve and excrete 
sodium and water is diminished. This may be because of age related reductions in 
vasoactive mediators such as plasma renin and aldosterone. This increases their Mark Uniacke    Chapter 2     
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vulnerability to developing an AKI in situations where salt and fluid depletion occur 
and make them more prone to dehydration 
244,281. This is potentially exacerbated by the 
use of diuretics.   
 
 
2.6 AKI and Outcomes 
 
There are a number of measurable outcomes which may be relevant to AKI. These 
include short and long-term mortality, hospital length of stay as well as patient 
morbidity. In addition, the burden of AKI in terms of costs to healthcare systems has 
been estimated in a number of populations. More recently there has been interest in 
the long-term impact of AKI on kidney function and its relationship to the incidence 
and progression of CKD. The association with CKD is the focus of this thesis and will 
be discussed in more detail in Chapter 3. 
 
2.6.1 AKI and Mortality 
 
AKI is associated with a high mortality in hospitalised patients. However, it was 
traditionally perceived that the presence of AKI reflected the severity of the underlying 
illness rather than having a direct negative role itself. This led to the well-known 
nephrological idiom that patients ‘ die with AKI and not from AKI’. There is now 
substantial evidence in the literature that this is not the case and that AKI alone is an 
important negative prognostic factor 
26,240. 
 
2.6.1 (i) Hospital and Short-term mortality 
 
Observational studies have shown that AKI is associated with a significantly increased 
risk of hospital mortality. This is illustrated in Appendix 11, which summarises the 
mortality outcomes from contemporary studies carried out over the past decade that 
contained a control group without AKI. Most importantly this association remains 
significant even with adjustment for other factors known to increase mortality. As 
expected, mortality is highest in the intensive care setting. Table 2.1 lists 
observational studies carried out in the general intensive care setting using the RIFLE 
or AKIN definitions to define AKI. There is a broad mortality range from 13 – 56% but 
the average mortality is 33%. Two of these studies carried out a clear multivariate 
adjustment with factors such as age, gender, illness severity defined by the APACHE II 
score, and comorbidities. Even with adjustment AKI remained a potent predictor of 
hospital mortality maintaining a three to four fold increased odds of death 
136,139.  
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Table 2.1 Hospital or ITU mortality reported for general intensive care patients by 
contemporary studies using the RIFLE and AKIN definitions. Mortality is given for 
those with and without AKI. In the studies by Bagshaw and Lopes data was available for 
both definitions.  
 
Author (Year) 
 
 
AKI Definition 
 
Hospital/ ITU Mortality 
 
    AKI  No AKI 
Hoste (2006)  RIFLE  13.3%  5.5% 
Ostermann (2007)  RIFLE  36%  8.4% 
Ostermann (2008)  AKIN  40.4%  16.9% 
Cruz (2007)  RIFLE  36.3%  - 
Bagshaw (2008)  AKIN  24.5%  8.5% 
  RIFLE  24.2%  8.9% 
Lopes (2008)  AKIN  39.8%  8.5% 
  RIFLE  41.3%  11% 
Barrantes (2008)  AKIN  45.8%  16.4% 
Garzotto (2011)  RIFLE  28.8%  8.1% 
Clec’h (2011)  RIFLE  27.6%  8.7% 
Mandelbaum (2011)  AKIN  16%  6.7% 
Fonseca (2011)  AKIN  32.1%  7.3% 
 
 
It is likely that the ITU case-mix and local intensive care policies account for the broad 
range in reported mortalities. Appendix 11shows that the cohort studied and 
underlying severity of illness can have an important impact on mortality. For example, 
studies that have reported specifically on those with septic AKI in critical care have 
reported mortalities in a range closer to 50 – 70% 
25,119,195,218. Koreny et al reported a 
mortality of 87% in a cohort with cardiogenic shock while Li et al reported a mortality 
of 67% with pancreatitis 
109,217.   
 
When the general hospital population has been studied the mortality is in the region of 
15% but again there is a broad range in the literature depending on the population 
studied 
22-24. Murugan et al reported on a cohort with pneumonia and found mortality to 
be 11% which is significantly higher than the 1.3% found in those without AKI 
31. On the 
other hand, in a cohort that had general surgery the mortality was much higher with 
AKI at 26.4% compared to 2.5% in controls 
154.  
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2.6.1 (ii) Factors influencing mortality 
 
Numerous factors have been shown to influence mortality 
26. Figure 2.10 lists the 
factors that may influence the hospital mortality outcomes associated with AKI.  
 
AKI severity 
 
The severity of the underlying AKI has been shown to be directly linked to hospital 
mortality. For example, in the general intensive care setting Cruz et al found a graded 
increased risk of mortality with worsening RIFLE class. Using the Risk group as a 
reference the adjusted odds ratio for the Injury class was 2.2 and this increased to 4.9 
for the Failure class 
186. These findings have also been reported in general hospital 
admissions. Uchino et al reported on the incidence and outcomes of AKI occurring in 
all admissions to an urban academic hospital in which only 14.7% were admitted to 
intensive care. They found that all RIFLE classes were significant predicators of hospital 
mortality with a steady increase with RIFLE class. After adjustment, the odds ratio for 
hospital death was 2.9 for the Risk class, 6.8 for Injury, and 8.0 for Failure 
183. The 
studies mentioned have all based severity of AKI on increasing stage according to the 
rise in serum creatinine. An increased mortality has also been found when severity has 
been expressed in terms of urine output. Oliguria has traditionally been seen as a 
marker of AKI severity and studies have demonstrated that mortality is higher in those 
who have oliguria during the AKI episode compared to those who do not 
2,228,284,285.  
 
AKI Duration 
 
AKI duration has been shown to influence outcomes in a variety of populations 
22,160,162,163. In a 2010 study involving post-operative AKI in diabetic veterans Coca et al 
found that for each AKI stage, longer duration of AKI was significantly associated with 
a graded higher rate of mortality. They found that the mortality rate for those with 
severe AKI (AKIN Stage 3) but of short duration (< 2 days) was nearly 50% lower than 
the mortality associated with mild AKI (Stage 1) but of longer duration. They 
postulated that duration may discriminate between patients with ‘prerenal’ AKI without 
true injury and those with true ‘intrinsic’ renal damage 
163. This may well be the case 
but there is also good evidence that even mild transient AKI is associated with worse 
outcomes than no AKI 
180.  
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The presence of pre-existing CKD 
 
Pre-existing CKD also appears to modulate the outcomes of AKI. Studies have reported 
a lower mortality in patients who have pre-existing CKD 
42,43,119,121,168,228. For example, in a 
cohort of patients from the intensive care setting Khosla et al found that patients with 
pre-existing CKD had a mortality 9% lower than those without a history of CKD despite 
being older and having more comorbidities 
121. Numerous reasons have been 
suggested to explain this phenomenon. Khosla et al postulated that the process of 
care may be different in patients with CKD and indeed demonstrated that these 
patients received earlier nephrology referral. This may have resulted in better 
management 
121.  Ali et al also reported earlier referral in a Scottish general hospital 
cohort and in addition they found that patients with CKD were more likely to have 
renal imaging performed 
187. Another reason that could explain better hospital 
outcomes in patients with CKD is that they may require a lesser burden of acute illness 
in order to reach the same level of AKI. Two studies that reported better outcomes in 
CKD patients found that the phenomenon disappeared when adjustment was made for 
severity of the acute illness 
119,286. Finally, the effect of small rises in creatinine of 
0.3mg/dl used in the AKIN definition on patients with lower levels of GFR remains 
unclear 
48. It is possible that different thresholds are needed to accurately define AKI at 
these levels and this may also partly explain the lower mortality in the CKD group in 
some studies. Some evidence to support this theory has been provided by Broce et al 
who conducted an analysis of nadir to peak serum creatinine increments and stratified 
them for baseline eGFR. In their fully adjusted model they found that the odds ratio for 
inhospital mortality became significant with a creatinine increment of just 0.2mg/dl in 
those with a baseline eGFR ! 60mls/min. On the other hand, the odds ratio for 
mortality did not become significant in those with an eGFR < 30mls/min until an 
increment in creatinine of 0.5mg/dl was reached 
23.  
 
Hospital-acquired AKI 
 
Several studies have demonstrated that the mortality is higher in patients who develop 
their AKI in hospital 
107,110,206,241. Sesso et al reported mortality rate of 59% in a cohort of 
elderly patients with hospital –acquired AKI compared to 41% in the community- 
acquired group 
110. This is likely to be related to the underlying illness severity and type 
of AKI. At present there has been little work conducted on this area of AKI 
48.  
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Cause of AKI 
 
Several studies have shown that the outcomes for AKI are worse when the cause is due 
to sepsis 
103,227. In the intensive care setting Bagshaw et al demonstrated that septic AKI 
had a significantly higher crude ITU and hospital mortality compared to non-septic AKI 
(19.8% v 13.4%). With adjustment for covariates the odds of death remained marginally 
higher in the septic group with an odds ratio of 1.54 compared to 1.43 
227. Overall 
however, there has been little work done on the influence of the underlying cause on 
mortality outcomes. This is partly due to the fact that the majority of recent studies in 
AKI have been retrospective and have lacked the clinical data needed to classify the 
episodes by cause.  
 
General management 
 
In terms of AKI management it has already been alluded to that early nephrology 
referral in hospital may improve outcomes. In addition there is evidence that the basic 
clinical management of the AKI is important. Grams et al used data from the FACTT 
trial which looked at conservative versus liberal fluid management in patients with 
acute lung injury. They demonstrated that post-AKI fluid balance was significantly 
associated with mortality in both crude and adjusted analysis 
287.  
 
Figure 2.10 Factors that may influence the mortality associated with AKI. 
 
Influencing Factor 
 
 
Effect on AKI mortality 
AKI severity  Graded increase in mortality 
Duration of AKI  Graded increase in mortality 
Underlying CKD  Associated with reduced mortality 
Setting  Hospital acquired AKI associated with 
increased mortality 
Cause of AKI  Sepsis associated with increased mortality 
General AKI management  Accumulated positive fluid balance 
associated with increased mortality 
 
2.6.1 (iii) Long-term mortality following recovery from AKI 
 
The mortality associated with AKI is not confined to the hospital setting. Few studies 
have reported long-term outcomes after AKI (see Appendix 11). However, there is 
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that this is also consistent across every clinical setting 
26. Ishani et al studied the 
outcomes of 29388 individuals who underwent cardiac surgery and followed them for 
just over five years. They found a graded increased mortality according to the severity 
of AKI after three months with an adjusted hazard ratio for death at three months of 
5.0 in the group with a rise in creatinine > 100% from baseline. This increased 
mortality risk attenuated over time but remained elevated after five years 
127. Similar 
results are found in studies that included outcomes in a general hospital population. 
For example, La France et al presented data on over two years of follow up of patients 
from the US Veterans Affairs database who were alive 90 days after discharge. The 
mortality in those who had sustained an AKI was 29.8% while in those without an AKI it 
was 16.1% during the follow up period. In a Cox Proportional Hazards model adjusted 
for age, sex, race, comorbidities, medication use, and post-discharge eGFR categories 
the hazard ratio for all-cause mortality in those with AKI was 1.41 
9. While these 
findings do not imply causality, studies that have performed multivariate analysis have 
shown that the strength of association between AKI and mortality is similar to or 
greater than other established risk factors such as diabetes, peripheral vascular 
disease, and chronic obstructive lung disease 
26.  
 
2.6.1 (iv) Trends in mortality from AKI 
 
There is evidence in the literature from several different populations that despite a 
rising incidence of AKI the mortality appears to be falling 
13,14,16,17. In the United States, 
Xue et al studied the outcomes of AKI using a 5% Sample of Medicare Beneficiaries. AKI 
was defined by ICD -9 codes. Between 1992 and 2001 there was a declining trend in 
mortality at 90 days after discharge despite the incidence rising by 11% per year. The 
authors felt that this reflected improvements in hospital care 
13. Similarly, using the 
ANZIC ITU database in Australia and New Zealand, Bagshaw et al found that the 
adjusted odds ratio for mortality associated with AKI fell from 1.54 to 1.33 between 
1996 and 2005. The authors were unsure of what could account for this decline. It may 
be due to an improvement in the overall care of ITU patients or by specific 
interventions or therapies such as improved renal replacement therapy 
16. Finally, 
Swaminathan et al used the US National Inpatient Sample Database to study the 
outcomes of patients that underwent coronary bypass surgery between 1988 and 
2003. Despite an increase in comorbid disease burden in this cohort mortality in the 
AKI group fell from 39.5% to 17.9%. They attributed this to improved care 
17.   
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2.6.2 AKI is a major healthcare burden 
 
Appendix 6 demonstrates that AKI is associated with a significantly prolonged length 
of stay in hospital. This is evident in every clinical setting. In the general hospital 
setting this can be anywhere from 3 to 9 days 
22,31,32. Few studies have analysed this 
phenomenon in depth, but in those that have, AKI remains a potent risk factor for 
prolonged length of stay even with adjustment for age and comorbidities 
23,24,32,136. 
Length of stay appears to be influenced by the severity of the AKI episode. Chertow et 
al demonstrated that larger increases in creatinine in a US Medicare population were 
associated with longer relative increases in hospital length of stay 
32. The reasons for 
this increased length of stay are unclear from the literature but it is reasonable to 
propose that it is related to illness severity. It may also be related to the fact that in 
clinical practice patients who demonstrate a rise in serum creatinine are often retained 
in hospital for monitoring until the creatinine settles.  
 
Studies have demonstrated that AKI is associated with an increased risk of discharge to 
extended care facilities 
17,22-23,224,227. For example, in their study on non-critically ill 
hospitalised patients with AKI, Barrantes et al found that AKI was associated with an 
odds ratio of 3.0 of discharge to an extended care facility after adjustment for age, 
sex, race and comorbidities. In this study 43.1% of AKI patients were discharged to 
care as opposed to 20.3% in the control group 
24. Similarly, in another cohort of 
hospitalised patients, Liangos et al found a two fold higher adjusted odds of discharge 
to a care facility 
224. Swaminathan et al showed similar results after cardiac surgery 
however, they also demonstrated a significant increase in baseline comorbidities 
suggesting that the underlying level of frailty may be playing an important role in 
these findings 
17.  
 
There is emerging evidence that patients who survive their episode of AKI are at an 
increased risk of readmission to hospital. There are several recent studies in the 
literature illustrating this 
30,34,288-290. Allaudeen et al conducted a retrospective study to 
identify factors associated with readmission within 30 days for general medical 
patients. After multivariate analysis an episode of AKI was independently associated 
with readmission 
290. There also appears to be a graded association between 
readmission and the severity of the AKI at least in some cases 
34. Grams et al reported 
on the outcomes of a large cohort of patients taking part in the Atherosclerosis Risk in 
Communities Study. They found that patients with an AKI hospitalisation at any point 
during the follow up period had more hospitalisations for any cause (6.0 
hospitalisations over 7 years) than there counterparts without an AKI hospitalisation 
(1.3 hospitalisations over 8 years) 
30. Mark Uniacke    Chapter 2     
        54 
Finally, very few studies have addressed the issue of quality of life after AKI however 
there is some suggestion that this too may be adversely affected 
252,291,292. Johansen et al 
recently reported on the health utility of 60-day survivors of severe AKI involved in the 
Acute Renal Failure Trial Network Study. This study enrolled adults in critical care units 
who had AKI attributable to acute tubular necrosis plus sepsis or additional organ 
failure. They used the Health Utilities Index Mark 3 to derive an overall health related 
quality of life score in 60- day survivors of AKI who had required RRT in the ITU. 27% of 
respondents at 60 days had health states that would be considered by the general 
population to be equivalent to or worse than death 
291. Another recent ITU based study 
by van Berendoncks et al used the SF-36 score to assess quality of life in AKI survivors 
at a mean of 20.3 months after hospital discharge. The SF-36 is a generic measure of 
health status with a physical component summary and a mental component summary. 
They found that the physical component health-related quality of life of the SF-36 score 
in the AKI survivors was lower compared to age-matched general populations. On the 
other hand, the mental health-related quality of life was found to be the same as in the 
general population 
252. These findings need to be interpreted with caution. The reduced 
physical component may reflect a greater severity of illness or burden of comorbid 
disease rather than the AKI itself. 
 
In summary, in addition to increased short and long-term mortality, AKI is associated 
with prolonged hospital stay, a tendency for multiple readmissions to hospital in the 
long-term, an increased risk of needing extended care after hospital discharge, and 
possibly a reduced quality of life. This is a considerable burden to the healthcare 
system if the estimated incidence of AKI in the general hospital population is between 
10 and 20%. As a result, several studies have reviewed the costs of AKI over the past 
decade 
32,293,294. In 2005 Chertow et al reviewed the impact of AKI in a US hospital 
population. As expected there was an increased cost associated with AKI episodes and 
in multivariate analysis these costs were found to increase in accordance with the 
severity of the AKI. They estimated for their own hospital that AKI was consuming 
roughly 5% of the overall hospital budget and offered a conservative estimate that AKI 
was costing the United States healthcare system more than $10 billion annually 
32. NHS 
Kidney care recently offered estimates for the NHS. They estimated that the total yearly 
cost of AKI (including acute admissions, critical care, and renal replacement therapy) 
was up to £620 million annually based on 2009-2010 budget figures. This is more 
than the cost of lung cancer and skin cancer combined 
295. 
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2.6.3 The pathological mechanisms underlying AKI Outcomes 
 
AKI remains a highly complex syndrome and association does not necessarily imply 
causality despite the efforts of researchers to adjust for established risk factors. As a 
result there has been a surge of work over the past decade in both humans and 
experimental animals that has provided good evidence that the pathophysiology of AKI 
may be having direct independent effects on outcomes. AKI is associated with 
numerous pathophysiological consequences and these are illustrated in Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some of the consequences of AKI such as fluid and electrolyte imbalances can have 
obvious direct clinical effects while others such as systemic inflammation and uraemic 
toxins have a more subtle influence through distant organ dysfunction. Some authors 
Acute Kidney Injury 
 
Fluid Overload 
Acidosis 
Electrolyte Imbalance 
Uraemia 
Systemic Inflammation 
Inadequate Nutrition 
Drug Dosing 
 
Systemic and distant organ 
effects 
‘Organ Cross Talk’ 
Figure 2.11  Consequences of AKI that may account for systemic and distant 
organ effects leading to adverse outcomes. 
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refer to the effects of AKI on distant organs as distant ‘organ cross talk’ or ‘multiorgan 
cross talk’ 
29,247,296. Changes have been described in virtually every organ system as a 
result of the uraemic milleu seen in AKI 
297.  
 
2.6.3 (i) Fluid overload 
  
Intravenous fluid resuscitation is one of the mainstays of treatment of AKI particularly 
those with oliguria. Patients with AKI will have reduced free water clearance and this 
combined with aggressive fluid resuscitation can lead to accumulation of fluid 
29. 
Bouchard et al reviewed the outcomes associated with fluid overload in 618 patients in 
critical care with AKI. They demonstrated that fluid accumulation resulting in a positive 
fluid balance is a frequent event in critically ill patients with AKI. Moreover, they 
showed that fluid-overloaded patients had a significantly higher mortality and the 
effects of this were maintained over 60 days. The association between fluid overload 
and mortality was highly significant even after adjustment for severity of illness and 
the need for dialysis. They also found that cumulative fluid overload may be associated 
with decreased likelihood of renal recovery 
262. Fluid overload can result in a broad 
range of complications that could account for increased morbidity and mortality. These 
include the development of tissue oedema, ascites and intra-abdominal hypertension, 
pleural effusion and pulmonary oedema 
29.  
 
2.6.3 (ii)  Acidosis 
 
Metabolic acidosis frequently occurs in the setting of AKI particularly in more severe 
cases. Acute acidosis is known to affect a number of organ systems and in particular 
the cardiovascular system where reductions in cardiac output and contractility can be 
seen 
298. In addition, acidosis has been found to increase nitric oxide production that 
leads to vasodilation and so may contribute to haemodynamic instability in critically ill 
patients 
299,300. Acidosis also appears to have important effects on immune function and 
contributes to increased inflammation and an impaired immune response although the 
processes involved are poorly understood at present 
298,300.  
 
2.6.3 (iii) Uraemic Toxins 
 
A consequence of renal failure is the inability of the kidneys to excrete metabolic 
waste products that can then accumulate as uraemic retention solutes. There are 
currently well over 100 uraemic retention solutes recognised and some are known to 
have an adverse biologic impact. For example, guanidine compounds are small water-Mark Uniacke    Chapter 2     
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soluble solutes that have been implicated in neurotoxicity, inhibition of inducible nitric 
oxide synthase and stimulation of leukocytes 
301.  
 
Until recently, interest in uraemic toxins has primarily involved their link to the adverse 
effects of CKD particularly their cardiovascular effects. However, there is now growing 
interest in the impact of uraemic toxins in AKI 
302. Uraemic toxins are known to play a 
role in blunting immune responses and endothelial cell dysfunction and it is likely that 
they play a role in the systemic effects of AKI as well. Rabb et al demonstrated in 
animal models of ischaemia/reperfusion injury that AKI is associated with 
downregulation of pulmonary epithelial sodium channels, Na,K-ATPase and aquaporin 
5. These features were seen in animals after bilateral nephrectomy and not after 
unilateral nephrectomy. This led the authors to conclude that they must result from 
systemic effects mediated by uraemic toxins 
303.  
 
2.6.3 (iv) Inflammation  
 
AKI is associated with a profound inflammatory reaction in the kidneys and systemic 
circulation 
29. Several authors have demonstrated marked derangement of elements of 
immune and inflammatory responses that may be having a direct effect on distant 
organ function. Much of this work has been carried out in animal models. Kelly et al 
demonstrated increased levels of TNF-α, interleukin-1 and intercellular adhesion 
molecule-1 mRNA in heart tissue after renal ischaemia. After 48 hours, functional 
changes in the heart included increased left ventricular end diastolic diameter, 
increased left ventricular end systolic diameter, and decreased fractional shortening 
leading the authors to conclude that these effects may be important in the morbidity 
and mortality observed clinically 
304. To complement these findings there is some 
evidence from human studies that cardiovascular outcomes are worse long-term in 
patients with AKI 
26.  
 
The interaction between the lungs and the kidney in the setting of AKI has attracted 
interest because of its implications in critical care. Kramer et al demonstrated that 
there was an increase in macrophage- mediated pulmonary vascular permeability in the 
setting of renal ischaemia 
305. Klein et al demonstrated that features of lung injury seen 
in AKI such as pulmonary oedema, increased capillary leak and leukocyte infiltration 
are reduced in animals deficient in interlukin- 6 
306. Interleukin-6 levels have been 
shown to be elevated significantly in patients with AKI and can predict mortality 
307.  In 
addition interleukin-10 has also been implicated in mediating systemic inflammation 
and lung changes in the setting of renal ischaemia 
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showed that patients with AKI who developed severe sepsis with pneumonia had 
higher concentrations of interleukin-6, 10, and TNF-α at presentation 
31.  
 
2.6.3 (v) Nutritional imbalance 
 
AKI is associated with a hypercatabolic state and it interferes with the metabolism of 
macronutrients 
309. This is thought to contribute to the nutritional depletion of ill 
patients particularly those in critical care. However, very little work has been done on 
this area to date. In addition to the hypercatabolic state, patients with AKI receiving 
renal replacement therapy will have additional losses of amino acids and proteins in 
the dialysate together with water soluble vitamins such as vitamin C, thiamine, and 
folic acid 
29.  
 
2.6.3 (vi) Deranged drug handling 
 
Alterations in drug metabolism in AKI are complex and are currently poorly 
understood. This is largely due to the fact that there is no mandate to conduct 
pharmacokinetic studies in AKI prior to drug approval 
310. It is quite likely that drug 
metabolism is significantly altered in AKI and this may have a number of knock on 
effects through underdosing or overdosing particular drugs. This may be particularly 
important in the case of antimicrobials in the setting of acute illness and sepsis 
29.  
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Chapter 3: AKI and its relationship to CKD 
 
3.1 Introduction 
 
Chronic kidney disease (CKD) denotes persistent structural or functional damage to the 
kidneys. Like AKI, it results from a heterogeneous group of disorders that affect the 
kidneys and the variation in its expression is related to its different causes and 
pathology, severity, and rate of progression 
311. In the past decade CKD has come to 
the forefront as a major public health problem and is an important cause of death in 
the industrialized world 
312. CKD is a chronic non-communicable disease. It epitomizes 
the epidemiological shift to the “age of degenerative and man-made diseases” 
described by Omran that developed countries and increasingly developing countries 
are now facing 
313. 
 
The evolution in our understanding of AKI has paralleled the growing importance of 
CKD. This is not by coincidence as the two are inherently linked. As discussed in 
Chapter 2, CKD renders people susceptible to sustaining an AKI and up to one third of 
hospitalized patients with AKI have a history of CKD. In addition, there has been 
considerable interest in the bidirectional association between AKI and CKD. On the one 
hand CKD confers a risk of developing an AKI: on the other, AKI appears to be 
associated with causing incident CKD and may augment its progression. This chapter 
will explore the current evidence base relating to this issue. 
 
3.2 Defining and staging CKD 
 
In 2002 KDOQI (Kidney Disease Outcomes Quality Initiative), which was established by 
the US National Kidney Foundation, released a proposal for the definition and staging 
of CKD. This was later endorsed by an international review board representing KDIGO 
(Kidney Disease Improving Global Outcomes) in 2004 
314,315. This definition was based 
on estimated GFR and the presence or absence of other evidence of kidney damage for 
three months or more. This time frame was arbitrarily included on the assumption that 
most acute kidney injury has resolved by three months. The rationale behind formally 
defining and staging CKD was to facilitate its earlier recognition and management 
314.  
 
In the UK the National Institute for Health and Clinical Excellence (NICE) published CKD 
guidelines in 2008 
74. The five stages of GFR were modified slightly by splitting Stage 3 
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that the adverse outcomes from CKD increased at levels of GFR below 45mls/min. The 
staging system with the NICE modification is illustrated in Figure 3.1.   
 
Figure 3.1  Stages of Chronic Kidney Disease (NICE 2008 
74) 
 
Stage 
 
 
GFR 
(ml/min/1.73m
2) 
 
Description 
1  !90  Normal or increased GFR, 
with other evidence of 
kidney damage 
 
2  60-89  Slight decrease in GFR, with 
other evidence of kidney 
damage 
 
3A 
3B 
45-59 
30-44 
Moderate decrease in GFR, 
with or without other 
evidence of  kidney damage 
 
4  15-29  Severe decrease in GFR, with 
or without other evidence of 
kidney damage 
 
5 
 
<15  Established renal failure 
 
 
The definition and staging system introduced by KDOQI has led to a major shift in the 
focus of kidney disease management. End stage kidney failure and its treatment with 
renal replacement therapy had for decades been the defining role of nephrology. 
Recognition of the earlier stages of CKD has changed the emphasis to one of 
prevention and early recognition 
312,316.  
 
3.3 The epidemiology of CKD 
 
The 2010 Health Survey of England reported the overall prevalence of moderate to 
severe CKD (Stages 3-5) as 6% using the abbreviated MDRD equation to estimate GFR. 
It was higher in women and it increased with age in both sexes from 1-2% in those 
aged 16-44 to over 30% in those aged over 75 
6. Prevalence estimates have also been Mark Uniacke    Chapter 3     
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reported in other countries although they cannot be directly compared to the HSE data 
because of differences in methodology and reporting. The US NHANES IV data reported 
an overall prevalence for CKD stages 1- 4 of 13.1% for the period 1999 – 2004. 
NHANES III had reported a prevalence of 10% for the period 1988-1994 and the 
increase in prevalence between the two periods had been attributed in part to the 
increasing prevalence of diabetes, hypertension and obesity. Data on CKD stage 5 was 
excluded from NHANES but assuming this is small for comparison with the HSE data, 
the prevalence of stages 3-4 were 8% 
7. It should be noted however that NHANES IV 
used the abbreviated MDRD equation to estimate GFR and when this is replaced by the 
CKD-EPI equation it results in a reduction in prevalence from 13.1% to 11.5% overall 
94. 
The MDRD equation will tend to place more individuals in CKD Stage 3 owing to 
underestimating higher levels of GFR and this influence can be seen in Figure 3.2. The 
revised prevalence figure of 11.5% is now being quoted for the US population 
311. 
Chadban et al reported the prevalence of either proteinuria, haematuria, and/or 
reduced GFR in the Australian population as 16%. This study used the Cockcroft and 
Gault equation to estimate GFR which may be overestimating the prevalence 
317.  
 
The rise in the prevalence of CKD recognized in the USA was one of the driving forces 
behind implementing formal recognition and preventive strategies for CKD 
315. There is 
no historical HSE data with which to compare however some indication of the 
prevalence of CKD over time in the UK can be obtained from QOF data. The Quality and 
Outcomes Framework (QOF) has been in existence since 2004 with data submitted on 
a yearly basis from primary care. The 2010/11 QOF data revealed a national 
prevalence of registered CKD stages 3-5 in persons over 18 of 4.3% . This is compared 
to a prevalence of 4.1% in 2008/2009 
318. 
 
Figure 3. 2 Cumulative eGFR distribution curves of NHANES participants from 
2001-2008 by method used to estimate GFR (USRDS 2011 
319). 
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3.4 Aetiology and Outcomes of CKD 
 
The aetiology of CKD is complex and poorly characterized in the literature. It is clear 
that certain uncommon conditions such as rapidly progressive glomerulonephritis can 
cause chronic irreversible damage. However, it usually develops in an insidious fashion 
in susceptible individuals and is associated with conditions that overlap as risk factors 
and true causes 
311. For example, hypertension is often perceived as a cause but it is 
also a secondary consequence of CKD and a known risk factor for disease progression. 
In many cases the cause of CKD is unknown. The primary method for making a 
definitive diagnosis of the cause is a renal biopsy. However this is not carried out in 
the majority of cases as it is an invasive procedure that generally does not alter clinical 
management. Consequently there is no clear delineation of the causes of CKD in the 
general population. However, the diversity and indeed the uncertainty can be found in 
those presenting for renal replacement therapy. Figure 3.3 lists causes attributed to 
the population starting RRT in the UK from the 2009 cohort described by the UK Renal 
Registry 
320. It can be seen that diabetic nephropathy figures prominently in all age 
groups but in the elderly over the age of 65 renal vascular disease becomes more 
prominent. However, in more than a quarter of patients there is no known cause.  
In the developed world, CKD is generally associated with old age, diabetes, 
hypertension, and cardiovascular disease 
311. It is now recognized as a part of the 
metabolic syndrome milieu 
321. The nephropathy associated with diabetes mellitus is 
well characterized however in the others the process appears to involve progressive 
age related vascular pathology but is incompletely understood 
322-324.  The end result in 
all cases is replacement of renal tissue with extracellular matrix, culminating in organ 
fibrosis 
325. Mark Uniacke    Chapter 3     
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Figure 3. 3  Percentage distribution of primary renal disease diagnosis by age in 
the 2009 UK Renal Registry cohort starting RRT 
320. 
 
Diagnosis 
 
 
Age < 65 
 
Age > 65 
 
All Patients 
Diabetes  27.3  23.2  25.3 
Glomerulonephritis  16.0  6.9  11.5 
Pyelonephritis  7.1  7.6  7.3 
Hypertension  6.0  7.9  6.9 
Polycystic kidney 
disease 
 
10.2 
 
3.1 
 
6.7 
Renal Vascular 
Disease 
 
2.0 
 
10.4 
 
6.1 
Other  16.5  14.4  15.5 
Uncertain Aetiology  15.0  26.6  20.7 
  
The importance of CKD from a public health viewpoint lies in its outcomes. The first is 
progression over time to end stage renal disease which requires substantial input from 
health services in both renal replacement therapy and end of life care. The second 
important outcome of CKD is cardiovascular disease. This contributes to considerable 
morbidity and mortality in the general population. 
 
Figure 3.4 illustrates the outcomes associated with CKD. End stage renal disease is 
important from a patient and healthcare point of view however only a very small 
proportion of those with CKD will ever reach this stage. Drey et al performed a 
retrospective cohort study of all new cases of CKD from the Southampton and South-
West Hampshire Health Authority and found an annual incidence of 1701 per million 
population but only 4% were accepted to renal replacement therapy during 5.5 years of 
follow up. In this study CKD was defined as a persistently elevated serum creatinine 
above 150μmol/l and so would have underestimated the incidence of CKD stage 3 
particularly in the elderly population. Therefore in today’s currency the proportion 
reaching ESRD would be even smaller 
326. In a large US cohort, Keith et al found that 
just 1.1% and 1.3% of CKD stages 2 and 3 progressed to requiring renal replacement 
therapy during a similar follow up period. The majority of patients appear either to 
remain stable over time or at least progress very slowly and die from another cause - 
particularly cardiovascular disease 
327-329. The risk of progressing to ESRD has been 
shown to increase exponentially at lower levels of eGFR. In addition, higher levels of 
albuminuria have been shown to independently increase the risk of progression to 
ESRD 
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There is evidence that cardiovascular disease is a leading causes of mortality in those 
with CKD and this mortality risk increases with lower levels of GFR 
4,326,327. In a large US 
cohort, Go et al found that the adjusted hazard ratio for cardiovascular events 
increased inversely with the estimated GFR from 1.4 for an eGFR of 45 to 59 mls/min 
to 3.4 for an eGFR of < 15mls/min 
4. CKD is now recognized as an independent risk 
factor for cardiovascular events 
5,312. Impaired kidney function and uraemia are 
associated with many physiological abnormalities that can account for this. Alterations 
of mineral metabolism and expression of mineral regulating proteins have been linked 
with increased arterial calcification. This is responsible for stiffening of the arteries 
leading to increased left ventricular afterload and hypertrophy as well as abnormal 
coronary perfusion 
331,332. CKD has also been independently linked to increased 
inflammatory and procoagulant biomarkers which may be important mediators in the 
overall process 
333. More recently the role of renal insufficiency in modulating the 
activity of macrophages and rendering them proatherogenic has been examined 
334.   
CKD has been linked with numerous other adverse outcomes, including an increased 
risk of cerebrovascular disease and stroke, impaired cognitive function and impaired 
physical function 
335-337. In addition evidence exists that CKD increases the risk of 
fractures and some cancers 
338,339. CKD has also recently been linked to an increased 
risk of hospitalization with pneumonia that may be contributing to the increased 
        CKD 
    ESRD 
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Figure 3. 4  Illustration of the outcomes of CKD. Mark Uniacke    Chapter 3     
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mortality 
340. Another recent study, by Daratha et al reported that patients with CKD 
after an index hospitalisation for any cause were at increased risk of subsequent 
hospitalizations. The top three reasons for readmission were heart failure, ischaemic 
heart disease and AKI 
341. It has already been discussed that CKD is an important risk 
factor for the latter. 
 
3.5 CKD Progression 
 
It is well established that more advanced stages of CKD are associated with adverse 
outcomes 
342. As a result, the progression of CKD and the factors influencing this is an 
area of major interest to the medical community. Several factors can contribute to the 
progression of CKD. With early identification and treatment, some of these can be 
modified to slow or arrest the progression and improve outcomes 
314. However, it 
should be noted that there is good evidence that not everyone with CKD will progress 
and this suggests that there may also be unidentified genetic or environmental factors 
involved 
327,328. 
 
The association of diabetes, hypertension and proteinuria with declining renal function 
has been demonstrated in numerous longitudinal and interventional studies 
343-346. In 
addition to these well-known risk factors, associations have also been made with the 
presence of cardiovascular disease, smoking, race, and the chronic use of non-
steroidal anti-inflammatory drugs 
74. The mechanisms involved in CKD progression are 
complex. Regardless of the cause of the inciting injury there appears to be a final 
common pathway in all cases of CKD resulting in a phenotype of tissue destruction, 
inflammation and scarring. Cell damage and activation leads to inflammation and 
cytokine imbalance which contributes to fibrosis, mesangial and vascular contraction 
347. In addition to maladaptive inflammatory and cellular responses alteration of renal 
haemodynamics may also be important. Renal hyperfiltration has been associated with 
sclerosis of the glomeruli and maneuvers to reduce this, such as the use of RAS 
blockers, have been shown to be effective 
348.  
 
Renal function declines slowly with age but the rates reported are variable depending 
on the population used 
74. There is some controversy over whether CKD in older people 
represents a disease or is a benign phenomenon 
349. In the Nijmegen Biomedical Study 
a reference population of healthy subjects was selected without a history of known 
hypertension, diabetes, cardiovascular or renal diseases. In these subjects the rate of 
decline in GFR was approximately 0.4mls/min/year 
350. In the Balitmore Longitudinal 
Study of Aging, Lindman et al reported an age related decline of 0.75mls/min year 
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351. Following a review of the available literature NICE concluded that a decrease of 
more than 2mls/min/year is more than can be accounted for by age alone, and 
therefore accounting for variation in measurement, NICE defined a clinically significant 
progression in CKD as a decline in eGFR of more than 5mls/min/year. 
 
It is notable that in compiling the 2008 CKD Guidelines the NICE group listed AKI as a 
factor associated with the progression of CKD but no studies were found examining 
this association at the time 
74. KDOQI also recognised AKI as a potential risk factor for 
CKD when the original staging system for CKD was produced in 2002 
314.  
 
3.6 AKI and the incidence and progression of CKD  
 
Historically recovery of renal function after an AKI episode has been thought of in 
terms of recovering enough function to no longer require renal replacement therapy. 
As this is achieved in most survivors it led to the perception that the functional 
prognosis after AKI was good or even completely reversible 
127,352. The long-term 
functional impact of AKI was not considered important. This perception has changed 
dramatically over the past decade as the influence of CKD on adverse outcomes has 
become appreciated.  
 
AKI is very common in hospitalised patients and therefore if it is causing incident CKD 
and contributing to its progression this will have major public health implications. The 
incidence of AKI appears to be rising and so could add considerably to the burden on 
healthcare resources. It could be partly responsible for the rising prevalence noted in 
CKD as well as contributing to the ESRD population.  
 
It is intuitive that an episode of AKI may lead to some degree of permanent loss of 
renal function and may potentiate pre-existing pathology 
324. It has recently been 
highlighted that every experienced nephrologist will come across a case where an 
individual with advanced kidney failure has been precipitated onto dialysis following an 
AKI episode 
50. In addition, there is literature containing examples of patients who have 
not recovered function fully after an AKI 
49,353-356. However, the precise nature of the link 
between AKI and functional outcomes has not been actively studied until very recently. 
In the following sections the historical, experimental, and contemporary evidence for 
the AKI/CKD association is reviewed.  
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3.6.1 Historical Evidence 
 
There has been evidence in the literature for over sixty years that AKI has the potential 
to cause a persistent loss of renal function. While these early studies were carried out 
in an era when the causes of AKI were quite different from today they nevertheless 
provided a valuable insight into the recovery patterns after episodes of severe AKI. All 
of the studies reviewed below undertook careful laboratory renal clearance 
measurements and one even performed follow- up renal biopsies. Arguably, they are 
more accurate than contemporary studies that have relied solely on serum creatinine 
measurements and eGFR. 
  
In 1952, KG Lowe produced one of the first follow up series after an episode of severe 
AKI 
49. It contained 14 women with a mean age of 28 years and all had experienced an 
episode of severe acute kidney injury with anuria or severe oliguria attributed to acute 
tubular necrosis. The causes of AKI in this series were listed in Figure 2.9. The author 
was careful to point out that none had had an illness before or after the AKI episode 
that may have influenced renal function at follow up. They were followed up after 
variable time periods but up to 3 years. All had para-aminohippurate (PAH), 
thiosulphate and creatinine clearances measured. Lowe found generally good renal 
recovery up to six months which was then sustained. However, in some cases it was 
sustained at a lower level than normal suggesting that CKD was a consequence of the 
AKI. Lowe speculated that there might be residual scarring and vascular damage 
following AKI. 
 
In 1956 Finkenstaedt and Merrill published a series of 16 patients treated in Boston 
355. 
All had survived an episode of severe anuric AKI. These patients were selected from a 
larger series for evaluation because they had no history of cardiovascular or renal 
disease. The mean age was 31 years and they were followed up after a mean period of 
18 months. In 7 cases measurements of renal function were taken on more than one 
occasion during follow up. As with Lowes series they found that good functional 
recovery was established by six months and that function was maintained thereafter. 
However, inulin clearances in the majority of patients were below normal at follow up 
leading the authors to conclude that there may have been permanent damage after the 
AKI. They found no evidence for a progressive diminution of function over time and 
neither did they find any correlation between the severity or duration of AKI and the 
outcome.  
 
Finally, Price and Palmer published a series of 14 patients that were followed up at 
various time points up to 10 years after an episode of severe AKI requiring dialysis 
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In 6 cases inulin clearance was reduced at follow-up and in five of these there was also 
a reduction in renal blood flow measured by PAH clearance. The authors carried out 
follow-up renal biopsies in some of these patients. These showed an increase in 
glomerulosclerosis compared to normal along with tubular atrophy and basement 
membrane thickening. These are all features of chronic kidney disease. There were 
also areas of chronic inflammation and focal interstitial fibrosis that led the authors to 
conclude that there could be a continuing ‘process’ that may have correlated with a 
subsequent decline in function noted in some patients.  
 
3.6.2 Experimental Evidence 
 
There is much experimental evidence in studies on animal models that lend plausibility 
to AKI having a causal role in the development and progression of CKD. The animal 
models that have been used have universally involved induction of ischaemic or toxic 
damage to the kidney. These models have been criticised by some as being a poor 
analogue of human AKI particularly in the case of septic AKI 
248,357. Nevertheless 
histological findings in animal models in the aftermath of AKI are remarkably similar to 
those found in humans with CKD.  
 
Fox published one of the earliest studies looking at the recovery pattern of ATN in 
experimental animals in 1967. Using a mouse model, it was demonstrated that 
recovery was followed by progressive deterioration in renal function accompanied by a 
reduction in renal size and interstitial fibrosis 
358. More recently, Pagtalunan et al 
conducted a detailed study of the effects of ischaemic injury in a rat model. They 
found that animals subjected to ischaemic injury showed an initial recovery phase that 
was incomplete and this was followed by further deterioration in function. Urinary 
protein excretion was markedly increased in the animals subjected to ischaemic injury. 
They hypothesized that the addition of tubular injury caused by proteinuria might 
account for the progressive loss of function. Histological examination on follow up 
revealed widespread tubulointerstitial injury accompanied by patchy interstitial 
fibrosis, infiltration with inflammatory cells and occasional calcification. The findings 
were largely made up of features generally associated with CKD 
359. In a similar rat 
model, Forbes et al demonstrated a marked increase in the deposition of collagen type 
III 180 days after the ischaemic episode. This increase was not seen early in the course 
of the recovery period. The authors felt that these findings supported the hypothesis 
that ischaemia may have long-term implications 
360. 
 
Basile et al have demonstrated a now well-recognized phenomenon of ‘vascular 
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significant reduction in microvasculature density after ischaemia in the kidney. The 
extent of the vessel loss was influenced by the duration of ischaemia and was most 
prominent in the outer medulla 
361. The loss of renal microvessels after AKI may 
contribute to tissue hypoxia and promote progressive damage. In more recent work 
the same group have demonstrated that the dropout phenomenon results from an 
impaired regenerative capacity in the damaged vasculature associated with endothelial 
cell phenotypic transition 
362.  
 
Finally, using an obese-diabetic rat model, Kelly et al have demonstrated that after 
bilateral renal ischaemia rats with obesity diabetes were characterized by progressive 
chronic kidney disease, increased proteinuria, and increased renal expression of 
proinflammatroy mediators. Leukocyte numbers in these kidneys were markedly 
increased for months after the renal injury. Intrarenal blood flow velocity was 
decreased and similar to the work of Basile et al they demonstrated reduced 
microvascular density. They concluded that accelerated persistent renal inflammation 
is a critical element of progressive renal failure complicated by AKI and coined the 
term ‘postischaemic inflammatory syndrome of diabetic nephropathy’ 
363. In a follow up 
study the same group tested the hypothesis that administration of an anti-
inflammatory agent would ameliorate the functional decline. In a similar rat model they 
administered mycophenolate mofitel and demonstrated that the reduction in renal 
inflammation improved long-term renal function, microvascular dysfunction, fibrosis 
and apoptosis and thus confirmed the role for inflammation at least in the diabetic 
kidney 
363.  
 
The evidence from animal models that AKI may contribute to CKD is compelling. 
Whether or not the findings can be extrapolated to humans is open to debate. At 
present the pathological processes involved are incompletely understood and are the 
subject of hypothesis rather than fact 
324. There are many pathological pathways along 
which AKI and CKD may be intertwined and these pathways may well overlap. However, 
one recent hypothesis concerning focal ischaemic injuries is worth mentioning. 
Venkatachalam et al speculated that because systemic blood pressure can fluctuate 
abnormally in the setting of decreased renal mass and impaired autoregulation, 
microenvironments in the kidney supplied by sclerotic arterioles may be vulnerable to 
hypoxia and ischaemia. They pointed out that there is some evidence for this 
phenomenon in rat models of hypertension and that recurring acute tubule damage in 
microenvironment foci could be contributing to disease progression even without overt 
clinical episodes of AKI 
324. If this hypothesis is correct it would provide some basis for 
the findings that relatively minor AKI episodes could be contributing to CKD 
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3.6.3 Contemporary Evidence 
 
A systematic search of Medline and Embase databases for the period 1990 - 2011 was 
carried out to identify cohort studies reporting renal function outcomes after an 
episode of AKI in adults. Using the search strategy described in Chapter 1 studies 
reporting clear functional outcomes from the point of hospital discharge to any follow-
up time point were reviewed in depth and are presented in summary in Appendix 12. A 
total of 73 studies were found.  
 
A striking feature of the studies summarized in Appendix 12 is the marked clinical and 
methodological heterogeneity and this makes it very difficult to carry out any 
meaningful comparison. The study cohorts were drawn from a wide variety of 
populations and different clinical circumstances which may have influenced reported 
outcomes. For example, four studies reported the incidence of CKD after AKI in 
patients who had undergone haematopoietic cell transplantation (HCT) 
147,375,391,394. It is 
known from autopsy series that acute renal dysfunction in this population is 
characterized by renal tubulitis that may be related to graft versus host disease 
375,396. 
This represents a very different renal insult to that which the general hospital 
population would be subjected. In addition, many of these patients are treated with 
cyclosporine during follow-up that may also have caused a reduction in renal function.  
Using the HCT population to generalize the outcomes of the hospital population as a 
whole would therefore be inappropriate. In terms of the study population it is also 
notable that no study has separated the populations into those of community origin or 
hospital origin. Given the differences in causes and outcomes in these groups it is 
possible there may be significant differences in functional outcomes.   
 
3.6.3 (i) Methodological Issues 
 
The varying study designs and methods that have been employed by different authors 
has led to substantial differences in reported outcomes. Indeed some of the 
methodological issues have prompted some to question the validity of the conclusions 
being made 
357.  The majority (78%) of the studies are retrospective. Therefore, they 
generally lack patient level clinical data and so adequate exploration of the potential 
causes, confounders, and severity of the AKI cannot be undertaken. In addition 
retrospective studies are known to be vulnerable to ascertainment bias during follow 
up. They rely on outpatient follow up blood samples having been performed and so 
eligible patients are likely to represent those that are arguably at a higher risk of 
incident CKD and CKD progression. A total of 52 studies (71%) have follow up for a 
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either based in intensive care populations or included cases of AKI that required renal 
replacement therapy only. Therefore there is no study currently in the literature 
reporting the prospective follow up of AKI in a general hospital population.  
The definition of baseline kidney function would be considered crucial to any 
conclusions drawn regarding the recovery of kidney function after AKI. However, of the 
73 studies included in Appendix 12, 25 of them did not specify a clear baseline 
definition. Another 10 studies used a combination of baselines that included 
estimates. In all, there are 13 definitions of baseline function. On top of this wide 
variation in baseline definition a total of 17 different definitions of AKI itself have been 
used.  
 
Finally, there is no consensus on how to define recovery of kidney function after AKI. In 
the 73 studies reviewed there are 19 different definitions of renal function outcomes 
after AKI. These are summarised in Appendix 13 . In some cases no definition of 
recovery was used. 
 
Different approaches have been taken in studies to record the evolution of renal 
function after an episode of AKI. Some use a threshold below which recovery is defined 
as complete. However the thresholds are widely variable. For example in the same year 
Bihorac et al defined recovery as a serum creatinine < 50% above baseline while Thakar 
et al defined it as < 25% above baseline 
155,189. This level of variation in thresholds has 
the potential to report very different outcomes. 
 
Five different approaches have been used to define progression of CKD. Several 
studies expressed this as a progression to ESRD. ESRD is a very uncommon outcome 
occurring in < 1% of survivors and gives no information of progression in those who do 
not reach it 
34,42,168,188,383,389. James et al used this outcome together with a doubling of 
serum creatinine 
231. Two studies defined progression as advancement to CKD stage 4 
365,369. Ishani et al used a similar approach but simply defined progression as 
advancement to the next CKD stage 
127. This approach by Ishani is potentially 
problematic as no threshold for the decline in GFR was specified. Therefore small 
changes in eGFR across the CKD stage thresholds, for example from an eGFR of 61 to 
59 mls/min, would be recorded as progression. Such changes in function may not be 
outside what would be expected from analytical variation. Finally, James et al defined 
rapid progression as a decline in eGFR > 4mls/min/year 
230. This is the only study to 
have defined a specific fall in eGFR. A fall of 4mls/min/year is less than that specified 
by NICE in their definition of rapid progression and whether or not it represents true 
progression when the variation in measurements is taken into account is open to 
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It was discussed in Chapter 2 that patients have an increased risk of readmission to 
hospital after AKI and hence a repeat AKI may occur. Thakar et al reviewed this 
phenomenon in a cohort of diabetic patients. They found that repeat episodes of AKI 
occur in up to one third of AKI patients who survive their initial hospitalisation. 
Moreover, each AKI episode was found to double the risk of advanced CKD in a 
cumulative fashion 
34. No other study has accounted for this in their reporting. 
Therefore outcomes reported in relation to a single AKI episode may be confounded by 
overestimating prognosis.  Whether or not the effect reported by Thakar in the VA 
diabetic population is applicable to the general population is unknown.  
 
Only one study has compared the decline in renal function after an AKI to any decline 
that was occurring prior to the index AKI episode. James et al reviewed the recovery 
patterns after AKI in a cohort of patients who had undergone coronary angiography. 
The decline in function was compared before and after the AKI In a subgroup of 
patients who also had eGFR measurements that spanned a minimum of 1 year during 
the pre-angiography period. The annual rate of decline before and after the 
angiography was unchanged in those without AKI or with mild AKI. Mild AKI in this 
study was defined as an increase in serum creatinine of 50-99% or by > 0.3mg/dl 
230. 
The population studied by James et al is restricted to those that underwent 
angiography and so is quite specific and limited to a single AKI insult. It is unknown if 
this is extendable to other populations but it differs from the findings reported in 
other studies to date. For example, Newsome et al reported a marked increase risk of 
ESRD in those with an AKI where the creatinine had risen by only 0.1mg/dl 
383. This is a 
much smaller rise in creatinine than that used by James et al which showed no 
influence on disease progression. It raises the possibility that there were additional 
factors influencing the outcomes in Newsome’s study. AKI and CKD share many risk 
factors and these findings raise concerns that there may be residual confounding in 
studies particularly relating to the milder levels of AKI.  
 
3.6.3. (ii) Incident CKD 
 
The general consensus in the literature at present is that AKI may be causing CKD in 
some populations and represents an important prognostic marker for the development 
of future CKD. This certainly appears to be true for severe cases of AKI however in the 
case of milder AKI episodes its role needs further characterisation. Differences in study 
population and methodology have led to some conflicting results and some authors 
have questioned the precise causative role of AKI in this phenomenon 
357. Table 3.1 
summarises contemporary studies published between 2008 and 2012 which reported 
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to distinguish between those with and without CKD at baseline. Studies involving 
haematopoietic cell transplantation (HCT) only were excluded from this summary for 
the reasons outline earlier in this section. 
 
Table 3. 1 Contemporary studies reporting functional outcomes after AKI when 
baseline CKD has been excluded.  
 
 
Author 
(Year) 
 
Setting 
 
Study Type 
 
AKI 
Definition 
 
Duration of 
follow up 
 
Outcome 
           
Ponte  
(2008)
386 
Hospital ATN  Retrospective  Creat. Rise > 
2mg/dl 
8 years  61.1% had 
some degree of 
CKD 
1.1% on RRT 
 
Schiffl  
(2008)
388 
ITU 
ATN only 
Prospective  RRT  5 years  86% normal 
function 
9% CKD 
5% RRT 
1% of total 
cohort required 
RRT at 5 years 
 
Ishani  
(2009)
42 
Hospital 
Medicare 
Retrospective  ICD-9 codes  2 years  Adjusted HR of 
ESRD 
AKI – 13.0 
AKI/CKD – 41.2 
CKD only – 8.4 
 
Triverio 
(2009)
392 
ITU  Randomised 
controlled 
trial 
 
RRT  3 years  40% had CKD at 
follow up 
Van Kuijk 
(2010)
124 
Vascular Surgery  Retrospective  > 10% fall in 
CKD-Epi 
RIFLE 
5 years  Adjusted RR of 
CKD with 
temporary 
decline in 
function 3.4 
RR 3.6 with 
persistent 
decline. Mark Uniacke    Chapter 3     
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Author 
  (Year) 
     Setting  Study Type  AKI 
Definition 
Duration of 
follow up 
Outcome 
Ishani  
(2011)
127 
Cardiac Surgery  Retrospective  Stratified rises 
in creat. From 
0% to > 100% 
5 years  Graded 
increased risk 
of incident CKD 
(adjusted HR 
2.33) and 
progression 
 
Siew  
(2011)
389 
Hospital 
AKI survivors 
Retrospective  AKIN  1 year  50.2% had 
returned to 
baseline 
< 1% of cohort 
required RRT 
 
Bucaloiu 
(2012)
194 
Hospital 
Recovered AKI 
Retrospective  50% rise in 
creatinine from 
baseline 
3.3 years  HR of de novo 
CKD 1.91 
           
 
 
There are some notable methodological issues with the studies summarized in Table 
3.1. There are also important differences between the results reported. Ponte et al 
reported some degree of CKD in 61.1% of patients with hospital ATN after 8 years of 
follow up 
386. In contrast to this, Schiffl et al reported that 86% of ATN survivors had 
normal function after 5 years 
45. This is despite the fact that Schiffl’s group included 
only those who had dialysis and so the AKI was more severe.  It is difficult to account 
for these differences. There may be a degree of survivor bias in Schiffl’s group but 
equally well there are likely to have been differences in the baseline characteristics of 
the patients and the aetiology of the ATN episode. The survivors in Schiffl’s study 
appear to have had a low burden of comorbid disease with a Charlson Score of 0.7. 
Ponte did not specify this in detail but did report that 81.3% of survivors had some 
degree of comorbidity. Detail on aetiology was also lacking in Ponte’s study but it is 
apparent that 13.6% of the cohort had ATN attributed to sepsis. This compares to 35% 
of survivors in the Schiffl study. These conflicting results would suggest that other 
factors have an important influence on the outcomes. This raises questions about the 
precise role of AKI in causality. How can an apparently milder level of AKI described by 
Ponte be associated with poorer functional outcomes than the more severe AKI 
episodes described by Schiffl if AKI has a direct causal role in this phenomenon? It is Mark Uniacke    Chapter 3     
        75 
worth noting however that neither study accounted for repeat AKI episodes during 
follow up.  
 
In the 2011 study by Ishani et al involving patients who had undergone cardiac 
surgery, it is notable that the very mild AKI class with a rise in creatinine from 0 - 24% 
was found to have a hazard ratio for the development of CKD of 2.1 
147. This is 
surprising as the rise in creatinine within this class may not have been outside the 
threshold of individual and analytical variation. It raises some important questions. 
Ishani used a single creatinine to define baseline function and this may not have been 
enough to rule out baseline CKD particularly at levels close to the defined threshold of 
60ml/min. As discussed earlier they did not specify the fall in eGFR necessary to define 
the decline in function. The results may therefore have been confounded by minor 
variations around the 60ml/min threshold. Ishani’s results are also difficult to 
reconcile with the results reported by James et al discussed earlier. James defined mild 
AKI as a rise in creatinine of 50-99% and yet found no change in the rate of decline of 
renal function during follow up 
230. While Ishani provides compelling evidence that AKI 
is associated with incident CKD at the more severe end of the AKI spectrum, the milder 
end is less clear.  
 
In the study by Siew et al, after 1 year of follow up 50% of those who had a baseline 
level of function > 60mls/min were found to have an eGFR < 60mls/min. Of the 50% 
who showed a decline in function into a CKD category the vast majority (96%) were in 
CKD stage 3 
389. Siew et al did not specify a decline in eGFR necessary to define disease 
progression and so the question remains how many of those with apparently incident 
CKD were actually on the cusp of the CKD stage 3 threshold before the AKI. The 
median baseline eGFR of Siews entire cohort was 56mls/min. This indicates that those 
classified as ‘normal’ are likely to have been quite close to the 60mls/min CKD stage 3 
threshold. This issue also raises another important question. Is the definition of 
“normal’ with a baseline eGFR above 60mls/min appropriate when exploring outcomes 
such as incident CKD? For example it could be argued that a patient with say an eGFR 
of 65mls/min already has reduced renal function. 
 
3.6.3 (iii) CKD Progression 
 
Substantial evidence exists supporting an association between AKI and the progression 
of CKD. However, as with incident CKD there are similar methodological issues in the 
studies reported. As discussed earlier different approaches have been taken in the 
literature to describing the progression of CKD after AKI. Some studies have defined it 
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describing the risk of progression across a specific threshold of CKD stage during 
follow up. It could be argued that at best AKI can be interpreted as a marker of risk in 
these studies.  
 
One of the first studies to describe the risk of progression to ESRD was reported by 
Newsome et al in 2008. This study used a dataset of patients admitted to hospital with 
the diagnosis of acute myocardial infarction. Patients over 65 years of age who had 
sustained an acute decline in renal function during hospitalisation were linked to the 
USRDS during follow up to identify those who developed ESRD. AKI was defined as an 
increase in serum creatinine of 0.1, 0.2, 0.3 to 0.5, or 0.6 to 3.0 mg/dl. The baseline 
serum creatinine was taken from the initial creatinine measured on hospital admission. 
For each level of rise in serum creatinine there was an increased risk of ESRD during 
four years of follow up. After adjustment for demographic characteristics the hazard 
ratio for a rise in creatinine of 0.1mg/dl was 1.45 and this increased in a graded 
manner to 3.26 for a rise of 0.6 to 3.0mg/dl. However, it is notable that ESRD was an 
uncommon outcome in this cohort. After ten years of follow up the incidence rate of 
ESRD was 3.8 per 1000 person-years whereas the incidence rate for death was 154.7 
per 1000 person years 
383.  
 
In 2009 several studies were published which came to a similar conclusion as 
Newsome. Ishani et al described an adjusted hazard ratio of 41.2 for the development 
of ESRD after AKI on CKD in a sample of US Medicare patients. This study relied 
entirely on coded data 
42. At the same time Wald et al reviewed the outcomes of 
survivors of AKI in intensive care that had required RRT. After three years of follow up 
there was an increased risk of developing ESRD in the RRT group compared to non-AKI 
controls with a hazard ratio of 3.26  
393. Hsu et al reported a similar study that used the 
Kaiser Permanente database in Northern California. It involved patients who had a pre-
existing baseline eGFR < 45mls/min who were hospitalized between 1996 and 2003. 
AKI was defined as a peak inpatient creatinine > 50% above baseline and requiring 
dialysis. Over 7 years of follow up the adjusted hazard ratio for the development of 
ESRD was 1.47 
188. It is notable that in this study the hazard ratio did not reach 
statistical significance. It also included only patients who had at least CKD stage 4 who 
were already at a high risk of progressing to ESRD.  
 
In the same year Amdur et al used the Veterans Affairs database in the US to describe 
the progression to CKD stage 4 after an AKI episode from a mean baseline eGFR which 
lay between 80 to 85mls/min. Using ATN and ARF codes they found an increased risk 
of progression to CKD stage 4 with a hazard ratio of 6.64 for the ATN group and 4.03 
for the ARF group during 75 months of follow up 
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of progression in disease in hospital survivors who had required RRT. All patients with 
an eGFR < 45mls/min were excluded. The adjusted hazard ratio for progression to 
CKD stage 4 was 28.1 
120.  
 
Several more studies in 2010 demonstrated an increased risk of ESRD after AKI. 
Lafrance et al reviewed data from the British Columbia CKD register during the period 
2002 to 2007. This study included only patients who had a baseline eGFR < 
30mls/min. During 19 months of follow up the adjusted relative risk of ESRD in those 
who were hospitalised with an AKI was 2.33 
125. In another Canadian study James et al 
reviewed the outcomes of patients who had sustained an AKI in a cohort of over 
900,000 Alberta residents. They found an increased risk of a composite outcome of 
ESRD or doubling of serum creatinine in those with AKI. However, this increased risk 
appeared to be greatest in those with higher baseline GFR. For those with a baseline 
eGFR < 30mls/min and heavy proteinuria admission to hospital with AKI did not 
further increase the risk of the composite outcome. This finding was unexplained. The 
study was retrospective and used routine coding to identify the occurrence of AKI. 
Therefore there was no indication of the type or severity of AKI in these patients. It is 
possible that the AKI episodes in those with advanced CKD were not severe enough to 
alter the outcomes 
231. James et al published another study in the same year that 
explored the kidney function outcomes in those who sustained an AKI following 
coronary angiography. They defined rapid progression of CKD as a fall in eGFR of > 
4mls/min per year. In the non-AKI control group the adjusted mean rate of decline in 
kidney function was 0.2mls/min/year. This increased to 0.8mls/min/year in those with 
mild AKI and 2.8mls/min/year in those with moderate or severe AKI 
230. This study is 
notable for a number of reasons. Firstly, those with a greater number of serum 
creatinine measurements during follow up had an increased rate of decline in eGFR. 
This suggests that ascertainment bias may be an issue in this type of study. However, 
the authors found that the relative increase in rate of decline and odds of rapid 
progression were comparable across all strata to those seen in their primary analysis. 
Secondly, the authors compared the rate of decline of kidney function prior to the AKI 
to the decline afterwards. In those with moderate or severe AKI there was a statistically 
significant increase in the rate of decline in renal function after the AKI episode. 
However, this was not the case in those with mild AKI where the rate of decline was 
found to be similar in both periods.  
 
Finally, Choi et al reported another study in 2010 looking at the risk of ESRD this time 
in a cohort of patients registered with HIV. AKI was defined using the AKIN criteria and 
it was reported that AKI increased the risk of ESRD in graded manner according to 
AKIN stage from 1.37 for AKIN 1, 3.8 for AKIN 2, to 20.36 for AKIN 3. There was no Mark Uniacke    Chapter 3     
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increased risk found in those with AKIN 1 who recovered fully by the time of discharge 
165.  
 
In 2011 Ishani et al studied the outcomes after AKI in a cohort of patients who had 
undergone cardiac surgery. Progression of CKD was defined as progression to the next 
CKD stage. Among the subjects with CKD at baseline who did not experience an AKI 
the incidence of CKD progression was 26.4%. Following an AKI episode the proportion 
progressing to the next CKD stage increased in a graded manner according to the 
magnitude of the AKI 
127. Also in 2011 Pannu et al explored the influence of baseline 
CKD on outcomes after AKI. They used the same Alberta database as James et al and 
defined AKI using the AKIN criteria. The impact of AKI was found to increase as eGFR 
decreased irrespective of the severity of AKI. The adjusted hazard ratio for death or 
ESRD in those with a baseline eGFR < 30mls/min who sustained an AKIN stage 3 AKI 
was 4.04. ESRD was uncommon during the two years of follow up in this study. The 
increased hazard ratio for the composite outcome of death or ESRD associated with 
progressively severe AKI at lower levels of eGFR was attributed primarily to increased 
mortality 
168.  
 
Finally, Thakar et al reported the outcomes of a cohort of diabetics from the US 
Veterans Affairs database that had sustained an AKI during hospitalization. AKI was 
defined using AKIN criteria and all patients with an eGFR < 30mls/min at baseline were 
excluded. The primary outcome was progression to CKD stage 4 during just under four 
years of follow up. The adjusted hazard ratio for progression was 3.56. 30% of patients 
in the cohort had experienced 2 or more AKI episodes during follow up and the risk of 
CKD progression was doubled in a cumulative manner 
34. This suggests that the hazard 
ratios attributed to AKI in the other studies discussed above are likely to be 
confounded by his phenomenon.  
 
3.6.3 (iv) Negative Studies 
 
The findings described in the previous sections have not been consistent in every 
study reporting AKI outcomes. Gude et al studied the outcomes of 585 patients who 
had undergone a heart transplant in Norway between 1983 and 2007. 145 (25%) 
patients experienced an AKI in the post-operative period. 71 of these required dialysis 
but all survivors were dialysis free at the time of hospital discharge. Patients were 
followed up for a mean of 6.6 years. Renal function was expressed in terms of the 
mean serum creatinine and patients were divided into four groups. Group 1 were those 
with no AKI who showed an improvement in creatinine during the first 7 days post-
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above the level of AKIN stage 1. Group 3 increased their creatinine above the level of 
AKIN stage 1 while Group 4 required dialysis. Figure 3.5 illustrates the mean creatinine 
for each of these groups during the follow up period. As expected the levels were 
separated in the immediate post-operative period however, after three months they 
began to converge. After two years there was no statistical difference between the 
groups. The authors concluded that AKI did not predict future functional outcomes 
159.  
It is unclear why these findings contrast with the findings reported in other AKI 
studies. The transplant population is quite specific and would have been subjected to 
further nephrotoxic agents such as cyclosporine that may have influenced results. 
There may also have been a degree of survivor bias in that those who were more likely 
to have not recovered function may have died during follow up. 
 
Figure 3.5  Evolution of the mean serum creatinine following heart transplant in 
the study by Gude et al. Reprinted by permission from John Wiley and Sons:[Clinical 
Transplantation]
159, Copyright 2010 John Wiley and Sons A/S. 
 
 
 
 
 
In a 2005 study from Sheffield, Abosaif et al applied the RIFLE criteria to a cohort of 
183 patients with AKI in the intensive care unit. Renal function was again expressed in 
terms of mean serum creatinine. After 6 months follow up the mean serum creatinine Mark Uniacke    Chapter 3     
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had actually improved in all the RIFLE groups. For example in the Failure Class the 
mean baseline was recorded as 2.4 mg/dl while after 6 months of follow up it was 
1.7mg/dl. This apparent improvement led the authors to conclude that the percentage 
change in serum creatinine levels mainly predicts short-term ITU survival, but does not 
impact on longer- term renal survival 
181. Abosaif et al used the serum creatinine on 
admission to ITU as the baseline level. This is likely to have already been elevated in 
many patients due to AKI and will overestimate the true baseline. In addition, the 
authors included only those patients who had impaired function on admission to ITU, 
excluding those developing AKI later during the ITU stay. This latter group is known to 
have worse outcomes as discussed in Chapter 2. There may also be a degree of 
survivor bias at the point of follow up.  
 
Another study by Van Berendoncks et al using survivors of dialysis requiring AKI in the 
intensive care setting reported similar findings to those discussed above. They found 
that the mean creatinine clearance at the point of discharge from hospital did not 
differ from that found at follow up after 1 year. Some clue to the reasons behind this 
finding is the wide variation in the evolution of renal function after discharge that was 
described in this study.13 patients discharged on dialysis became dialysis independent 
while 7 additional patients developed ESRD 
252. It is possible that the changes in 
function in the opposite directions of recovery and decline may cancel each other out 
to leave the mean unchanged. This may also partly explain the findings in the study by 
Gude and Abosaif.  
 
3.6.3 (v) Published Meta-Analyses of recovery after AKI 
 
There have been three studies published to date that have conducted a meta-analysis 
of functional outcomes after AKI 
26,352,397. Schmitt et al conducted a meta-analysis of 
published literature to determine the incidence of non-recovery of kidney function 
after AKI as a function of age. They included studies published between 2000 and 
2007 that reported a clear definition of renal recovery of function, assessed renal 
recovery as a primary or secondary outcome, and reported the participant’s age. 17 
studies were included in this meta-analysis and included the pooled data of 5,529 
participants. In keeping with the findings in the literature discussed earlier in this 
section, the study populations and clinical settings showed marked heterogeneity. 12 
of the 17 studies examined patients with only severe dialysis requiring AKI. 10 of the 
studies had data only for recovery at the time of hospital discharge. The authors found 
heterogeneous definitions of AKI and renal recovery but the most striking 
methodological issue was that few studies included data on baseline kidney function 
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definition of recovery is essentially meaningless. The authors found that 31.3% of 
elderly patients over 65 years of age failed to recover function after AKI compared to 
26% in patients under 65 years of age. Heterogeneity was significant with an I
2 Index of 
55%. The authors attempted to reduce the heterogeneity by pooling studies according 
to the definition of renal recovery. When independence of RRT was used to define 
recovery results showed a strong effect of age with a relative risk of 1.56. Overall the 
authors concluded that recovery after an episode of AKI is approximately 28% less 
likely to occur in the elderly over the age of 65 years 
397. The validity of this conclusion 
is questionable given the marked heterogeneity encountered in the studies. 
Nevertheless, independence from RRT is a more robust outcome and age was strongly 
associated with this. The authors could not explain the effect of age on recovery. It 
may relate to the effects of age itself on kidney function or may be related to the 
increased number of comorbidities encountered in this age group.  
 
In 2009 Coca et al published a meta-analysis that attempted to characterize the 
relations between AKI and the long-term outcomes of CKD, cardiovascular disease, and 
death. They included studies from 1985 onwards with at least 6 months of follow-up of 
patients after a defined AKI episode. 27 studies from a total of 48 analyzed provided 
data on the incidence of CKD or ESRD in patients who survived hospitalisation with AKI. 
21 of these studies included patients with CKD. 23 reported ESRD as an outcome while 
11 reported some form of CKD as an outcome but definitions varied. The rate of CKD 
after AKI was reported as 7.8 per 100 patient years while that for ESRD was 4.9 per 
100 patient years. The authors were unable to calculate the relative risks as no study 
had compared outcomes with a group of controls without AKI. This meta-analysis 
highlighted all of the methodological issues discussed earlier in this section 
26.  
 
Finally, Coca et al conducted a second meta-analysis in 2011 and attempted to 
estimate the risk for CKD and ESRD after an episode of AKI. This is something they 
were unable to do in the 2009 analysis. 13 studies published between 2006 and 
2011were included in the analysis all of which were retrospective. The authors found 
that the pooled adjusted hazard ratio for CKD after an episode of AKI was 8.8 and for 
ESRD it was 3.1. In keeping with the previous meta-analysis the reported heterogeneity 
was very high with an I
2 Index > 75%. The authors were unable to reduce the statistical 
heterogeneity to below 75% with deletion of studies from the pooled analysis 
397. The 
results of this analysis are therefore of questionable validity. In deriving the pooled 
relative risk of CKD after AKI, Coca et al used seven studies from markedly different 
populations including two from the general hospital population 
231,365, two containing 
those with haemopoetic bone marrow transplantation only 
147,394, one from cardiac 
surgery 
127, one from coronary angiography 
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120. The authors were careful to describe the findings in this study as an ‘association’ 
and did not suggest that AKI was playing a causal role 
352. They felt that residual 
confounding may still be a problem. For example, six (nearly half) of the studies 
included in the analysis used ICD-9 codes for ascertainment of important confounders 
such as CKD, diabetes, hypertension, and heart disease.  Therefore they are likely to 
have under-reported them.  
 
3.7 Recovery Patterns after AKI 
 
Many of the studies summarized in Appendix 12 reported the state of recovery at the 
point of discharge from hospital. There is clear evidence that recovery continues to 
occur in some patients after hospital discharge. Therefore an assessment of function 
at discharge will not be an accurate reflection of the final outcome. The question is 
how much time should be given before deciding a patient has reached their maximum 
point of recovery?  
 
Several studies have reported a rough approximation for the recovery timeframe and it 
appears that recovery continues for between 3 and 6 months after the AKI episode and 
the function then plateaus 
46,159,365,388. Figure 3.5 has already illustrated this type of 
pattern of recovery in those with AKI after a heart transplant 
159. Figure 3.6 illustrates 
the recovery pattern presented by Amdur et al. This study involved patients from the 
US Veterans Affairs system who had been coded for either ATN or ARF at the time of 
discharge from hospital. The ATN group in this case is likely to represent a more 
severe form of AKI however it is demonstrated that in all cases of AKI the point of 
maximal recovery appears to occur roughly between three and six months 
365. Based on 
the available evidence it appears that six months would be a reasonable time point 
from which to follow up patients after AKI to assess its immediate impact on kidney 
function. However, in the longer-term there is likely to be a further decline in function 
particularly those with CKD.  Mark Uniacke    Chapter 3     
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Figure 3.6 Recovery patterns after AKI demonstrated by Amdur et al in patients 
coded for ATN or ARF at the time of discharge from hospital. Reprinted by 
permission from Macmillan Publishers Ltd:[Kidney International]
365 , copyright 2009. 
 
 
 
 
Several of the studies discussed earlier demonstrated an increased risk of progression 
of CKD after an episode of AKI. The pathological process involved is unknown.  Figure 
3.7 illustrates the outcomes of patients in the study by James et al after coronary 
angiography. The patients included had a baseline eGFR<90mls/min. This study 
demonstrated an increased rate of decline in kidney function after moderate to severe 
AKI 
230. Whether the increased rate of decline is due to the effects of the AKI episode 
itself is unknown.  
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Figure 3.7 The decline in renal function after an episode of AKI reported by James 
et al in patients who had undergone coronary angiography. Reprinted by 
permission from Macmilan Punlishers Ltd:[Kidney International]
230, copyright 2010. 
 
 
 
 
Figure 3.7 gives the impression of a smooth process of decline after the AKI however 
as with virtually all of the studies to date, James et al did not account for inter-current 
events during follow up. It is likely to be far more complex. As discussed earlier 
patients may be at an increased risk of another AKI after their initial episode and the 
pathway may be one of repeated step-downs in function rather than a steady decline. 
This hypothesis was illustrated recently by Bedford et al and is shown in Figure 3.8 
398. 
This graph shows the possible outcomes after an episode of AKI. Firstly, there may be 
complete recovery. Secondly, AKI may initiate a relentless process of repair and 
fibrosis causing progressive CKD, or thirdly repeat AKI episodes may cause gradual 
step-downs in function.  In addition to the possible effects of the AKI itself on function, 
during any prolonged follow up period the patient will be subject to the effects of 
aging and inter-current illnesses. The latter may be associated with medication 
changes that could influence kidney function. For example, the starting of an ACE 
Inhibitor could result in a decline in GFR. No study to date has taken these issues into 
account. Overall the precise influence of any single AKI episode on long-term renal 
function is unclear and is currently only the subject of hypothesis and speculation. It 
appears unlikely that a single episode is responsible for the long-term outcomes 
reported in studies to date and it may be that a single AKI can only be considered a 
poor prognostic marker.  
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Figure 3.8 Hypothetical patterns of decline in renal function associated with AKI 
398. Reprinted with permission from Elselvier, Copyright 2012.  
 
 
3.7.1 Factors influencing recovery of renal function after AKI 
 
Factors that may influence the recovery of renal function after an AKI episode have 
been reviewed by several studies and are listed in Figure 3.9. These factors are poorly 
characterized in the literature and their interpretation is complicated by the fact that 
they overlap with the risk factors for the progression of CKD itself. 
  
Older age has been consistently shown to be associated with less likelihood of 
recovery after AKI 
21,122,194,369,386. This association appears to be a strong one and was 
confirmed in the meta-analysis by Schmitt 
397. The reason for this increased risk of non-
recovery is unclear but is likely to be related to the reduction in renal reserve that 
occurs with aging together with a rising burden of comorbidities.   
 
The effect of baseline kidney function on recovery has been poorly studied, but some 
studies have reported a paradoxical effect in that patients with lower baseline GFR may 
actually show better recovery after an AKI episode. James et al found that the risk of 
the composite outcome of ESRD or doubling of serum creatinine was higher in those 
with AKI but this risk grew progressively smaller with lower baseline eGFR or heavier 
proteinuria 
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death or ESRD was lower in those with an eGFR between 10 and 20mls/min than at 
higher levels 
125. Several reasons could account for these findings. Firstly, it is possible 
that the definition of AKI that has been used in these studies is not appropriate at 
lower levels of eGFR where the relative changes in creatinine may not represent the 
same extent of injury. For example, an increase in creatinine of 0.3mg/dl according to 
the AKIN definition is likely to represent a far greater injury in someone with a normal 
baseline creatinine compared to a higher baseline. Another important factor is the 
interpretation of these statistics in terms of the absolute and relative risks. For 
example in the study by Wald et al, the absolute risk of ESRD in those without AKI and 
decreased baseline GFR was 9.8% and this increased to 18.4% for those with AKI and 
decreased baseline. On the other hand for those with normal baseline and no AKI the 
risk was 0.4% and this increased to 4.6% with AKI 
393. This represents more than a ten-
fold increased risk compared to the two-fold increase at lower levels on account of the 
extremely low probability of ESRD in those with normal baseline that do not sustain an 
AKI. Hence the relative risks at normal levels of renal function are higher but the 
absolute risk difference is lower 
352. Overall it is unclear from the literature how the 
baseline level of function is influencing outcomes. 
 
The impact of the cause of the AKI on recovery is an important consideration. 
However, owing to the fact that the majority of studies published to date are 
retrospective they have lacked the patient level data necessary to define the cause. 
Bagshaw et al reported the 90 day follow up of patients who had required RRT in the 
ITU and found that the adjusted odds of recovery were increased in those who had 
septic shock 
366. This suggests that the cause may be relevant to outcomes however 
Piccini et al reported the opposite in their study of intensive care patients with AKI 
defined by RIFLE. In this study patients with sepsis appeared to be less likely to recover 
function 
251. No other studies reviewed have reported the influence of cause on 
outcomes and so it remains poorly characterized. Along similar lines the impact of 
community versus hospital acquired AKI on outcomes has not been reported.  
 
Several studies have reported an increased risk of non-recovery with higher burdens of 
comorbidities 
122,194,366,369. In particular congestive cardiac failure, diabetes mellitus, and 
a low serum albumin. These findings are arguably non-specific as they are risk factors 
that would be shared with CKD for poor outcomes in general.  
 
Gender may play a role in renal recovery. Bagshaw et al found that the odds of 
recovery were increased in males 
366. Many studies have shown that the severity of the 
AKI is linked with recovery 
155,186,190,230,369. For example, James et al demonstrated a clear Mark Uniacke    Chapter 3     
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increased risk of decline in renal function after AKI in those with moderate to severe 
AKI compared to those with mild AKI and this has been illustrated in Figure 3.7 
230.  
The clinical management of AKI is likely to be very relevant to functional outcomes. No 
study to date has reviewed this in any detail.  
Figure 3.9  Factors that may be influencing recovery after an episode of AKI.  
 
Factors associated with AKI recovery 
 
 
Influence 
Older Age  Recovery less likely 
Baseline function  Unclear 
AKI cause  Unclear 
Gender  Males may show better recovery 
Comorbidities  Increased risk of non-recovery 
-  Diabetes 
-  Heart Failure 
-  Low albumin 
AKI Severity  Graded increased risk of non-recovery 
AKI management  Unclear 
 
 
It is notable that Schiffl et al has published the only prospective study to date carrying 
out an assessment of potential risk factors for functional recovery. This study followed 
up patients who had required RRT in the ITU for one year. The authors found that after 
multivariate analysis neither age, gender, comorbidity, severity of illness, cause of ATN 
nor mode of RRT were independently associated with partial recovery of function from 
an episode of ATN 
388. However, this study may have lacked the power to draw any firm 
conclusions from these findings. The original cohort consisted of 425 patients but only 
25% of these survived the five years of follow up.  
 
Finally, there is some evidence that the demographics of recovery have changed in 
recent decades. McCarthy et al reported the outcomes of patients who required 
dialysis in their intensive care unit during two separate periods from 1977 to 1979 and 
then 1991 to 1992. They found that the overall survival had improved in the later era 
and this was despite an increase in the age and burden of comorbidities of the 
patients. The authors attributed this to improved ITU management. However, in 
relation to recovery from the need for dialysis the later era faired worse. In the earlier 
period 96% of patients (22 of 23) had recovered to come off dialysis after one year 
compared to 78% (29 of 37) in the later period 
382. These findings indicate the 
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findings highlight the important implications of AKI in the modern era. If more patients 
are surviving the hospitalisation and AKI is playing a causal role in the incidence and 
progression of CKD its contribution to the CKD population will be increasing.  
 
3.8 Summary 
 
The precise nature of the association between AKI and CKD is still debated in the 
literature 
50,357,398,399. However, there is agreement that rigorous prospective studies are 
needed to better characterize the AKI/CKD interaction 
50,399.  There are many problems 
with the current body of evidence: 
 
-  Many of the risk factors for AKI are shared with CKD itself and so separating 
the two along a causal pathway is difficult. Some authors have suggested that 
AKI may simply serve as a prognostic marker for the development of CKD in 
those who are already at high risk and destined to develop it. AKI in this sense 
may simply represent a failed ‘stress test’ 
352,399. 
-  There is a lack of consensus in the literature on the definition of baseline 
kidney function, AKI itself, and the definition and evaluation of recovery and 
progression. Indeed many studies have failed to adequately define baseline 
function or have used estimates. This may have resulted in AKI occurring on 
top of previously unrecognized CKD and then being reported as having caused 
CKD.  
-  There is conflicting evidence in the literature particularly in relation to the 
outcomes of milder episodes of AKI. Some studies have demonstrated an 
increased risk of progressive disease even after a very mild AKI. In the only 
study to review the slope of decline of renal function before and after the AKI 
episode there was no increased decline in function demonstrated for mild cases 
of AKI 
230. 
-  Studies to date have focused on follow up at a single time point to assess renal 
function and have done this retrospectively. They have not taken into account 
the effects of inter-current medical events and in particular repeat episodes of 
AKI. There is now evidence that up to one third of patients may experience a 
repeat AKI. As such a single index AKI cannot be said to result in the outcomes 
reported and it is likely that the evolution of function after an AKI is far more 
complex.  
-  There is currently no prospective study in the literature of general hospital 
based patients with follow up beyond discharge. As a result the natural history 
of AKI and its relationship to CKD is unclear because of a lack of patient level 
data. Many important issues remain and these include the association of Mark Uniacke    Chapter 3     
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different AKI causes with recovery, the risk factors for non-recovery, and the 
association of hospital based versus community based AKI with recovery.  
 
In recent years researchers have focused on trying to establish a link between AKI and 
CKD. It appears that this link has never been in doubt and what is actually needed is 
more focused studies to better describe its characteristics and ascertain if the 
outcomes are modifiable. This cannot be done without a proper description of the 
clinical history of the condition and it is hoped this present research will provide this.  Mark Uniacke    Chapter 4     
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Chapter 4: Methods 
4.1 Introduction 
 
The aim of this research was to study the natural history of AKI in the general hospital 
population with a focus on its relationship to the aetiology and progression of CKD. 
This was achieved by conducting a prospective observational study. This chapter 
describes the overall study design as it was outlined in the original study proposal 
beginning with these objectives. During the course of the study, particularly during the 
initial recruitment period, some amendments to the original design occurred. Where 
necessary, these amendments are outlined in detail within the relevant section in this 
chapter.  
 
 4.2 Ethical Approval 
 
Ethical approval for this study was obtained from the Milton Keynes Research Ethics 
Committee on the 30
th September 2009.  REC Ref. 09/H0603/26. 
 
4.3 Objectives 
 
This study was designed to answer the following questions: 
 
1.  In patients with moderate to severe CKD (stages 3-4) does AKI lead to a 
clinically significant persistent reduction in kidney function? 
2.  To what extent does AKI in patients who previously did not have moderate to 
severe CKD (eGFR ! 60) lead to incident moderate to severe CKD? 
3.  What is the relationship between the severity of AKI and progression of pre-
existing moderate to severe CKD or the occurrence of moderate to severe CKD 
in those who previously did not have it in hospitalized patients? 
4.  What socio-demographic and clinical factors predict persistent loss of function 
after AKI both in individuals previously without moderate to severe CKD and 
those with pre-existing moderate to severe CKD? 
 
4.4 Design 
 
This study was a prospective observational cohort study. It was proposed that patients 
would be followed up at 6 and 12 months after recruitment.  Mark Uniacke    Chapter 4     
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The study consisted of two main recruitment arms (see Figure 4.1): 
 
1.  The AKI Group –  patients who had no history of moderate to severe CKD (eGFR 
! 60) and sustained an AKI either on admission to hospital or during their 
hospital stay. 
2.  The AKI on CKD Group – patients in whom a history of pre-existing moderate to 
severe CKD was identified.  Subjects in this population fell into two groups (a) 
those that had CKD and then sustained an episode of AKI either on admission 
to hospital or during their hospital stay, and (b) those that had a history of CKD 
but did not sustain an AKI during their hospital stay. It was proposed that 
patients in Group (a) would be studied to ascertain the effects of AKI on their 
pre-existing CKD, while those in Group (b) would serve as a control group.  
 
Figure 4.1 Flow chart of study recruitment arms. 
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4.5 Sample Sizes 
 
Group 2 AKI on CKD Group 
 
Based on existing evidence of disease progression in those with stable CKD 
progression in the CKD control group was not expected to exceed a 5% fall in eGFR 
over the course of twelve months. For 80% power at the 5% level with a 2 sided test, in 
order to detect a difference of 10% in absolute terms i.e. 15% in the AKI on CKD Group, 
then 160 patients would be needed per group. Allowing for attrition due to losses to 
follow up (death, moved away, non-response to follow up checks) the projected 
number required was rounded up to 250 patients per group. Several assumptions were 
made to arrive at this final number. The inhospital and follow up mortality after an 
episode of AKI reported in the literature while designing this study was widely variable. 
Stevens et al reported a 1 year mortality of 65% in a UK sample however this study 
included largely severe AKI with all cases having a serum creatinine > 300μmol/l 35. Ali 
et al reported a 6 month mortality of 50% 187. We therefore assumed a mortality rate of 
roughly 50% at one year and assuming a drop out rate in the region of 5% the rounded 
figure of 250 was adopted.  
 
Group 1 AKI Group 
  
The AKI group was expected to have fewer co-morbid diseases and particularly would 
be lacking the influence of known CKD. Thus the mortality was expected to be 
substantially lower than in the AKI on CKD group. It was therefore assumed the overall 
attrition rate would be approximately 30%. It was decided to also aim to recruit 250 in 
this group. With this number and 70% follow-up, the 95% confidence limits would be ± 
2.9% if the observed percentage developing moderate to severe CKD was 4%.   
 
4.6 Definitions 
 
4.6.1 Baseline Renal function 
 
Pre-existing moderate to severe CKD 
 
Subjects had at least two eGFR readings < 60mls/min over the previous twelve months 
at least three months apart that did not differ by more than 5mls/min. 
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Pre-existing eGFR ! 60 (not moderate to severe CKD) 
 
Subjects had at least one eGFR ! 60mls/min within the previous twelve months. 
 
4.6.2 Acute Kidney Injury 
 
AKI was defined using the Acute Kidney Injury Network Definition (AKIN) definition 
which was outlined in Chapter 2, Figure 2.5 
39.  
 
The original AKIN stipulated that the criteria be used in the context of the clinical 
presentation and following adequate fluid resuscitation when applicable 
39. As there is 
no reliable or validated way of assessing fluid status this was not applied in this study. 
No study to date where the AKIN definition has been employed has attempted to apply 
rigorous assessment of fluid status.  
 
In this study it was intended to record urine output when this information was 
available. However, as this study was designed to include patients outside of the 
intensive care setting where urine output is generally not reliably recorded only the 
serum creatinine criteria were used in patient recruitment. Finally, the 48 hour 
timeframe was not applied to patients with AKI evident on admission to hospital as the 
precise timing was unknown.  
 
4.6.3 Progression of CKD  
 
Significant progression in CKD was considered to have occurred if there was a 
sustained fall in eGFR  ! 5mls/min from baseline at the time of follow up.  
 
4.6.4 Discussion on definitions 
 
A discussed in Chapter 3, a key question in AKI research design is how to define 
progressive or incident CKD. This study uses the definition of progression in CKD 
recommended by the National Institute for Health and Clinical Excellence 
74. It was also 
applied to the definition of baseline kidney function in those with previous CKD. 
The first arm of the study containing patients without moderate to severe CKD is 
intended to represent those with ‘normal’ baseline function. What constitutes normal 
function in terms of eGFR is subject to debate. However, a threshold was required and 
that of an eGFR ! 60 has been widely applied in the literature previously.  
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4.7 Setting and Population 
 
Recruitment took place in a single centre at Queen Alexandra Hospital Portsmouth 
(Portsmouth Hospitals NHS Trust). 
 
Portsmouth Hospitals NHS trust is an acute trust, which accepts unselected 
admissions, serving a population of approximately 600,000. It is a non-tertiary district 
general hospital but includes the regional tertiary renal service. There is no 
cardiothoracic, neurosurgical, or trauma service on site. The catchment area includes 
the city of Portsmouth with a population of approximately 200,000. Records from the 
Centre for Demography at the Office for National Statistics for 2009 show that the 
ethnic origin of Portsmouth City is 88.8% White with 4.9% Asian or Asian British and 
2.2% Black or Black British. Data from the Quality Outcomes Framework database for 
2011 shows that Portsmouth City Teaching Primary Care Trust has a prevalence of 
registered CKD of 2.9% compared to the UK prevalence of 3.4% 
318. These data relate to 
registered cases only and so will underestimate the true prevalence.  
 
4.8 Study Inclusion Criteria 
 
All patients over 16 years of age admitted to hospital who met the definition of AKI, 
either with or without moderate to severe CKD. 
 
4.9 Study Exclusion Criteria 
 
The following groups were excluded from the study: 
 
1.  Patients already receiving renal replacement therapy including renal 
transplants. 
2.  Patients with malignancy whose prognosis was considered 
      by the clinicians managing them to be less than one year. 
3.   Patients who lacked the capacity to give informed consent and were unlikely to  
      regain this capacity before discharge from hospital; largely older individuals  
      with dementia.  
 
During recruitment, the exclusion criterion pertaining to terminal illness above was 
found to be too restrictive as it did not account for other illnesses such as severe heart 
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therefore amended to include anyone with terminal illness of any cause where the 
prognosis was considered by the clinicians managing them to be less than one year. 
 
4.10 Case Identification and Recruitment 
 
The entire study, from case identification to recruitment, data recording, follow up and 
administration was undertaken by the author.  
 
The steps involved in screening for potential recruits and the recruitment process itself 
are outlined in Figure 4.2. 
 
4.10.1 Screening and Recruitment 
 
Step 1: The hospital biochemistry laboratory provided a daily list of patients who had 
an eGFR < 60mls/min from the previous day. The eGFR was determined using the 
abbreviated MDRD formula 
89. This list contained the patient names and hospital 
numbers together with their location within the hospital and their eGFR. The 
biochemistry laboratory ran a computer program so that this list printed daily onto a 
specified printer to which the author had access for the duration of the study.  
 
The Queen Alexandra Hospital Laboratory processes over 4,000 biochemistry samples 
per day. The list of patients with an eGFR<60mls/min served as a filter to identify 
subjects potentially suitable for inclusion. The laboratory computer algorithm was set 
up to automatically filter samples from origins that would be unsuitable for 
recruitment. This included the dialysis unit, the outpatient department, and those 
received from general practice.  
 
Step 2: All hospital laboratory results are recorded on a system called APEX. Referring 
to the list provided by the laboratory the author screened each case individually on 
APEX to ascertain if the eGFR represented an acute change in renal function using the 
associated serum creatinine. By applying the AKIN criteria patients were identified as 
having an AKI. Blood test records from the previous year were then reviewed to identify 
cases that met the definition of baseline kidney function as defined above. All cases 
potentially suitable for recruitment were recorded on an Excel spreadsheet throughout 
the study which served as a record of the screening process.  
 
Step 3: After generating the list of potential recruits the wards on which the patients 
were staying were visited to review their suitability. The medical notes were reviewed 
and the case discussed with the managing team to insure that the patient did not meet Mark Uniacke    Chapter 4     
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any of the exclusion criteria. If suitable for recruitment, a short invitation to participate 
in the study was given to the patient before approaching them.  
 
Step 4: Patients expressing an initial interest were given an information sheet to 
inform them about the study and what it involved. A separate information sheet was 
used for each of the groups recruited to the study. A copy of each information sheet 
can be viewed in Appendix 14. 
 
Between steps 3 and 4 if a patient was found to be unsuitable or did not want to take 
part this was recorded on the screening spreadsheet and the reason why. Those 
suffering from acute confusion which was expected to settle with treatment of their 
underlying illness were retained on the screening list and reviewed again after a few 
days to assess if they had improved to the point where they could be recruited.  
 
Step 5:  If they agreed to take part the patient was asked to sign a consent form and 
was assigned a study identification number designated by the order of their 
recruitment. Three copies of this consent form were made. One was retained for the 
study records, one placed in the patients’ notes and one given to the patient to keep 
along with the information sheet. A copy of the consent form, which was universal for 
all groups in the study, can be viewed in Appendix 15.   
 
Step 6: A study review form specifically designed for the study was used to record all 
of the baseline data required. This information was obtained from the patient 
themselves, hospital notes, laboratory records, and radiology records. No intervention 
took place with regard to the management of the patient. The study review form used 
can be found in Appendix 16 and is discussed in detail below. 
 
Step 7: Patients recruited to the study were recorded on an Excel spreadsheet with one 
spreadsheet for each group in the study. This recorded their study identification 
number, date of recruitment and the projected dates for follow up in order to keep 
track of the follow up process. Having been recorded in this manner a letter was sent 
to the patients’ general practitioner informing them of their involvement in the study. 
All data on the study review form was later transferred to an SPSS database for data 
analysis. 
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Figure 4.2 Flowchart of recruitment process. 
 
4.10.2 Recruitment Study Review Form 
 
The study review form went through multiple revisions during the initial recruitment 
period before the final version used throughout the study was established. The form 
submitted with the original study proposal (Version 2) and the final version used 
(Version 11) can be viewed in Appendix 16.  
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Problems with the original review form included: 
1.  The original was designed without accounting for the fact that data would 
eventually be transferred to an SPSS database for analysis. There were open- 
ended questions that would not be amenable to statistical analysis on SPSS. The 
form was revised to dichotomize the data recording where possible and a tick 
box format was adopted. 
2.  Certain aspects of the original were time-consuming. It was planned to record 
baseline blood results along with discharge data on the form. This was 
abandoned as it was taking up valuable time and the information was easily 
accessible on the hospital APEX system. 
3.  Recording hospital discharge data such as blood pressure made the study 
unfeasible for a single individual. To capture these data the subject’s status in 
the hospital needed to be monitored and the ward staff requested to alert the 
investigator when the time of discharge arrived. It then required a second visit 
to the ward to collect this data. Initially the option of requesting the managing 
team to record this data was explored. This would have required a significant 
change to the site approvals for the study and it was unclear how reliable the 
process would be. It was decided that the discharge data was not necessary for 
the questions being asked in this study. Discharge blood test results and the 
inhospital outcome could be obtained from the hospital computer system so 
this section of the original form was abandoned.   
4.  Whilst reworking the form a number of additional pieces of information were 
added as outlined below. This included information on the patients’ social 
situation.  
 
4.10.3 AKI Study Review Form Summary and Explanation 
 
Section 1. Patient Details 
 
This section recorded simple information including the study identification number, 
admission date, age and sex. The group the patient was assigned to was also 
recorded. To facilitate analysis, the groups were stratified by AKIN stage and in the 
case of CKD patients the CKD stage was also stratified by the KDOQI classification 
described in Chapter 3.  
 
Section 2. Pre – admission details 
 
This section recorded the subjects comorbidities and for this the Charlson Index were 
used 
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unclear at the time of designing this study however the Charlson Index has been 
widely used in the literature in AKI studies 
168,231,235,352,393. For this study the original index 
as described by Charlson has not been modified and is outlined in Appendix 17. This 
index consists of 19 medical conditions weighted by scores from 1 – 6. A sum score is 
then calculated to yield the total comorbidity score. With regard to patients included in 
the CKD arms of the study these automatically started with a score of 2.  
 
In addition to the comorbidities listed in the Charlson index other parameters were 
added to this section because they were felt relevant to AKI. These included a history 
of obesity and measures to calculate Body Mass Index. A smoking history was recorded 
together with a history of hypertension and the number of antihypertensives in use.  
An effort was made to record some sociodemographic information. This included 
whether or not they lived alone or required carers.  
 
To record an indicator of the subjects’ functional capacity prior to the AKI the Katz 
index was included. After reviewing the literature the Katz index, using a modified 
version from the US Gerontology Society, was chosen because of its simplicity. This is a 
simple numbered scale from 1-6 scoring 1 or 0 for bathing, dressing, toileting, 
transferring, continence and feeding. It has been validated by Brorsson 
401.  
 
Finally, the pre-admission details section recorded a list of the medications taken prior 
to the AKI with a focus on the indication for the use of RAS-blockers. In addition other 
potentially nephrotoxic drugs such NSAIDS were recorded. 
 
Section 3 AKI Details 
 
This section recorded essential details surrounding the period when the AKI occurred. 
It included the admitting specialty and timing of the AKI including whether it occurred 
in hospital or was found on admission. Data recorded included whether or not a urine 
dipstick and renal ultrasound were performed. It was originally planned to request a 
urine Albumin Creatinine Ratio at this point however after reviewing the literature no 
evidence was found that this test would be valid in the setting of an AKI. If the subject 
had documented hypotension within 72 hours of the AKI this was noted and the nadir 
blood pressure recorded.  
 
An effort was also made to record urine output. This is notoriously difficult as many 
patients do not have a urinary catheter placed at the time of an AKI. The urine records 
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simplified to record if a patient was oliguric ( urine output < 300mls/day) or anuric in 
the 72 hours prior to the AKI or afterward. 
 
As discussed earlier, no validated way exists to assess hydration status and this 
element of the AKIN definition has not been used. A record of the clinical impression 
of the subject’s fluid status at the time of the AKI was included in this section of the 
review form to explore this area.  
 
Finally, to record the clinical condition of the patient at the time of the AKI the MEWS 
System was used (Modified Early Warning System). The MEWS system relies on 
recording baseline parameters such as temperature and heart rate and is used on all 
patients routinely in Queen Alexandra Hospital. It is presented as a MEWS score and is 
easily accessible. The MEWS system has been reviewed and validated by several 
authors 
402. It was felt that using a more complex scoring system such as APACHE II 
which is used commonly in the intensive care setting would overcomplicate the data 
collection process.  
 
Section 4 AKI Type 
 
This section was used to record further baseline data on the nature of the AKI. AKI has 
been traditionally divided into Pre-renal, Intrinsic, and Post-renal causes and this 
continues in the recent KDOQI AKI Guidelines 
48. This approach was maintained in this 
study but greater detail was required for the pre-renal type. This was to insure that the 
data could be reproducible and would allow further exploration of this area in the 
analysis. 
 
Traditional pre-renal causes were divided. In the case of sepsis a rigorous definition 
was used adapted from the American College of Chest Physicians and Society of 
Critical Care Medicine 2001 International Sepsis definitions conference 
403. A minimum 
of two criteria were required to diagnose an infection associated AKI – a documented 
or suspected infection with a clear focus and one feature of the systemic inflammatory 
response syndrome. Culture status was recorded but was not essential for diagnosis. 
By definition, as there was an AKI present, these patients automatically fell into the 
category of severe sepsis with organ dysfunction regardless of their overall clinical 
state. 
 
Intrinsic AKI was only recorded if there was biopsy evidence or a high clinical suspicion 
recorded by a consultant nephrologist. The latter was bearing in mind that not all 
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Finally, the review sheet ended with a record of any formal review by the renal service, 
admission to intensive care, or any form of renal replacement therapy. 
 
 
4.10.4 Discussion on recruitment 
 
An initial period of recruitment to this study began in November 2009 and continued 
through to December 2009. During this time the methods outlined were put into 
practice and the recruitment process was assessed. Many problems were identified 
with the original design during this period and recruitment was suspended in 
December 2009 in order to address these issues. 
 
1. The recruitment study review form 
 
As outlined above extensive changes were made to the study review form. 
 
2. Feasibility of recruitment numbers 
 
Pilot Study 
To aid the design of this study a pilot was undertaken from 16/03/2008 to 
24/03/2008 inclusive. The purposes of this pilot were as follows: 
1.  To establish how the data collection would be undertaken. 
2.  To estimate the duration of the data collection process on a daily basis, 
ensuring it would be within reasonable time limits. 
3.  To estimate how many patients could potentially be enrolled during the study 
time period, ensuring that projected numbers could be achieved. 
 
The pilot was carried out using the same conditions specified in the protocol and 
illustrated earlier in Figure 4.2. The time it took to conduct this process was recorded 
on a daily basis together with the numbers of potential recruits. A sample of the cases 
was reviewed on the wards and data was recorded on the study review form. The time 
taken to conduct these reviews was also recorded. 
 
It took an average of 64 minutes per day to review the eGFR list provided by the 
laboratory. An average of 5 cases per day met the study criteria and were suitable for 
review (range 1-8). 15 cases meeting the AKI Group criteria were identified and 21 
cases meeting the AKI on CKD Group criteria. Based on these numbers it was 
estimated that there would be roughly 277 AKI Group cases over 6 months and 388 
AKI on CKD cases over 6 months that would be available for recruitment. It was Mark Uniacke    Chapter 4     
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originally proposed that recruitment would take place over 6 months and so it was felt 
that these numbers were adequate as there would be lee way to extend the 
recruitment period. During the pilot it took on average twenty minutes to review the 
cases and taken with the time it took to review the eGFR list it was felt that the process 
would be manageable. 
 
In hindsight, there were several problems with these assumptions which became 
readily apparent when actual recruitment to the study began. 
 
1.  The time estimate for reviewing one eGFR list was accurate however it was not 
considered that there would be three lists present on a Monday after a 
weekend. 
2.  The pilot demonstrated a marked range of daily cases from 1 to 8. It is likely 
that if the pilot was carried on for longer it may have given a better indication 
of how many cases would be eligible.  An extreme example would be three 
days of 8 cases over a weekend leading to 24 cases to be reviewed on a 
Monday. 
3.  The time estimate for reviewing the patients did not account for time spent 
locating them within the hospital. It was also a rough overview of the time 
needed to recruit and did not actually involve explaining the study to the 
patients and the time needed to obtain consent. 
4.  The distribution of the AKIN Criteria stages was not taken into account. 
 
Taking these issues into consideration a longer and more thorough pilot study may 
have altered the approach to the recruitment process from the outset. 
 
Problems with recruitment numbers 
 
When recruitment began in November 2009 the numbers of cases meeting the 
recruitment criteria after screening were far higher than was anticipated from the pilot 
study. In addition, the list of potential recruits was overwhelmed by the milder AKIN 
Stage 1 cases in both the AKI Group and the AKI on CKD Group.  
 
After recruitment was temporarily suspended in December 2009 screening continued 
on a daily basis during the months that followed in order to explore ways of dealing 
with this problem. To preserve the integrity of the selection process it was decided to 
adopt a randomization process for the AKIN stage 1 cases. In the case of the AKI on 
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group. CKD Stage three was therefore split to 3A and 3B and the 3A Group was added 
to the randomization process. 
 
Various levels of randomization were assessed in order to find the most appropriate 
that would keep the numbers of all AKIN Stages at a roughly similar level. A 1:5 
randomization was settled upon and a 1:5 random number list was generated from a 
program freely available online (www.randomizer.org). Using this list the AKIN stage 1 
subjects screened were selected at random yielding one fifth the number of potential 
recruits from the sample. 
 
3. Work load on the wards 
 
Several issues became apparent during the recruitment of the patients that meant the 
workload was too much for a single individual and contributed to the recruitment time 
period being extended significantly. 
 
1.  Queen Alexandra Hospital officially opened a large extension to the hospital in 
October 2009. Many services which had been based at another trust site were 
moved to the new hospital and this may have contributed to an increase in the 
numbers of AKI cases within the hospital. The hospital itself was now one of 
the largest in the region with close to 1400 beds making even getting around it 
time consuming. These issues were not factored into the planning at the time 
of the pilot study. 
2.  Patients were frequently found to have moved wards within the hospital and so 
were not present on the wards that the eGFR list indicated they should be on. 
This resulted in the need to frequently log back on to the hospital computer 
system to locate the patients and so more time was spent. 
3.  With regard to patient movement the Medical Assessment Unit and Surgical 
Assessment Unit were found to be particularly problematic. Patients that 
appeared on the list with an AKI who were located on the assessment units 
were frequently moved to another location in the hospital by the time they were 
reviewed. It was eventually decided to stop attempting to recruit patients on 
the assessment units and to wait for them to appear on the list at ward 
locations within the hospital. This resulted in some patients being missed as 
they were discharged directly from the assessment units back into the 
community. 
4.  The original plan to speak to the admitting team prior to approaching the 
patients also had to be abandoned. The presence of the ward teams was found 
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wasted looking for members of the ward team or trying to contact them 
through the hospital bleep system. It was eventually decided to make an 
assessment of the patient suitability directly from the notes and by speaking to 
the nursing staff involved in their care. 
5.  The timing of visiting the wards was also an unseen issue when recruitment 
began. Ward rounds tended to take place in the morning at various times and it 
was felt to be inappropriate to approach patients while these were taking place 
as it hampered patient care. Likewise, it was felt to be inappropriate to 
approach patients around mealtimes. Considerable organisation was required 
to overcome these problems. A list of ward round times for each ward was kept 
to minimize disruption and lunchtimes were spent screening the days eGFR list 
rather than approaching patients.   
6.  Mondays proved to be particularly problematic in terms of recruitment as there 
were three eGFR lists to be reviewed and more than double the number of 
patients. The only way around this problem working as a single individual was 
to come to the hospital at weekends during recruitment in order to screen the 
lists and have them ready for the following Monday.  
7.  The actual time it took to recruit each patient was also greatly underestimated 
by the original pilot. The information sheet was four pages long and it could 
take over an hour at times to explain everything to the patients and obtain 
informed consent.  
 
4. The CKD Control Group and Recruitment Problems 
 
In the study design it was planned that for each AKI on CKD patient recruited another 
patient with CKD without an AKI would be recruited using the same baseline function 
criteria. These would be matched for age, sex and CKD stage as well as relevant 
comorbidities such as diabetes and hypertension. It was proposed to screen for them 
while doing the daily eGFR list. The recruitment of controls proved to be extremely 
difficult for a number of reasons which resulted in numbers for this group not reaching 
anywhere near the original target. 
 
The problems with CKD control recruitment included: 
1.  Matching for the specified criteria was simply not possible for one person to 
juggle while also trying to screen for patients with AKI. The original proposal 
was overmatching the samples. It was eventually simplified to match for just 
age and CKD stage but even this proved to be onerous. 
2.  There was an inevitable time delay between recruiting a patient and then trying 
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those selected had already been discharged. Presumably, this was influenced 
by the fact that these patients were not as unwell as the patients who had 
experienced an AKI. Indeed, the length of hospital stay was eventually found to 
be considerably different in the results analysis. 
3.  Some patients who were successfully recruited went on to have an AKI during 
their hospital stay and switched arms in the study. To overcome this an attempt 
was made to observe patients for a few days to ensure stability prior to 
recruiting them however again this resulted in many being discharged early. 
 
Overall, the control population in this study was not feasible under the circumstances. 
The workload was too much for one person and was not helped by the study design. 
Ideally, in order to recruit controls of this type one would need a process of blanket 
recruitment of all with CKD. This would require far more resources and was beyond the 
scope of this study. Personal communication with a member of the ASSESS AKI group  
in the United States who are currently undertaking a study of a very similar design has 
revealed that they are also experiencing problems recruiting controls.  
 
4.11 Serum Creatinine and EGFR Measurements 
 
All blood tests carried out in this study and used in the analysis of renal function were 
carried out in the same laboratory in Queen Alexandra Hospital. Tests were done using 
the Jaffe Method described in Chapter 2 using a Beckman Coulter Analyser – Unicel 
DXC 800. The laboratory runs continuous automated quality control testing of this 
analyser up to seven times per day to ensure the accuracy of its calibration. This is one 
of the strengths of this study as it eliminates interlaboratory variation in the 
measurement of serum creatinine and hence eGFR calculation.  
 
4.12 Overall Timeframe of the Study 
 
The original timeframe allotted for this project was two years. It was proposed that 
recruitment would take place over the first six months. Patients would then be 
followed up once at six months and again at twelve months taking the time for the 
study up to 18 months. This would allow six months for data analysis.  
 
As outlined above the recruitment process was far more onerous than expected and 
the time needed considerably longer. After a period of recruitment in November and 
December 2009 it was put on hold in order to rectify the problems encountered. This 
was further hampered by a period of compassionate leave for the author so that formal 
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follow up plans was undertaken. It was recognized that follow up of twelve months for 
each patient was unlikely to be possible in the timeframe remaining. It was thus 
shortened to a single six month follow up for each patient. The basis for doing this 
was researched and found to be reasonable. A review of the literature revealed several 
studies where the recovery pattern of patients after an AKI was illustrated. It was found 
that recovery continued for up to three months after the AKI but plateaued from six 
months onwards. This was described in detail in Chapter 3. It was therefore felt to be 
reasonable to conduct a single follow up at six months in order to answer the 
questions the study was asking. 
 
The overall timeframe for the study therefore was: 
 
Recruitment  -  November 2009 to April 2011 
 
Follow up      -  complete in October 2011. 
 
4.13 Follow up Process 
 
After discharge from hospital a letter was sent to the patients general practitioner 
informing them of the patients recruitment to the study. 
 
The follow up information planned were  
 
1.  A serum Creatinine with eGFR  
2.  A urine Albumin creatinine ratio 
3.  A list of current medications  
4.  Weight 
 
The two groups had separate follow up plans: 
 
AKI on CKD Group 
 
Patients with pre-existing CKD under current guidelines should be undergoing 
monitoring by their general practitioners at least on a yearly basis and in more severe 
cases on a six monthly basis. It was agreed with the ethics panel and the local Primary 
Care Trusts that it would be reasonable to request that the general practitioner 
conduct a follow up blood test for renal function with serum creatinine and eGFR 
together with a urine ACR. The letter to the GP explained this and requested that the 
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practice one month before the due date with a proforma requesting they provide 
confirmation that the blood test and urine sample had been requested. A letter was 
also sent to the patient reminding them that the tests would be due.  
 
This overall process was helped considerably by the fact that many patients were 
already booked for monitoring blood tests by their general practice. Responses to 
requests were initially found to be slow but the overall response rate was excellent. For 
those where no response was received the patient was eventually telephoned directly 
and given the option of coming to the renal unit to have the tests done. In a number of 
cases the patients were willing to take part but not to come to the hospital. In this 
situation the author called directly to their homes to take the blood sample and record 
the necessary information.    
Many GP practices performed the blood test but did not provide a urine ACR. It was felt 
that this was because in patients without diabetes the general practitioners did not feel 
that it was indicated. These tests are not without cost. Rather than pursuing this 
matter it was decided to abandon the need for a urine ACR. The study participants for 
the most part did not have a baseline ACR performed at any stage prior to the AKI and 
without anything to compare with the follow up sample would be futile in terms of 
results analysis.  
 
AKI Group 
 
Patients without CKD prior to the AKI would not be expected to be having monitoring 
at their GP practice. For this reason it was agreed that these patients would be 
followed up in the hospital renal unit by the author. A reminder was posted to the 
patients one month prior to the due date with an appointment to attend the renal unit 
for follow up. This was quickly found to be an impractical way of making contact with 
the patients and non-attendance was high. The letter to the patient was revised and 
rather than sending a set appointment they were reminded of the follow up due and 
told that they would be contacted directly by telephone to make the appointment. This 
was successful and with this method few patients were missed. Those that were 
unprepared to return as in the AKI on CKD Group were offered a follow up visit at 
home. 
 
Prior to contacting any patient before follow up the hospital computer system was 
consulted to see if the patients were still alive.  
 
After follow up a brief report was posted to each general practitioner informing them 
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particularly severe CKD and in a few cases the general practitioner was advised to refer 
the patients to the renal unit for formal review in the event that there were concerns 
about ongoing care. An example of such a letter from the study is shown in Appendix 
18. 
 
4.14 Review of pre-admission details 
 
To facilitate exploration of admission patterns and recurrent episodes of AKI a 
retrospective review of hospital and biochemistry records was carried out. In addition, 
previous biochemistry records were used to calculate the eGFR slope during the three 
years prior to the index AKI. 
 
4.14.1 Hospital admissions prior to the index AKI 
 
Portsmouth Hospitals NHS Trust records all hospital admission on a computer 
database called PAS. The PAS system was reviewed for all patients recruited to the 
study to record admission during the year prior to the index AKI. 
 
4.14.2 Possible previous AKI episodes 
 
The hospital APEX system was used to review all of the biochemistry records of each 
recruit extending back four years from the index AKI. Any rises in creatinine that met 
the AKIN criteria for AKI were recorded. 
 
4.14.3 eGFR slope prior to the AKI 
 
In order to explore the influence of prior renal function on outcomes further, a 
regression line was used to calculate the eGFR slope for each patient prior to the index 
AKI. A uniform approach was taken in each case to create the regression line. Hospital 
biochemistry records were retrospectively reviewed over the three years prior to the 
baseline eGFR at six monthly intervals. If an outpatient eGFR was present in the three 
months on either side of each six month interval then this was selected for inclusion. If 
more than one was available then the highest was chosen. Therefore over the three 
years reviewed a patient could have a maximum of seven eGFR results to create a 
regression line from which to calculate the slope. The slope of the regression line was 
calculated using SPSS.  
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4.15 Confidentiality and Data Protection 
   
Strict confidentiality and data protection was carried out throughout the study and 
good clinical practice standards were observed.  
 
Each patient recruited to the study was assigned a Study Identification number which 
was used throughout. Patient details with this study number were kept in a separate 
file with no clinical data attached. All data was recorded on password protected 
computers using the study number only so no link could be made to the patients 
involved. All files pertaining to the study were stored in the research laboratory of the 
Wessex Renal and Transplantation Service at Queen Alexandra Hospital which is locked 
when unoccupied by research staff.  
 
4.16 Data Analysis 
 
Data was analysed using SPSS 19 with help and advice from Dr. Scott Harris from the 
Department of Public Health Sciences and Clinical Statistics at the University of 
Southampton. 
 
The data are presented as percentages, mean ± standard deviation or median with 
interquartile range where appropriate. The groups were compared using the Chi-
squared test or Fishers Exact Test for categorical data. Continuous data was compared 
using the independent samples T-test if normally distributed with 95% Confidence 
Intervals or if non-parametric the Mann – Whitney U test.  Categorical data was tested 
using the Chi-squared test for trend while continuous data was compared using the 
method of one-way Analysis of Variance or the Kruskall - Wallis test where appropriate. 
A p-value of <0.01 is taken as significant. Univariate and multivariate binary logistic 
regression analysis was carried out to explore the factors influencing the study 
outcomes. Univariate data is presented as the Beta coefficient, odds ratio with 95% 
confidence interval and p value. Multivariate analysis was carried out on a priori factors 
of interest.  Mark Uniacke    Chapter 5     
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Chapter 5: Results 1 – Study Population 
 
5.1 The AKI population 
 
This study was designed to evaluate the impact of AKI on CKD. To do this a rigorous 
definition of baseline renal function was used and is described fully in Chapter 4. This 
restricted recruitment to those who had previous measurements of their kidney 
function on record. Therefore the sample is not representative of the entire AKI 
population. The recruitment process is outlined here to describe how the study 
population was obtained in order to facilitate interpretation of the results.  
 
Figure 5.1 shows the framework of recruitment of the study population which took 
place in two stages. Firstly, the screening stage during which patients with an eGFR < 
60 meeting the study criteria were identified. This was followed by the recruitment 
stage during which eligible patients were reviewed and recruited. Two groups did not 
fit into this framework and may have represented additional AKI cases that were not 
identified by this study: 
 
1. Community Only AKI 
 
AKI is known to occur in the community in patients who are not admitted to hospital. 
This group could not be studied. Therefore the impact of these AKI episodes cannot be 
assessed. The blood test records for the four years preceding the index admission of 
all 401 patients recruited for this study were retrospectively reviewed. Just two patients 
had evidence of a rise in serum creatinine meeting the AKIN definition that occurred in 
the community without an admission to hospital. This represents < 0.5% of the sample 
and as these patients represent those most vulnerable to sustaining an AKI this figure 
serves as a crude indicator that this group may be very small. 
 
2. Uncertain Group not meeting study criteria 
 
Patients in the Uncertain group were found to have an eGFR < 60 during the index 
hospitalization but did not meet the study criteria for baseline kidney function and so 
could not be classified into any of the groups eligible for recruitment. These could 
have fallen into one of the groups outlined in Table 5.1. Firstly, there were those with 
an eGFR < 60 but no values on record in the previous year. These may have 
represented an AKI, AKI/CKD or may have been stable CKD. As outlined in Chapter 2 
many studies used a back calculation in this scenario.  Mark Uniacke    Chapter 5     
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Secondly, those with an eGFR < 60 with just one previous value < 60 on record. These 
may have been in the stable CKD group or could have been AKI/CKD. Thirdly, there 
were some with two or more previous values < 60 but these were differing by more 
than 5mls/min or were not more than three months apart. These may have included 
those with a rapid progression of CKD in the absence of AKI or may have been 
AKI/CKD.  Finally, during the screening stage another group was identified that did not 
meet the 48 hour rise in creatinine in hospital specified by the AKIN definition. In this 
Queen Alexandra Hospital Catchment 
Population 
Community Only AKI 
Hospital Admission. 
Found to have eGFR < 60 
Possible AKI or CKD 
Two eGFRs < 60 
in previous year 
Stable CKD 
AKI/CKD 
Group 
 
Uncertain 
Group 
 
Control 
Group 
   
AKI  
Group 
 
Stage 1. 
Screening 
One eGFR ! 60 
in previous year 
AKI / CKD 
by AKIN 
 
AKI 
by AKIN 
Stage 2. 
Recruitment 
Figure 5.1. Flowchart illustrating the stages leading to recruitment of the study 
population. 
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group the rise in creatinine tended to be slow and delayed sometimes by several days 
and may have fluctuated. These may or may not have also had an AKI.  
 
Table 5.1. Outline of potential diagnoses within the Uncertain Group. 
   
  a. Hospital eGFR < 60 but no previous values      - possible AKI 
        possible AKI/CKD 
        possible stable CKD 
   
  b. Hospital eGFR < 60 with one previous value 
      < 60  
    - possible stable CKD 
      possible AKI/CKD 
   
 c. eGFR < 60 with ! 2 previous values < 60 but 
    differing by > 5mls/min or < 3 mts apart 
    - possible AKI/CKD 
      possible rapid progression of CKD 
     
   
  d. Those meeting baseline criteria but not  
      AKIN timeframe within hospital 
    - possible AKI 
   
 
Analysis of the screening data outlined in more detail below revealed that this 
uncertain group comprised approximately 15% of the eGFR < 60 tests screened. Those 
found to meet study criteria for AKI in the two groups accounted for just over 5% of the 
samples screened while the remaining approximately 80% had stable CKD according to 
study criteria. It must be highlighted that these proportions are estimates. 
 
5.2 Stage 1 – Screening of laboratory eGFR tests 
 
The daily lists of eGFRs < 60 provided by the laboratory were reviewed to ascertain the 
numbers screened. Eight of the original screening lists were missing – these were not 
printed at the time of screening because of occasional transient power outages within 
the hospital which shut down the printer. The average number screened per day for 
the rest of that month was substituted in their place. In total 44,655 tests with eGFR 
<60 were screened. This excludes cases where a patient had more than one eGFR on 
the same day. However, it does not account for the repeats that would have occurred 
during the patients hospital stay and likewise does not account for repeat admissions 
during the study period. Chapter 6 contains information on the admission patterns of 
the recruits in the study during follow up where it was found that over 40% in each 
group was readmitted at least once. Given the large numbers of tests involved and the 
fact that the screening of the eGFR lists was performed by hand it was not possible to Mark Uniacke    Chapter 5     
        113 
monitor this repeat sampling. Only the cases who were already recruited could be 
excluded if they were readmitted. Repeat sampling and readmissions are likely to 
contribute significantly to the overall number of tests screened. It therefore must be 
highlighted that the tests do not represent patient numbers and are likely to 
considerably overestimate actual patient numbers. The total of 44,655 gives an 
average of 144 eGFRs < 60 screened per day during the study period. There was some 
evidence of seasonal variation in numbers during the study and this is illustrated in 
Figure 5.2.  
 
 
 
 
 
 
5.2.1 Uncertain Group estimation 
 
During the screening process the tests falling into the four uncertain groups described 
in Table 5.1 were highlighted. To estimate the numbers in this group three random 
days were selected from each full month of the recruitment period from June 2010 
through to March 2011. The random selection was undertaken using a standard table 
of random numbers and all months of the recruitment period were sampled to account 
for the seasonal variation demonstrated above. In the thirty randomly selected days 
there was a total of 4506 tests with eGFRs < 60 screened and of these 592 tests did 
not meet study criteria because of a lack of previous results while 88 tests were in the 
delayed category. This was 13% and 1.9% of the total respectively. Therefore a crude 
estimate of 15% of the tests screened fell into the uncertain group.  As mentioned 
earlier, the 44655 tests screened did not exclude cases where a patient had more than 
one test during their hospital stay and so the actual proportion of patients in this 
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Figure 5.2. On the left is shown the seasonal variation of the numbers identified with 
eGFR < 60 on a daily basis per month. On the right is the mean number of patients 
eligible for recruitment on a daily basis per month.  Both graphs demonstrate the 
increase in available numbers and hence AKI during the winter months.  Mark Uniacke    Chapter 5     
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group cannot be reasonably estimated but it can be inferred from the 15% test 
estimate that this group was not small. 
 
5.2.2 Eligible patients following initial screening 
 
A total of 2408 patients met the study criteria for either the AKI group or the AKI/CKD 
group after screening the 44655 eGFR tests. 61.4% (n=1480) of these were in the AKI 
group and 38.5% (n=928) were in the AKI/CKD group. This is illustrated in the flow 
chart in Figure 5.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The distribution of the eligible patients according to AKIN stage in each of the groups 
is illustrated in Figure 5.4 and Figure 5.5.  In the case of the AKI/CKD group the 
distribution is divided according to CKD stage.  This clearly illustrates that over 60% in 
both groups were in the milder AKIN Stage 1 without sampling of this group.  
 
Figure 5.3.  Flowchart highlighting the 2408 patients meeting study criteria 
for the two AKI groups during screening.  
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Figure 5.4. Distribution of the screened AKI group by % AKIN stage. 
 
 
  AKI Group (N=1480) 
                 AKIN Stage            No. % 
                        1        769 (51.9) 
                        2        439 (29.6) 
                        3        272 (18.4) 
 
Figure 5.5. Distribution of the screened AKI/CKD group by % AKIN Stage. 
 
 
       AKI/CKD Group        (N=928)   
      CKD Stage    AKIN 1 (No. %)     AKIN 2 (No.%)    AKIN 3 (No.%) 
           3A       316 (34)         87 (9.3)        43 (4.6) 
           3B       255 (27.4)         68 (7.3)        26 (2.8) 
           4       104 (11.2)         17 (1.8)         2 (<.01) 
           5           10 (.01)           0         0 
Total      685 (73.8)       172 (18.5)        71 (7.7) 
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To explore the distribution of the CKD stages by AKIN stage it was necessary to 
combine CKD Stage 4 and CKD Stage 5 because of the smaller numbers. This is 
illustrated in Table 5.2. The Chi-Squared test for trend was used to compare the CKD 
stages. A significant difference was found in the distribution of the AKIN stages 
according to CKD stage (p=0.005). A significantly larger portion of CKD stage 4/5 was 
in the milder AKIN stage 1.  
 
Table 5.2. Distribution of the screened AKI/CKD group with AKIN stage expressed 
as N(%) of each CKD Stage. CKD Stages 4 and 5 are merged.  
 
  AKI/CKD Group  (N=928)     
CKD Stage   AKIN 1  AKIN 2  AKIN 3  Total 
3A N(%)  316 (70.8))  87 (19.5)  43 (9.6)  446 
3B N(%)  255 (73)  68 (19.4)  26 (7.4)  349 
4/5 N(%)  114 (85.7)  17 (12.7)  2 (0.02)  133 
Total  685  172  71  928 
 
5.3 Stage 2 – Recruitment of eligible patients 
 
The flowchart in Figure 5.6 provides a summary of the recruitment stage of the study. 
 
5.3.1 Random Sampling of AKIN Stages 1 
 
It was necessary to randomly sample AKIN Stage 1 in this study and the rationale for 
this can is outlined here. Figure 5.4 and Figure 5.5 illustrate how the majority of 
eligible patients in both groups were in the milder AKIN stage 1. As there was scope to 
recruit at most between 15 and 20 patients per week by a single investigator there was 
a danger that the recruited cohort would be overwhelmed by AKIN stage 1. This in 
theory would be the group least likely to show the impact on CKD incidence and 
progression that was being studied. Therefore random sampling of AKIN Stage 1 in the 
AKI group and the AKIN 1/CKD stage 3A cases in the AKI/CKD group took place. This 
resulted in the deliberate over-sampling of AKIN stages 2 and 3. 
 
5.3.2 Problems with random sampling of AKIN Stage 1 
 
A formal review of the recruitment process and numbers obtained was undertaken in 
December 2010. A key finding was that the AKIN stage 1 numbers were far lower than 
expected. For example, in the AKI group 538 AKIN stage 1 cases had been found to be Mark Uniacke    Chapter 5     
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eligible and 102 of these were randomised for potential recruitment. Just 11 patients 
from this group were actually recruited. The reason for this was found to be the high 
discharge rate in this group prior to them being reviewed. 59 (58%) of those 
randomised had been discharged by the time they were approached for review, some 
within 24 hours. This may be explained by the fact that these patients were less sick 
and had milder kidney injuries but also the milder injury may not have been 
recognised by the clinical team. However, it was also found that 18 (17.6%) of the 
randomised cases had died in hospital before they could be recruited. As the natural 
losses in this group were so high it was decided to abandon the randomisation process 
for the remainder of the study. Random sampling was therefore carried out for the first 
seven months of the recruitment period from the 25
th May 2010 to 24
th December 
2010 and abandoned for the remaining three months. 
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5.3.3 Recruitment losses 
 
Figure 5.6 shows that there were considerable losses from the eligible group with 
2044 lost during the recruitment period. Table 5.3 summarizes the reasons for these 
losses.  
 
Stable CKD 
by study 
criteria  
 
 
Stage 2. 
Recruitment 
AKI  
by AKIN 
 
  N = 1480  
     
AKI/CKD 
by AKIN 
 
N = 928 
AKIN 1 Not 
Randomised 
429 
AKIN 1 Not 
Randomised 
201 
Losses 
RIP  120 
Discharge 274 
Malignancy 18 
Palliative 32 
Confused 87 
Other 14 
Refused 5 
Losses 
RIP  188 
Discharge 434 
Malignancy 48 
Palliative 41 
Confused 77 
Other 69 
Refused 7 
AKI  
Recruits 
 
   N = 187 
     
AKI 
Recruits 
 
N = 177 
CKD Control 
Recruits 
 
N = 28 
 
Figure 5 6  Flowchart illustrating how the recruited groups were derived 
from the eligible patients.  Mark Uniacke    Chapter 5     
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Table 5.3  Losses from the eligible groups during recruitment. 
 
Losses from eligible group  N = 2044     No. (%) 
Death  308 (15.1) 
Discharged  708 (34.6) 
Declined to take part  12 (.006) 
Confused/dementia  164 (8.0) 
Advanced malignancy  66 (3.2) 
Palliative  73 (3.6) 
Other  83 (4.1) 
AKIN 1 Not randomised due to sampling  630 (30.8) 
 
As expected, a large proportion was not randomised from the AKIN 1 group during the 
first seven months of recruitment. Another large proportion of patients (34.6%) was 
discharged prior to being able to review them. This includes 228 (32.2% of total 
discharged) that were lost while the investigator was on compassionate leave. As 
mentioned earlier, there is a concern that some cases were discharged without the 
clinical team recognising the importance of the AKI. On several occasions the 
investigator had to intervene and inform the clinical team that they had discharged 
patients with an evolving AKI that required them to call the patients and get them to 
return. One of these patients had a severe AKI requiring a formal renal review.  
A substantial portion of the eligible group had died by the time the investigator 
approached them. The ‘Other’ group included a wide variety of reasons for being 
unsuitable for recruitment including several patients under mental health section, 
overseas visitors and even one prisoner awaiting deportation. Very few patients in the 
population (0.006%) declined to participate.  
 
5.3.4 The Sampling Fraction 
 
An effort was made to establish the sampling fraction of each AKIN Stage subgroup 
recruited. This is relevant to any conclusions that can be drawn from comparisons 
within and between groups. It also illustrates the effect of the random sampling and 
losses described above. It proved impossible to derive this with 100% accuracy and so 
the proportion is expressed as an adjusted estimate. The reason that an estimate has 
to be used is because of a small shift that occurred between groups following 
recruitment. This is a feature of prospective recruitment whereby a patient found to be 
eligible for a particular subgroup on a given day continued to evolve after recruitment 
and progressed to a higher AKIN stage. The proportions expressed are therefore only 
estimates as there would have been a similar small shift within the losses from each Mark Uniacke    Chapter 5     
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eligible group that cannot be quantified.  The proportions sampled from those eligible 
for each AKIN stage are outlined in Table 5.4 and Table 5.5 for the AKI and AKI/CKD 
groups respectively. 
 
In the AKI Group it can be seen that there were 769 patients found to be eligible from 
the screening process. The total recruited was 45 and when added to the losses 
including those not randomly sampled the total is 767. The difference is accounted for 
by two patients that were screened as AKIN stage 1 and recruited but who continued to 
evolve immediately after recruitment and progressed to AKIN stage 3. The proportion 
sampled is therefore calculated by taking the 45 recruits for this stage as a proportion 
of 767 instead of 769 and gives 5.9%. In a similar manner ten patients shifted from 
AKIN stage 2 to stage 3 and so the sampled proportion of 16.3% is calculated from the 
adjusted total. For AKIN stage 3 the total eligible was increased by the 12 that shifted 
from lower groups when doing the calculation. Table 5.4 illustrates that the proportion 
of each AKIN stage in the AKI group differs from how it is distributed in the population 
studied. Just 5.9% of eligible AKIN stage 1 patients were recruited as opposed to 25.4% 
of those eligible for AKIN stage 3. AKIN stage 1 is therefore under represented in the 
final cohort and this needs to be accounted for when discussing the generalizability of 
the results obtained in the study.  
 
In the AKI/CKD group the same phenomenon occurred with 14 patients shifting from 
AKIN stage 1 to higher stages so adjustments were necessary as described above. 
14.3% of those eligible for AKIN stage 1 were recruited, 27.7% of AKIN stage 2 and 40% 
of AKIN stage 3. Like the AKI group this highlights the difference in the proportions of 
AKIN stage in the final cohort compared to the population studied.  Mark Uniacke    Chapter 5     
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Table 5.4 The adjusted sampling estimate for each AKIN Stage of the AKI group 
accounting for losses and adjusted for the stage shift following recruitment. 
 
  AKIN Stage 1 
N(%) 
AKIN Stage 2 
N(%) 
AKIN Stage 3 
N(%) 
No. Eligible  769  439  272 
Death  38(5)  85(19)  65(24) 
Discharge  182(24)  171(39)  81(30) 
Malignancy  14(2)  17(4)  17(6) 
Palliative  10(1)  18(4)  13(5) 
Dementia  21(3)  38(9)  18(7) 
Refused  0  2  5 
Others  28(4)  28(6)  13(5) 
Not Randomised  429     
Recruited  45  70  72 
Total  767  429  284 
Number shifting to 
higher stage after 
recruitment 
 
 
2 
 
 
10 
 
Number added to 
group after shift from 
lower stage 
     
 
12 
Adjusted Sampling 
Estimate 
 
5.9% 
 
16.3% 
 
25.4% 
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Table 5.5 The adjusted sampling estimate for each AKIN Stage of the AKI /CKD 
group accounting for losses and adjusted for the stage shift following 
recruitment. 
  AKIN Stage 1 
N(%) 
AKIN Stage 2 
N(%) 
AKIN Stage 3 
N(%) 
No. Eligible  685  172  71 
Death  64(9)  41(24)  15(21) 
Discharge  199(29)  56(33)  19(27) 
Malignancy  15(2)  0  3(4) 
Palliative  24(4)  4(2)  4(6) 
Dementia  60(9)  21(12)  6(8) 
Refused  3  1  1 
Others  9  5  0 
Not Randomised  201     
Recruited  96  49  32 
Total  671  177  80 
Number shifting to 
higher stage after 
recruitment 
 
 
14 
   
Number added to 
group after shift from 
lower stage 
   
 
5 
 
 
9 
Adjusted Sampling 
Estimate 
 
14.3% 
 
27.7% 
 
40% 
 
 
5.4 The Final Study Population  
 
The final AKI study population consisted of 375 patients together with 26 CKD controls 
taking the total to 401. The assembly of this population is summarised in Figure 5.7.  
The original pilot in November 2009 recruited 9 patients – 6 for the AKI/CKD group 
and 3 for the AKI group. These were added to the final cohort. In addition 2 patients 
that were originally recruited to the CKD control group were later switched to the 
AKI/CKD group as they were found to have sustained an AKI during their admission 
after recruitment.  
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The distribution of the final AKI cohort of 375 patients by AKIN stage is illustrated in 
Figure 5.8. The distribution of the sample is notable for the deliberate under sampling 
of AKIN stage 1which can be contrasted with the actual eligible numbers illustrated in 
Figures 5.4 and 5.5 earlier in the chapter. In Figure 5.8 the AKI/CKD group is also 
distributed by CKD stage. It is notable that in the three AKIN stages of the AKI/CKD 
group there were very few of the higher CKD stages 4 and 5. For this reason, during 
analysis of the data the CKD stages will be merged for each AKIN subgroup. 
Figure 5.7  Flowchart illustrating the assembly of the final study population. 
CKD Control 
Recruits 
 
N = 28 
  
 
Final Study 
Population 
AKI 
Recruits 
 
N = 187 
 
AKI / CKD 
Recruits 
 
   N = 177 
3 added from 
pilot 
6 added from 
pilot 
2 Controls 
switched to 
AKI/CKD 
 
Final 
AKI Group 
 
N = 190 
     
Final 
AKI/CKD 
Group 
N = 185 
Final  
CKD Control 
Group 
N = 26 
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Figure 5.8 Distribution of the Final AKI Cohort by AKIN stage. The AKI/CKD group 
is also distributed by CKD stage.  
 
 
 
  AKI Group 
N = 190 
AKI/CKD Group 
N=185 
 
AKIN Stage No, %  1  46  (24.2)  99  (53.51) 
  2  71  (37.4)  53  (28.64) 
  3  73  (38.4)  33  (17.83) 
 
 
 
 
 
 
 
;)
4;)
?;)
N;)
O;)
R;)
:;)
U;)
T;)
<=>E)4) <=>E)?) <=>E)N)
<=>)/3"+$)CE"5)FH)<=>E)G&'/0D)
;)
R)
4;)
4R)
?;)
?R)
N;)
NR)
O;)
OR)
R;)
<=>E)4) <=>E)?) <=>E)N)
@=A)N<)
@=AN6)
@=AO)
@=AR)
<=>X@=A)23"+$)CE"5)FH)<=>E)#&'/0)',.)@=A)#&'/0D)Mark Uniacke    Chapter 6     
        125 
Chapter 6: Baseline Characteristics, AKI and 
Outcomes 
 
6.1 Baseline characteristics of Study Population 
 
6.1.1 The AKI and AKI/CKD Groups 
 
Table 6.1 outlines the baseline characteristics of the final AKI and AKI/CKD cohorts. As 
the AKIN stage 1 subgroup was deliberately under sampled in both groups the 
baseline characteristics of the AKIN stages within both groups were compared to 
assess if comparison of the overall groups is valid. These data are presented in Table 
6.2 and Table 6.3.  
 
Table 6.1 Comparison of the baseline characteristics of the AKI and AKI/CKD 
groups.  
    AKI Group 
N = 190 
AKI/CKD Group 
N=185 
 
P 
Age,ys, 
Median (IQR) 
   
68 (59-75) 
 
75 (72-84) 
 
<0.001 
Gender, Male, %    58.4  47.6  0.04 
Ethnicity,  
Caucasian % 
   
98.9 
 
100 
 
Social History, N(%)  Lives Alone  62  (32.6)  82  (44.3)  0.02 
Mean, SD  Katz Index  5.86 (0.65)  5.66 (0.88)  0.02 
Comorbidities  
No., (%) unless stated 
 
 
Hypertension 
 
 
123  (64.7) 
 
 
164  (88.6) 
 
 
<0.001 
  No. Antihypertensives 
Mean, SD 
 
 
1.13 (1.08) 
 
 
1.62 (0.99) 
 
 
<0.001 
  Coronary Heart 
Disease 
39  (20.5)  56  (30.3)  0.03 
  Heart Failure  10  (5.3)  46  (24.9)  <0.001 
  Cerebrovasc. Dis.  17  (8.9)  39  (21.1)  0.001 
  Peripheral Vascular 
Disease 
15  (7.9)  28  (15.1)  0.03 
  Dementia  0  4  (2.2)  0.06 
  Chronic Lung Dis.  25  (13.2)  40  (21.6)  0.03 
  Peptic Ulcer Dis.  0  0   
  Rheumatic. Dis  11  (5.8)  13  (7)  0.62 
  Mild Liver Disease  0  2  (1.1)  0.24 
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AKI Group 
N = 190 
 
AKI/CKD Group 
N=185 
P 
  Diabetes without 
Complications 
41  (21.6)  29  (15.7)  0.14 
  Diabetes with 
Complications 
15 (7.9)  53  (28.6)  0.001 
  Diabetes Overall  56  (29.5)  82  (44.3)  0.003 
  Hemiplegia  1  (0.5)  0   
  Neoplasia  13  (6.8)  18  (9.7)  0.31 
  Severe Liver Dis.  5  (2.6)  0  0.06 
  Leukaemia  0  1  (0.5)   
  Metastases  0  0   
  Lypmhoma  0  4  (2.2)  0.06 
  AIDS  0  0   
Comorbidity Score  Charlson Score Mean, 
SD 
 
1.24 (1.25) 
 
4.19 (1.48) 
 
<0.001 
Other Risk Factors  Smoking History 
(Current and past) 
 
99  (52.1) 
 
107  (57.8) 
 
0.27 
  BMI 
Mean, SD 
28.16  (7.76) 
(n=153) 
29.08  (6.71) 
(n=145) 
0.27 
Medications prior to 
AKI N(%) 
       
On Ace Inhibitor    76  (40)  92  (49.7)  0.06 
On ARB      24  (12.6)  48  (25.9)  0.001 
On RAS blocker     99  (52.1)  137  (74.1)  <0.001 
Indication for RAS 
Blockade N(%) 
       
  Previous M.I.  27 (27.2)  46 (33.5)  <0.001 
  Heart Failure  7 (7.1)  31 (22.6)  <0.001 
  Diabetes with 
microalbuminuria 
 
14 (14.1) 
 
32 (23.4) 
 
<0.001 
  Hypertension  95 (96)  132 (96.4)  <0.001 
  More than 1 
indication 
 
37 (37.4) 
 
81 (59.1) 
 
0.001 
 
Aspirin 
 
 
 
59  (31.1) 
 
86  (46.5) 
 
0.002 
NSAID    31  (16.3)  13  (7)  0.005 
Furosemide    32  (16.8)  98  (53)  <0.001 
Bendroflumethiaz.    22  (11.6)  22  (11.9)  0.93 
Spironolactone    6  (3.2)  29  (15.7)  <0.001 
Trimethoprim    5  (2.6)  10  (5.4)  0.17 
Statin    75  (39.5)  105  (56.8)  0.001 
Metformin    32  (16.8)  34  (18.4)  0.69 
Beta Blocker    41  (21.6)  76  (41.1)  <0.001 
Calcium Ch.    38  (20)  45  (24.3)  0.31 
Alpha Blocker    7  (3.7)  18  (19.7)  0.02 
Allopurinol 
PPI 
  12  (6.3) 
57  (30) 
19  (10.3) 
68  (36.8) 
0.16 
0.17 Mark Uniacke    Chapter 6     
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There are significant differences between the AKI and AKI/CKD groups.  The AKI/CKD 
group is older and more likely to be living alone. The differences between the scores in 
the Katz Index indicate a greater degree of dependency in this group. The AKI/CKD 
group also carries a much greater burden of comorbid illness which is reflected in the 
higher Charlson Score. When the Charlson Index is divided into separate comorbidities 
it demonstrates more cardiac failure, cerebrovascular disease and diabetes with 
complications within the group. There is also more history of hypertension. 
Nevertheless, the AKI Group itself is also characterized by a burden of comorbid 
disease with a mean Charlson score of 1.24.  
 
As expected with the quite marked difference in comorbidities, the baseline 
medications in the groups are also significantly different. The AKI/CKD group is 
characterised by a greater use of cardiovascular medications including aspirin, 
furosemide, spironolactone, statins, Beta-blockers and blockers of the renin-
angiotensin system. The only medications which more common in the AKI group are 
NSAIDS. This may be because those with known CKD are routinely advised to avoid 
NSAIDS in clinical practice. 
 
It is clear from the comparisons made in Tables 6.2 and 6.3 that there was no 
significant difference between the baseline characteristics of the three AKIN stages 
within either group. This makes it unlikely that the under sampling of AKIN stage 1 
had an effect on the baseline characteristics of the overall groups which would have 
questioned the validity of the between group analysis and its generalisability.  
 
Table 6.2 Baseline Characteristics and comparison of the AKIN stages within the 
AKI Group. 
 
   
AKIN 1 
N = 46 
AKI Group 
AKIN 2 
N = 71 
 
AKIN 3 
N = 73 
 
p 
Age,ys, 
Median (IQR) 
 
69 (60–74) 
 
69 (62-80) 
 
65 (57-75) 
 
0.16 
Gender, Male,N%  33 (71.7)  39 (54.9)  39 (53.4)  0.11 
Social History, N(%)   
 
 
 
 
 
 
 
Lives Alone  10 (21.7)  28 (39.4)  24 (32.9)  0.14 
Comorbidities  
No., (%) unless stated 
       
Hypertension  28 (60.9)  50 (70..4)  45 (61.6)  0.45 
No. Antihypertensives 
Mean, SD 
0.96 (0.96)  1.18 (1.09)  0.96 (0.96)  0.21 Mark Uniacke    Chapter 6     
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AKIN 1 
N = 46 
 
AKI Group 
AKIN 2 
N = 71 
 
AKIN 3 
N = 73 
 
p 
Coronary Disease  9 (19.6)  13(18.3)  17 (23.3)  0.75 
Heart Failure  0  8 (11.3)  2 (2.7)  0.01 
Cerebrovas. Dis.  5 (10.9)  8 (11.3)  4 (5.5)  0.42 
Peripheral Vascular 
Disease 
6 (13)  5 (7)  4 (5.5)  0.31 
Dementia  0  0  0   
Chronic Lung Dis.  9 (19.6)  8 (11.3)  8 (11)  0.34 
Peptic Ulcer Dis.  0  0  0   
Rheumatic. Dis  0  5 (7)  6 (8.2)  0.15 
Mild Liver Disease  0  0  0   
Diabetes without 
Complications 
10 (21.7)  17 (23.9)  14 (19.2)  0.79 
Diabetes with 
Complications 
4 (8.7)  6 (8.5)  5 (6.8)  0.91 
Diabetes Overall  14 (30.4)  23 (32.4)  19 (26)  0.69 
Hemiplegia  0  1 (1.4)  0   
Neoplasia  3 (6.5)  4 (5.6)  6 (8.2)  0.82 
Severe Liver Dis.  0  0  5 (6.8)   
Leukaemia  0  0  0   
Metastases  0  0  0   
Lypmhoma  0  0  0   
AIDS  0  0  0   
Charlson Score Mean, 
SD 
1.26 (1.27)  1.21 (1.2)  1.26 (1.27)  0.98 
Smoking History 
(Current and past) 
 
26 (56.5) 
 
35 (49.3) 
 
38 (52.1) 
 
0.75 
BMI 
Mean, SD 
 
28.13 (8.92) 
 
27.71 (7.03) 
 
28.13 (8.92) 
0.82 
Medications prior to 
AKI N(%) 
       
On Ace In. N(%)  17 (37)  29 (40.8)  30 (41.1)   
On ARB  N(%)  9 (19.6)  8 (11.3)  7 (9.6)   
On RAS blocker N(%)  25 (54.3)  37 (52.1)  37 (50.7)  0.93 
Aspirin  15 (32.6)  20 (28.2)  24 (32.9)  0.80 
NSAID  10 (21.7)  10 (14.1)  11 (15.1)  0.51 
Furosemide  5 (10.9)  14 (19.7)  13 (17.8)  0.44 
BZF  9 (19.6)  9 (12.7)  4 (5.5)  0.06 
Spironolactone  0  3 (4.2)  3 (4.1)  0.37 
Trimethoprim  1 (2.2)  3 (4.2)  1 (1.4)  0.55 
Statin  21 (45.7)  28 (39.4)  26 (35.6)  0.55 
Metformin  8 (17.4)  28 (39.4)  26 (35.6)  0.62 Mark Uniacke    Chapter 6     
        129 
   
AKIN 1 
N = 46 
 
AKI Group 
AKIN 2 
N = 71 
 
AKIN 3 
N = 73 
 
p 
Beta Blocker  10 (21.7)  19 (26.8)  12 (16.4)  0.32 
Calcium Ch.  10 (21.7)  15 (21.1)  13 (17.8)  0.83 
Alpha Blocker  1 (2.2)  3 (4.2)  3 (4.1)  0.82 
Allopurinol 
PPI 
4 (8.7) 
17 (37) 
1 (1.4) 
19 (26.8) 
7 (9.6) 
21 (28.8) 
0.09 
0.48 
 
 
Table 6.3 Baseline characteristics and comparison of the AKIN stages within the 
AKI/CKD group. 
    
AKIN 1 
N = 99 
AKI/CKD Group 
AKIN 2 
N = 53 
  
AKIN 3 
N = 33 
 
p 
Age,ys, 
Median (IQR) 
 
79 (71-84) 
 
77 (72-83) 
 
80 (75-85) 
 
0.47 
Gender,Male,N%  50 (50.5)  23 (43.4)  15 (45.5)  0.68 
Social History, N(%)   
 
 
 
 
 
 
 
Lives Alone  46 (46.5)  23 (43.4)  13 (39.4)  0.77 
Comorbidities  
No., (%) unless stated 
       
Hypertension  88 (88.9)  46 (86.8)  30 (90.9)  0.84 
No. Antihypertensives 
Mean, SD 
 
1.61 (1.08) 
 
 
1.64 (0.9) 
 
 
1.64 (0.93) 
 
 
0.68 
Coronary Disease  27 (27.3)  20 (37.7)  9 (27.3)  0.38 
Heart Failure  21 (21.2)  17 (32.1)  8 (24.2)  0.34 
Cerebrovas. Dis.  22 (22.2)  8 (15.1)  9 (27.3)  0.37 
Peripheral Vascular 
Disease 
12 (12.1)  10 (18.9)  6 (18.2)  0.47 
Dementia  1 (1)  2 (3.8)  1 (3)  0.49 
Chronic Lung Dis.  22 (22.2)  9 (17)  9 (27.3)  0.52 
Peptic Ulcer Dis.  0  0  0   
Rheumatic. Dis  4 (4)  7 (13.2)  2 (6.1)  0.11 
Mild Liver Disease  1 (1)  0  1 (3)  0.42 
Diabetes without 
Complications 
13 (13.1)  10 (18.9)  6 (18.2)  0.59 
Diabetes with 
Complications 
29 (29.3)  15 (28.3)  9 (27.3)  0.97 
Diabetes Overall  42 (42.4)  25 (47.2)  15 (45.5)  0.85 
Hemiplegia  0  0  0   Mark Uniacke    Chapter 6     
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AKIN 1 
N = 99 
 
AKI/CKD Group 
AKIN 2 
N = 53 
  
AKIN 3 
N = 33 
 
p 
Neoplasia  7 (7.1)  5 (9.4)  6 (18.2)  0.18 
Severe Liver Dis.  0  0  0   
Leukaemia  0  0  1 (3)   
Metastases  0  0  0   
Lypmhoma  2 (2)  1 (1.9)  1 (3)  0.93 
AIDS  0  0  0   
Charlson Score Mean, 
SD 
4 (1.5)  4.34 (1.41)  4.55 (1.44)  0.27 
Smoking History 
(Current and past) 
 
51 (51.5) 
 
36 (67.9) 
 
20 (60.6) 
 
0.14 
BMI 
Mean, SD 
 
28.57 (6.46) 
 
29.58 (7.17) 
 
30.11 (6.91) 
 
0.93 
Medications prior to 
AKI N(%) 
       
On Ace In. N(%)  53 (53.5)  26 (49.1)  13 (39.4)   
On ARB  N(%)  19 (19.2)  17 (32.1)  12 (36.4)   
On RAS blocker N(%)  70 (70.7)  42 (79.2)  25 (75.8)  0.51 
Aspirin  44 (44.4)  24 (45.3)  18 (54.5)  0.59 
NSAID  7 (7.1)  3 (5.7)  3 (9.1)  0.83 
Furosemide  50 (50.5)  27 (50.9)  21 (63.6)  0.39 
BZF  11 (11.1)  8 (15.8)  3 (9.1)  0.66 
Spironolactone  15 (15.2)  9 (17)  5 (15.2)  0.95 
Trimethoprim  6 (6.1)  2 (3.8)  2 (6.1)  0.82 
Statin  50 (50.5)  33 (62.3)  22 (66.7)  0.17 
Metformin  14 (14.1)  15 (28.3)  5 (15.2)  0.09 
Beta Blocker  37 (37.4)  23 (43.4)  16 (48.5)  0.49 
Calcium Ch.  28 (28.3)  6 (11.3)  11 (33.3)  0.03 
Alpha Blocker  8 (8.1)  5 (9.4)  5 (15.2)  0.49 
Allopurinol 
PPI 
13 (13.1) 
37 (37.4) 
4 (7.5) 
17 (32.1) 
2 (6.1) 
14 (42.4) 
0.38 
0.62 
 
6.1.2 AKI/CKD group and the CKD Controls 
 
The characteristics of the CKD control group alongside the AKI/CKD Group are 
outlined in Table 6.4. The groups are similar in terms of age and sex but there is a 
trend toward more diabetes overall and a greater burden of comorbid illness in the 
AKI/CKD group (p=0.011). The only significant differences between these groups is a 
greater tendency to use furosemide and blockers of the renin-angiotensin system in Mark Uniacke    Chapter 6     
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the AKI/CKD group. These findings must be interpreted with caution in the presence of 
such low numbers in the control group. 
 
Table 6.4 Baseline Characteristics of the AKI/CKD Group compared to the CKD 
Control Group. 
    AKI/CKD Group 
N=185 
CKD Control 
Group 
N=26 
 
P 
Age,ys, 
Median (IQR) 
   
75 (72-84) 
 
78 (74-85) 
 
0.98 
Gender, Male, %    47.6  38.5  0.41 
Social History, N(%)  Lives Alone  82 (44.3)  13 (52)  0.47 
  Katz Index  5.66  5.85 (0.78)  0.32 
Comorbidities  
No., (%) unless stated 
 
 
Hypertension 
 
 
164 (88.6) 
 
 
21 (80.8) 
 
 
0.33 
  No. Antihypertensives 
Mean, SD 
 
 
1.62 (0.99) 
 
 
1.35 
 
 
0.19 
   
Coronary Heart 
Disease 
 
 
56 (30.3) 
 
 
9 (34.6) 
 
 
0.65 
  Heart Failure  46 (24.9)  3 (11.5)  0.21 
  Cerebrovas. Dis.  39 (21.1)  3 (11.5)  0.31 
  Peripheral Vascular 
Disease 
28 (15.1)  1 (3.8)  0.22 
  Dementia  4 (2.2)  1 (3.8)  0.49 
  Chronic Lung Dis.  40 (21.6)  3 (11.5)  0.30 
  Peptic Ulcer Dis.  0  0   
  Rheumatic. Dis  13 (7)  3 (11.5)  0.43 
  Mild Liver Disease  2 (1.1)  0   
  Diabetes without 
Complications 
29 (15.7)  2 (7.7)  0.38 
  Diabetes with 
Complications 
53 (28.6)  3 (11.5)  0.09 
  Diabetes Overall  82 (44.3)  5 (19.2)  0.02 
  Hemiplegia  0  0   
  Neoplasia  18 (19.7)  3 (11.5)  0.73 
  Severe Liver Dis.  0  0   
  Leukaemia  1 (0.5)  0   
  Metastases  0  0   
  Lymphoma  4 (2.2)  0   
  AIDS  0  0   
Comorbidity Score  Charlson Score Mean, 
SD 
4.19 (1.48)  3.42 (1.13)  0.01 
Other Risk Factors  Smoking History 
(Current and past) 
107 (57.8)  17 (65.4)  0.46 Mark Uniacke    Chapter 6     
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    AKI/CKD Group 
N=185 
CKD Control 
Group 
N=26 
 
 
P 
  BMI 
Mean, SD 
29.08 (6.71) 
(n=145) 
29.58 (7.2) 
(n=18) 
0.77 
Medications prior to 
AKI N(%) 
       
On Ace In. N(%)    92 (49.7)  7 (26.9)  0.03 
On ARB  N(%)    48 (25.9)  5 (19.2)  0.46 
On RAS blocker N(%)     
137 (74.1) 
 
12 (46.2) 
 
0.003 
Indication for RAS 
Blockade N(%) 
       
  Previous M.I.  46 (33.5)  4 (15.4)   
  Heart Failure  31 (22.6)  1 (3.8)   
  Diabetes with 
microalbuminuria 
 
32 (23.4) 
 
2 (7.7) 
 
 
  Hypertension  132 (96.4)  10 (38.5)   
  More than 1 
indication 
 
81 (59.1) 
 
6 (23.1) 
 
 
 
Aspirin 
 
 
 
86  (46.5) 
 
10(38.5) 
 
0.44 
NSAID    13  (7)  2 (7.7)  1 
Furosemide    98  (53)  6 (23)  0.004 
BZF    22  (11.9)  5 (19.2)  0.29 
Spironolactone    29  (15.7)  2 (7.7)  0.38 
Trimethoprim    10  (5.4)  0  0.62 
Statin    105  (56.8)  14 (53.8)  0.78 
Metformin    34  (18.4)  2 (7.7)  0.27 
Beta Blocker    41.1  (76)  11 (42.3)  1 
Calcium Ch.    45  (24.3)  5 (19.2)  0.57 
Alpha Blocker    18  (19.7)  1 (3.8)  0.48 
Allopurinol 
PPI 
  19  (10.3) 
68  (36.8) 
0 
12(46.2) 
0.14 
0.36 
 
6.2 AKI Details 
 
6.2.1 AKI Details – AKI and AKI/CKD Groups 
 
Table 6.5 compares additional clinical details relating to baseline kidney function and 
the AKI episode recorded at the time of recruitment between the AKI group and the 
AKI/CKD group. In the AKI group it is notable that an ACR was available at baseline in 
24.2% of patients. Just over 80% of these were diabetic. Of those with an ACR available, 
16 patients had evidence of microlbuminuria and these make up 8.4% of the AKI Mark Uniacke    Chapter 6     
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group. All of these patients had diabetes suggesting that there may have been some 
degree of early diabetic nephropathy present.   
 
In the AKI group 60% were admitted under a medical specialty while 68% of the 
AKI/CKD group were medical (p=0.128). In the case of surgical admissions 15% of the 
AKI/CKD group were admitted as elective cases compared to 41% of the AKI group 
(p=0.001). There was a trend toward a greater percentage of the AKI episodes in the 
AKI/CKD group being present on admission and hence having occurred in the 
community (73% v 62%, p=0.025).A more detailed analysis of the admission and 
inhospital AKI episodes in each group is presented later in this chapter.  
 
There was no difference in the distribution of the primary causes of the AKI between 
the groups. Over 95% in each group had a mechanism that would have been described 
as ‘Prerenal” AKI. The most common causal mechanism was ‘hypoperfusion’ with 46% 
and 42% in the AKI and AKI/CKD groups respectively. Sepsis accounted for 23% of the 
AKI group cases and 31% of the AKI/CKD group cases (p=0.057). Complex cases with 
more than one causal insult recorded accounted for 28% and 26% of the respective 
groups. 
In terms of the clinical findings and basic investigations performed there were no 
significant differences between the groups. There was a trend toward more fluid 
overload in the AKI/CKD group which could be expected given the more prominent 
history of cardiac failure in this group at baseline (p=0.019). There was also a trend 
that patients in the AKI/CKD group were less likely to have had their urine output 
measured during the episode (p=0.035). Approximately 50% or less of each group had 
a urine dipstick performed at the time of the episode and one third in each group had 
a renal ultrasound.  
Table 6. 5 Comparison of baseline clinical details relating to renal function and 
the AKI episode between the AKI and AKI/CKD groups. 
    AKI Group 
N = 190 
 
AKI/CKD Group 
N=185 
 
P 
Function  ACR available N(%)  46  (24.2)  117  (63.24)  <0.001 
  Abnormal ACR N(%)  16 (8.4)  56 (30.2)  <0.001 
  Normal ACR N(%)  30 (15.8)  61 (32.9)  <0.001 
  No ACR available N(%)  144 (75.8)  68 (36.7)  <0.001 
  Baseline Creatinine 
Mean (SD) 
 
75.5  (15.5) 
 
147.3  (70.9) 
 
<0.001 
  Baseline eGFR 
Mean (SD) 
 
77.9 (9.9) 
 
39.6 (12.2) 
 
<0.001 
  Peak Creatinine 
Median  (IQR) 
 
180 (143-251) 
 
242 (190-341) 
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    AKI Group 
N = 190 
 
AKI/CKD Group 
N=185 
 
P 
Admitting 
Specialty   N(%) 
 
Medicine 
 
114  (60%) 
 
125  (67.6) 
 
0.128 
  Surgery  74  (38.9)  60  (32.4)  0.316 
  Obs/Gynae  2  (1.1)  0  0.499 
Surgical  Elective  30(40.5)  9(15)  0.001 
  Emergency  44(59.5)  51(85)  0.001 
         
AKI   N(%)  On Admission  118  (62.1)  135  (73)  0.025 
  Age of admission 
group  
Median (IQR) 
 
 
68.5 (58.7-75.5) 
 
 
79 (71-84) 
 
 
0.007 
Cause on admission 
N(%) 
 
Septic 
 
38 (22.2) 
 
45 (33.3) 
 
0.849 
  Hypoperfusion  44 (37.3)  54 (40)  0.659 
  Nephrotoxic  1 (0.8)  1 (0.7)  1 
  Complex  30 (25.4)  35 (25.9)  0.927 
  Pure Intrinsic  2 (1.7)  0  0.217 
  Pure Obstructive  3 (2.5)  0  0.1 
         
AKI   N(%)  In hospital  72  (37.9)  50  (27)  0.025 
  Age of in hospital 
group  
Median (IQR) 
 
 
67.5 (60-75.8) 
 
 
80 (75.5-86) 
 
 
0.011 
Cause of in hospital 
cases N(%) 
 
Septic 
 
5 (6.9) 
 
13 (26) 
 
0.004 
  Hypoperfusion  43 (59.7)  24 (48)  0.201 
  Nephrotoxic  0  0   
  Complex  24 (33.3)  13 (26)  0.386 
  Pure Intrinsic  0  0   
  Pure Obstructive  0  0   
         
Primary cause overall   
N(%) 
 
Septic 
 
43  (22.6) 
 
58  (31.4) 
 
0.057 
  Hypoperfusion  87  (45.8)  78  (42.2)  0.479 
  Nephrotoxic  1  (0.5)  1  (0.5)  1 
  Complex  54  (28.4)  48  (25.9)  0.590 
  Pure Intrinsic  2  (1.1)  0  0.499 
  Pure Obstructive  3  (1.6)  0  0.248 
         
Urine Dip performed 
N(%) 
   
88  (46.3) 
 
94  (50.8) 
 
0.384 
Ultrasound  
Performed N(%) 
   
70  (36.8) 
 
64  (34.6) 
 
0.650 
Fluid Status  N(%)  Dry  146  (76.8)  129  (69.7)  0.119 Mark Uniacke    Chapter 6     
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    AKI Group 
N = 190 
 
AKI/CKD Group 
N=185 
 
P 
  Euvolaemic  32  (16.8)  31  (16.8)  0.982 
  Overloaded  12  (6.3)  25  (13.5)  0.019 
Urine Output  N(%)   
Normal 
 
123  (64.7) 
 
113  (61.1) 
 
0.464 
  Oliguria  31  (16.3)  18  (9.7)  0.059 
  Anuria  1  (0.5)  3  (1.6)  0.366 
  Not done  35  (18.4)  51  (27.6)  0.035 
Hypotension  N(%)  None  44  (23.2)  53  (28.6)   
Systolic Pressure  101 - 110  33  (17.4)  35  (18.9)   
  91 - 100  52  (27.4)  48  (25.9)   
  81 - 90  37  (19.5)  36  (19.5)   
  < 80  24  (12.6)  13  (7)   
  Overall       
  >90  129  (67.9)  136  (73.5)  0.232 
  <90  61  (32.1)  49  (26.4)   
         
 
 
6.2.2 AKI Details – AKI Group by AKIN Stage 
 
Table 6.6 outlines the clinical details relating to baseline kidney function and the AKI 
episode of the AKI Group divided by AKIN stage. There were no differences found in 
baseline kidney function between the three stages. There were no significant 
differences between admitting specialties although there was a trend toward the more 
severe AKIN stage 3 occurring under medical specialties (p=0.071). There was 
significantly more AKIN stage 3 evident on admission to hospital as opposed to 
occurring in hospital (p=0.007). Of the admission cases, there were no significant 
differences in causal mechanism though there was a trend toward more hypoperfusion 
cases in AKIN stage 1 with more complex cases in AKIN stage 3. No differences were 
found between the cases occurring in hospital with regard to cause. With admission 
and inhospital cases combined, significantly more of the milder AKIN 1 cases were due 
to hypoperfusion causes (p=0.004). The overall trend indicates that more severe AKI 
episodes were associated with complex causes or sepsis.  
 
As expected, the more severe the AKI, the more likely the patient was to have had a 
urine dip or renal ultrasound performed. In addition, the severe cases were 
significantly more likely to be clinically dehydrated or have oliguria. No differences 
were found in nadir blood pressure levels at the time of the AKI between the three 
stages.  
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Table 6.6 AKI clinical details of the AKI Group with comparison of AKIN stages. 
 
   
AKIN 1 
N = 46 
AKI Group 
AKIN 2 
N = 71 
 
AKIN 3 
N = 73 
 
p 
Function N(%)         
ACR available  10 (21.7)  23 (32.4)  13 (17.8)  0.112 
Abnormal ACR  4 (8.7)  8 (11.3)  4 (5.5)  0.337 
Normal ACR  6 (13)  15 (21.1)  9 (12.3)   
No ACR available  36 (78.3)  48 (67.6)  60 (82.3)   
Baseline Creatinine 
Mean (SD) 
 
 
83.17 (11.4) 
 
 
74.37 (14.49) 
 
 
71.88 (17.16) 
 
 
0.301 
Baseline eGFR 
Mean (SD) 
 
74.67 (8.88) 
 
78.15 (9.95) 
 
79.67 (9.54) 
 
0.331 
Peak Creatinine 
Median IQR 
 
133.5 (118-149) 
 
179 (152-216) 
 
294 (228-425) 
 
<0.001 
Admitting 
Specialty   N(%) 
 
 
 
 
 
 
 
Medicine  21 (45.7)  45 (63.4)  48 (65.8)  0.071 
Surgery  24 (52.2)  26 (36.6)  24 (32.9)  0.232 
Obs/Gynae  1 (2.2)  0  1 (1.4)  0.501 
Surigcal         
Elective  10(41.7)  11(42.3)  9(37.5)  0.933 
Emergency  14(58.3)  15(57.7)  15(62.5)   
         
On Admission  22 (47.8)  41 (57.7)  55 (75.3)  0.007 
Age of admission 
group 
Median (IQR) 
 
 
70 (62 to 74) 
 
 
71 (59 to 81) 
 
 
65 (55 to 75) 
 
 
0.248 
Cause on admission 
N(%) 
 
 
 
 
 
 
 
 
Septic 
 
7 (31.8) 
 
14 (34.1) 
 
17 (30.9) 
 
0.944 
Hypoperfusion  13 (59.1)  16 (39)  15 (27.3)  0.032 
Nephrotoxic  0  0  1 (1.8)  0.561 
Complex  1 (4.5)  11 (26.8)  18 (32.7)  0.036 
Pure Intrinsic  0  0  2 (3.6)  0.312 
Pure Obstructive  1 (4.5)  0  2 (3.6)  0.429 
         
In hospital  24 (52.1)  30 (42.3)  18 (24.7)  0.007 
Age of in hospital 
group 
Median (IQR) 
 
 
68 (55 to 75) 
 
 
68 (63 to 80 
 
 
65 (59 to 74) 
 
 
0.574 
Cause in hospital 
N(%) 
 
 
 
 
 
 
 
 
Septic 
 
1 (42.) 
 
2 (6.7) 
 
2 (11.1) 
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AKIN 1 
N = 46 
 
AKI Group 
AKIN 2 
N = 71 
 
AKIN 3 
N = 73 
 
p 
Hypoperfusion  17 (70.8)  16 (53)  10 (55.6)  0.392 
Nephrotoxic  0  0  0   
Complex  6 (25)  12 (40)  6 (33.3)  0.509 
Pure Intrinsic  0  0  0   
Pure Obstructive  0  0  0   
         
Primary cause overall   
N(%) 
 
 
 
 
 
 
 
Septic  8 (17.4)  16 (22.5)  19 (26.2)  0.548 
Hypoperfusion  30 (65.2)  32 (45.1)  25 (34.2)  0.004 
Nephrotoxic  0  0  1 (1.4)  0.447 
Complex  7 (15.2)  23 (32.4)  24 32.9)  0.074 
Pure Intrinsic  0  0  2 (2.7)  0.198 
Pure Obstructive  1 (2.2)  0  2 (2.7)  0.391 
Urine Dip performed 
N(%) 
 
18 (39.1) 
 
28 (39.4) 
 
42 (57.5) 
 
0.05 
Ultrasound  
Performed N(%) 
 
10 (21.7) 
 
16 (22.5) 
 
44 (60.3) 
 
<0.001 
Fluid Status  N(%)         
Dry  28 (60.9)  56 (78.9)  62 (84.9)  0.009 
Euvolaemic  15 (32.6)  11 (15.5)  6 (8.2)  0.002 
Overloaded  3 (6.5)  4 (5.6)  5 (6.8)  0.954 
Urine Output  N(%)     
 
 
 
 
Normal  35 (76.1)  53 (74.6)  35 (47.9)  0.001 
Oliguria  3 (6.5)  7 (9.9)  21 (73)  0.001 
Anuria  0  0  1 (1.4)  0.447 
Not done  8 (17.4)  11 (15.5)  16 (21.9)  0.597 
Systolic Pressure         
>90  33 (71.7)  53 (74.6)  43 (58.9)  0.105 
<90  13 (28.3)  18 (25.4)  30 (41.1)   
 
 
6.2.3 AKI Details – AKI/CKD Group by AKIN Stage 
 
Table 6.7 outlines the clinical details relating to baseline kidney function and the AKI 
episode of the AKI/CKD Group divided by AKIN stage. Findings are similar to those 
found in the AKI group. There were no differences found in baseline kidney function 
between the three groups and no differences between admitting specialties. Like the 
AKI group, there was a trend toward the more severe AKIN stage 3 being found on 
admission (p=0.033). No differences were found in the cause of the AKI between the 
three stages either on admission or in hospital. Mark Uniacke    Chapter 6     
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More severe AKI cases were more likely to have had a urine dip and renal ultrasound. 
The severe cases were more likely to have had oliguria but no differences were found 
between stages with regard to nadir blood pressure at the time of the AKI.  
 
Table 6.7 AKI clinical details of the AKI/CKD Group with comparison of AKIN 
stages. 
 
    
 
AKIN 1 
N = 99 
AKI/CKD Group 
 
AKIN 2 
N = 53 
  
 
AKIN 3 
N = 33 
 
 
p 
Function  N(%)         
ACR available  63 (63.6)  31 (58.5)  23 (69.7)  0.573 
Abnormal ACR  30 (30.3)  19 (35.8)  7 (21.2)  0.08 
Normal ACR  33 (33.3)  12 (22.6)  16 (48.5)   
No ACR Available  36 (36.4)  22 (41.5)  10 (30.3)   
Baseline Creatinine 
Mean (SD) 
 
 
157.86 (83.3) 
 
 
131.43 (43.9) 
 
 
140.85 (61.19) 
 
 
0.724 
Baseline eGFR 
Mean (SD) 
 
37.37 (11.85) 
 
42.74 (11.69) 
 
41.42 (13.13) 
 
0.464 
Peak Creatinine 
Mean   (SD) 
 
210 (172-254) 
 
294 (239-348) 
 
436 (332-713) 
 
<0.001 
Admitting 
Specialty   N(%) 
 
 
 
 
 
 
 
Medicine  65 (65.66)  36 (67.92)  24 (72.72)  0.752 
Surgery  34 (34.34)  17 (32.07)  9 (27.27)   
Obs/Gynae  0  0  0   
Surigcal         
Elective  5(14.7)  2(3.8)  2(22.2)  0.775 
Emergency  29(85.3)  15(88.2)  7(77.8)   
AKI   N(%)         
On Admission  67 (67.68)  38 (71.69)  30 (90.9)  0.033 
Age of admission 
group  
Median (IQR) 
 
 
78 (71-83) 
 
 
77 (71.8-84.3) 
 
 
79.5 (74-84.3) 
 
 
0.504 
Cause on admission 
N(%) 
 
 
 
 
 
 
 
Septic  21 (31.3)  12 (31.6)  12 (40)  0.680 
Hypoperfusion  30 (44.8)  16 (42.1)  8 (26.7)  0.231 
Nephrotoxic  0  0  1 (3.3)  0.172 
Complex  16 (23.9)  10 (26.3)  9 (30)  0.815 
Pure Intrinsic  0  0  0   
Pure Obstructive  0  0  0   
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AKIN 1 
N = 99 
AKI/CKD Group 
 
AKIN 2 
N = 53 
  
 
AKIN 3 
N = 33 
 
 
p 
AKI   N(%)         
In hospital  32 (32.32)  15 (28.3)  3 (9.09)  0.033 
Age of in hospital 
group  
Median (IQR) 
 
 
80.5 (76-86.8) 
 
 
80 (72-82) 
 
 
82 
 
 
0.465 
Cause in hospital 
N(%) 
 
 
 
 
 
 
 
Septic  7 (21.9)  5 (33.3)  1 (33.3)  0.675 
Hypoperfusion  18 (56.3)  5 (33.3)  1 (33.3)  0.298 
Nephrotoxic  0  0  0   
Complex  7 (21.9)  5 (33.3)  1 (33.3)  0.675 
Pure Intrinsic  0  0  0   
Pure Obstructive  0  0  0   
Primary cause overall   
N(%) 
 
 
 
 
 
 
 
Septic  28 (28.28)  17 (32.07)  13 (39.39)  0.487 
Hypoperfusion  48 (48.48)  21 (39.62)  9 (27.27)  0.092 
Nephrotoxic  0  0  1 (3)  0.099 
Complex  23 (23.23)  15 (28.3)  10 (30.3)  0.651 
Pure Intrinsic  0  0  0   
Pure Obstructive  0  0  0   
Urine Dip performed 
N(%) 
 
42 (42.42) 
 
30 (56.6) 
 
22 (66.67) 
 
0.033 
Ultrasound  
Performed N(%) 
 
23 (23.23) 
 
18 (33.96) 
 
23 (69.69) 
 
<0.001 
Fluid Status  N(%)         
Dry  62 (62.62)  41 (77.36)  26 (78.79)  0.078 
Euvolaemic  23 (23.23)  5 (9.43)  3 (9)  0.041 
Overloaded  14 (14.14)  7 (13.2)  4 (12.12)  0.955 
Urine Output  N(%)         
Normal  73 (73.73)  29 (54.72)  11 (33.33)  <0.001 
Oliguria  2 (2)  5 (9.43)  11 (33.33)  <0.001 
Anuria  0  0  3 (9.09)  0.001 
Not done  24 (24.24)  19 (35.85)  8 (24.24)  0.279 
Systolic Pressure         
>90  72 (72.73)  42 (79.25)  22 (66.67)  0.423 
<90  27 (27.27)  11 (20.75)  11 (33.33)   
 
 
6.2.4 AKI Details – Community AKI and Hospital AKI 
 
Tables 6.8 and 6.9 outline the comparisons made between the community acquired 
cases of AKI which were present on admission and the hospital acquired AKI cases in 
the AKI group and AKI/CKD group respectively. In the AKI group, Table 6.8 shows that Mark Uniacke    Chapter 6     
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there were no age or sex differences found however there was a trend toward a greater 
burden of comorbidity in the admission group. There were more admission cases 
found under medical specialties. This might be expected given that a large portion of 
the surgical group were elective and already in hospital at the time of their AKI. More 
of the admission cases were caused by sepsis while more of the in hospital cases were 
recorded as hypoperfusion. This again may reflect the elective surgical portion of this 
group with perioperative low blood pressure as a cause. The admission group was 
more likely to have had a urine dipstick recorded or renal ultrasound (p<0.001). 
Finally, there were significantly more nadir blood pressures < 90 systolic recorded in 
the inhospital group. This may be that the low pressures were missed in the admission 
group whilst in the community however it parallels the finding of more hypoperfusion 
AKI in hospital. 
 
In the AKI/CKD group the findings were broadly similar although there was no 
difference in the burden of comorbidities as was found in the AKI group. In addition, 
unlike the AKI group there were no differences found in nadir blood pressure between 
the admission and inhospital cases. 
 
Table 6.8 Comparison of the admission and inhospital AKI cases in the AKI Group. 
 
    AKI Group 
On Admission 
N = 118 
AKI Group 
In Hospital 
N = 72 
 
P 
Age  
Median (IQR) 
   
68.5 (58.7-75.5) 
 
67.5 (60-75.8) 
 
0.740 
Male N(%)    71 (60.2)  40 (55.6)  0.531 
Charlson Score 
Mean(SD) 
   
1.42(1.28) 
 
.94(1.16) 
 
0.012 
         
Function  ACR available N(%)  33 (28)  13 (18.1)  0.122 
  Abnormal ACR N(%)  12 (10.2)  4 (5.6)  1.0 
  Normal ACR N(%)  21 (17.8)  9 (12.5)  1.0 
  No ACR available N(%)   
85 (72) 
 
59 (81.9) 
 
0.122 
  Baseline Creatinine 
Mean (SD) 
 
76.21 (16.26) 
 
74.44 (14.27) 
 
0.448 
  Baseline eGFR 
Mean (SD) 
 
77.35 (10.04) 
 
78.79 (9.07) 
 
0.320 
  Peak Creatinine 
Median  (IQR) 
 
190 (152-255) 
 
162 (130-247) 
 
0.40 
         
Admitting 
Specialty   N(%) 
 
Medicine 
 
90 (76.3) 
 
24 (33.3) 
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    AKI Group 
On Admission 
N = 118 
 
AKI Group 
In Hospital 
N = 72 
 
P 
  Surgery  28 (23.7)  46 (63.9)   
  Obs/Gynae  0  2 (2.8)   
Surigcal  Elective  1(3.6)  29(63)  <0.001 
  Emergency  27(96.4)  17(37)   
         
Primary cause   N(%)   
Septic 
 
38 (22.2) 
 
5 (6.9) 
 
<0.001 
  Hypoperfusion  44 (37.3)  43 (59.7)  0.003 
  Nephrotoxic  1 (0.8)  0  1.0 
  Complex  30 (25.4)  24 (33.3)  0.241 
  Pure Intrinsic  2 (1.7)  0  0.527 
  Pure Obstructive  3 (2.5)  0  0.290 
         
Urine Dip performed 
N(%) 
 
 
 
69 (58.5) 
 
19 (26.4) 
 
<0.001 
Ultrasound  
Performed N(%) 
   
55 (46.6) 
 
15 (20.8) 
 
<0.001 
Fluid Status  N(%)  Dry  97 (82.2)  49 (68.1)  0.025 
  Euvolaemic  14 (11.9)  18 (25)  0.019 
  Overloaded  7 (5.9)  5 (6.9)  0.781 
Urine Output  N(%)   
Normal 
 
71 (60.2) 
 
52 (72.2) 
 
0.092 
  Oliguria  22 (18.6)  9 (12.5)  0.266 
  Anuria  0  1 (1.4)  0.199 
  Not done  25 (21.2)  10 (13.9)  0.208 
Systolic Pressure         
  >90  89 (75.4)  40 (55.6)  0.004 
  <90  29 (24.6)  32 (44.4)   
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Table 6.9 Comparison of the admission and inhospital AKI cases in the AKI/CKD 
Group. 
 
    AKI/CKD Group 
On Admission 
N = 135 
AKI /CKD Group 
In Hospital 
N = 50 
 
P 
Age  
Median (IQR) 
   
79 (71-84) 
 
80 (75.5-86) 
 
0.105 
Male N(%)    68 (50.4)  20 (40)  0.210 
Charlson Score 
Mean(SD) 
   
4.27(1.52) 
 
3.98(1.35) 
 
.230 
         
Function  ACR available N(%)  90 (66.7)  27 (54)  0.113 
  Abnormal ACR N(%)  47 (34.8)  9 (18)  0.085 
  Normal ACR N(%)  43 (31.9)  18 (36)  0.085 
  No ACR available N(%)        45 (33.3)  23 (46) 
 
         0.113 
  Baseline Creatinine 
Mean (SD) 
 
153.57 (80.41) 
 
130.2 (28.25) 
 
0.046 
  Baseline eGFR 
Mean (SD) 
 
39.17 (13.25) 
 
40.88 (8.88) 
 
0.4 
  Peak Creatinine 
Median  (IQR) 
 
255 (190-391) 
 
223.5 (187-277) 
 
0.024 
         
Admitting 
Specialty   N(%) 
 
Medicine 
 
103 (76.3) 
 
22 (44) 
 
<0.001 
  Surgery  32 (23.7)  28 (56)   
  Obs/Gynae  0  0   
Surigcal  Elective  3(9.3)  6(21)  0.192 
  Emergency  29(91)  22(79)   
         
Primary cause   N(%)   
Septic 
 
45 (33.3) 
 
13 (26) 
 
0.340 
  Hypoperfusion  54 (40)  24 (48)  0.328 
  Nephrotoxic  1 (0.7)  0  1.0 
  Complex  35 (25.9)  13 (26)  0.992 
  Pure Intrinsic  0  0   
  Pure Obstructive  0  0   
         
Urine Dip performed 
N(%) 
 
 
 
80 (59.3) 
 
14 (28) 
 
<0.001 
Ultrasound  
Performed N(%) 
   
53 (39.3) 
 
11 (22) 
 
0.028 
Fluid Status  N(%)  Dry  102 (75.6)  27 (54)  0.005 
  Euvolaemic  17 (12.6)  14 (28)  0.013 
  Overloaded  16 (11.9)  9 (18)  0.277 
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    AKI/CKD Group 
On Admission 
N = 135 
AKI /CKD Group 
In Hospital 
N = 50 
 
P 
Urine Output  N(%)   
Normal 
 
83 (61.5) 
 
30 (60) 
 
0.854 
  Oliguria  15 (11.1)  3 (6)  0.298 
  Anuria  2 (1.5)  1 (2)  0.804 
  Not done  35 (25.9)  16 (32)  0.412 
Systolic Pressure         
  >90  99 (73.3)  37 (74)  0.927 
  <90  36 (26.7)  13 (26)   
         
 
 
6.2.5 AKI Details – AKI/CKD Group and Controls 
 
Table 6.10 outlines the comparison between the AKI/CKD group and the CKD controls. 
Findings here must be interpreted with caution given the low number in the control 
group. Overall, few differences were found between the groups. Baseline kidney 
function was similar. As might be expected, patients in the control group were more 
likely to be euvolaemic and to have a normal urine output. There were no differences 
found in nadir blood pressure readings between the two groups. 
 
Table 6.10 Comparison of baseline details between AKI/CKD group and the CKD 
Control group. 
 
    AKI/CKD Group 
N=185 
CKD Control 
Group 
N=26 
 
P 
Function  ACR available N(%)  117  (63.24)     
  Abnormal ACR N(%)  56 (30.2)     
  Normal ACR N(%)  61 (32.9)     
  No ACR available N(%)  68 (36.7)     
  Baseline Creatinine 
Mean (SD) 
 
147.3  (70.9) 
 
 
 
 
  Baseline eGFR 
Mean (SD) 
 
39.6 (12.2) 
 
41.85 (12.18) 
 
0.388 
  Peak Creatinine 
Median  (IQR) 
 
242 (190-341) 
 
 
 
 
         
Admitting 
Specialty   N(%) 
 
Medicine 
 
125  (67.6) 
 
 
 
 
  Surgery  60  (32.4)  8 (30.76)  0.865 
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    AKI/CKD Group 
N=185 
CKD Control 
Group 
N=26 
 
 
P 
Surgical  Elective  9(15)  2(25)  0.471 
  Emergency  51(85)  6(75)   
         
Urine Dip performed 
N(%) 
   
94  (50.8) 
 
8 (30.8) 
 
0.056 
Ultrasound  
Performed N(%) 
   
64  (34.6) 
 
2 (7.7) 
 
0.006 
Fluid Status  N(%)  Dry  129  (69.7)  9 (34.6)  <0.001 
  Euvolaemic  31  (16.8)  15 (57.7)  <0.001 
  Overloaded  25  (13.5)  2 (7.7)  0.405 
Urine Output  N(%)   
Normal 
 
113  (61.1) 
 
24 (92.3) 
 
0.002 
  Oliguria  18  (9.7)  0  0.137 
  Anuria  3  (1.6)  0  1 
  Not done  51  (27.6)  2 (7.7)  0.03 
Systolic Pressure         
  >90  136  (73.5)  21 (80.8)  0.427 
  <90  49  (26.4)  5 (19.2)   
         
 
 
6.3 Preadmission Details 
 
Later in this chapter the readmission pattern of the AKI recruits is outlined. To 
facilitate exploration of this phenomenon a retrospective review was carried out of 
each recruit to record admissions in the year prior to the index AKI. In addition, 
hospital biochemistry records were reviewed to record any rises in serum creatinine 
that met the study criteria for AKI during the previous four years. This retrospective 
search was limited to admissions and biochemistry recorded on the Portsmouth 
Hospitals NHS Trust database and therefore may have missed episodes that occurred 
elswhere. These data are outlined in Table 6.11. During the year prior to the index 
admission, 32.1% of the AKI group and 42.7% of the AKI/CKD group were admitted to 
hospital at least once while 5.3% and 20.5% of each group respectively had evidence of 
an AKI meeting AKIN criteria occurring during admission. This was significantly higher 
in the AKI/CKD group (p<0.001). Extending the search back to four years the 
proportion of patients who had evidence of a previous AKI increased to 8.9% in the AKI 
group and 34.6% in the AKI/CKD group.  
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6.3.1 eGFR slope prior to study AKI 
 
In order to explore the influence of prior renal function on outcomes further, a 
regression line was used to calculate the eGFR slope for each patient prior to the index 
AKI. The method used to calculate this has been described in Chapter 4. In the case of 
the AKI group 169 patients (89%) had two or more outpatient eGFR results (range 2-7, 
median 5). In the AKI/CKD group 183 patients (99%) had two or more results (range 2-
7, median 5). The mean change in eGFR slope over the three years in the AKI group 
was +1.21mls/min/year while in the AKI/CKD group the mean change was -
3.16mls/min/year (p<0.001). The influence of the eGFR slope on outcomes is explored 
further in regression analysis in Chapter 7.  
 
Table 6.11 Basic preadmission details for the AKI and AKI/CKD groups. 
     
AKI Group 
N = 190 
 
AKI/CKD Group 
N=185 
 
p 
Before study  AKI N(%)  
Adm. prev. 12 mts 
 
61  (32.1) 
 
79  (42.7) 
 
0.034 
  AKI prev 12 mts  10  (5.3)  38  (20.5)  <0.001 
  AKI prev 4 yrs  17  (8.9)  64  (34.6)  <0.001 
         
    N=169  N=183   
eGFR slope 
mls/min/year 
Mean(SD) 
   
1.21(4.90) 
 
-3.16 (5.45) 
 
<0.001 
         
 
 
6.4 Hospital Outcomes – AKI Group and AKI/CKD Group 
 
Table 6.12 compares the hospital outcomes of the AKI and AKI/CKD groups, followed 
by an analysis of the outcomes in each group divided by AKIN stage in Tables 6.13 and 
6.14.  
 
6.4.1 Hospital mortality 
 
16 patients (8.6%) in the AKI/CKD group and 7 patients (3.7%) in the AKI group died 
whilst in hospital (p=0.045). In the AKI group the mortality pattern was consistent with 
the severity of the AKIN stage but did not reach statistical significance (p=0.137). In 
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higher in AKIN stage 2 (p=0.007). However, as the mortality is low in both groups 
there is insufficient power to draw any firm conclusions regarding the ability of AKIN to 
predict mortality.  
 
6.4.2 Recovery of function at hospital discharge 
 
The mean change in eGFR at discharge compared to baseline, described as ‘Delta 
eGFR’, was significantly different between the groups. The mean change was -11.75 in 
the AKI group while in the CKD group the mean change was +0.11 (p<0.001). This is 
illustrated in the Box-Whisker plot in Figure 6.1 below. The changes did not reach 
significance by AKIN stage in each group. However, there was a trend toward a more 
negative change with increasing AKIN stage. When viewed as a failure to recover 
function according to the study criteria of a fall in eGFR of >5mls/min, 52.6% of the 
AKI group had not recovered and 31.4% of the AKI/CKD group had not recovered 
(p<0.001). Lack of recovery was not significantly different between AKIN stages in 
either group and this is illustrated graphically in Figure 6.2 and Figure 6.3 respectively. 
 
Figure 6.1 Box-whisker plots of the mean change in eGFR (Delta eGFR) at the time 
of discharge from hospital in the AKI and AKI/CKD groups. 
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Figure 6. 2 Graphical illustration of recovery of eGFR to within 5mls/min of 
baseline at the time of discharge in the AKI group. The red bars represent the 
proportion failing to recover in each AKIN stage. 
 
Figure 6.3 Graphical illustration of recovery of eGFR to within 5mls/min of 
baseline at the time of discharge in the AKI/CKD group. The red bars represent 
the proportion failing to recover in each AKIN stage. 
 
 
The time taken for the serum creatinine to fall below the level of AKIN stage 1 was 
taken as the time to recover. The median time for this to occur in the AKI group was 3 
days compared to 4 days in the AKI/CKD group (p=0.021). The time to recover 
function was predicted by AKIN stage in both groups.  
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6.4.3 Length of hospital stay 
 
The median length of hospital stay in the AKI group was 10 days compared to 12 days 
in the AKI/CKD group (p=0.04). This is likely to be accounted for by the increased age 
and burden of comorbidities in the AKI/CKD group at baseline. There was no 
significant difference in length of hospital stay according to AKIN stage in either 
group.  
 
6.4.4 General management  
 
There was a trend toward a greater proportion of the AKI group (14.2% v 7%) being 
managed in intensive care (p=0.024). Although numbers were low, there was a trend 
toward more of the AKI group receiving renal replacement therapy in the ITU (48% v 
23%, p=0.019). These differences may reflect differing thresholds for admission and 
less aggressive management in the AKI/CKD group which was older and had more 
comorbidity.  
 
Overall, 8.4% (n=16) patients in the AKI group and 5.4% (n=10) patients in the AKI/CKD 
group received renal replacement therapy during their hospital stay. All of the AKI 
group had recovered sufficiently to come off dialysis at the time of discharge from 
hospital while 3 patients (1.6%) in the AKI/CKD group remained on dialysis at the time 
of discharge.  
 
Only 3 patients from the entire cohort (0.8%) received a renal biopsy. All of these were 
from the AKI group. One showed features of a rapidly progressive glomerulonephritis, 
one had features consistent with scleroderma kidney, while one had non-specific 
features felt most likely to be due to acute tubular necrosis.  
 
As a part of the clinical management of the AKI, over 90% of patients in each group 
who had been taking RAS-blockers had them stopped by the admitting team.  
 
It is notable that significantly more of the AKI/CKD group received a formal review by 
the renal team in hospital although most had no review (20.5% v 8.9%, p=0.002). 
Within the AKI group all of these reviews were requested in patients with AKIN stage 3 
but accounted for only 23% of this stage. On the other hand, in the AKI/CKD group 
12% of AKIN stages 1 and 2 received a renal consultation in hospital while more than 
77% of AKIN stage 3 received one. The reasons for these marked differences are 
unclear but may reflect a greater awareness of renal disease in those with established 
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Finally, the discharge summaries of each patient were reviewed after the patients left 
the hospital to assess the ICD-10 coding practices. In the AKI group 38.9% had an AKI 
coded on their discharge summary while 50.8% of the AKI/CKD group were coded 
(p=0.021). The code used in the majority of cases in both groups was N17.9 – ARF 
unspecified. This again likely reflects the greater recognition of renal problems in 
those with established CKD. When divided by AKIN stage coding improved significantly 
with increasing AKIN stage however nearly 40% of the most severe AKIN stage 3 in the 
AKI group were still not coded. The coding is derived from the discharge summary to 
the general practitioner. These findings indicate that a large proportion of patients 
who have a severe AKI in hospital are discharged without their general practitioners 
being informed.  
 
Table 6.12  Hospital Outcomes and comparison of the AKI Group and AKI/CKD 
Group. 
    AKI Group 
N = 190 
 
AKI/CKD Group 
N=185 
 
P 
ITU Admission  N(%)    27  (14.2)  13  (7)  0.024 
  Dialysis in ITU  N(%)  13 (48)  3(23.07)  0.019 
Renal Review  N(%)    17  (8.9)  38  (20.5)  0.002 
Renal Review by AKIN 
Stage  N(%) 
 
Stage 1 
 
0 
 
11 (12.2) 
 
 
  Stage 2  0  6 (12.2)   
  Stage 3  17 (23%)  21 (77.7)   
Total dialysed  N(%)    16  (8.4)  10 (5.41)  0.250 
RASB stopped   N(%)    91  (90.1)  131  (92.3)  0.556 
Biopsy   N(%)    3  (1.6)  0  0.248 
Hospital mortality 
N(%) 
   
7  (3.7) 
 
16  (8.6) 
 
0.045 
Mortality by AKIN 
N(%) 
 
Stage 1 
 
0 
 
4  (4) 
 
 
  Stage 2  2  (2.8)  10  (18.9)   
  Stage 3  5  (6.8)  2  (6)   
Overall LOS,  
Median (IQR) 
   
10 (6-19) 
 
12 (8-23.5) 
 
0.04 
LOS by AKIN 
Median (IQR) 
 
Stage 1 
 
9 (5-15.25) 
 
12 (8-24) 
 
 
  Stage 2  9 (6-17)  13 (7-26)   
  Stage 3  13 (7-34.25)  12 (10-22)   
Delta eGFR @ D/C 
Mean (SD) 
   
-11.75  (21.1) 
 
+0.11  (12.7) 
 
<0.001 
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    AKI Group 
N = 190 
 
AKI/CKD Group 
N=185 
 
P 
Delta by AKIN 
Mean (SD) 
 
Stage 1 
 
-6.26  (16.1) 
 
+0.99  (10.3) 
 
 
  Stage 2  -10.33  (17.7)  -0.35  (14.8)   
  Stage 3  -16.91   (25.7)  -2.18  (16.3)   
Not recovered  N(%)     
100  (54.64) 
 
57  (33.7) 
 
<0.001 
By AKIN %  Stage 1  25 (54.35)  26 (27.3)   
  Stage 2  39 (56.52)  16 (37.2)   
  Stage 3  36 (52.94)  15 (48.38)   
Dialysis @ D/C  N(%)     
0 
 
3 (1.6) 
 
0.110 
Duration of recovery 
Median (IQR) 
   
 
3 (3-5) 
 
 
4 (3-7) 
 
 
0.020 
  Stage 1  2 (2-3)  4 (2-6)   
  Stage 2  3 (3-5)  5 (4-6)   
  Stage 3  5 (3-9.8)  7 (4-9)   
AKI coded @ D/C N%     
74 (38.9) 
 
94 (50.8) 
 
0.021 
By AKIN  N%  Stage 1  4 (8.7)  38 (38.38)   
  Stage 2  25 (35.21)  27 (50.94)   
  Stage 3  45 (61.64)  29 (87.9)   
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Table 6.13 Hospital Outcomes in AKI Group divided by AKIN stage. 
   
AKIN 1 
N = 46 
AKI Group 
AKIN 2 
N = 71 
 
AKIN 3 
N = 73 
 
p 
 
ITU Admission  N(%) 
 
4 (8.69) 
 
7 (9.86) 
 
16 (21.92) 
 
0.055 
 
Dialysis in ITU  N(%) 
 
0 
 
0 
 
13 (17.81) 
 
<0.001 
 
Renal Review  N(%) 
 
0 
 
0 
 
17 (23.29) 
 
<0.001 
 
Total dialysed  N(%) 
 
0 
 
0 
 
16 (21.92) 
 
<0.001 
RASB stopped   N(%)  20 (80)  35 (92.1)  36 (94.74)  0.139 
Biopsy   N(%)  0  0  3 (4.11)  0.087 
Hospital mortality 
N(%) 
0  2 (2.82) 
 
5 (6.85) 
 
0.137 
 
Overall LOS,  
Median (IQR) 
 
9 (5-15.25) 
 
9 (6-17) 
 
13 (7-34.25) 
 
0.066 
Delta eGFR @ D/C 
Mean (SD) 
 
 
-6.26  (16.1) 
 
 
-10.33  (17.7) 
 
 
-16.91   (25.7) 
 
 
0.014 
Not recovered  N(%)   
25 (54.35) 
 
39 (56.52) 
 
36 (52.94) 
 
0.914 
Dialysis @ D/C  N(%)   
0 
 
0 
 
 
0 
 
 
Duration of recovery 
Median (IQR) 
2 (2-3)  3 (3-5) 
 
 
5 (3-9.8) 
 
 
,0.001 
 
 
AKI coded @ D/C N%  4 (8.7) 
 
25 (35.21) 
 
45 (61.64) 
 
<0.001 
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Table 6.14 Hospital Outcomes in AKI/CKD Group divided by AKIN stage. 
 
    
 
AKIN 1 
N = 99 
AKI/CKD Group 
 
AKIN 2 
N = 53 
  
 
AKIN 3 
N = 33 
 
 
p 
ITU Admission  N(%)  4 (4.04)  5 (9.43)  4 (12.12)  0.209 
 
Dialysis in ITU  N(%)  0  0  3 (0.09)  0.001 
Renal Review  N(%)  11 (12.2) 
 
6 (12.2) 
 
21 (77.7)  <0.001 
Total dialysed  N(%)  0 
 
0 
 
10 (5.41)  <0.001 
RASB stopped   N(%)  65 (89.04)  41 (97.62)  25 (92.59)  0.253 
Biopsy   N(%)  0  0  0   
Hospital mortality 
N(%) 
4 (4.04)  10 (18.87) 
 
2 (6.06) 
 
0.007 
 
Overall LOS,  
Median (IQR) 
 
12 (8-24) 
 
13 (7-26) 
 
12 (10-22) 
 
0.947 
Delta eGFR @ D/C 
Mean (SD) 
 
+0.99  (10.3) 
 
-0.35  (14.8) 
 
 
-2.18  (16.3) 
 
 
0.353 
Not recovered  N(%)  26 (27.3) 
 
16 (37.21)  15 (48.39) 
 
0.114 
Dialysis @ D/C  N(%)  0  0  3 (9.68)  0.001 
Duration of recovery 
Median (IQR) 
 
4 (2-6) 
 
5 (4-6) 
 
7 (4-9) 
 
<0.001 
AKI coded @ D/C N%  38 (38.38) 
 
27 (50.94) 
 
29 (87.88) 
 
<0.001 
 
 
 
A further comparison was made between the hospital outcomes of the AKI/CKD group 
and the CKD controls. This is outlined in Table 6.15. As the control numbers are small 
interpretation of these data are difficult. However, an important finding was a 
significant difference in the hospital length of stay. The median length of stay was 5 
days longer in the AKI/CKD group (p=0.002). It is also notable that of those who were 
taking RAS blockers in the CKD control group 73% had these stopped during their 
admission. This may reflect increased awareness on the part of the clinical team of the 
risk of AKI.  
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Table 6.15  Hospital Outcome comparison between the AKI/CKD Group and CKD 
Controls. 
    AKI/CKD Group 
N=185 
CKD Control 
Group 
N=26 
 
P 
ITU Admission  N(%)     
13  (7) 
 
0 
 
0.376 
Renal Review  N(%)     
38  (20.5) 
 
0 
 
0.006 
RASB stopped   N(%)     
131  (92.3) 
 
8 (72.7) 
 
0.065 
Hospital mortality 
N(%) 
   
16  (8.6) 
 
1 (3.8) 
 
0.701 
Overall LOS,  
Median (IQR) 
   
12 (8-23.5) 
 
7 (4.5-14) 
 
0.002 
Delta eGFR @ D/C 
Mean (SD) 
   
+0.11  (12.7) 
 
+2.4 (-11-12) 
 
0.374 
 
Dialysis @ D/C  N(%)     
3 (1.6) 
 
0 
 
1 
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6.5 Outcomes after 6 months follow up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4 Flowchart illustrating the outcomes from recruitment of each group and 
available numbers in each group for functional analysis after follow up. 
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Figure 6.4 describes the outcomes of each group from recruitment through to the 
follow up at 6 months. Most importantly it describes the numbers in each group 
available for functional analysis at discharge and again after follow up. In the AKI 
group contact was lost with 6 patients while in the AKI/CKD group contact was lost 
with only 3 patients. NHS records and patients general practice was checked to confirm 
these patients were still alive but they have been removed from the respective groups 
for the final functional analysis. In addition, 2 patients in each of the groups had 
moved from the area and while blood test results were provided by their general 
practice these too were removed from the final analysis as they were performed in a 
different laboratory. This made a total of 158 (83%) available for follow up of renal 
function in the AKI group and 135 (73%) in the AKI/CKD group. The overall follow up 
data for the AKI group and AKI/CKD group is outlined in Table 6.12 and a comparison 
between the groups is presented. In addition, Tables 6.17 and 6.18 outline the same 
follow up data divided by AKIN stage for each group respectively.  
 
The median follow up time for each group was 7 months (interquartile range 6-8 
months). No patients were followed up before six months.  
 
6.5.1 Mortality after 6 months 
 
A formal survival analysis using the Kaplan Meier method was not undertaken as all 
patients were followed for the same length of time. Mortality is therefore expressed as 
a simple comparison of proportions. The overall mortality including in hospital was 
24.3% in the AKI/CKD group and 12.6% in the AKI group (p=0.003). When divided by 
AKIN stage there was no mortality difference between stages in the AKI group while in 
the AKI/CKD group there was significantly increased mortality in AKIN stage 2. Overall, 
the AKIN stages do not appear to predict mortality on follow up in this study. 
 
6.5.2 Recovery of function after 6 months 
 
Similar to the findings at discharge there was a significant difference in delta eGFR 
after follow up between the groups. In the AKI group, eGFR fell by a mean of 
8.88mls/min while in the AKI/CKD group the fall was 0.47mls/min (p<0.001). These 
are illustrated in the box-whisker plot in Figure 6.5 below. The fall in eGFR did not 
reach significance by AKIN stage in the AKI group though there was a trend toward a 
worsening fall with increasing stage (p=0.044). In the AKI/CKD group there was no 
significant difference between the AKIN stages according to the change in eGFR.  
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Figure 6.5 Box-whisker plots of the mean change in eGFR (Delta eGFR) from 
baseline after 6 months of follow up in the AKI and AKI/CKD groups. 
 
 
 
After at least six months follow up it was found that 53% of the AKI group and 34% of 
the AKI/CKD group had failed to recover within 5mls/min of baseline kidney function. 
This failure to recover was found across all AKIN stages and is illustrated graphically in 
Figure 6.6 for the AKI and AKI/CKD groups.  
 
The original study protocol defined failure to recover function as a fall of at least 
5mls/min in eGFR. This could arguably be subject to error. The relative percentage fall 
in function would be much less at higher levels of eGFR and in addition there may be 
within-subject variation. Therefore in order to strengthen the findings the definition of 
recovery was expanded to allow for possible variation and error.  
 
Firstly, the criterion for failure to recover was expanded to a fall in eGFR of at least 
10mls/min or more. This was chosen as it is above the reported within-individual 
variation in eGFR of 6.7mls/min discussed in Chapter 2 and so reduces the likelihood 
of a chance fall due to within subject and analytical variation. In this case the pattern 
of findings was similar between the groups but was attenuated with 41% in the AKI 
group failing to recover and 19% of the AKI/CKD group. This is illustrated graphically 
in Figures 6.7 for the AKI and AKI/CKD groups.  
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Secondly, the criteria put forward by the ASSESS AKI study group was applied 
404. In the 
AKI group a fall of at least 25% of baseline eGFR together with progression to at least 
CKD stage 3 was required. 19.6% of cases failed to recover function according to this 
definition and thus indicates not only a loss of function after an AKI episode but also 
progression into the moderate to severe CKD category. In the AKI/CKD group, a 50% 
fall in baseline eGFR was required to define CKD progression. Only 3.7% of patients 
satisfied this definition. The ASSESS AKI definition outcomes are illustrated in Figures 
6.8.  
 
Finally, as the event rates were so low in the AKI/CKD group with a fall of 50% both 
groups were examined using a general definition of a fall in eGFR of 25%. In the case 
of the AKI group the proportion that failed to recover was 20.8%. In the AKI/CKD group 
14.8% showed a fall of at least 25% in eGFR. These findings are illustrated in Figures 
6.9 for each group. 
 
The study therefore supports the hypothesis that AKI is contributing to the 
progression of moderate to severe CKD and is causing loss of function in those 
without moderate to severe CKD. Further strength is added to these findings when the 
comparison between the outcomes in the AKI/CKD group and CKD controls are 
examined. These are shown in Table 6.19. Despite the low numbers in the CKD control 
group there is a difference in functional outcomes. This is not readily apparent when a 
definition of a fall in eGFR of 5mls/min is used as the outcome, however when it is 
extended to 10mls/min the difference approaches statistical significance (p=.016) with 
20% of the AKI/CKD group reaching this endpoint but none in the CKD control group.  
 
Figure 6.6 Graphical illustration of the percentage of patients with a fall in eGFR 
of 5mls/min or more from baseline after 6 months (in red) in the AKI and 
AKI/CKD groups.  
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Figure 6.7 Graphical illustration of the percentage of patients with a fall in eGFR 
of 10mls/min or more from baseline after 6 months (in red) in the AKI and 
AKI/CKD groups.  
 
Figure 6. 8 Graphical illustration of the percentage of patients with a fall in eGFR 
according to the ASSESS AKI criteria from baseline after 6 months – a fall of 25% in 
eGFR and reaching at least CKD stage 3 in the AKI group and a fall in eGFR of at 
least 50% in the AKI/CKD group.  
 
Figure 6.9 Graphical illustration of the percentage of patients with a fall in eGFR 
of at least 25% from baseline after 6 months in the AKI and AKI/CKD groups. 
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Dialysis after 6 months 
 
In the AKI group 16 patients received renal replacement therapy during their AKI 
episode. Two of these patients died in hospital and another died during follow up. The 
remaining 13 patients remained independent of dialysis at the time of follow up. Of 
these, 6 returned to within 5mls/min of baseline function and were considered to have 
recovered fully. The remaining 7 (54%) patients who did not recover demonstrated a 
fall of at least 10mls/min in eGFR while 3 (23%) had a fall of at least 25% from baseline 
and reached CKD stage 3. 
 
In the AKI/CKD group 10 patients received renal replacement therapy during the AKI 
episode. Two of these died in hospital. Three patients were discharged requiring 
dialysis and one of these died during follow up. During follow up another patient from 
the AKI/CKD group started dialysis but had not required dialysis during their AKI. 
Therefore after 6 months 3 patients from the AKI/CKD group were dialysis dependent 
which account for 1.6% of the original AKI/CKD cohort or 2.1% of survivors.  
 
6.5.3 Sensitivity analysis for AKI Group 
 
One potential limitation in any study of the impact of AKI on baseline function is the 
definition of baseline function itself. In this study baseline function in the AKI group 
was defined as at least one eGFR ! 60mls/min measured as an outpatient in the year 
prior to the index AKI. Given the variation that can occur in eGFR measurement it is 
possible that some patients may have been misclassified. It was noted during the 
extended review of previous results when calculating the eGFR slope described earlier 
that some patients in the AKI group had evidence of an eGFR below 60 mls/min at 
some point over the three years prior to the chosen baseline despite having no 
evidence of this during the year immediately prior to the AKI.  In addition, some 
patients with diabetic nephropathy manifested by evidence of microalbuminuria may 
have an eGFR above the 60mls/min threshold i.e. lie in CKD stages 1 or 2. As shown in 
Table 6.5 8.4% of patients in the AKI group had evidence of microalbuminuria. It is 
therefore possible that some of the lack of recovery found in the AKI group may have 
occurred in patients who already had evidence of CKD.  
 
The hospital biochemistry database was searched for each patient in the AKI group 
over the three year period prior to their study baseline eGFR for any evidence of an 
eGFR recorded as < 60mls/min in the outpatient setting. At least one was found in 28 
patients (14.7%). These were combined with those with evidence of microalbuminuria 
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eGFR values < 60mls/min are needed to define CKD these patients were removed from 
the original cohort and this new group of 152 patients was analysed separately to 
assess if this would make any difference to the outcomes found. The outcomes in this 
group are outlined in Table 6.20 and are compared to the outcomes found in the 
subgroup of 38 patients removed. It can be seen that no significant difference was 
found in mortality or in recovery of function using any of the definitions described. 
The 38 patients in the original cohort are therefore unlikely to be distorting the 
results.  
 
Table 6.16  Follow up data after 6 months for the AKI and AKI/CKD groups with 
between group analysis. 
    AKI Group 
 
N = 158 
AKI/CKD Group 
 
N=135 
 
P 
Time to follow up 
eGFR in months 
Median (IQR) 
   
 
 
7 ( 6-8) 
 
 
 
7 (6-8) 
 
 
 
0.422 
Over all Mortality  
N(%) 
   
24  (12.6) 
 
45  (24.3) 
 
0.003 
Mortality by AKIN  
N(%) 
 
 
Stage 1 
 
 
5  (10.9) 
 
 
17 (17.1) 
 
 
 
  Stage 2  9  (12.7)  21 (39.6)   
  Stage 3  10 (13.7)  7 (21.2)   
Mortality by CKD  
Stage N(%) 
 
Stage 3A 
   
14 (21.9) 
 
  Stage 3B    27 (31.4)   
  Stage 4    4 (12.1)   
Delta eGFR @ 6mts 
Mean (SD) 
   
 
-8.88  (16.5) 
 
 
-0.47  (11.5) 
 
 
<0.001 
Delta by AKIN  Stage 1  -4 (11.52)  -0.13 (9.15)   
  Stage 2  -8.51 (14.26)  -1.5 (15.36)   
  Stage 3  -12.42 (20.24)  -0.32 (13.67)   
Failure to recover by 
study criteria 
Fall in eGFR 
>5mls/min N(%) 
   
 
 
 
83  (52.5) 
 
 
 
 
46  (34.1) 
 
 
 
 
0.002 
By AKIN  N(%)  Stage 1  18 (46.15)  21 (25.92)   
  Stage 2  33 (55.93)  15 (50)   
  Stage 3  32 (53.33)  10 (41.67)   
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    AKI Group 
N = 158 
AKI/CKD Group 
N=135 
 
P 
Fall in eGFR >10 
mls/min  N(%) 
   
64  (40.5) 
 
27  (20) 
 
<0.001 
By AKIN N(%)  Stage 1  11 (28.2)  10 (12.3)   
  Stage 2  26 (44.1)  9 (30)   
  Stage 3  27 (45)  8 (33.33)   
ASSESS AKI Criteria         
Fall 25% and to CKD   
N(%) 
   
31  (19.6) 
   
By AKIN N(%)  Stage 1  3 (7.7)     
  Stage 2  12 (20.34)     
  Stage 3  16 (26.67)     
50% fall in eGFR in 
CKD Group N(%) 
     
 
5  (3.7) 
 
 
 
Fall in eGFR by  
!25% N(%) 
   
33(20.8) 
 
20(14.8) 
 
By AKIN N(%)  Stage 1  3 (7.7)  8 (9.9)   
  Stage 2  13 (22)  6 (24)   
  Stage 3  17 (28.3)  6 (33)   
Total on Dialysis @ 
6mts   N(%) 
   
0 
 
3 (2.1) 
 
0.101 
  On dialysis since d/c  
N(%) 
 
0 
 
2 (1.4) 
 
 
  Started dialysis since 
d/c N(%) 
 
0 
 
1 (0.7) 
 
         
On RASB after 6mts 
N(%) 
AKI: N=155 
AKI/CKD: N=119 
 
67 (43.2) 
 
60 (50.4) 
 
0.237 
  On RASB after 6mts 
who were on it at 
time of AKI  N(%) 
 
 
 
59 (73) 
 
 
 
59 (65.5) 
 
 
 
0.247 
Readmitted  N(%)     
71  (40.1) 
 
72  (43.1) 
 
0.572 
Another AKI in 6mts 
N(%) 
   
 
23 (12.1) 
 
 
36 (19.5) 
 
 
0.082 
Failing to recover by 
study criteria with 
another AKI 
N(%) 
   
 
 
 
7(8.4) 
 
 
 
 
9(19.6) 
 
 
 
 
0.093 
Failing to recover by 
study criteria with 
readmission 
N(%) 
   
 
 
 
27 (32.5) 
 
 
 
 
20 (43.5) 
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Table 6.17 Follow up data for the AKI group divided by AKIN stage. 
 
   
AKIN 1 
N = 46 
AKI Group 
AKIN 2 
N = 71 
 
AKIN 3 
N = 73 
 
p 
Time to follow up 
eGFR in months 
Median (IQR) 
 
 
7 (6-8) 
 
 
7 (6-8) 
 
 
7 (6-8) 
 
Over all Mortality  
N(%) 
 
5  (10.9) 
 
9  (12.7) 
 
10 (13.7) 
 
0.903 
Delta eGFR @ 6mts 
Mean (SD) 
 
-4 (11.52) 
 
-8.51 (14.26) 
 
-12.42 (20.24) 
 
0.044 
Failure to recover by 
study criteria 
Fall in eGFR 
>5mls/min N(%) 
 
 
 
18 (46.15) 
 
 
 
33 (55.93) 
 
 
 
32 (53.33) 
 
 
 
0.630 
Fall in eGFR >10 
mls/min  N(%) 
 
11 (28.2) 
 
26 (44.1) 
 
27 (45) 
 
0.196 
ASSESS AKI Criteria         
Fall 25% and to CKD   
N(%) 
 
3 (7.7) 
 
12 (20.34) 
 
16 (26.67) 
 
0.066 
Total on Dialysis @ 
6mts   N(%) 
 
0 
 
0 
 
0 
 
On RASB after 6mts 
N(%) 
 
18 (46.2) 
 
25 (43.9) 
 
24 (40.7) 
 
0.860 
On RASB after 6mts 
who were on it at 
time of AKI   N(%) 
 
 
15 (71.4) 
 
 
22 (73.3) 
 
 
22 (75.9) 
0.938 
Readmitted  N(%)  18 (41.9)  23 (34.3)  30 (44.8)  0.451 
Another AKI in 6mts 
N(%) 
 
 
6 (13) 
 
 
8 (11.3) 
 
 
9 (12.3) 
 
 
0.994 
Failing to recover by 
study criteria with 
another AKI 
N(%) 
 
 
 
2 (11.1) 
 
 
 
3 (9.1) 
 
 
 
2 (6.3) 
 
 
 
0.826 
Failing to recover by 
study criteria with 
readmission 
N(%) 
 
 
 
6 (33.3) 
 
 
 
9 (27.3) 
 
 
 
12 (37.5) 
 
 
 
0.677 
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Table 6.18  Follow up data for the AKI/CKD group divided by AKIN stage. 
 
    
 
AKIN 1 
N = 99 
AKI/CKD Group 
 
AKIN 2 
N = 53 
  
 
AKIN 3 
N = 33 
 
 
p 
Time to follow up 
eGFR in months 
Median (IQR) 
 
 
7 (6-8) 
 
 
7 (7-8.25) 
 
 
6 (6-7) 
 
 
0.002 
Over all Mortality  
N(%) 
 
17 (17.1) 
 
21 (39.6) 
 
7 (21.2) 
 
0.008 
Delta eGFR @ 6mts 
Mean (SD) 
 
-0.13 (9.15) 
 
-1.5 (15.36) 
 
-0.32 (13.67) 
 
0.337 
Failure to recover by 
study criteria 
Fall in eGFR 
>5mls/min N(%) 
 
 
 
21 (25.92) 
 
 
 
15 (50) 
 
 
 
10 (41.67) 
 
 
 
0.041 
Fall in eGFR >10 
mls/min  N(%) 
 
10 (12.3) 
 
9 (30) 
 
8 (33.3) 
 
0.023 
ASSESS AKI Criteria         
50% fall in eGFR in 
CKD Group N(%) 
 
1 (1.2) 
 
1 (3.3) 
 
3 (12.5) 
 
0.037 
Total on Dialysis @ 
6mts   N(%) 
 
1 (1.2) 
 
0 
 
2 (7.4) 
 
0.087 
On dialysis since d/c  
N(%) 
 
0 
 
0 
 
2 (7.4) 
 
Started dialysis since 
d/c N(%) 
 
1 (1.2) 
 
0 
 
2 (7.4) 
 
         
On RASB after 6mts 
N(%) 
 
36 (50) 
 
14 (56) 
 
10 (45.5) 
 
0.766 
On RASB after 6mts 
who were on it at 
time of AKI  N(%) 
 
 
35 (66) 
 
 
14 (66.7) 
 
 
10 (62.5) 
 
 
0.959 
Readmitted Y/N  N(%)   
43 (45.3) 
 
18 (42.9) 
 
11 (36.7) 
 
0.709 
Another AKI in 6mts 
N(%) 
 
 
18 (18.2) 
 
 
13 (24.5) 
 
 
5 (15.2) 
 
 
0.008 
Failing to recover by 
study criteria with 
another AKI 
N(%) 
 
 
 
4 (19) 
 
 
 
4 (26.7) 
 
 
 
1 (10) 
 
 
 
0.587 
Failing to recover by 
study criteria with 
readmission 
N(%) 
 
 
 
10 (47.6) 
 
 
 
6 (40) 
 
 
 
4 (40) 
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Table 6.19  Comparison of outcomes of the AKI/CKD group and CKD control group 
after 6 months of follow up.  
 
    AKI/CKD Group 
N=185 
CKD Control 
Group 
N=26 
 
P 
Time to follow up 
eGFR in months 
Median (IQR) 
   
 
 
7 (6-8) 
 
 
 
6 (6-7.75) 
 
 
 
0.323 
Over all Mortality  
N(%) 
   
45  (24.3) 
 
1 (3.8) 
 
0.02 
Delta eGFR @ 6mts 
Mean (SD) 
   
 
-0.47  (11.5) 
 
 
+ 1.46 (7.48) 
 
 
0.432 
Total on Dialysis @ 
6mts   N(%) 
   
3 (2.1) 
 
0 
 
 
Fall in eGFR 
>5mls/min N(%) 
   
46 (34) 
 
4 (16.7) 
 
.091 
Fall in eGFR >10 
mls/min  N(%) 
   
27 (20) 
 
0 
 
.016 
Fall in eGFR by  
!25% N(%) 
   
20 (14.8) 
 
0 
 
.044 
On RASB after 6mts 
N(%) 
   
60 (50.4) 
 
7 (38.9) 
 
0.328 
  On RASB after 6mts 
who were on it at 
time of AKI  N(%) 
 
 
 
59 (65.5) 
   
Readmitted   N(%)     
72  (43.1) 
 
10 (40) 
 
0.769 
 AKI in 6mts 
N(%) 
   
36 (19.5) 
 
3 (11.5) 
 
0.423 
 Mark Uniacke    Chapter 6     
        165 
Table 6.20 The AKI group split into those with and without evidence of at least 
one eGFR < 60mls/min during the three years prior to the chosen baseline and/or 
evidence of microalbuminuria. Comparison of the outcomes in these subgroups after 
6 months is made and no difference can be seen between them in terms of mortality 
or functional recovery.  
 
     
 
AKI Group 
 
N = 190 
AKI Group 
without previous 
eGFR < 60 and/or 
raised ACR 
N=152 
AKI Group 
with previous 
eGFR < 60 and/or 
raised ACR 
N= 38 
 
P 
Over all 
Mortality  N(%) 
   
24  (12.6) 
 
  21(13.8) 
 
3(7.9) 
 
0.326 
Mortality by 
AKIN  
N(%) 
 
 
Stage 1 
 
 
5  (10.9) 
 
 
5 (13.1) 
 
 
0 
 
 
 
  Stage 2  9  (12.7)  7 (13.4)  2 (10.52)   
  Stage 3  10 (13.7)  9 (14.5)  1(9.0)   
Failure to 
recover by 
study criteria 
Fall in eGFR 
>5mls/min N(%)  
   
N=158 
 
 
83  (52.5) 
 
N=123 
 
 
  63 (51.2) 
 
N=35 
 
 
20 (57.1) 
 
 
 
 
0.536 
By AKIN  N(%)  Stage 1  18 (46.15)  15 (48)  3 (37.5)   
  Stage 2  33 (55.930  23 (54.7)  10 (58.8)   
  Stage 3  32 (53.33)  25 (50)  7 (70)   
Fall in eGFR >10 
mls/min  N(%) 
   
64  (40.5) 
 
 50 (40.7) 
 
14 (40) 
 
0.945 
By AKIN N(%)  Stage 1  11 (28.2)  10 (32)  1 (12.5)   
  Stage 2  26 (44.1)  19 (45)  7 (41.1)   
  Stage 3  27 (45)  21 (42)  6 (60)   
ASSESS AKI 
Criteria 
         
Fall 25% and to 
CKD   N(%) 
   
31  (19.6) 
 
22(17.9) 
 
9 (25.7) 
 
0.304 
By AKIN N(%)  Stage 1  3 (7.7)  3 (9.7)  0   
  Stage 2  12 (20.34)  7 (16.6)  5 (29.4)   
  Stage 3  16 (26.67)  12(24)  4 (40)   
 
Table 6.16 outlines the comparison of the AKI/CKD group and the CKD control group 
after 6 months. Again the small numbers in the control group make it difficult to draw 
any firm conclusion from these data. There was a trend toward a higher mortality in 
the AKI/CKD group (p=0.02). It is notable that the mean change in eGFR in the control 
group was +1.46mls/min compared to -0.47mls/min in the AKI/CKD group although Mark Uniacke    Chapter 6     
        166 
this difference did not reach statistical significance possibly because of a lack of 
power. 
 
Table 6.21 Comparison of outcomes of the AKI/CKD group and CKD control group 
after 6 months of follow up.  
 
    AKI/CKD Group 
N=185 
CKD Control 
Group 
N=26 
 
P 
Time to follow up 
eGFR in months 
Median (IQR) 
   
 
 
7 (6-8) 
 
 
 
6 (6-7.75) 
 
 
 
0.323 
Over all Mortality  
N(%) 
   
45  (24.3) 
 
1 (3.8) 
 
0.02 
Delta eGFR @ 6mts 
Mean (SD) 
   
 
-0.47  (11.5) 
 
 
+ 1.46 (7.48) 
 
 
0.432 
Total on Dialysis @ 
6mts   N(%) 
   
3 (2.1) 
 
0 
 
 
Fall in eGFR 
>5mls/min N(%) 
   
46 (34) 
 
4 (16.7) 
 
.091 
Fall in eGFR >10 
mls/min  N(%) 
   
27 (20) 
 
0 
 
.016 
Fall in eGFR by  
!25% N(%) 
   
20 (14.8) 
 
0 
 
.044 
On RASB after 6mts 
N(%) 
   
60 (50.4) 
 
7 (38.9) 
 
0.328 
  On RASB after 6mts 
who were on it at 
time of AKI  N(%) 
 
 
 
59 (65.5) 
   
Readmitted   N(%)     
72  (43.1) 
 
10 (40) 
 
0.769 
 AKI in 6mts 
N(%) 
   
36 (19.5) 
 
3 (11.5) 
 
0.423 
 
 
6.5.4 Evolution of kidney function after AKI 
 
There are two paradoxical findings described in the results above that required further 
exploration. Firstly, at the time of discharge from hospital it was found that the mean 
change of eGFR in the AKI/CKD group was positive 0.11mls/min. This contrasts with 
the finding that 31.4% of the group had not recovered function. Secondly, it is notable 
that there was little difference between the proportion who failed to recover function Mark Uniacke    Chapter 6     
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at discharge according to the study criteria and the proportion who failed to recover 
after 6 months of follow up. For example, in the AKI group, 52.6% of patients were 
found to have failed to recover within 5mls/min of baseline function at the time of 
discharge from hospital while after 6 months follow up this figure was unchanged at 
52.5%. A similar pattern was seen in the AKI/CKD group. If it is presumed these are the 
same people this is a surprising finding as some degree of recovery would be expected 
to have occurred.  
 
To resolve these issues each group at the time of discharge was divided into three 
subgroups. Those whose function remained unchanged at discharge and so remained 
within  ± 5mls/min of baseline, those with a fall of ! 5mls/min and hence failure to 
recover, and those who showed a gain of function with a rise in eGFR from baseline ! 
5mls/min. The mean change in eGFR was calculated for each of the subgroups and the 
results of these for both the AKI group and AKI/CKD group are illustrated in Table 
6.22.  As expected there is an overall fall in the mean eGFR in the group that failed to 
recover within 5mls/min of baseline. This is attenuated in the overall mean change in 
eGFR by a rise in eGFR in the subdivision that apparently gains function at the time of 
discharge. This is most marked in the AKI/CKD group and explains why the overall 
mean change is positive 0.11 mls/min despite finding that more than 30% failed to 
recover.  
 
The outcome for each subgroup was then explored after the 6 months of follow up to 
assess how the position of patients within these subgroups may have changed and this 
is illustrated in Table 6.23 and Table 6.24 for the AKI and AKI/CKD groups 
respectively. It can be seen that in both groups a marked exchange between the 
subdivisions takes place between discharge and follow up. For example, in the AKI 
group at the time of discharge 100 patients fell into the failure to recover division. 
After 6 months 36% of these that were available for analysis had recovered to join 
either the ‘gain’ or ‘no change’ divisions. However, a similar number from the ‘gain’ 
and ‘no change’ groups at discharge switch to the failure to recover group after 6 
months and balance this.  
 
This explains the finding in the results described in this chapter that there appeared to 
be no overall change in the percentage that recovered at follow up. The answer lies in 
the fact that the patients in this subdivision at follow up are not entirely the same 
patients that were in the subdivision at discharge.  
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Table 6.22 Mean change in eGFR at discharge in each group in subdivisions of a 
gain in eGFR , no change, and a fall in eGFR together with the overall mean 
change. 
 
     
 
 
AKI Group 
Mean change in Discharge 
eGFR (±SD) 
Overall mean mean change 
at discharge (±SD) 
Gain in eGFR ! 5mls/min  +14.24 (7.5)   
No change ± 5mls/min  +0.16 (1.9)   
Fall in eGFR ! 5 mls/min  -26.43 (16.6)   
    -11.75 (21.1) 
AKI/CKD Group     
Gain in eGFR ! 5mls/min  + 13.75 (9.1)   
No change ± 5mls/min  -0.66   (2.5)   
Fall in eGFR ! 5 mls/min  -12.31 (7.6)   
    +0.11 (12.7) 
     
 
Table 6. 23 AKI Group divided by functional status at discharge into a gain in 
eGFR of !5mls/min, no change ±5mls/min, and a fall of !5mls/min relative to 
baseline. The status of each of these divisions after 6 months of follow up is 
tabulated.  
 
eGFR status at discharge from 
hospital relative to baseline 
 
eGFR status after 6 months of follow up relative to baseline 
   
RIP/Lost 
Gain of Y5mls/min 
N(%) 
 
No change  
N(%) 
Fall of Y 5mls/min  
N(%) 
Gain of Y5mls/min 
 N=34 
 
4 
 
10(33) 
 
9 (30) 
 
11(37) 
No change 
 N=49 
 
10 
 
1 (3) 
 
23 (58) 
 
15 (38) 
Fall of Y5mls/min 
 N= 100 
 
11 
 
16 (18) 
 
16 (18) 
 
57 (64) 
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Table 6. 24 AKI/CKD Group divided by functional status at discharge into a gain in 
eGFR of !5mls/min, no change ±5mls/min, and a fall of !5mls/min relative to 
baseline. The status of each of these divisions after 6 months of follow up is 
tabulated. 
 
eGFR status at discharge from 
hospital relative to baseline 
 
eGFR status after 6 months of follow up relative to baseline 
   
RIP/Lost 
Gain of Y5mls/min 
N(%) 
 
No change  
N(%) 
Fall of Y 5mls/min 
 N(%) 
Gain of Y5mls/min  
N=51 
 
11 
 
17(44) 
 
17 (44) 
 
6(13) 
No change 
 N=61 
 
11 
 
10 (20) 
 
27 (54) 
 
13 (26) 
Fall of Y5mls/min 
 N= 57 
 
12 
 
4 (9) 
 
14(31) 
 
27 (60) 
         
 
 
6.5.5 Repeat hospitalisation and repeat AKI during follow up 
 
During the six months following the AKI 40% of the AKI group and 43% of the AKI/CKD 
group were readmitted to hospital at least once. No difference was found in 
readmission rates according to AKIN stage within the groups. 19.5% of the AKI/CKD 
group had evidence of another AKI episode meeting AKIN criteria while 12.1% of the 
AKI group had another AKI episode. When divided by AKIN stage there was no 
difference in repeat AKI rate between stages in the AKI group while in the AKI/CKD 
group more repeat episodes occurred in AKIN stage 2. The AKIN stages did not predict 
readmission or repeat AKI according to stage during follow up.  
 
To assess the influence of repeat AKI episodes on recovery patterns the numbers who 
failed to recover according to study criteria and had a repeat AKI episode were 
explored. In the AKI group 8.4% of those who failed to recover had a repeat episode 
while in the AKI/CKD group 19.6% had a repeat episode (p=0.093).  No differences 
were found according to AKIN stage in either group.  
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The finding that a substantial proportion of both groups experienced repeat AKI 
episodes is important when viewed together with the preadmission findings. 5.3% of 
the AKI group and 20.5% of the AKI/CKD group also showed evidence of an AKI in the 
12 months prior to the index AKI. Of the 23 patients in the AKI group who had a 
repeat AKI during follow up, 3 patients (13%) had evidence of an AKI in the previous 12 
months. Of the 36 patients in the AKI/CKD group who had a repeat episode, 7 patients 
(19.4%) had an AKI during the previous 12 months. This suggests that at least in some 
patients particularly in the AKI/CKD group, AKI is a recurrent phenomenon. Whether or 
not repeat AKI episodes predicted failure to recover function will be explored further 
using regression analysis in Chapter 7.   
 
6.5.6 Use of ACE inhibitors at the time of follow up 
 
52.1% of the AKI Group and 74.1% of the AKI/CKD group were on RAS-blockers at the 
time of their AKI. These were stopped in over 90% in each group at the time of the AKI 
as a part of their clinical management. The status in relation to the use of RAS- 
blockers after 6 months was available in all but 6 patients in the AKI group and 18 
patients in the AKI/CKD group. Missing data was not made available by the general 
practitioner at the time of follow up.  
 
After follow up, 43% of the AKI group (N=155) and 50% of the AKI/CKD group (N=119) 
were on RAS-blockers. Comparison was made between the status of those prior to the 
AKI and after follow up. It was found that of the survivors at 6 months who were on 
RAS blockers before the AKI, 73% in the AKI group and 65.5% in the AKI/CKD group 
were on them after follow up. This indicates that many of those who had their RAS 
blocker medication discontinued at the time of the AKI did not have them restarted. 
There was no difference between AKIN stages in each group in this regard.  
 
6.6 Comparison of outcomes between community-acquired 
and hospital-acquired AKI 
 
Tables 6.25 and 6.26 compare the hospital and 6 month outcomes between those 
cases where AKI was present on admission, and hence community- acquired, and cases 
with hospital -acquired AKI in each of the two groups. There is a trend toward 
increased mortality both in hospital and at 6 months in community-acquired cases in 
the AKI group. There is no difference in mortality at either time point in the AKI/CKD 
group. In terms of failure to recover function there is no significant difference in this 
outcome either at hospital discharge or after 6 months between hospital and 
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Table 6.25 Hospital and 6 month outcomes of those with AKI present on 
admission (Community AKI) compared to hospital-acquired AKI in the AKI group. 
 
    AKI Group 
    Admission AKI 
N = 118 
AKI Group 
 Hospital AKI 
N = 72 
 
P 
Hospital mortality 
N(%) 
   
7(5.9) 
 
0 
 
.035 
Not recovered 
function at 
discharge N(%) 
   
 
58 (52.2) 
 
 
42 (58.3) 
 
 
.420 
   
 
 
N=98 
 
N=68 
 
 
Over all  
6 month Mortality  
N(%) 
   
 
20 (16.9) 
 
 
4 (5.5) 
 
 
.024 
Fall in eGFR 
>5mls/min N(%) 
   
 
47 (50) 
 
 
36 (56) 
 
 
.440 
Fall in eGFR >10 
mls/min  N(%) 
   
 
38 (40.4) 
 
 
26 (40.6) 
 
 
.980 
Fall in eGFR by  
!25% N(%) 
   
24 (25.5) 
 
9 (14) 
 
.082 
         
 
Table 6.26 Hospital and 6 month outcomes of those with AKI present on 
admission (Community AKI) compared to hospital-acquired AKI in the AKI/CKD 
group. 
 
         
    AKI/CKD Group 
 Admission AKI 
N = 135 
AKI Group 
 Hospital AKI 
N = 50 
 
P 
Hospital mortality 
N(%) 
   
11(8.1) 
 
5(10) 
 
.891 
Not recovered 
function at 
discharge N(%) 
   
 
47 (37.9) 
 
 
10 (22.2) 
 
 
.057 
   
 
 
N=102 
 
N=38 
 
 
Over all  
6 month Mortality  
N(%) 
   
 
33 (24.4) 
 
 
12 (24) 
 
 
.956 
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    AKI/CKD Group 
 Admission AKI 
N = 135 
AKI Group 
 Hospital AKI 
N = 50 
 
P 
Fall in eGFR 
>5mls/min N(%) 
   
 
34 (34.3) 
 
 
12 (33.3) 
 
 
.913 
Fall in eGFR >10 
mls/min  N(%) 
   
 
21 (21.2) 
 
 
6 (16.6) 
 
 
.559 
Fall in eGFR by  
!25% N(%) 
   
16 (16.1) 
 
4(11.1) 
 
.465 
         
 
6.7 12 month mortality 
 
The mortality status on all patients at 12 months was obtained using NHS tracing. In 
the AKI group a further 7 patients died between 6 and 12 months. In the AKI/CKD 
group a further 11 patients died during this period. This brings the total mortality at 
12 months to 16.3% in the AKI group and 30.2% in the AKI/CKD group. These data are 
outlined in Table 6.27 and are divided by AKIN stage.  
 
Table 6.27 Mortality at 12 months in the AKI and AKI/CKD groups overall and 
divided by AKIN stage.  
 
    AKI Group 
 
N = 190 
AKI/CKD Group 
 
N=185 
 
P 
Over all Mortality 
at 12 months  
N(%) 
   
 
31  (16.3) 
 
 
56 (30.2) 
 
 
0.001 
         
Mortality by AKIN 
Stage 
N(%) 
 
 
Stage 1 
 
 
16  (15.7) 
 
 
26 (26.2) 
 
 
 
  Stage 2  9  (16.7)  22 (41.5)   
  Stage 3  6 (17.6)  8 (24.2)   
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6.8 Summary of key findings 
 
1. 53% of the AKI group and 34% of the AKI/CKD group failed to recover their eGFR to 
within 5mls/min of baseline. 20.8% of the AKI group and 14.8% of the AKI/CKD group 
demonstrated a fall in eGFR of at least 25% from baseline. Therefore this study 
demonstrates clearly that AKI causes de novo CKD in those with a baseline eGFR > 
60mls/min and progression of CKD in those who already have it.  
 
2. Those in the AKI/CKD were older and had a greater burden of comorbidities. In both 
groups, the majority had an AKI in which the primary insult occurred in the community 
and was evident on admission to hospital – 62% in the AKI group and 73% in the 
AKI/CKD group. In over 95% of cases the cause of the AKI in each group was pre-renal. 
Sepsis was prominent in both groups with 23% in the AKI group and 31% in the 
AKI/CKD group. More than one causal insult was found in 28% of the AKI group and 
26% of the AKI/CKD group.  
 
3. Hospital mortality was 3.7% in the AKI group and 8.6% in the AKI/CKD group. AKIN 
staging did not predict hospital mortality. Comparing the AKI/CKD group to the CKD 
controls the median length of hospital stay was significantly longer. At 6 months 
mortality in the AKI group was 12.6% while in the AKI/CKD group it was 24.3%. AKIN 
staging did not predict mortality.  
 
4. After 12 months of follow up mortality in the AKI group was 16.3% while in the 
AKI/CKD group it was 30.2%. This clearly demonstrates the poor prognostic 
significance of an AKI. 
 
5. The findings also demonstrate a pattern of repeat admission and repeat AKI in this 
cohort. During the 6 months after discharge 40% of the AKI group and 43% of the 
AKI/CKD group were readmitted and of these 12.1% and 19.8% experienced another 
AKI.  
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Chapter 7: Results 3 – Regression analysis 
 
7.1 Introduction 
 
In this chapter the data are explored further using binary logistic regression analysis. 
Univariate analysis was preformed on a variety of clinical variables to assess their 
influence on mortality at 6 and 12 months after the index AKI and recovery of function. 
In addition, the combined outcome of death or failure to recover defined by a fall in 
eGFR of 5mls/min was explored. Finally, the influence of recovery of function at 
discharge, readmission, and repeat AKI during follow up was explored. The univariate 
analysis was then followed by multivariate logistic regression which is described later 
in this chapter.  The findings presented are discussed at length in Chapter 8.  
 
7.2 Univariate analysis 
 
7.2.1 Mortality 
 
Tables 7.1 and 7.2 outline the univariate binary logistic regression analysis using 
mortality at 6 and 12 months respectively as the dependent variables. Results are 
described for both the AKI and the AKI/CKD groups. In Tables 7.3 and 7.4 the factors 
that reached the study level of significance (P<.01) in each group are summarised. 
 
7.2.1 (i) Preadmission variables 
 
Admission to hospital during the 12 months prior to the index AKI increased the odds 
of mortality in both groups. This approached statistical significance for mortality at 12 
months in the AKI group (p=0.037). In the AKI group a history of a previous AKI during 
the 4 years prior to the index AKI increased the odds of mortality significantly at 6 
months (OR 4.697, p=0.006). The significance of this finding was reduced at 12 
months (p=0.034). In the AKI/CKD group a history of a previous AKI did not 
significantly influence mortality.  
 
The slope of decline in eGFR over the three years prior to the index AKI was not found 
to influence either 6 or 12 month mortality in the AKI or the AKI/CKD groups. In 
addition the influence of baseline eGFR did not reach significance in either group.  
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7.2.1 (ii) Baseline variables 
 
Increasing age and Charlson comorbidity score significantly increased the odds of 
mortality at both 6 and 12 months in the AKI group. However in the AKI/CKD group 
the findings were less clear except at 12 months where age increased the odds of 
mortality (P=.029). Sex did not appear to influence mortality in either group. 
 
A potentially important finding was that use of RAS-blockers prior to the AKI had a 
protective effect in the AKI/CKD group and this approached statistical significance at 6 
months (OR .468, 95% C.I .227 - .965, p=0.04). The use of furosemide increased the 
odds of mortality in both groups and this reached statistical significance at 12 months 
in the AKI group (p=0.004). This effect is presumably related to underlying 
comorbidities that required the use of furosemide and indeed it was reduced with 
adjustment for age and Charlson score. 
  
Increased body mass index reduced the odds of mortality for the AKI/CKD group at 12 
months (OR .933, 95 C.I. .876-.995, p=0.034). A surprising finding was that a history 
of previous hypertension appeared to exert a protective effect in the AKI/CKD group 
particularly for 6 month mortality (OR .375, 95% C.I. .146 - .960, p=0.041). Given the 
large proportion of patients using RAS blockers in this group (74%), adjustment was 
made for their use and the effect was reduced (OR .540, 95% C.I. .176 – 1.653, 
p=0.281).  
 
7.2.1 (iii) AKI related variables 
 
The variable that appeared to exert the strongest influence on mortality was the 
admitting specialty in the AKI/CKD group. When admission was under a medical 
specialty the odds of mortality was increased and this was statistically significant at 6 
and 12 months. Those who had evidence of AKI on admission to hospital and hence 
had community acquired AKI in the AKI group had increased odds of mortality at both 
6 and 12 months. This approached significance at both time points (p=0.029 and 
p=0.025 respectively). This effect was not found in the AKI/CKD group.  
 
AKIN stage did not prove to be a predictor of mortality in the AKI group perhaps 
because of insufficient power in the study. In the AKI/CKD group increased AKIN stage 
did predict mortality and reached statistical significance overall (p=0.01). Interestingly, 
AKIN stage 2 had the highest odds ratio. The reason for this increased risk compared 
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between these groups in terms of baseline function or AKI details. This finding is 
therefore likely to be due to chance.   
The cause of AKI appeared not to have an influence in either group although in the 
AKI/CKD group the odds of mortality were increased for septic and complex AKI at 12 
months (p=.062).  
 
ITU admission did not predict mortality in either group. This is most likely bias from 
the selection of younger fitter patients for intensive care. A formal renal review at the 
time of the AKI had no influence on mortality at either time point. Finally, in the case 
of those who recovered to baseline by the time of discharge from hospital, the longer 
it took to recover increased the odds of mortality in the AKI group at 12 months 
(p=0.023). 
  
Table 7.2 Univariate binary logistic regression analysis using mortality at 6 
months as the dependent variable for the AKI and AKI/CKD groups. 
 
AKI Group  AKI/CKD Group 
  B  OR  95% CI  Sig.  B  OR  95% CI  Sig. 
PreAKI  ACR  -.107  .898  (.905 - 1.145)  .386  -.001  .999  (.990 – 1.008)  .860 
eGFR slope  -.028  .972  (.884 – 1.070))  .566  .023  1.023  (.961 – 1.089)  .475 
Admit. In prev. 
12 months 
 
1.265 
 
3.545 
 
(1.472 - 8.557) 
 
.379 
 
.569 
 
1.766 
 
(.898 – 3.475) 
 
.099 
AKI in prev. 
12 months 
 
1.674 
 
5.333 
 
(1.386 – 20.529) 
 
.015 
 
-.602 
 
.134 
 
(.506 – 2.584) 
 
.748 
AKI in prev. 
4 years 
 
1.547 
 
4.697 
 
(1.551 – 14.224) 
 
.006 
 
-.074 
 
.838 
 
(.456 – 1.890) 
 
.929 
Baseline eGFR  .034  1.034  (.989 – 1.082)  .143  -.007  .993  (.966 – 1.021)  .638 
                 
Age  .059  1.061  (1.019 – 1.104)  .004  .033  1.034  (.994 – 1.075)  .098 
Sex  .402  1.495  (.606 – 3.686)  .383  .652  1.919  (.958 – 3.844)  .066 
Charlson Score  .509  1.664  (1.2 – 2.308)  .002  .057  1.059  (.844 – 1.329)  .622 
Diabetes  .206  1.229  (.493 – 3.062)  .658  -.607  .545  (.270 – 1.100)  .090 
Hypertension  .098  1.103  (.446 – 2.729)  .832  -.981  .375  (.146 - .960)  .041 
Smoking hist.  -.096  .908  (.386 – 2.138)  .825  .365  1.441  (.719 – 2.888)  .304 
BMI  -.031  .970  (.906 – 1.038)  .379  -.042  .959  (.898 – 1.025)  .215 
                 
RASB preAKI  -.096  .908  (.386 – 2.138)  .825  -.758  .468  (.227 - .965)  .040 
Aspirin  -.102  .903  (.353 – 2.309)  .831  .127  1.136  (.580 – 2.225)  .710 
NSAID  -.351  .704  (.197 – 2.522)  .590  -.606  .545  (.116 – 2.559)  .442 
Furosemide  1.085  2.958  (1.141 – 7.669)  .026  .623  1.865  (.931 – 3.735)  .079 
Statin  -.522  .593  (.233 – 1.509)  .273  .176  1.192  (.602– 2.361)  .614 
Betablocker  .469  1.599  (.614 – 4.165)  .337  .062  1.064  (.539 – 2.102)  .858 
Allopurinol  -.490  .613  (.076 – 4.970)  .646  .118  1.125  (.382 – 3.317)  .831 
PPI  -.046  .955  (.373 – 2.447)  .924  .182  1.200  (.602 – 2.391)  .604 
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AKI Group  AKI/CKD Group 
AKI  present on 
admission 
 
1.244 
 
3.469 
 
(1.135 – 10.603) 
 
.029 
 
.024 
 
1.025 
 
(.480 – 2.187) 
 
.950 
Medical   .783  2.187  (.826 – 5.793)  .115  1.644  5.176  (1.924 – 13.926)  .001 
AKIN Stage        .903        .010 
AKIN 1 (ref)    1.00        1.00     
AKIN 2  .174  1.190  (.372 – 3.806)  .769  1.152  3.165  (1.482 – 6.761)  .003 
AKIN 3  .264  1.302  (.415 – 4.083)  .651  .261  1.299  (.485– 3.476)  .603 
                 
BP < 90  .675  1.963  (.823 – 4.680)  .128  -.650  .522  (.224 – 1.217)  .132 
AKI Cause        .834        .262 
Hypoperfusion (ref)    1.00        1.00     
Septic  .222  1.249  (.422 – 3.697)  .688  .639  1.895  (.844 – 4.256)  .121 
Complex  .292  1.339  (.493 – 3.636)  .567  .529  1.698  (.718 – 4.013)  .228 
                 
ITU admission  .544  1.722  (.584 – 5.085)  .325  -.606  .545  (.116 – 2.559)  .442 
Renal review  -.897  .408  (.052 – 3.222)  .395  -.044  .957  (.414-2.210)  .918 
AKI duration  .077  1.080  (.978 – 1.193)  .130  .017  1.017  (.944 – 1.095)  .664 
 
Table 7.3 Univariate binary logistic regression analysis using mortality at 12 
months as the dependent variable for the AKI and AKI/CKD groups. 
 
AKI Group  AKI/CKD Group 
  B  OR  95% CI  p  B  OR  95% CI  p 
                 
PreAKI  ACR  -.074  .929  (.779 – 1.107)  .409  -.001  .999  (.991 – 1.008)  .891 
eGFR slope  -.016  .984  (.900 – 1.075)  .720  .018  1.019  (.961 – 1.080)  .538 
Admit. In prev. 
12 months 
 
.834 
 
2.303 
 
(1.052 – 5.041) 
 
.037 
 
.529 
 
1.697 
 
(.901 – 3.195) 
 
.101 
AKI in prev. 
12 months 
 
1.329 
 
3.778 
 
(.999 – 14.729) 
 
.050 
 
.077 
 
1.080 
 
(.500 – 2.333) 
 
.844 
AKI in prev. 
4 years 
 
1.172 
 
3.229 
 
(1.095 – 9.520) 
 
.034 
 
-.042 
 
.959 
 
(.495 – 1.857) 
 
.900 
Baseline eGFR  .025  1.026  (.985 – 1.068)  .220  .007  1.007  (.981 – 1.033)  .605 
                 
Age  .059  1.060  (1.023 – 1.099)  .001  .042  1.043  (1.004 – 1.083)  .029 
Sex  .018  1.018  (.467 – 2.220)  .965  .377  1.457  (.773 – 2.748)  .245 
Charlson Score  .405  1.499  (1.117 – 2.012)  .007  .119  1.126  (.910 – 1.394)  .274 
Diabetes  .332  1.393  (.618 – 3.140)  .424  -.510  .600  (.314 – 1.146)  .122 
Hypertension  .160  1.174  (.517 – 2.664)  .702  -.624  .536  (.212 – 1.355)  .187 
Smoking hist.  -.178  .837  (.388 – 1.808)  .651  .277  1.319  (.694 – 2.510)  .398 
BMI  -.010  .990  (.936 – 1.047)  .728  -.069  .933  (.876 - .995)  .034 
                 
RASB preAKI  -.024  .977  (.452 – 2.110)  .952  -.571  .565  (.283 – 1.127)  .105 
Aspirin  -.114  .892  (.383 – 2.076)  .791  -.106  .899  (.479 – 1.688)  .740 
NSAID  -.691  .501  (.142 – 1.765)  .282  -.923  .397  (.085 – 1.855)  .240 
Furosemide  1.285  3.164  (1.518 – 8.603)  .004  .775  2.171  (1.131 – 4.168)  .020 Mark Uniacke    Chapter 7     
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AKI Group  AKI/CKD Group 
Statin  -.551  .576  (.250 – 1.332)  .197  -.082  .922  (.490 – 1.734)  .800 
Betablocker  .284  1.328  (.545 – 3.238)  .533  .105  1.111  (.588 – 2.097)  .746 
Allopurinol  -.802  .448  (.056 – 3.606)  .451  -.217  .805  (.275 – 2.355)  .692 
PPI  -.055  .946  (.406 – 2.205)  .946  .155  1.168  (.612 – 2.228)  .638 
                 
AKI  present on 
admission 
 
1.084 
 
2.957 
 
(1.149 – 7.609) 
 
.025 
 
-.111 
 
.895 
 
(.444 – 1.801) 
 
.755 
Medical   .765  2.148  (.906 – 5.096)  .083  1.585  4.882  (2.053 – 11.607)  <.001 
AKIN Stage        .523        .110 
AKIN 1 (ref)    1.00        1.00     
AKIN 2  .609  1.838  (.608 – 5.556)  .281  .689  1.993  (.983 – 4.038)  .056 
AKIN 3  .575  1.777  (.588 – 5.365)  .308  -.107  .898  (.360 – 2.240)  .818 
                 
BP < 90  .349  1.418  (.639 – 3.147)  .391  -.388  .678  (.322 – 1.427)  .306 
AKI Cause        .565        .062 
Hypoperfusion (ref)    1.00        1.00     
Septic  .357  1.429  (.536 – 3.808)  .476  .788  2.199  (1.021 – 4.737)  .044 
Complex  .469  1.599  (.650 – 3.932)  .307  .844  2.325  (1.042 – 5.186 )  .039 
                 
ITU admission  .456  1.577  (.579 – 4.297)  .373  -.923  .397  (.085 – 1.855)  .240 
Renal review  -.412  .662  (.144 – 3.053)  .597  -.080  .923  (.422 – 2.022)  .842 
AKI duration  .112  1.118  (1.016 – 1.230)  .023  .005  1.005  (.935 – 1.081)  .885 
 
Table 7.3 Summary of factors that reached the study threshold of significance 
(p<.01) in the AKI or AKI/CKD groups on univariate analysis with mortality at 6 
months as the dependent variable. 
 
  AKI Group  AKI/CKD Group 
Factor  OR  95% C.I.  Sig.  OR  95% C.I.  Sig 
AKI in 
previous 4 
years 
 
4.697 
 
(1.551 – 
14.224) 
 
.006 
 
.838 
 
(.456 – 
1.890) 
 
.929 
Age  1.061  (1.019 – 
1.104) 
.004  1.034  (.994 – 
1.075) 
.098 
Charlson 
Score 
1.664  (1.2 – 2.308)  .002  1.059  (.844 – 
1.329) 
.622 
Medical 
Admission 
2.187  (.826 – 
5.793) 
.115  5.176  (1.924 – 
13.926) 
.001 
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Table 7.4 Summary of factors that reached the study threshold of significance 
(p<.01) in the AKI or AKI/CKD groups on univariate analysis with mortality at 12 
months as the dependent variable. 
 
  AKI Group  AKI/CKD Group 
Factor  OR  95% C.I.  Sig.  OR  95% C.I.  Sig 
Age  1.060  (1.023 – 
1.099) 
.001  1.043  (1.004 – 
1.083) 
.029 
Charlson 
Score 
1.499  (1.117 – 
2.012) 
.007  1.126  (.910 – 
1.394) 
.274 
Furosemide  3.164  (1.518 – 
8.603) 
.004  2.171  (1.131 – 
4.168) 
.020 
Medical 
Admission 
2.148  (.906 – 
5.096) 
.083  4.882  (2.053 – 
11.607) 
<.001 
             
 
7.2.2 Recovery of function 
 
Tables 7.5 outlines the univariate binary logistic regression analysis for failure to 
recover function according to the original study criteria defined by a fall in eGFR of 
5mls/min from baseline. Tables 7.6 and 7.7 outline the same data for the definition 
extended to a fall in eGFR of 10mls/min and a fall of 25%. Results are described for 
both the AKI and the AKI/CKD groups. In Table 7.8 the factors that reached the study 
level of significance (P<.01) in each group are summarised. 
 
7.2.2 (i) Preadmission variables 
 
The strongest finding among the preadmission variables and the most surprising is a 
protective effect associated with an increased slope of decline in eGFR during the three 
years prior to the index AKI. In the AKI group this was highly significant when using 
the definition of a fall in eGFR of 5mls/min (OR .879, 95% C.I. .800 to .965, p=.007). 
Using the same definition in the AKI/CKD group there was also a protective effect but 
it did not reach the same level of significance (OR .920, 95% C.I. .851 to .995, 
p=0.036). This protective effect persisted with extension of the definition of failure to 
recover to a fall of 10mls/min but was lost when a fall of 25% from baseline was used. 
 
A lower baseline eGFR also appeared to exert a protective effect. In the AKI/CKD group 
this was highly significant for a fall in eGFR of 10mls/min (OR .944, 95% C.I. .908 to 
.982, p=.005). However, when failure to recover function was defined as a fall in eGFR 
of 25% this effect disappears.  
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7.2.2 (ii) Baseline variables 
 
None of the baseline variables appear to have a substantial impact on recovery of 
function. In the AKI group increasing age raised the odds of failure to recover but this 
did not reach significance (OR 1.026, 95% C.I. 1.001-1.051, p=.040). This was not the 
case in the AKI/CKD group. In both groups the burden of comorbidities at baseline did 
not appear to influence the recovery outcome.  
 
RAS-blocker use was associated with increased odds of failure to recover in the AKI 
group. For a fall in eGFR of 25% this association was strongest and approached 
statistical significance (OR 2.337, 95% C.I. 1.028 to 5.312, p=0.043). Conversely, in the 
AKI/CKD group the association was less clear. A potentially important observation is 
that there is a trend toward a protective effect with the use of aspirin or a statin at the 
time of the AKI. In the case of the AKI/CKD group this approached significance using a 
definition of a fall in eGFR of 5mls/min in the case of a statin (OR .472, 95% C.I. .229 
to .973, p=.042). 
 
7.2.2 (iii) AKI related variables 
 
The severity of the AKI defined by the AKIN stage appeared to be predictive of non-
recovery in both groups although this did not reach statistical significance presumably 
due to insufficient power. This trend with increasing AKIN stage becomes much clearer 
using the definition of a fall of 25% in eGFR.  
 
Having a nadir BP < 90 systolic recorded at the time of the AKI appears to exert a 
protective effect in terms of recovery. In the AKI group this approached statistical 
significance for a fall in eGFR of 5mls/min (OR .439, 95% C.I. .218 to .884, p=.021).  
 
Finally, obtaining a formal renal review while in hospital increased the odds of failure 
to recover function. This effect was clearest when the definition of a fall of 25% is used 
and in the case of the AKI group is highly significant (OR 4.680, p=.005). This is likely 
to be a form of bias by indication, reflecting the severity of the AKI. However, in clinical 
practice many renal reviews are simply single assessments and so it raises important 
questions about the follow up of patients after hospital discharge.  
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Table 7.5 Univariate binary logistic regression analysis for failure to recover 
function according to the original study criteria defined by a fall in eGFR of 
5mls/min from baseline. Results are shown for the AKI group and the AKI/CKD 
group.  
 
AKI Group  AKI/CKD Group 
  B  OR  95% CI  Sig.  B  OR  95% CI  Sig. 
PreAKI  ACR  -.038  .963  (.874 – 1.060)  .442  .009  1.009  (.999 – 1.019)  .068 
eGFR slope  -.129  .879  (.800 - .965)  .007  -.084  .920  (.851 - .995)  .036 
Admit. In prev. 
12 months 
 
.311 
 
1.365 
 
(.673 – 2.770) 
 
.389 
 
.039 
 
1.040 
 
(.501 – 2.159) 
 
.916 
AKI in prev. 
12 months 
 
-.523 
 
.593 
 
(.096 – 3.647) 
 
.572 
 
-.254 
 
.776 
 
(.310 – 1.938) 
 
.587 
AKI in prev. 
4 years 
 
-1.428 
 
.240 
 
(.048 – 1.193) 
 
.081 
 
-.149 
 
.862 
 
(.406 – 1.831) 
 
.699 
Baseline eGFR  .000  1.000  (.967 – 1.034)  .985  -.036  .965  (.936 - .994)  .019 
                 
Age  .025  1.026  (1.001 – 1.051)  .040  -.004  .996  (.964 – 1.029)  .816 
Sex  -.279  .757  (.401 – 1.426)  .389  -.020  .981  (.481 – 1.999)  .957 
Charlson Score  -.093  .911  (.699 – 1.187)  .490  -.079  .924  (.729 – 1.171)  .513 
Diabetes  -.266  .766  (.385 – 1.525)  .448  .112  1.119  (.549 – 2.281)  .757 
Hypertension  .609  1.838  (.945 – 3.574)  .073  .478  1.612  (.415 – 6.271)  .491 
Smoking hist.  -.519  .595  (.317 – 1.118)  .107  -.078  .925  (.451 – 1.899)  .832 
BMI  .023  1.024  (.974 – 1.076)  .359  .000  1.000  (.943 – 1.060)  1.000 
                 
RASB preAKI  .549  1.732  (.921 – 3.257)  .088  -.091  .913  (.382 – 2.180)  .837 
Aspirin  -.148  .665  (.441 – 1.687)  .665  -.647  .524  (.253 – 1.086)  .082 
NSAID  -.391  .676  (.294 – 1.555)  .357  .924  2.520  (.726 – 8.753)  .924 
Furosemide  -.118  .889  (.361 – 2.189)  .798  -.154  .857  (.420 – 1.747)  .671 
Statin  -.070  .932  (.495 – 1.756)  .828  -.752  .472  (.229 - .973)  .042 
Betablocker  .115  1.122  (.510 – 2.469)  .774  .577  1.781  (.865 – 3.667)  .117 
Allopurinol  -.108  .897  (.249 – 3.231)  .868  .081  1.084  (.341 – 3.445)  .891 
PPI  -.026  .975  (.494 – 1.921)  .941  -.393  .675  (.316 – 1.441)  .310 
                 
AKI  present on 
admission 
 
-.251 
 
.778 
 
(.411 – 1.472) 
 
.440 
 
.045 
 
1.046 
 
(.466 – 2.346) 
 
.913 
Medical   -.522  .593  (.311 – 1.130)  .112  .194  1.214  (.509 – 2.898)  .662 
AKIN Stage        .631        .045 
AKIN 1 (ref)    1.00        1.00     
AKIN 2  .393  1.481  (.657 – 3.338)  .344  1.050  2.857  (1.195 – 6.829)  .018 
AKIN 3  .288  1.333  (.594 – 2.993)  .486  .713  2.041  (.788 – 5.285)  .142 
                 
BP < 90  -.823  .439  (.218 - .884)  .021  -.153  .858  (.392 – 1.877)  .702 
AKI Cause        .748        .835 
Hypoperfusion (ref)    1.00        1.00     
Septic  -.309  .734  (.328 – 1.641)  .451  .049  1.050  (.448 – 2.463)  .911 
Complex  -.064  .938  (.443 – 1.984)  .866  .262  1.300  (.543 – 3.112)  .556 
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AKI Group  AKI/CKD Group 
ITU admission  .309  1.362  (.546 – 3.397)  .508  .523  1.687  (.486 – 5.855)  .410 
Renal review  1.099  3.000  (.923 – 9.748)  .068  -.254  .776  (.310 – 1.938)  .587 
AKI duration  .049  1.050  (.953 – 1.158)  .322  .033  1.033  (.912 – 1.171)  .606 
 
Table 7.6 Univariate binary logistic regression analysis for failure to recover 
function defined by a fall in eGFR of 10mls/min from baseline. Results are shown 
for the AKI group and the AKI/CKD group.  
AKI Group  AKI/CKD Group 
  B  OR  95% CI  p  B  OR  95% CI  p 
PreAKI  ACR  -.084  .920  (.807 – 1.048)  .210  -.001  .999  (.989 – 1.009)  .869 
eGFR slope  -.097  .907  (.831 - .990)  .029  -.092  .912  (.833 - .998)  .045 
Admit. In prev. 
12 months 
 
.208 
 
1.231 
 
(.606 – 2.502) 
 
.565 
 
1.068 
 
2.909 
 
(1.224 – 6.914) 
 
.016 
AKI in prev. 
12 months 
 
-1.030 
 
.357 
 
(.039 – 3.271) 
 
.362 
 
.432 
 
1.540 
 
(.573 – 4.137) 
 
.392 
AKI in prev. 
4 years 
 
-1.768 
 
.171 
 
(.021 – 1.399) 
 
.100 
 
.512 
 
1.669 
 
(.706 – 3.941) 
 
.243 
Baseline eGFR  -.008  .992  (.959 – 1.027)  .662  -.057  .944  (.908 - .982)  .005 
                 
Age  .019  1.019  (.994 – 1.044)  .137  -.020  .296  (.945 – 1.017)  .296 
Sex  -.632  .532  (.275 – 1.029)  .061  .001  1.000  (.430 – 2.326)  1.000 
Charlson Score  -.235  .790  (.598 – 1.045)  .099  .064  1.066  (.809 – 1.405)  .650 
Diabetes  -.341  .711  (.349 – 1.451)  .349  .560  1.751  (.744 – 4.123)  .199 
Hypertension  .340  1.405  (.712 – 2.773)  .327  1.081  2.948  (.364 – 23.895)  .311 
Smoking hist.  -.551  .576  (.303 – 1.094)  .092  .076  1.079  (.458 – 2.543)  .862 
BMI  .024  1.024  (.974 – 1.076)  .351  .010  1.010  (.943 – 1.082)  .768 
                 
RASB preAKI  -.166  1.181  (.624 – 2.236)  .610  .879  2.410  (.669 – 8.674)  .178 
Aspirin  -.153  .858  (.432 – 1.706)  .662  -.338  .713  (.303 – 1.678)  .439 
NSAID  -.789  .454  (.180 – 1.149)  .096  .446  1.562  (.385 – 6.334)  .532 
Furosemide  -.203  .816  (.321 – 2.076)  .670  -.111  .895  (.385 – 2.081)  .796 
Statin  -.297  .743  (.388 – 1.422)  .369  -.487  .614  (.263 – 1.434)  .260 
Betablocker  .238  1.268  (.575 – 2.800)  .238  .754  2.125  (.905 – 4.990)  .084 
Allopurinol  .411  1.508  (.418 – 5.439)  .530  .097  .888  (.285 – 4.263)  .888 
PPI  .069  1.071  (.538 – 2.134)  .844  -.374  .422  (.276 – 1.714)  .422 
                 
AKI  present on 
admission 
 
-.008 
 
.992 
 
(.519 – 1.894) 
 
.980 
 
.297 
 
1.346 
 
(.495 – 3.660) 
 
.560 
Medical   -.522  .593  (.311 – 1.130)  .112  .194  1.214  (.509 – 2.898)  .662 
AKIN Stage        .203         
AKIN 1 (ref)    1.00        1.00    .029 
AKIN 2  .696  2.006  (.843 – 4.770)  .115  1.113  3.043  (1.093 – 8.470)  .033 
AKIN 3  .734  2.083  (.878 – 4.937)  .096  1.267  3.550  (1.210 – 10.416)  .021 
                 
BP < 90  -.389  .677  (.333 – 1.379)  .283  .379  1.461  (.603 – 3.542)  .401 
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AKI Group  AKI/CKD Group 
AKI Cause        .326        .048 
Hypoperfusion (ref)    1.00        1.00     
Septic  -.205  .815  (.351 – 1.892)  .634  1.216  3.375  (1.245 – 9.149)  .017 
Complex  .444  1.559  (.732 – 3.319)  .250  .369  1.446  (.457 – 4.581)  .530 
                 
ITU admission  .449  1.566  (.634 – 3.867)  .331  -.128  .875  (.179 – 4.331)  .875 
Renal review  1.647  5.192  (1.592 – 16.931)  .006  -.118  .888  (.302 – 2.611)  .830 
AKI duration  .090  1.094  (.987 – 1.212)  .086  -.004  .957  (.852 – 1.164)  .957 
 
Table 7.7 Univariate binary logistic regression analysis for failure to recover 
function defined by a fall in eGFR of 25% from baseline. Results are shown for the 
AKI group and the AKI/CKD group.  
AKI Group  AKI/CKD Group 
  B  OR  95% CI  p  B  OR  95% CI  p 
PreAKI  ACR  -.056  .945  (.826 – 1.082)  .413  .007  1.007  (.999 – 1.015)  .092 
eGFR slope  -.063  .939  (.855 – 1.031)  .188  -.050  .951  (.868 – 1.042)  .283 
Admit. In prev. 
12 months 
 
.192 
 
1.212 
 
(.522 – 2.814) 
 
.654 
 
1.286 
 
3.619 
 
(1.336 – 9.805) 
 
.011 
Baseline eGFR  .013  1.013  (.972 – 1.056)  .534  .017  1.017  (.981 – 1.056)  .359 
                 
Age  .040  1.040  (1.005 – 1.077)  .024  -.026  .975  (.936 – 1.014)  .207 
Sex  -1.200  .301  (.122 - .745)  .009  .087  1.091  (.422 – 2.820)  .858 
Charlson Score  -.062  .940  (.676 – 1.307)  .713  -.047  .954  (.696 – 1.309)  .772 
Diabetes  .425  1.529  (.679 – 3.443)  .425  .087  1.091  (.422 – 2.820)  .858 
Hypertension  1.031  2.805  (1.079 – 7.291)  .034  .698  2.010  (.245 – 16.488)  .516 
Smoking hist.  -.482  .618  (.285 – 1.341)  .223  -.606  .545  (.210 – 1.420)  .214 
BMI  -.001  .999  (.942 – 1.060)  .975  .031  1.031  (.957 – 1.111)  .417 
                 
RASB preAKI  .849  2.337  (1.028- 5.312)  .043  .053  1.055  (.323 – 3.448)  .929 
Aspirin  .436  1.546  (.697 – 3.430)  .284  -.353  .702  (.267 – 1.846)  .474 
NSAID  -1.355  .258  (.058 – 1.151)  .076  .269  1.309  (.261 – 6.557)  .744 
Furosemide  -.199  .820  (.257 – 2.612)  .737  -.017  .983  (.380 – 2.540)  .971 
Statin  .345  1.412  (.653 – 3.051)  .381  -.606  .545  (.210 – 1.420)  .214 
Betablocker  .767  2.153  (.895 – 5.181)  .087  .921  2.512  (.951 – 6.633)  .063 
Allopurinol  .522  1.686  (.411 – 6.909)  .468  .965  2.625  (.735 – 9.378)  .137 
PPI  -.005  .995  (.432 – 2.293)  .991  -.332  .718  (.257 – 2.007)  .527 
                 
AKI  present on 
admission 
 
.740 
 
2.095 
 
(.901 – 4.871) 
 
.086 
 
.433 
 
1.542 
 
(.479 – 4.964) 
 
.468 
Medical   .157  1.170  (.535 – 2.560)  .694  .549  1.732  (.621 – 4.830)  .294 
AKIN Stage        .064        .138 
AKIN 1 (ref)    1.00        1.00     
AKIN 2  1.221  3.391  (.898 – 12.810)  .072  .825  2.281  (.719 – 7.238)  .162 
AKIN 3  1.557  4.744  (1.287 – 17.492)  .019  1.112  3.042  (.937 – 9.874)  .064 
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AKI Group  AKI/CKD Group 
AKI Cause        .875        .573 
Hypoperfusion (ref)    1.00        1.00     
Septic  .074  1.077  (.388 – 2.990)  .887  .542  1.719  (.553 – 5.346)  .350 
Complex  .243  1.275  (.505 – 3.215)  .607  .521  1.684  (.517 – 5.488)  .387 
                 
ITU admission  .126  1.134  (.385 – 3.342)  .819  .269  1.309  (.261 – 6.557)  .744 
Renal review  1.543  4.680  (1.604 – 13.656)  .005  .651  1.918  (.660 – 5.576)  .231 
AKI duration  -.018  .982  (.848 – 1.137)  .807  .091  1.095  (.918 – 1.307)  .313 
 
Table 7.8 Summary of factors that reached the study threshold of significance 
(p<.01) in the AKI or AKI/CKD groups on univariate analysis with failure to recover 
function using the thresholds of a fall of 5mls/min, 10mls/min, and 25% from 
baseline eGFR. 
    AKI Group  AKI/CKD Group 
  Factor  OR  95% C.I.  Sig.  OR  95% C.I.  Sig 
Fall in 
eGFR by 
5mls/min 
             
  eGFR Slope  .879  (.800 - .965)  .007  .920  (.851 - .995)  .036 
Fall in 
eGFR by 
10mls/min 
             
  Baseline 
eGFR 
.992  (.959 – 
1.027) 
.662  .944  (.908 - .982)  .005 
Fall in 
eGFR by 
25% 
             
  Sex  .301  (.122 - .745)  .009  1.091  (.422 – 
2.820) 
.858 
  Renal 
Review 
 
4.680 
 
(1.604 – 
13.656) 
 
.005 
 
1.918 
 
(.660 – 
5.576) 
 
.231 
               
 
 
7.2.3 Combined outcome of failure to recover and mortality 
 
Table 7.9 outlines the univariate binary logistic regression analysis for the combined 
outcome of failure to recover function using the original study definition of a fall in 
eGFR of 5mls/min and mortality at 6 months. In Table 7.10 the factors that reached 
the study level of significance (P<.01) in each group are summarised. 
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7.2.3 (i) Preadmission variables 
 
The most striking feature in this analysis is again the protective effect evident with an 
increasing slope of decline in eGFR prior to the index AKI. In the AKI group this is 
highly significant (OR .883, 95% C.I. .808 - .965, p=.006). This effect is less marked in 
the AKI/CKD group (p=.200). Due to insufficient statistical power the influence of 
previous AKI episodes on the combined outcome is difficult to interpret. A reduced 
baseline eGFR appears to have a protective effect in the AKI/CKD group (OR .973, 95% 
C.I. .939 to .997. p=0.028).  
 
7.2.3 (ii) Baseline variables 
 
In the baseline variables age is the strongest predictor of the combined outcome. In 
the AKI group the effect of increased age reaches statistical significance (OR 1.010, 
p=.005). None of the other baseline variables analysed gave a clear indication of an 
influence on the combined outcome.  
 
7.2.3 (iii) AKI related variables 
 
Admission to a medical specialty increases the risk of the combined outcome in the 
AKI/CKD group (OR 2.145, 95% C.I. 1.137 to 4.046, p=.018). AKIN stage did not clearly 
predict the outcome in the AKI group presumably due to insufficient statistical power. 
In the case of the AKI/CKD group the stage was significant although the risk was 
highest in AKIN stage 2 (overall p=0.001). The influence of AKI cause on the combined 
outcome was unclear and results for both groups did not reach significance. It is likely 
that that there were insufficient numbers to demonstrate any clear associations.  
 
Table 7.9 Univariate binary logistic regression analysis for the combined outcome 
of failure to recover function defined by a fall in eGFR of 5mls/min and mortality 
at 6 months. Results are shown for the AKI group and the AKI/CKD group.  
 
AKI Group  AKI/CKD Group 
  B  OR  95% CI  Sig.  B  OR  95% CI  Sig. 
PreAKI  ACR  -.051  .950  (.863 – 1.046)  .295  .007  1.007  (.998 – 1.017)  .117 
eGFR slope  -.124  .883  (.808 - .965)  .006  -.037  .964  (.912 – 1.020)  .200 
Admit. In prev. 
12 months 
 
.597 
 
1.816 
 
(.939 – 3.514) 
 
.076 
 
.308 
 
1.361 
 
(.751 – 2.468) 
 
.310 
AKI in prev. 
12 months 
 
.355 
 
1.426 
 
(.345 – 5.890) 
 
.624 
 
-.110 
 
.895 
 
(.434 – 1.847) 
 
.765 
AKI in prev. 
4 years 
 
-.242 
 
.785 
 
(.272 – 2.266) 
 
.655 
 
-.150 
 
.861 
 
(.465 – 1.594) 
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AKI Group  AKI/CKD Group 
Baseline eGFR  .007  1.007  (.977 – 1.038)  .662  -.028  .973  (.949 - .997)  .028 
                 
Age  .032  1.033  (1.010 – 1.056)  .005  .011  1.011  (.982 – 1.041)  .460 
Sex  -.329  .720  (.395 – 1.312)  .283  .334  1.396  (.775 – 2.515)  .266 
Charlson Score  .046  1.047  (.827 – 1.326)  .702  -.023  .977  (.803 – 1.190)  .820 
Diabetes  -.189  .828  (.435 – 1.575)  .565  -.242  .785  (.435 – 1.417)  .422 
Hypertension  .547  1.727  (.928 – 3.214)  .085  -.288  .750  (.299 – 1.880)  .539 
Smoking hist.  -.481  .618  (.340 – 1.122)  .114  .103  1.108  (.610 – 2.012)  .735 
BMI  .011  1.011  (.969 – 1.056)  .608  -.014  .987  (.939 – 1.037)  .593 
                 
RASB preAKI  .454  1.575  (.869 – 2.853)  .134  -.495  .610  (.307 – 1.210)  .157 
Aspirin  -.159  .853  (.453 – 1.608)  .624  -.379  .685  (.380 – 1.235)  .208 
NSAID  -.427  .652  (.297 – 1.431)  .287  .470  1.600  (.503 – 5.094)  .426 
Furosemide  .228  1.256  (.559 – 2.822)  .581  .197  1.218  (.677 – 2.194)  .511 
Statin  -.181  .835  (.458 – 1.523)  .556  -.450  .638  (.351 – 1.160)  .141 
Betablocker  .231  1.260  (.603 – 2.634)  .539  .405  1.500  (.824 – 2.730)  .184 
Allopurinol  -.184  .832  (.244 – 2.832)  .768  .080  1.084  (.418 – 2.809)  .869 
PPI  -.036  .965  (.508 – 1.833)  .912  -.197  .821  (.448 – 1.506)  .524 
                 
AKI  present on 
admission 
 
-.002 
 
.998 
 
(.542 – 1.837) 
 
.995 
 
.046 
 
1.047 
 
(.540 – 2.028) 
 
.892 
Medical   -.197  .821  (.448 – 1.503)  .522  .763  2.145  (1.137 – 4.046)  .018 
AKIN Stage        .589        .001 
AKIN 1 (ref)  1.00        1.00       
AKIN 2  .389  1.475  (.685 – 3.178)  .321  1.332  3.789  (1.832 – 7.837)  .000 
AKIN 3  .314  1.370  (.640 – 2.930)  .418  .725  2.065  (.902 – 4.729)  .086 
                 
BP < 90  -.528  .590  (.314 – 1.108)  .101  -.389  .678  (.348 – 1.319)  .252 
AKI Cause        .808        .486 
Hypoperfusion (ref)  1.00        1.00       
Septic  -.235  .791  (.372 – 1.679)  .541  .330  1.391  (.695 – 2.787)  .351 
Complex  -.005  .995  (.490 – 2.020)  .989  .401  1.493  (.717 – 3.108)  .284 
                 
ITU admission  .394  1.483  (.627 – 3.509)  .370  .130  1.139  (.367 – 3.533)  .822 
Renal review  .898  2.455  (.768 – 7.848)  .130  -.181  .834  (.401 – 1.735)  .628 
AKI duration  .066  1.069  (.974 – 1.173)  .161  .061  1.063  (.957 – 1.181)  .257 
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Table 7.10 Summary of factors that reached the study threshold of significance 
(p<.01) in the AKI or AKI/CKD groups on univariate analysis with the combined 
outcome of mortality and failure to recover function defined by a fall in eGFR of 
5mls/min at 6 months as the dependent variable. 
 
  AKI Group  AKI/CKD Group 
Factor  OR  95% C.I.  Sig.  OR  95% C.I.  Sig 
eGFR Slope  .883  (.808 - .965)  .006  .964  (.912 – 
1.020) 
.200 
Age  1.033  (1.010 – 
1.056) 
.005  1.011  (.982 – 
1.041) 
.460 
             
 
 
7.2.4 Analysis of recovery at discharge, readmission and repeat AKI 
 
Table 7.11 through to table 7.15 outline the univariate analysis of recovery at 
discharge, readmission during follow up, and repeat AKI during follow up using the 
outcomes already covered. As patients who died during admission were not exposed 
to these events they were removed from this analysis.  
  
7.2.4 (i) Recovery at discharge 
 
Recovery of function at the time of discharge was defined as a return to within 
5mls/min of baseline. Patients who achieved this were significantly less likely to show 
a decline in function after 6 months according to any of the definitions reviewed. In 
addition patients who recovered function at discharge were significantly less likely to 
reach the combined endpoint of failure to recover within 5mls/min of baseline or 
death at 6 months. Recovery of function appears to have little effect on the outcome of 
mortality at 6 months. 
 
7.2.4 (ii) Readmission 
 
Readmission at some point during the 6 months of follow up was associated with an 
increased risk of mortality in both the AKI and AKI/CKD groups. In terms of functional 
recovery at 6 months the findings are less clear as are the combined outcomes of 
death and recovery within 5mls/min of baseline.  
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7.2.4 (iii) Repeat AKI 
 
In the AKI group the occurrence of a repeat AKI during follow up was one of the 
strongest predictors of mortality on univariate analysis. The odds ratio for mortality at 
6 months in the AKI group was 8.647 (95% C.I. 2.507 to 29.821, p=.001).  In the 
AKI/CKD group, repeat AKI had a similar effect but was not as strong (OR 2.762 95% 
C.I. 1.162 to 6.568, p=.022). However, there was no significant influence of repeat AKI 
episodes on functional recovery. This was surprising but may have been due to 
insufficient power in the study.  
 
Table 7.11 Univariate binary logistic regression analysis of survivors to discharge 
using mortality at 6 months as the dependent variable.  
 
AKI Group  AKI/CKD Group 
  B  OR  95% CI  Sig.  B  OR  95% CI  Sig. 
Recovered at d/c  .076  1.079  (.397 – 2.932)  .882  -.041  .960  (.414 – 2.229)  .925 
Readmission  1.309  3.702  (1.094 – 12.530)  .035  .934  2.545  (1.116 – 5.804)  .026 
Repeat AKI  2.157  8.647  (2.507 – 29.821)  .001  1.016  2.762  (1.162 – 6.568)  .022 
                 
 
Table 7.12 Univariate binary logistic regression analysis of survivors to discharge 
using a fall in eGFR of more than 5mls/min at 6 months as the dependent 
variable.  
 
AKI Group  AKI/CKD Group 
  B  OR  95% CI  Sig.  B  OR  95% CI  Sig. 
Recovered at d/c  -1.080  .339  (.177 - .651)  .001  -1.724  .178  (.082 - .390)  .000 
Readmission  -.324  .723  (.377 – 1.387)  .330  .266  1.305  (.633 – 2.694)  .471 
Repeat AKI  -.513  .599  (.216 – 1.662)  .325  .182  1.200  (.480 – 2.998)  .696 
                 
 
Table 7.13 Univariate binary logistic regression analysis of survivors to discharge 
using a fall in eGFR of more than 10mls/min at 6 months as the dependent 
variable.  
 
AKI Group  AKI/CKD Group 
  B  OR  95% CI  Sig.  B  OR  95% CI  Sig. 
Recovered at d/c  -1.109  .330  (.167 - .651)  .001  -1.580  .206  (.084 - .502)  .001 
Readmission  -.240  .787  (.404 – 1.533)  .481  .645  1.905  (.814 – 4.462)  .138 
Repeat AKI  -.546  .579  (.194 – 1.732)  .328  .357  1.429  (.506 – 4.037)  .501 
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Table 7.14 Univariate binary logistic regression analysis of survivors to discharge 
using a fall in eGFR of more than 25% at 6 months as the dependent variable.  
 
AKI Group  AKI/CKD Group 
  B  OR  95% CI  Sig.  B  OR  95% CI  Sig. 
Recovered at d/c  -2.885  .056  (.013 - .244)  .000  -1.572  .208  (.076 - .567)  .002 
Readmission  -.152  .859  (.382 – 1.930)  .712  .515  1.674  (.645 – 4.349)  .290 
Repeat AKI  -.232  .793  (.214 – 2.940)  .728  .172  1.187  (.359 - 3931)  .778 
                 
 
Table 7.15 Univariate binary logistic regression analysis of survivors to discharge 
using the combined outcome of a fall in eGFR of more than 5mls/min at 6 months 
and mortality  as the dependent variable. 
  
AKI Group  AKI/CKD Group 
  B  OR  95% CI  Sig.  B  OR  95% CI  Sig. 
Recovered at d/c  -.959  .383  (.207 - .710)  .002  -1.331  .264  (.133 - .525)  .000 
Readmission  -.105  .900  (.484 – 1.673)  .739  .537  1.712  (.916 – 3.199)  .092 
Repeat AKI  .030  1.030  (.425 – 2.500)  .947  .571  1.770  (.831 – 3.767)  .139 
                 
 
 
7.3 Multivariate analysis 
 
Multivariate binary logistic regression analysis was undertaken to further explore the 
factors that may be influencing the outcomes found in this study. Factors used in the 
regression modelling were selected a priori. Variables identified in the literature as 
having an influence on the outcomes were reviewed. In addition the results of the 
univariate analysis carried out for this study were taken into account.  
 
7.3.1 Mortality  
 
In chapter 2 several factors were identified in the literature that may have an influence 
on mortality after an AKI episode (see Figure 2.11). In this study the strongest 
predictors of mortality in the AKI group found on univariate analysis included 
increasing age, higher Charlson comorbidity score, a history of a previous AKI, and 
finally the presence of AKI on admission i.e. community acquired AKI. In the AKI/CKD 
group the use of RAS blockers at the time of the AKI appeared to have a protective 
effect while AKIN stage and AKI occurring in medical admissions appeared to be 
associated with an increased risk.   
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Based on theses observations the five principal variables selected for exploration were 
AKI stage, AKI cause, the use of RAS blockers, the presence of AKI on admission, and if 
the AKI was medical. For uniformity the same variables were used in both the AKI and 
AKI/CKD groups. Each variable was adjusted in stages for age (model 2), age and sex 
(model 3), and age,sex, Charlson score and hypertension (model 4). Hypertension was 
added as this was considered an important comorbid factor but is not part of the 
Charlson Index. Model 4 was then adjusted for AKI cause (model 5), the use of RAS 
blockers (model 6), AKI on admission (model 7) and AKIN stage (model 8). A total of 
eight models were explored for each variable and can be found in Appendix 19. An 
outline of the findings are presented here and will be discussed further in Chapter 8.  
 
7.3.1 (i) AKIN stage 
 
In the AKI group AKIN stage did not appear to be a useful predictor of mortality at 
either follow up time point. In the AKI/CKD group the influence of AKIN stage reaches 
statistical significance.  However, in all models the odds of death at 6 months is higher 
in AKIN stage 2. As discussed earlier, this is likely to be due to chance or a lack of 
power in the study. There is a notable increase in risk in model 6 when adjustment for 
the use of RAS blockers is made. At 12 months the increased risk of mortality 
associated with AKIN stage is attenuated and no longer significant. In the case of AKIN 
stage 3 the odds are actually reversed in terms of risk relative to the reference AKIN 
stage 1.  
 
7.3.1 (ii) AKI Cause 
 
In the models used to assess AKI cause, Hypoperfusion AKI was used as the reference 
level. In the univariate analysis AKI cause had no influence on mortality in the AKI 
group. This persisted with adjustment for all covariates in multivariate analysis.  
 
In the AKI/CKD group both septic AKI and Complex AKI increase the odds of death at 
12 months but this influence was not found at 6 months. At 12 months in model 8 
where adjustment is also made for AKIN stage in addition to age,sex and 
comorbidities, septic AKI has an odds ratio of 2.405 while complex AKI has one of 
2.871 (overall p=0.03).  
 
7.3.1 (iii) Use of RAS blockers 
 
In the AKI group the use of RAS blockers at the time of the AKI was not found to affect 
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In the AKI/CKD group the unadjusted model for 6 month mortality showed a protective 
effect for the use of RAS blockers which approached statistical significance (OR .468, 
95% C.I. .227 to .965, p=0.04). This protective effect persists with adjustment for age 
and sex but is attenuated substantially with adjustment for comorbidities in model 4. 
At 12 months this apparent protective effect in the unadjusted model is lost.  
 
7.3.1 (iv) AKI on admission 
 
Patients who had community acquired AKI evident at the time of admission were 
compared to the hospital acquired cases as a reference. Community AKI appears to 
have a strong influence on mortality in the AKI group. In all models the findings 
approached statistical significance. In model 2 with adjustment for age alone, 
community AKI was associated with an odds ratio for death at 6 months of 3.975 
(p=0.018). This influence was reduced only marginally with adjustment for 
comorbidities, however it was reduced substantially with adjustment for AKIN stage in 
model 8. This suggests that the severity of the AKI may play an important role in these 
findings. For 12 month mortality the findings are similar. 
 
In the AKI/CKD group the results are less convincing and difficult to interpret both at 6 
and 12 months. Community AKI appears not to have the same impact.  
 
7.3.1 (v) Medical admission    
 
In the AKI group the admitting specialty whether medical or surgical did not influence  
mortality at 6 or 12 months. In the AKI/CKD group the influence of medical admission 
on mortality was strong. For 6 month mortality the unadjusted odds ratio was 5.176 
(p=.001). This was reduced with adjustment in model 4 but remained highly significant 
(OR 4.476, p=0.004). These findings persisted even with adjustment for AKI cause in 
model 6 and AKIN stage in model 8. The findings were similar but with increased 
significance levels in the 12 month mortality analysis 
 
7.3.1 (vi) Supplementary modelling 
 
Univariate analysis showed that patients who had evidence of an AKI during the 12 
month and four year periods prior to the index episode in the AKI group had a 
significantly increased risk of mortality at 6 months. In those with evidence of an AKI 
in the previous four years regardless of its severity the odds ratio for mortality at 6 
months was 4.697 (95% C.I. 1.551 – 14.224, p=.006). This was not found to be the 
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To explore this finding further multivariate analysis was carried out to adjust for age, 
sex, and comorbidities. This is illustrated in Table 7.16. It can be seen that this 
influence persisted even with adjustment for comorbidities in model 4. 
 
Table 7.16 Multivariate analysis exploring the relationship between mortality at 6 
months and a history of at least one previous AKI episode during the 4 years prior 
to the index AKI in the AKI group. 
 
     
  OR  95% C. I.  P  OR  95% C.I.  P 
  Model 1 (Unadjusted)    Model 2   
AKI in Previous 4 
years 
           
No (ref)  1.00      1.00     
Yes  4.697  (1.551 – 14.224)  .006  6.018  (1.783 – 20.310)  .004 
             
  Model 3  Model 4 
No (ref)  1.00      1.00     
Yes  6.049  (1.777 – 20.591)  .004  3.895  (1.076 – 14.095)  .038 
             
 
Model 1 – unadjusted      Model 3 – adjusted for age and sex     
                                
Model 2 – adjusted for age   Model 4 – adjusted for age, sex, Charlson Score and hypertension        
                                      
 
7.3.2 Recovery of function 
 
The risk factors for failure to recover function after an episode of AKI were discussed 
in Chapter 3 (see Figure 3.9). In this study a number of additional factors appeared to 
have an important influence on univariate analysis. A greater slope of decline in eGFR 
during the three years prior to the AKI episode appears to have a paradoxical 
protective effect in both the AKI and AKI/CKD groups. In the AKI group the use of RAS 
blockers appears to increase the risk of non-recovery whereas in the AKI/CKD group 
the trend was toward a protective effect. The recording of a nadir blood pressure < 90 
systolic at the time of the AKI appears to have a protective effect in the AKI group. 
 
Based on these findings and using existing literature six variables were chosen for 
analysis including AKIN stage, AKI Cause, the use of RAS blockers, pre-AKI slope of 
decline in eGFR, nadir BP at the time of the AKI, and the presence of the AKI on 
admission to hospital. As with the mortality analysis, for the purpose of uniformity the 
same variables were used in both the AKI and AKI/CKD groups. The results of this 
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        193 
failure to recover function covered in the univariate analysis – a fall in eGFR of 
5mls/min, a fall of 10mls/min, and a fall of 25% from baseline. An outline of the main 
findings is presented here. 
 
7.3.2 (i) AKIN Stage 
 
In the AKI group the odds of failure to recover function increase with increasing AKIN 
stage although this is apparent as a trend only. This influence becomes clearer as the 
definition of failure to recover function is extended from a fall of 5mls/min to a fall of 
10mls/min and a fall of 25%. In the case of a fall in eGFR of 25% from baseline the 
odds of failing to recover in model 4 with AKIN stage 2 was 4.356 and this increases to 
7.748 with AKIN stage 3 (p=.015).  
 
A similar pattern is seen in the AKI/CKD group. However, using the definition of a fall 
in eGFR of 5mls/min the highest odds are seen in AKIN stage 2. This is reversed when 
the definition is extended. For example, in model 4 the odds of a fall in eGFR of 
5mls/min are 3.015 and 2.270 for AKIN stage 2 and 3 respectively. This reverses in 
model 4 for the odds of a fall in eGFR of 25% to 2.444 and 3.508.  
 
7.3.2 (ii) AKI Cause 
 
The influence of the cause of AKI on functional outcomes is unclear from these data. It 
is notable that in the fall of 25% models there is a marked drop in the odds of failure 
to recover when adjustment for AKIN stage is made suggesting that AKI severity is 
important in these outcomes rather than the cause per se.  
 
In the AKI/CKD group there is a clear trend of an increased risk associated with septic 
and complex AKI although the effects of using different definitions of recovery are 
again seen. With all definitions a fall in the odds ratios is noted when adjustment for 
AKIN severity is made.  
 
7.3.2 (iii) Use of RAS blockers 
 
In the AKI group there appears to be an increased risk of a failure to recover function 
in those using RAS-blockers at baseline. In the case of a fall of 25% from baseline the 
unadjusted odds of this occurring was 2.337 (95% C.I. 1.028 – 5.312, p=.043). The 
influence becomes uncertain when adjustment for age, sex, and comorbidities is 
made. In the AKI/CKD group the influence of RAS blockers on recovery is unclear.  
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7.3.2 (iv) Pre-AKI slope of decline in function 
 
An increasing slope of decline in eGFR during the three years prior to the index AKI 
appears to have substantial protective effect in terms of recovery. This paradoxical 
finding is evident in both groups but is most marked in the AKI group. In the AKI 
group the odds ratio for a fall in eGFR of 5mls/min is .877 (95% C.I. .798 to .964, p= 
.006) in model 4 with adjustment for age, sex, and comorbidities. This protective 
effect is evident for all definitions of recovery although the significance is lost as the 
definition is extended to a fall of 25%. For the AKI/CKD group there is again a 
protective effect and in the case of a fall in eGFR of 5mls/min the odds ratio was .906 
in model 4 (95% C.I. .833 to .986, p=.022).  
 
7.3.2 (v) Nadir blood pressure < 90 systolic 
 
The influence of having had a nadir BP of < 90 systolic was explored in these models 
because of the finding that this may reduce the odds of non-recovery on univariate 
analysis. While this finding appears to be counter-intuitive there may be some basis for 
it. Evidence exists that remote ischaemic pre-conditioning can have a protective effect 
on the kidney 
405.  
 
In the AKI group having had a systolic pressure recorded < 90 at the time of the AKI 
appears to have a substantial protective effect in terms of failure to recover function. 
For a fall in eGFR of 5mls/min the odds ratio was .377 in model 5 where adjustment is 
made for age, sex, comorbidities and AKIN stage (95% C.I. .180 to .787, p=.009). Using 
the definition of a fall of 25% these findings are similar (OR .308 95% C.I> .108 to .880, 
p=.028).  
 
In the AKI/CKD group the results are less clear. The odds ratios for a fall of 5mls/min 
also suggest a protective effect but this is only a trend.  
 
7.3.2 (vi) AKI on admission 
 
An AKI which was evident on admission was shown earlier to be associated with a 
higher mortality in the AKI group but findings were less clear in the AKI/CKD group. In 
this analysis the outcomes of recovery of function were explored in this subgroup of 
patients. In both groups the results of these data are difficult to interpret and did not 
reach significance. 
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7.3.2 (vii) Supplementary modelling 
 
On univariate analysis it was shown that statin use at the time of the AKI may have a 
protective effect in terms of recovery of function in the AKI/CKD group when the 
definition of a fall in eGFR of 5mls/min is used (OR .472, 95% C.I. .229 to .973, 
p=0.042). This was not observed in the AKI group. As this is a potentially important 
finding and has been the subject of much interest in the literature recently it was 
explored further in multivariate analysis 
118,169,406,407.  Table 7.17 summarises the results 
of the various models explored in relation to statin therapy. In model 4 with 
adjustment for age, sex, Charlson score and a history of hypertension the association 
between statin therapy and a reduced risk of a failure to recover increases. It increases 
further when this model is adjusted for AKIN stage in model 5 (OR.358, 95% C.I. .159 - 
.806, p=.013). Further consideration was given to other factors that could be 
potentially acting as covariates in this association and so in model 6 additional 
adjustments are made for the use of aspirin therapy and in model 7 for the use of RAS 
blockers. These medications theoretically may also be having a protective effect. In the 
case of aspirin therapy the association is weakened and loses significance. Results are 
largely unaltered by adjustment for the use of RAS blockade. Finally in model 8 
adjustment is made for the slope of decline in eGFR prior to the AKI and this does not 
alter the findings appreciably.  
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Table 7.17 Multivariate analysis of statin therapy at the time of the AKI with a fall 
in eGFR of more than 5mls/min after 6 months as the dependent variable. 
 
     
  Model 1 (Unadjusted)  Model 2 
  OR  95% C. I.  P  OR  95% C.I.  P 
On Statin             
No (ref)  1.00      1.00     
Yes  .472  (.229 - .973)  .042  .040  (.226 - .966)  .040 
             
  Model 3  Model 4 
No (ref)  1.00      1.00     
Yes  .466  (.225 - .965)  .040  .440  (.207 - .938)  .033 
             
  Model 5  Model 6 
No (ref)  1.00      1.00     
Yes  .358  (.159 - .806)  .013  .506  (.229 – 1.120)  .093 
             
  Model 7  Model 8 
No (ref)  1.00      1.00     
Yes  .451  (.210 - .970)  .042  .443  (.205 - .959)  .039 
             
 
Model 1 – unadjusted                   Model 5 – model 4 and AKIN stage 
Model 2 – adjusted for age                             Model 6 – model 4 and aspirin 
Model 3 – adjusted for age and sex                 Model 7 – model 4 and RASB 
Model 4 – adjusted for age, sex, Charlson Score and hypertension       Model 8 – model 4 and eGFR slop 
 
 
7.3.3 Combined outcome of failure to recover and mortality 
 
Multivariate binary logistic regression analysis for the combined outcome of failure to 
recover function defined by a fall in eGFR of 5mls/min or more and mortality at 6 
months in the AKI and AKI/CKD was also undertaken. This explored the same six 
factors described for the analysis of recovery of function described above. The 
modelling can be found in Appendix 21 while an outline of the findings is presented 
here. 
 
7.3.3 (i) AKIN stage 
 
In the AKI group there is a trend for an increased risk of the combined outcome 
according to AKIN stage in all models although none reach statistical significance. The 
association is stronger in the AKI/CKD group. In this case the odds are highest in AKIN 
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the combined outcome were 3.823 and 2.116 for AKIN stage 2 and AKIN stage 3 
respectively (p=.001).  
 
7.3.3 (ii) AKI Cause 
 
In the AKI group the influence of cause on the combined outcome is unclear from 
these data. In the AKI/CKD group there is a trend for an increased risk in the septic 
and complex cases though none reach significant levels.  
 
7.3.3 (iii) Use of RAS blockers 
 
The influence of the use of RAS blockers on the combined outcomes is also unclear 
from these data. No firm conclusions can be reached most likely due to insufficient 
power in the study. 
 
7.3.3 (iv) Pre-AKI slope of decline in function 
 
In the AKI group an increasing slope of decline in eGFR during the three years prior to 
the index AKI is associated with a reduced risk of the combined outcome that reaches 
statistical significance in all of the models tested. A similar pattern is observed in the 
AKI/CKD group though the association is weaker and does not reach significance.  
 
7.3.3 (v) AKI on admission 
 
In both groups the association between an admission AKI and the combined outcome 
is weak and it is not possible to draw any conclusions.  
 
7.4 Analysis of recovery at discharge, readmission and 
repeat AKI 
 
Multivariate analysis was also undertaken to explore the influence of recovery at 
discharge, readmission during follow up, and repeat AKI during follow up on 6 month 
outcomes. The full models can be found in Appendix 22 for mortality at 6 months and 
Appendix 23 for recovery of function after 6 months. The findings are outlined below. 
As with the univariate analysis patients who died in hospital who were not exposed to 
these events were excluded.  
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7.4.1 Mortality 
 
In both groups recovery at discharge appears to have little effect on mortality at 6 
months.  
 
Patients who were readmitted to hospital during the 6 month follow up period showed 
an increased risk of mortality in both groups. In the AKI group the odds ratio for 
mortality at 6 months was 3.702 (95% C.I. 1.094 to 12.530, p=.035). This fell 
marginally with adjustment for age, sex, and comorbidities in model 4 (OR 3.149). 
Adjustment for additional variables in models 5 to 8 had little impact.  
In the AKI/CKD group findings were similar across all groups. In model 4 with 
adjustment for age, sex, and comorbidities the odds ratio for death at 6 months was 
2.313 (95% C.I. .976 to 5.482, p=.057). 
 
The occurrence of a repeat AKI was one of the strongest predictors of mortality at 6 
months in both groups particularly in the AKI group. In model 4 with adjustment for 
age, sex, and comorbidities the odds ratio for death at 6 months in the AKI group was 
8.260 (95% C.I. 1.953 to 34.938, p=.004). Adjustment for additional variables had little 
effect on this finding. In the AKI/CKD the pattern was similar although the strength of 
the association fell with adjustment for comorbidities in model 4.  
 
7.4.2 Recovery of function 
 
Appendix 23 contains the full models used for recovery of function for each group 
using the three definitions of failure to recover function already described.  
 
7.4.2 (i) Recovered at discharge 
 
Patients who had recovered function at the time of discharge showed a reduced 
likelihood of meeting the criteria for failure to recover function after 6 months of 
follow up in both groups. This association was strong and remained largely unchanged 
after adjustment in the regression models. In the AKI group the odds ratio for a fall in 
eGFR of 5mls/min or more after 6 months was .366 in model 4 with adjustment for 
age, sex, and comorbidities (95% C.I. .188 to .715, p=.003). The same model in the 
AKI/CKD group revealed an odds ratio of .160 (95% C.I. .071 to .362, p<.001).  
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7.4.2 (ii) Readmission 
 
In the AKI group the data on hospital readmission is difficult to interpret. In the 
AKI/CKD group the findings are similar. There may be a trend toward an increased risk 
of failure to recover but no firm conclusions can be drawn. 
 
7.4.2 (iii) Repeat AKI 
 
The occurrence of a repeat AKI during follow up was not shown to have any impact on 
recovery using these data but it is highly likely that the study was underpowered to 
demonstrate this. In the AKI/CKD group the influence of a repeat AKI appears to be 
strongest and there is a consistent trend toward an increased risk of non-recovery for 
all of the recovery definitions used.  
 
7.5 Summary 
Table 7.18 summarises the findings presented in this chapter. It highlights the factors 
found to have a significant influence on the outcomes studied in univariate analysis 
using the study threshold of P<0.01. In addition, factors that may also be of interest 
(P<0.05) which have been highlighted in the chapter are included. 
Table 7.18 Summary of factors found to have an influence on the study outcomes 
in univariate analysis.  
 
  AKI Group  OR  P  AKI/CKD Group  OR  P 
Outcome             
6 Month 
Mortality 
AKI in prev. 12 mths 
AKI in prev. 4 years 
Age 
Charlson Score 
Use of Furosemide 
AKI on admission 
5.333 
4.697 
1.061 
1.664 
2.958 
3.469 
.015 
.006 
.004 
.002 
.026 
.029 
Hypertension Hx. 
Use of RASB pre-AKI 
Medical Admission 
AKIN Stage 
.375 
.468 
1.644 
 
.041 
.040 
.001 
.010 
             
12 Month 
Mortality 
Admitted in prev. 12 
mths. 
AKI in prev. 12 mths 
AKI in prev. 4 years 
Age 
Charlson Score 
Use of Furosemide 
AKI on admission 
AKI duration 
2.303 
 
3.778 
3.229 
1.060 
1.499 
3.164 
2.957 
1.118 
.037 
 
.050 
.034 
.001 
.007 
.004 
.025 
.023 
Age 
Use of Furosemide 
Medical Admission 
 
1.043 
2.171 
4.882 
.029 
.020 
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Fall in eGFR 
by 5mls/min 
eGFR Slope 
Age 
BP < 90 
.879 
1.026 
.439 
.007 
.040 
.021 
eGFR Slope 
Baseline eGFR 
Statin use 
AKIN Stage 
.920 
.965 
.472 
 
.036 
.019 
.042 
.045 
             
Fall in eGFR 
by 
10mls/min 
eGFR Slope 
Renal Review 
.907 
5.192 
.029 
.006 
eGFR Slope 
Baseline eGFR 
AKIN Stage 
AKI Cause 
.912 
.944 
 
.045 
.005 
.029 
.048 
             
Fall in eGFR 
of 25% 
Age 
Male Sex 
Hypertension 
Use of RASB 
Renal Review 
1.040 
.301 
2.805 
2.337 
4.680 
.024 
.009 
2.805 
2.337 
.005 
Admitted in prev. 12 
mths. 
 
3.619  .011 
             
Combined 
mortality and 
fall 5mls/min 
eGFR Slope 
Age 
 
.883 
1.033 
.006 
.005 
AKIN Stage    .001 
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Chapter 8: Summary and Discussion 
 
8.1 Introduction 
 
In this chapter the principal findings of this study are discussed. The focus will initially 
be on the recovery of function after an episode of AKI. This will be followed by the 
other outcomes of clinical interest including hospital length of stay and mortality after 
AKI. The performance of the AKIN staging system will also be reviewed. Many 
additional findings were identified and these will be discussed under the separate 
headings of contributions to the natural history of AKI, management practices in AKI, 
and methodological issues. The chapter ends with a review of the study strengths and 
limitations together with an outline of future research directions. 
 
8.2 Recovery of renal function after acute kidney injury 
 
It was highlighted in Chapter 3 that the natural history of AKI and its relationship to 
CKD is poorly characterized in the literature. The findings in this study substantially 
improve the understanding of this natural history.  
 
8.2.1 General summary of findings 
 
At the time of hospital discharge 52.6% of survivors in the AKI group and 31.4% in the 
AKI/CKD group had failed to recover function to within 5mls/min of baseline (p<.001). 
In the AKI group 8.4% had required dialysis during hospitalisation but all of the 
survivors recovered sufficiently to remain independent of dialysis at discharge. In the 
AKI/CKD group 5.4% required dialysis in hospital and 3 remained dialysis-dependent at 
discharge (1.8% of survivors).  
 
After 6 months of follow up 53% of the AKI group and 34% of the AKI/CKD group had 
failed to recover (p=0.002). During follow up one of the patients dependent on dialysis 
in the AKI/CKD group died and another started dialysis. Therefore 3 patients were 
dialysis dependent at follow up (2.1% of survivors). This suggests that AKI may be 
contributing to the incident dialysis population. 
 
As a fall in eGFR of 5mls/min at a single time point could be attributed to individual 
and analytical variation, the definition of failure to recover was extended to a fall of 
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AKI/CKD groups that failed to recover function according to each definition are 
summarised in Table 8.1. A substantial proportion of hospitalised patients failed to 
recover function across all AKIN stages. The definition of failure to recover proposed 
by the ASSESS AKI study consortium was also applied and tested 
4. Results showed that 
19.6% of patients in the AKI group had a fall in eGFR of 25% from baseline and 
progressed to at least CKD stage 3. In the AKI/CKD group the ASSESS study defines 
progression as a fall in eGFR of at least 50% from baseline. In this study only 3.7% of 
survivors demonstrated this. It is likely that the event rates in the ASSESS study for 
progression of CKD will be low and may under-report the phenomenon.  
 
The findings in this study relating to the AKI/CKD group are strengthened when 
comparison is made to the CKD control group. 20% of the AKI/CKD group 
demonstrated a fall of at least 10mls/min while none in the control group did 
(p=0.016). No attempt was made to recruit a control group for the AKI group however 
it is highly unlikely that 20% of a group of controls would have progressed to CKD 
stage 3 within 6 months as was found in this study. Overall, the results in this study 
confirm that AKI across all its stages of severity is associated with incident CKD and 
progression of underlying CKD.  
 
It is accepted in the literature that in severe cases of AKI there is a persistent decline in 
renal function in some individuals. The position on milder episodes of AKI remains 
subject to debate. This is largely due to the methodologies used in recent studies 
50,357. 
It is possible, particularly where estimates of baseline function have been used, that 
patients with pre-existing CKD stages 3-5 are misclassified as having an eGFR > 
60mls/min. Therefore in the case of mild episodes of AKI the failure to recover 
function may represent a return to the true baseline. Additional sensitivity analysis was 
undertaken which involved searching the records of all patients extending back three 
years from the time the study baseline level was selected. 14.7% of patients in the 
group had at least one eGFR < 60 mls/min taken as an outpatient during this period. 
8.4% of patients, all of whom were diabetic, had evidence of microalbuminuria on ACR 
measurement. These patients were removed from the analysis, however this did not 
alter the overall findings significantly. Even when the ASSESS AKI definition is applied 
7.7% of patients in the mild AKIN stage 1 demonstrated a fall in eGFR of 25% and 
progression to at least CKD stage 3 after 6 months.  
 
This study was able to investigate the influence of repeat episodes of AKI during the 
follow up period. This did not have a major influence on the findings. In the AKI Group 
with AKIN stage 1, 66% of patients who failed to recover according to the study criteria 
did not have a repeat episode recorded. None of those in AKIN stage 1 who met the Mark Uniacke    Chapter 8     
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more rigorous ASSESS AKI criteria and demonstrated reaching CKD stage 3 had a 
repeat episode. Therefore with every effort made to ensure the classification of 
patients was correct this study shows unequivocally that even so called mild AKI 
episodes may result in a substantial decline in renal function.  
  
Table 8.1 Summary of the proportions of patients in the AKI and AKI/CKD Groups 
who failed to recover function after 6 months according to each of the definitions 
of failure to recover explored in this study. 
 
 
Fall in eGFR from 
baseline 
 
AKIN Stage 
 
AKI Group 
N = 158 
 
AKI/CKD Group 
N = 135 
       
By 5mls/min, N%    83(52.5)  46(34.1) 
  1  18(46.1)  21(25.9) 
  2  33(55.9)  15(50) 
  3  32(53.3)  10(41.7) 
       
By 10mls/min, N%    64(40.5)  27(20) 
  1  11(28.2)  10(12.3) 
  2  26(44.1)  9(30) 
  3  27(45)  8(33.3) 
       
By 25%, N%    33(20.8)  20(14.8) 
  1  3(7.7)  8(9.9) 
  2  13(22)  6(24) 
  3  17(28.3)  6(33) 
 
 
8.2.2 Findings in the context of current literature 
 
The literature currently does not contain a prospective study of AKI in general 
hospitalised patients with systematic follow up beyond hospital discharge. No study to 
date has reviewed the outcomes in those with and without CKD in the detail that this 
study has done. Therefore there is little with which to compare the results of this 
study. Most contemporary work involves the retrospective review of clinical databases 
with a focus on expressing long-term function in terms of the relative risk of 
progression of CKD or progressing to ESRD. Ultimately most of these studies maybe 
flawed as they do not take into account the occurrence of repeat AKI episodes during Mark Uniacke    Chapter 8     
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follow up. For example, Ishani et al reported the incidence of CKD after AKI in patients 
following cardiac surgery. They reported the overall incidence during over five years of 
follow up. While this study confirmed an increased risk of CKD after an AKI episode it 
did not take into account repeat episodes or inter-current medical events during the 
five-year follow up period. Therefore it is difficult to attribute these findings to a single 
AKI event 
127. 
 
Kwon et al have published the only prospective study of AKI defined by AKIN staging to 
date. They found that 50% of patients had not returned to baseline function at the time 
of discharge form hospital 
190. This study had only 96 patients and did not present 
follow up beyond discharge. In addition, it was restricted to hospital acquired AKI only 
and did not distinguish between those with and without CKD. However, the result is 
not too dissimilar to the overall finding in this study of a failure to recover at discharge 
in 45% of patients with and without CKD at baseline.  
 
8.2.3 Outcomes in those with and without pre-existing CKD 
 
This study provides an important insight into the quite marked differences in 
outcomes between those with and without CKD who sustain an AKI. As discussed 
above a significantly larger proportion of patients in the AKI group failed to recover 
function (53% v 34%, p = .002). This may partly be explained by a degree of survivor 
bias, as mortality in the AKI/CKD group was significantly higher. However, this alone is 
unlikely to explain the large difference in recovery patterns. The same large difference 
in recovery was seen at the time of discharge from hospital despite the mortality 
difference between the groups not reaching significance. Bagshaw et al made a similar 
observation in a study of ITU patients who had undergone renal replacement therapy. 
A higher pre-RRT serum creatinine was associated with reduced odds of recovery 
366.  
One explanation could be that the relative severity of the AKI and the severity of the 
underlying illness in the AKI group were greater and more likely to result in a lack of 
recovery. As those with CKD already have impaired function the same relative rise in 
serum creatinine might take a far lesser injury. Similar reasoning can be used to 
explain the lower hospital mortality in those with CKD and AKI compared to those 
without CKD and AKI found in some studies 
168,228. For example, Pannu et al in a study 
involving Canadian hospitalized patients found an adjusted hazard ratio for death in 
hospital of 10.62 in those with AKIN stage 3 and a baseline eGFR > 60mls/min, 
whereas those with AKIN stage 3 and a baseline eGFR < 60 had a significantly lower 
adjusted hazard ratio of 4.71 
168. If the hypothesis that the CKD group have a lesser 
injury is correct then it raises the point that the use of the same creatinine based Mark Uniacke    Chapter 8     
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estimates of changes in renal function in those with and without CKD is likely to be 
incorrect as a measure of AKI severity.  
 
If the differences in recovery are not entirely due to differences in severity then 
another possible explanation is that the pathological processes involved are different. 
It is possible that an AKI episode on a normal kidney excites a more vigorous 
inflammatory response than one on an already damaged kidney where response 
mechanisms may be blunted or protective mechanisms may already be up-regulated. 
 
Finally, it was noted during this study that significantly more patients in the AKI/CKD 
group received a formal nephrology review. It is conceivable that better AKI 
management may have improved outcomes. However the referral rate would be 
insufficient to account for the outcomes in all of the patients. In addition, regression 
analysis did not reveal any influence of referral on functional outcomes.  
  
No study to date has described these differences in this detail. Ali et al separated their 
cohort into an AKI and AKI/CKD group in a retrospective review of AKI in hospitalised 
patients defined by the RIFLE criteria. They reported that 92.5% of patients in the AKI 
group had full recovery at 90 days compared to 65% in the AKI/CKD group 
187. This is 
contrary to the results reported in this present study and indeed the recovery appears 
to be substantially better. The explanation for the differences lies in the definitions 
used. Ali et al defined full recovery of function as a return to below a threshold serum 
creatinine of 150μmols/litre. Below this threshold still represents CKD in many 
patients and it is likely to have grossly overestimated recovery in the AKI group.  
 
Two studies by Lo et al and James et al have reported the risk for CKD in those with 
and without decreased baseline GFR.  Coca et al reviewed these studies in a meta-
analysis 
120,230,352. The relative risk for CKD was higher in those without decreased 
baseline GFR and this supports the findings in this study. In a similar manner the 
relative risk for ESRD was found by Coca et al to be higher in those with AKI and 
without decreased baseline function. This latter finding was accounted for by Coca et 
al by the fact that the difference between the absolute risks for ESRD in those without 
decreased baseline function with and without AKI was far greater than the difference 
between the absolute risk for ESRD in those with decreased baseline function. This is 
because ESRD is an extremely uncommon event in those without decreased baseline 
function and no AKI. Hence the relative risk is higher. While this is a valid argument in 
the case of ESRD, it does not hold up as robustly in the case of the risk for CKD and 
certainly would not explain the findings in this study. 
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8.2.4 Recovery patterns after AKI 
 
Another interesting finding in this study is the impact of expressing changes in 
function in terms of the mean change in eGFR. In the AKI/CKD group it was shown in 
Figure 6.17 that a large proportion of patients have a mean increase in eGFR at the 
time of discharge that balances the mean fall derived from those who have failed to 
recover. This resulted in a positive mean change of 0.11mls/min despite the study 
showing that over 30% had failed to recover. This finding may explain why some 
studies in the literature which were discussed in Chapter 3 reported no change in renal 
function at the time of follow up because they expressed changes in function in terms 
of the mean of the overall group 
159,181,252.  
 
A novel aspect of this study is the clear demonstration of the complex nature of 
recovery patterns that follow an AKI. In Chapter 6 it was shown that 38% of those who 
had recovered completely at discharge had progressed to a fall in eGFR of more than 
5mls/min after 6 months. In the AKI/CKD group 21% of patients demonstrated this 
phenomenon. Therefore recovery at discharge is a poor predictor of recovery after 6 
months. In this study the positive predictive values for the AKI and AKI/CKD groups 
were only 62% and 79% respectively. There are several possible explanations for this 
finding. Firstly, patients may have lost muscle mass during their acute illness and 
hence have a lower serum creatinine. This would not reflect their true renal function. 
Loss of function may be masked on discharge only to manifest during follow up when 
they have regained their muscle mass. Secondly, patients may have received vigorous 
fluid resuscitation during their admission that again may result in a lowering of the 
serum creatinine through dilution. Finally, over 90% of patients in both groups had 
their RAS-blockers discontinued. This almost certainly would have led to an increase in 
GFR in many patients and if these drugs were recommenced during follow up a fall in 
GFR would be noted. 
  
Defining these patterns has important clinical implications. While it was shown in 
multivariate regression analysis that recovery at discharge increased the odds of being 
in the recovered group at follow up this is not universal. Even in the patients who have 
recovered function it may be advisable to repeat their renal function after discharge. It 
also highlights that recovery of function at discharge should not be used as an 
endpoint in AKI studies. The question then arises regarding the appropriate duration 
of any follow up period. Amdur et al demonstrated that recovery of AKI peaks between 
3 and 6 months 
365. This was expressed in terms of the mean creatinine of the overall 
group and would have included patients exhibiting a decline in function that have been 
identified in this study. It follows that those who show a decline in function following Mark Uniacke    Chapter 8     
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discharge are also likely to stabilise between 3 and 6 months if the mean has 
stabilised. Therefore the 6 month follow up point used in this study seems reasonable. 
A recent NIDDK workshop report on the design of AKI clinical trials suggested using 
recovery of function at 60-90 days as a suitable endpoint 
408. This needs to be 
reconsidered in light of the findings discussed here.  
 
8.2.5 Readmission and repeat AKI episodes 
 
One of the most important findings described in this study is the pattern of admission 
and repeat AKI episodes that occurs. A review of hospital records revealed that 32% of 
patients in the AKI group had at least one admission to hospital in the 12 months prior 
to the index AKI. In the AKI/CKD group this figure was 43%. Likewise during the 6 
month follow up period 40% of the AKI group was readmitted to hospital at least once 
while 43% of the AKI/CKD group was readmitted. These findings highlight the 
vulnerable nature of these patients and this is reflected in the substantial comorbidity 
load evident in both groups at baseline. It is worth noting however, that this study was 
limited by design to those with previous serum creatinine values on record in order to 
calculate baseline function. This approach will be bias to these more vulnerable 
patients as they are more likely to have previous blood tests. Therefore it may not 
describe the complete natural history of AKI. AKI occurring in possibly younger fitter 
patients without blood test records will not have been included and these may not 
exhibit repeat admissions. In this study approximately 15% of those screened fell into 
this group.  
 
A pattern of recurrent AKI episodes was evident in both groups associated with repeat 
admissions. In the AKI group 8.9% had at least one AKI during the four years prior to 
the index AKI while 34.6% of the AKI/CKD group showed evidence of this. During 
follow up 12% of the AKI group had at least one repeat episode while 20% of the 
AKI/CKD group experienced one. It is likely that these episodes are in themselves 
contributing to the decline in renal function in these patients. It highlights the fact that 
the vast majority of contemporary studies on AKI that have reported long-term 
functional outcomes are likely to be influenced by this phenomenon. At present only 
one study, by Thakar et al, has taken this into account. In this study of AKI in 
hospitalised diabetic patients that were under observation for over 60 months the 
authors reported more than 2 AKI episodes occurring in 30% of patients during the 
period of observation. They found that one AKI episode increased the risk of 
progressing to CKD stage 4 with a hazard ratio of 3.56 and each subsequent AKI 
episode doubled this risk in a cumulative fashion 
34.  
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This study failed to show a significant influence of these repeat episodes on recovery 
of function after 6 months follow up in logistic regression analysis of survivors to 
discharge. However while failure to recover was common it is likely the study was 
underpowered. Nevertheless this study clearly demonstrates that this phenomenon 
occurs in general hospitalised patients and not just in diabetics.  
 
8.2.6 Influence of the slope of decline in eGFR prior to the AKI 
 
This study describes the slope of decline in renal function prior to the AKI episode. 
This revealed a mean slope of +1.21mls/min/year in the AKI group while in the 
AKI/CKD group this was -3.16mls/min/year. In Chapter 3 the natural progression of 
CKD was discussed and it was noted that the NICE review group considered a decline 
in GFR of more than 2mls/min/year to be more than could be explained by aging alone 
74. The study by Hemmelgarn et al reviewed the rate of decline in renal function in a 
large elderly population over 66 years in Canada and reported a rate of decline of 0.8 
and 1.4 mls/min/year in women and men without diabetes. In those with diabetes 
these figures rose to 2.1 and 2.7 mls/min/year 
409. The decline of 3.16mls/min/year 
identified in this AKI/CKD population is therefore higher. This raises some important 
questions. Chief among these is whether or not this population represents a subset of 
the population that by virtue of their comorbidities and other risk factors are 
vulnerable to repeat AKI episodes and a more rapid decline in renal function. AKI could 
therefore be more than just a marker of future decline but an important variable in 
‘rapid progressors’ similar to proteinuria. Another important question that stems from 
this is whether or not prevention of these AKI episodes or better management and 
follow up can arrest or slow this functional decline.  
 
James et al have reported the only study to date that has examined the rate of decline 
in renal function after an AKI episode. In a population who had undergone coronary 
angiography they found that the mean annual rate of decline in eGFR during a mean 
follow up of 2.5 years was 0.1mls/min/year in those who did not have an AKI, 
1.0mls/min/year in those with a mild AKI (AKIN stage 1), and 3.1mls/min/year in those 
with moderate to severe AKI (AKIN stages 2 and 3). With adjustment for age, sex and 
comorbidities, including the presence of proteinuria, the rate of decline in the 
moderate to severe group was 2.8mls/min/year. In addition, they compared this to the 
slope of decline during the year prior to the AKI episode and found that the rate of 
decline was unchanged in the mild AKI group but had increased by 1.8mls/min/year in 
the moderate/severe group 
230. James et al used only a 12 month time period with 
which to calculate the slope prior to the AKI episode which is unlikely to be an accurate 
reflection of the true trajectory particularly when such small changes are being Mark Uniacke    Chapter 8     
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recorded 
410. Their study was also limited to a very specific population after coronary 
angiography where the cause of the AKI was more likely to be contrast related. 
Nevertheless their findings lend some support to the findings in this study discussed 
above.  
 
An unexpected finding was the influence of the slope of decline on recovery of 
function after 6 months. Univariate logistic regression analysis revealed a reduced risk 
of failure to recover function according to the study criteria of a fall in eGFR of 
5mls/min. This was most marked in the AKI group where the odds ratio was .879 (95% 
C.I. .800 to .965, p=.007) but was also evident in the AKI/CKD group (OR .920, 95% 
C.I. .851 to .995, p=.036). This protective effect persisted when the definition of 
recovery was extended to a fall of 10mls/min/year but was lost when failure to recover 
function was defined by a fall of 25% in eGFR from baseline. The finding of reduced 
odds of failing to recover persisted in every model on multivariate analysis. This effect 
is counter-intuitive however there may a plausible explanation. It was previously 
highlighted that recovery of function appears to be better in those with pre-existing 
renal impairment. This might be explained by differences in the relative severities of 
the AKI episodes themselves. The same idea could be applied to those with pre-
existing evidence of a decline in function. This is not suggesting that AKI does not 
worsen these cases but rather that the AKI episode necessary to bring this about needs 
to be more severe when expressed in terms of changes in serum creatinine. This 
theory is supported by the finding that the protective effect exerted by a steeper 
decline in function prior to the AKI episode is lost when the definition of recovery is 
extended to the more robust definition of fall in eGFR of 25% from baseline. To achieve 
this greater decline in function a more severe AKI may be needed. Another interesting 
feature of this analysis is that adjustment for AKIN stage in the multivariate models 
had little if any impact on the findings. This does not rule out the theory that AKI 
severity is the key to these findings. Instead it may be another example of how 
measuring acute renal dysfunction and injury by changes in serum creatinine could be 
inaccurate and not truly reflect the extent of the underlying injury.  
 
8.2.7 Factors influencing failure to recover function 
 
Regression analysis was used to explore factors that may influence failure to recover 
function after an AKI episode. The strongest factor was the slope of decline in eGFR 
prior to the episode as discussed above. Notably, the occurrence of at least one AKI 
episode during the 12 month and 4 year periods prior to the index AKI did not appear 
to increase the risk of failure to recover function. This suggests that repeat episodes in 
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relative severity of the underlying renal injury with the episode that is important. 
Baseline eGFR did not predict the outcome of failure to recover function in the AKI 
group. However in the AKI/CKD group on univariate analysis, for a fall in eGFR of 
5mls/min, reduced baseline eGFR had a protective effect with an (OR .965, 95% C.I. 
.936 to .994, p=0.019). With a fall in eGFR of 10mls/min this became highly significant 
(p=.005). The lack of influence of baseline on recovery in the AKI group is unsurprising 
as this group has relatively normal kidney function. In the AKI/CKD group the finding 
of a protective effect fits with the earlier theory that pre-existing CKD requires a more 
severe AKI (as expressed by changes in creatinine) to cause any lasting impact on 
function.  
 
Increasing age was found to increase the risk of failure to recover in the AKI group but 
not in the AKI/CKD group. A possible explanation for this is that all of the AKI/CKD 
group encompassed a smaller age range (median 75years, IQR 72-84). Overall gender 
was not found to have an influence on recovery in either group although in the AKI 
group for a fall in eGFR of 25% from baseline male sex showed a marked protective 
effect (OR .301, 95%C.I. .122 to .745, p=.009). This was unaffected by adjustment for 
age, comorbidities and AKIN stage. Bagshaw et al reported a similar finding in a 
Canadian population of ITU survivors who had undergone renal replacement therapy 
366. The reason for this protective effect in males is unclear but there may be a degree 
of survivor bias as over two thirds of the deaths in the AKI group at 6 months were 
male.  
 
The baseline level of comorbidity expressed by the Charlson score in this study was 
not found to influence recovery of function in either group. The use of RAS-blockers at 
the time of the AKI episode does not appear to influence recovery in either group. In 
the AKI group when the definition of a fall of 25% in eGFR is used the use of RAS 
blockers was found to increase the risk of non-recovery on univariate analysis (OR 
2.337 95% C.I. 1.028 to 5.312, p=0.043). However, this effect was lost with adjustment 
for increasing age.  
 
A potentially important finding in this study was a reduced risk of failing to recover in 
the AKI/CKD group in those taking a statin although the finding may be due to chance. 
This was found on univariate analysis when the definition of a fall in eGFR of 5mls/min 
was used but was not found when the other recovery definitions were used. On 
multivariate analysis this protective effect increased with adjustment for age, sex, 
Charlson Score and hypertension. It increased further when AKIN stage was added to 
this model (OR .358, 95%  C.I. .159 - .806, p=.013). The only factor that was found to Mark Uniacke    Chapter 8     
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reduce the protective effect associated with statin therapy was the addition of aspirin 
to the models.  
 
There is a sound theoretical basis for a possible protective effect of statin therapy in 
the setting of AKI and this has been demonstrated in experimental animals. Statins 
increase Nitric Oxide synthesis, and reduce both inflammation and the production of 
reactive oxygen species. On this background, Sabbatini et al studied the impact of low 
dose atorvastatin in aging rats subjected to ischemic AKI. Atorvastatin was found to 
independently increase the expression of endothelial NO synthase (eNOS)-mRNA 
expression with a resulting increase in nitric oxide production. Nitric oxide can reduce 
vasoconstriction and Sabbatini et al demonstrated that in treated experimental animals 
atorvastatin significantly attenuated the ischaemic tubular injury found on histological 
examination 
411. In another study using experimental animals Yasuda et al reported 
that simvastatin improved sepsis- induced AKI. This occurred through a reversal of the 
reduced intra-renal microvascular perfusion induced by the AKI and a reduction in 
renal tubular hypoxia. Like Sabbatini et al the authors found a reduction in tubular 
damage 
412.  
 
Observational work has been undertaken examining the impact of statin therapy on 
the occurrence of AKI but reports have been mixed. Mithani et al conducted a 
retrospective review of patients who underwent cardiac surgery and found that the use 
of statins did not lower the risk of postoperative AKI 
169. Conversely, in another 
retrospective study, Billings et al showed a lower incidence of AKI after cardiac surgery 
in those given statin therapy early postoperatively in both chronic and naïve statin 
users 
406. Prowle et al found that short-term perioperative use of atorvastatin was not 
associated with a reduced risk of post-operative AKI 
413. These reports are specific to 
cardiac surgery patients. Molnar et al reviewed a large population of patients following 
major elective surgery of any kind and found that after adjustment for patient and 
surgical characteristics statin therapy was associated with 16% lower odds of AKI 
407. 
Whelten et al reviewed the immediate outcomes after vascular surgery. In 2170 
patients they found that post operative AKI occurred in 664(34%) and of these 47% had 
a complete recovery within 3 days. The use of statin therapy did not reduce the risk of 
AKI but did improve the odds of complete recovery by day three 
118.  
 
Work to date has largely focused on the ability of statin therapy to prevent AKI and not 
on long-term recovery of function. While Whelten et al did not find a reduced risk of 
AKI the fact that statin therapy increased the chances of recovery, albeit in the first 
three days, may be important. Statins may not prevent AKI events from occurring but 
they may attenuate them. The findings in this study might support this theory as the Mark Uniacke    Chapter 8     
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protective effect was lost when more severe failure to recover was considered. This is 
presumably because they had a more severe injury that outweighed any potential 
beneficial effects.  
 
Follow up findings may also be related to the chronic use of statins in the aftermath of 
the AKI episode. However, data on the influence of statin therapy on the progression of 
CKD are conflicting 
414. There is some evidence in the literature that statins may slow 
the progression of CKD. Sandhu et al conducted a meta-analysis of 27 trials of statins 
that reported kidney function outcomes and found that statin therapy reduced 
proteinuria modestly and resulted in a small reduction in the rate of kidney function 
decline. This was most marked in those with cardiovascular disease 
415. Conversely, the 
recent SHARP study did not report a beneficial effect on progression of renal disease in 
those on statin therapy over nearly 5 years of follow up using the endpoint of a 
doubling of serum or creatinine or reaching ESRD 
416. No study to date has looked at 
the subset of CKD patients who have experienced an AKI episode. As experimental 
evidence suggests that some of the benefit of statin therapy may lie in its effects on 
reducing renal ischaemia, this may be the patient group that could show a benefit. 
This is an area that needs further work.  
 
This study showed no difference in recovery outcomes depending on whether the AKI 
was community acquired (present on admission) or hospital acquired. Increasing AKIN 
stage resulted in an increased risk of failing to recover function in both groups but this 
finding varied with the definition of recovery used. In the AKI group, using a fall in 
eGFR of 5mls/min as failure to recover, AKIN stage was not useful at predicting this 
outcome. However for a fall in eGFR of 25% from baseline the association was much 
clearer. In model 4 with adjustment for age, sex, and comorbidities the adjusted OR 
ratio of failure to recover for AKIN stage 2 was 4.356 (95% C.I. 1.077 – 17.621) which 
increased to 7.748 for AKIN stage 3 (95% C.I. 1.922 – 31.323. overall p=.015). This 
finding supports a theory raised earlier. It may be that a fall in eGFR of 5mls/min is not 
adequate to describe this phenomenon as it may be heavily influenced by individual 
and analytical variation and could be too weak to reflect true injury.  
 
In chapter 3 it was highlighted that the influence of cause of AKI on recovery of 
function was unclear from the literature. In this study when the cause of the AKI is 
divided into hypoperfusion, septic and complex causes, the recovery outcomes were 
not significantly different. There is a trend toward an increased risk of failing to 
recover in the septic and complex groups but this trend is attenuated by adjustment 
for AKIN stage. This suggests that AKI severity rather than cause per se is the 
important factor.  Mark Uniacke    Chapter 8     
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A curious finding in this study is that the risk of failing to recover function appears to 
be reduced in those who have had a nadir blood pressure recorded < 90 systolic at the 
time of the AKI. In the AKI group this effect was found to be substantial and persisted 
in all of the multivariate models explored. For a fall in eGFR of 5mls/min the odds ratio 
was .377 when adjustment was made for age, sex, comorbidities and AKIN stage (95% 
C.I. .180 to .787, p=.009). Using the definition of a fall of 25% these findings are 
similar (OR .308 95% C.I> .108 to .880, p=.028).  In the AKI/CKD group this protective 
effect was weaker and apparent only as a trend. The finding that significantly reduced 
blood pressure is protective seems counter-intuitive. However, the effects of remote 
ischemia pre-conditioning are well described in the literature. It is known that transient 
non-lethal ischaemia applied to an organ or tissue protects another organ or tissue 
from subsequent lethal ischaemic injury. This phenomenon is thought to be due to 
alterations in the expression of signalling mechanisms in the inflammatory cascade. 
These alterations persist and protect other tissue and organs from repeat ischaemia. 
This concept has been applied in practice in patients undergoing cardiac surgery. 
Venugoppal et al recently reported a secondary analysis of two randomised controlled 
trials in which remote ischaemic pre-conditioning, involving three 5 minute cycles of 
right forearm ischaemia using a blood pressure cuff, was applied to patients about to 
undergo cardiac surgery. They found that pre-conditioning reduced the risk of AKI 
405.  
 
There is some evidence in the literature that the duration of the AKI may have an 
impact on outcomes. Coca et al studied a group of diabetic patients who had sustained 
an AKI after cardiac surgery. They found that the duration of the AKI was significantly 
associated with mortality in a dose dependent manner 
163. They did not report on 
functional outcomes. In this study the duration of the AKI episode was defined as the 
time taken to recover to a creatinine value that was below the threshold for AKIN stage 
1. The duration to reach this point was not found to influence function after 6 months 
of follow up.  
 
Finally, patients who had a formal review by the renal team were studied. On univariate 
analysis it was found that those in the AKI group who had a review were at a 
significantly increased risk of failing to recover function after follow up. This was 
associated with an odds ratio of a fall in eGFR of 25% from baseline after 6 months of 
4.68 (1.604-13.656, p=.005). This is almost certainly related to the severity of the 
illness and underlying AKI. However, it is worth highlighting because in clinical practice 
many of these renal reviews are for advice only and patients do not receive subsequent 
follow up.  
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8.3 Mortality 
 
As discussed in Chapter 2, it is well established in the literature that AKI is 
independently associated with increased hospital and long-term mortality. This study 
highlights the high mortality associated with AKI in both those with and without 
underlying CKD. 
 
8.3.1 General Summary of findings 
 
At 6 months mortality reached 24% in the AKI/CKD group and 12.6% in the AKI group 
(p=.003). When the AKI/CKD group was compared to the CKD control group mortality 
was higher and approached statistical significance despite the low numbers in the 
control group (p=.02). It would not be appropriate to generalise these results to the 
general population as this study was designed primarily to explore the impact of AKI 
on kidney function. The study cohort was enriched with more severe AKIN stages 
through the under-sampling of AKIN stage 1.Nevertheless it provides an insight into 
the poor outcomes that can be expected with AKI.  
 
8.3.2 Outcomes in those with and without pre-existing CKD 
 
In this study hospital mortality was higher in the AKI/CKD group compared to the AKI 
group (8.6% v 3.7%, p=.045). This is not unexpected given that this group was 
significantly older and had more comorbidities. Many previous studies have associated 
AKI/CKD with a lower mortality. Those studies were largely set either in the intensive 
care setting or in severely ill patients where patient selection and underlying illness 
severity are likely to have played an important role. This is supported by the findings 
by Cerda et al who found a lower mortality in the CKD group in a group of critically ill 
patients requiring renal replacement therapy. This was effectively removed when 
adjustment was made for illness severity 
286. The findings in this study are in keeping 
with the findings of Ali et al who also found a higher mortality in hospital in those with 
pre-existing CKD 
187.  
 
8.3.3 Factors influencing mortality outcomes 
 
Regression analysis demonstrated several notable findings when examining mortality 6 
months after the AKI episode. Univariate analysis demonstrated that an increasing 
slope of decline in eGFR prior to the AKI did not influence mortality outcomes. This is 
surprising given that CKD progression is associated with a higher mortality in the 
general population 
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association and in addition the follow up period may have been too short. However, 
the slope of decline was found to have a protective effect in terms of recovery of 
function. It was highlighted in Chapter 3 that incident CKD and progression of CKD 
may account for the increased mortality after an AKI episode. If the slope of decline is 
associated with a reduced risk of failing to recover function then this might explain the 
lack of association with mortality at least in the aftermath of an AKI episode.  
 
In the AKI group univariate analysis revealed an increased risk of mortality associated 
with an admission to hospital in the 12 months preceding the index AKI. In addition 
those who had evidence of an AKI in the 4 years prior to the index AKI were found to 
be at a significantly increased risk of dying in the following 6 months (OR 4.697, 95% 
C.I. 1.551 – 14.224, p=.006). This apparent cumulative effect is at least partly due to 
the presence of underlying comorbidities as it is weakened when adjustment is made 
for increasing Charlson Score (OR 2.898, 95% C.I. .887 – 9.468). This association was 
not found in the AKI/CKD group. This may have implications for clinical practice as a 
history of a previous AKI is easily identifiable. It may identify a subgroup of patients 
that will benefit from preventive strategies and aggressive management of their AKI. 
This area needs further study.   
 
Increasing age was found to be an important risk factor for mortality in the AKI group 
(p=.004) but not in the AKI/CKD group. As discussed earlier, this may be due to the 
tighter age range evident in the AKI/CKD group and perhaps a lack of power in the 
study. Likewise, increasing Charlson comorbidity score was found to have a strong 
influence on mortality in the AKI group but not in the AKI/CKD group. In the AKI/CKD 
group most patients had a high comorbidity load (mean Charlson Score 4.19 ) and it is 
likely the patient numbers in this group were insufficient to detect any differences. 
Gender did not influence mortality in either group. 
 
RAS-blockers did not influence mortality in the AKI group. In the AKI/CKD group, 
univariate analysis revealed a reduced odds of mortality at 6 months in those taking 
RAS-blockers (OR .468 95% C.I. .227 - .965, p=.04). This protective effect was reduced 
when adjustment was made for age, sex, and co-morbidities. It is possible that this 
effect is due to the their use in patients with less co-morbidity and therefore possible 
more likely to recover. Nevertheless this finding is important as 35% of those who had 
their RAS blocker stopped at the time of their AKI in the AKI/CKD group did not have 
them restarted during follow up. This may be because it was felt to be clinically 
inappropriate. On the other hand it may be an oversight on the part of the managing 
physicians. If there is a protective effect then these patients are being denied a drug 
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With regard to the other medications reviewed in this study it is notable that the use of 
statin therapy was not associated with mortality in either group. This study is likely to 
have been underpowered to detect any association.  
 
The setting of the AKI appears to have an important influence on mortality outcomes 
in both groups. In the AKI group, community acquired AKI evident on admission to 
hospital was associated with a more than 3 fold increased risk of mortality at 6 months 
(OR 3.469, 95% C.I. 1.135 – 10.603, p=.029). This was not the case in the AKI/CKD 
group. The increased risk in the AKI group was weakened when adjustment was made 
for comorbidities and AKIN stage. This suggests that AKI severity may be partly 
responsible for this finding. In the AKI/CKD group admission under a medical specialty 
was strongly associated with an increased risk of mortality. This was not influenced by 
adjustment in any of the multivariate models. The explanation for this finding may that 
patients selected to be suitable for surgery are likely to be younger and fitter. 
Therefore they will have better outcomes. In addition the nature of the AKI and the 
underlying illness are likely to be more severe in medical patients compared to elective 
surgical patients.   
 
AKIN stage was not found to predict mortality outcomes in the AKI group. In the 
AKI/CKD group AKIN staging was associated with an increased risk of mortality. 
However, the highest risk was found in AKIN stage 2 in all of the models analysed. 
Numerous studies in the literature have found an increased mortality with increasing 
AKIN stage 
155,167,170. However, others have not. In a validation study in the intensive care 
setting Ostermann et al found that only AKIN stage 3 predicted mortality 
137. These 
findings will be discussed further below.  
 
In terms of the cause of the AKI episode, this did not appear to have a strong influence 
on mortality outcomes at 6 months in either group. In the AKI/CKD group septic AKI 
and complex AKI were associated with an increased risk of mortality at 12 months and 
this association persisted even with adjustment for comorbidities and AKIN stage. 
There is limited evidence in the literature associating AKI cause with mortality 
outcomes. Bagshaw et al demonstrated an increased risk of mortality in septic cases in 
intensive care 
227. This study is the first to look at longer-term outcomes in relation to 
cause and it appears that this has little influence on 6 month outcomes. Although an 
association was found in the AKI/CKD group at 12 months, medical events in the 
months prior to this time point are not known and so making a causal link with AKI 
cause is tenuous at best.  
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In this study AKI duration was defined as the time taken for the rise in creatinine to 
return to levels below the threshold for AKIN stage 1. Duration was not found to 
influence 6 month mortality in either group on univariate analysis. Several studies in 
the literature, albeit in quite specific patient groups, have associated a longer duration 
of AKI with increased mortality. Some have concluded that it adds additional 
prognostic information 
160,162,163. For example, using the same definition of duration as 
this study, Coca et al found that increasing duration of AKI increased long-term 
mortality in a cohort of diabetic surgical patients even with adjustment for AKI severity 
163. This study may have lacked the power to demonstrate this association or it may be 
that this association does not exist in a more diverse general hospital population.  
 
8.4 Combined outcome of failure to recover function and 
mortality at 6 months 
 
In the AKI group logistic regression showed that an increasing slope of decline in eGFR 
prior to the AKI episode had a strong protective effect on the combined outcome of 
mortality or a fall in eGFR of 5mls/min or more from baseline. This was the strongest 
influencing factor. On univariate analysis the odds ratio for the combined outcome was 
.883 (95% C.I. .808 to .965, p=.006). This was largely unaffected by adjustment in the 
multivariate models. This association was not found in the AKI/CKD group.  
 
Increasing age was found to increase the risk of the combined outcome in the AKI 
group but not in the AKI/CKD group. On univariate analysis lower baseline eGFR was 
associated with a reduced risk of the combined outcome in the AKI/CKD group but not 
in the AKI group. This fits with the earlier findings for the individual outcomes and 
supports the theory that the relative impact of the AKI episode may be different in the 
AKI/CKD group.  
 
Admission under a medical specialty appears to increase the risk of the combined 
outcome in the AKI/CKD group but not in the AKI group. AKIN stage had no influence 
on the combined outcome in the AKI group. In the AKI/CKD group AKIN stage was 
associated with an increased risk. This persisted with adjustment for comorbidities in 
multivariate analysis. However, the highest risk was associated with AKIN stage 2.  
 
8.5 Length of hospital stay 
 
In this study the median length of hospital stay in the AKI/CKD group was significantly 
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study to demonstrate this in a prospective review of general hospitalised patients. It 
confirms the findings of numerous retrospective studies. This is one of the key issues 
highlighting AKI as a major drain on healthcare resources 
32.  
 
8.6 Contributions to the natural history of AKI 
 
8.6.1 AKI Group compared to the AKI/CKD group 
 
This study highlights numerous differences in characteristics and outcomes of the AKI 
group and AKI/CKD group.  
 
Both groups are substantially different at baseline. The AKI/CKD group is older and 
has a greater comorbidity burden. As a result the AKI/CKD group showed differences 
in terms of the medications in use. In the case of RAS blockers, 74% of the AKI/CKD 
group were taking these compared to 52% in the AKI group (p<.001). Baseline 
characteristics also appear to influence the setting of the AKI episode in each group. In 
the AKI/CKD group significantly more patients in the surgical category were 
emergencies (85% v 59.5%, p=0.001). This will have an influence on the nature and 
management of the AKI episodes rendering any meaningful comparison impossible. 
More of the AKI/CKD group had a history of previous AKI episodes. In addition, 
mortality was higher at all time points in the AKI/CKD group however functional 
recovery in this group appears to be better.  
 
These differences highlight the need to separate these groups carefully in the design 
of AKI studies. As discussed earlier, the relative effects of each AKI stage on those with 
pre-existing CKD may be quite different to those with normal renal function and this 
may account for the better recovery patterns in the AKI/CKD group. The possibility 
also exists that the pathological responses of an already impaired kidney to an AKI 
insult may be different to those seen in a normal kidney. These issues raise questions 
about the appropriateness of using the same definition of AKI in each of these groups. 
It highlights how biomarkers that reflect actual injury rather than relative changes in 
function may be more suitable for studying AKI.  
 
8.6.2 Community-acquired AKI compared to Hospital-acquired AKI 
 
The recent NCEPOD report in the UK, AKI: Adding Insult to Injury, identified a good 
overall standard of care in only 50% of patients with AKI. This fell to 30% in cases that 
occurred in hospital 
36. KDIGO recently identified the need to better delineate the risk 
for hospital-and community-acquired AKI 
48. If better management of AKI is to be Mark Uniacke    Chapter 8     
        219 
achieved an improved understanding of the epidemiology and natural history of these 
subsets of the AKI population is needed.  
 
This is the first study to examine the differences in characteristics and outcomes 
between community and hospital acquired AKI in the same population. It was 
highlighted in Chapter 2 that the epidemiology of community and hospital–acquired 
AKI is unclear in the literature. KDIGO suggested that hospital–acquired cases are 5 to 
10 times more common however there is a lack of evidence to support this claim in the 
literature 
48. In fact community – acquired AKI appears to be more common in some 
studies 
107,110,168. In this study it is not possible to give a clear description of the relative 
proportions that are community or hospital-acquired. In the overall cohort community–
acquired cases are more common with over two thirds of cases being evident on 
admission (67.4%). However, examination of the distribution of admission cases by 
AKIN stage in each group revealed a trend toward there being more AKIN stage 1 in 
the hospital–acquired subset. This means that the under-sampling of AKIN stage 1 
used in the recruitment in this study would have underestimated the number of 
hospital-acquired cases. Nevertheless, as there were no significant differences found in 
the baseline characteristics between stages in either group it is possible to comment 
on the general differences between community and hospital –acquired cases. 
 
There was no age difference found between these subsets in either group. There was a 
trend toward there being a greater burden of comorbidity in the community-acquired 
cases in the AKI group. In both groups a significant majority of the community –
acquired cases were admitted under a medical specialty. In the AKI group there were 
significantly more septic AKI cases on admission (p=.001) while more perfusional cases 
were found in the hospital –acquired subset (p=.003). No difference in the distribution 
of causes were found in the AKI/CKD group. In terms of management practices the 
findings in this study are in keeping with the NCEPOD report 
36. Patients with AKI 
present on admission were more likely to have had a urine dipstick and renal 
ultrasound in both groups. 
 
No differences in recovery patterns were found between the subsets in either group. In 
the AKI group mortality was higher in community – acquired cases both in hospital and 
after 6 months. This finding would not have been affected by the under-sampling of 
AKIN stage 1. More of these cases would have been in the hospital-acquired subset 
and so would have increased the mortality difference even further. The only study with 
which to compare this finding is that of Sesso et al who found an increased mortality in 
hospital-acquired AKI in the elderly 
110. The finding that community acquired cases in 
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addition to implementing preventive strategies within hospitals, community 
management by general practitioners will also need to be addressed.  
 
8.6.3 The influence of AKI cause on outcomes 
 
In this study an effort was made to describe the causes of AKI clearly and to examine 
their influence on outcomes. The traditional ‘pre-renal’ variety of AKI was divided into 
septic, hypoperfusion and complex cases. This was done because as discussed in 
Chapter 2, evidence exists that there may be differences in the pathology and 
outcomes in relation to the septic causes.  
 
In Chapter 6 it was seen that at baseline there was no difference in the distribution of 
causes between the AKI and AKI/CKD groups. Approximately 40% of cases in each 
group were hypoperfusion indicating that the primary cause was due to a 
haemodynamic disturbance. Between one quarter and one third of cases in each group 
were septic in origin while a quarter of cases had more than one primary cause and fell 
into the complex category. This latter finding is in keeping with the literature. Liano et 
al found more than one aetiology in 16% of cases of AKI in hospital 
20. Complex cases 
included cases of obstruction and nephrotoxic AKI. The latter was made up largely of 
contrast–induced AKI. In fact all of the contrast-related cases in both groups were 
considered to be complex and had at least one additional cause associated with it. 
Pure intrinsic AKI was very uncommon making up just 1.7% of the AKI group and no 
case was found in the AKI/CKD group.  
 
In terms of outcomes, the cause of the AKI episode was not found to have a marked 
influence. Cause did not influence mortality in the AKI group. In the AKI/CKD group 
there was a trend toward an increased mortality in the septic and complex cases at 12 
months but not at 6 months. Recovery of function was not influenced by cause in 
either group. 
 
8.6.4 Recurrent AKI episodes 
 
An important finding in this study was a pattern of repeat AKI episodes evident both 
before the AKI and during follow up. Thakar et al recently detected this phenomenon 
in a study of diabetic patients but it has not been described in a general hospitalised 
cohort 
34.  
 
In this study a review of records up to four years prior to the index AKI revealed that 
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met AKIN criteria (p=.001). During the 6 month follow up period 8.4% of survivors in 
the AKI group and 19.6% of the AKI/CKD group had at least one more such AKI 
episode. This included cases that occurred solely in the community. Of those who had 
demonstrated a fall in eGFR of at least 5mls/min after 6 months 8.4% in the AKI group 
and 19.6% in the AKI/CKD group had had a repeat AKI episode. These episodes may 
also be contributing to the outcomes found.  
 
Logistic regression was used to assess their impact in patients who had survived to 
discharge. A repeat AKI episode was found to be one of the strongest predictors of 
mortality at 6 months in the AKI group. In the unadjusted model the odds of death 
were increased nearly 9 fold (OR 8.647, 95% C.I. 2.507 to 29.821, p=.001). This was 
largely unaffected by adjustment in multivariate models. The influence was weaker in 
the AKI/CKD group and was lost when adjustment was made for comorbidities in the 
multivariate analysis. There was surprisingly no influence found on recovery of 
function in either group. The overall event rates were low however and it is likely that 
the study lacked the numbers to demonstrate any significant differences in recovery 
outcomes.  
 
This finding is very important. Other than the study by Thakar et al no study to date 
has considered the influence of repeat AKI episodes. Therefore all of the recent reports 
of long-term outcomes in AKI studies are potentially flawed and the effects of 
individual AKI episodes and the relative risks associated with them are overestimated. 
AKI epidemiology needs to take account of the multiple nature of these events and 
further work needs to be done to better understand their potential cumulative effect. 
 
8.7 Management Practices 
 
This study has identified a number of areas in the management of AKI in hospitalised 
patients that need further review as they have important implications for clinical 
practice.  
 
8.7.1 General management 
 
The NCEPOD report identified a number of deficiencies pertaining to the basic 
management of AKI patients who had died in hospital. This report involved patients 
who were coded as having a death associated with AKI and so were almost certainly at 
the more severe end of the spectrum. 33% of patients were found to have had 
inadequate basic investigations. This included no urine dipstick in 14% and no renal 
ultrasound in 18% 
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This study was carried out during the two years after the publication of the NCEPOD 
report. Despite this the deficiencies described by NCEPOD are evident and in fact 
appear worse because milder episodes of AKI are included. Urine dipstick 
measurement was performed in only 46% of the AKI group and 51% of the AKI/CKD 
group. When the groups were divided by AKIN stage there were still a substantial 
number not having this basic investigation even in AKIN stage 3. In the AKI group only 
58% of AKIN stage 3 had a urine dipstick while 60% in the AKI/CKD group had one.  
36.8% in the AKI group and 34.6% in the AKI/CKD group had a renal ultrasound 
performed. In clinical practice it would not be considered appropriate to perform a 
renal ultrasound in many of the milder cases of AKI. However, when divided by AKIN 
stage it was shown that even in AKIN stage 3 only 60% of the AKI group and 70% of the 
CKD group had an ultrasound. In the case of a fall in eGFR of 25% from baseline after 6 
months (the most severe reduction in function reviewed) 42% of the AKI group who 
reached this endpoint did not have an ultrasound performed at the time of their AKI 
(p=.007). Finally, in this study accurate urine output measurement was missing in a 
large proportion of patients in each group. While this may have implications for 
management it also highlights how urine output is of limited use in the definition of 
AKI in general hospitalised patients.  
 
8.7.2 Nephrology Referral 
 
One of the key findings in the NCEPOD report on acute kidney injury related to referral 
practices. Of the 561 AKI cases reviewed only 31% had been referred for nephrology 
advice and management. It was the opinion of the advisory team that a further 20% 
should have been referred for specialist opinion 
36.  
 
Evidence exists that nephrology referral and support may alter outcomes. Meier et al 
recently reported the outcomes of 4296 non-critically ill patients that had sustained an 
AKI. They divided patients into those who had not received a referral, those who had a 
late referral defined as greater than 5 days after the onset of the AKI, and those who 
had an early referral. In that study referral rates were high which probably reflects local 
practices. In total 78% of patients were referred for nephrology review. The authors 
found that mortality was significantly higher in those who had no referral or a late 
referral compared to those who had an early referral 
174. It is likely that nephrology 
referral improves AKI management and may prevent deterioration to a higher AKI 
stage. Further support for this can be found in a recent study by Abraham et al who 
found that the mortality associated with AKI in hospitals in England was significantly 
higher in those hospitals without onsite nephrology cover 
37.  
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In this study 8.9% of patients in the AKI Group were reviewed by a nephrologist while 
in the AKI/CKD group 20.5% had a review (p=.002). When divided by AKIN stage it was 
found that in the AKI group no patient in AKIN stages 1 or 2 were referred. This leaves 
23% of AKIN stage 3 having had a review. In the case of the AKI/CKD group 12% in 
each of AKIN stages 1 and 2 received a referral and 78% in AKIN stage 3. In regression 
analysis renal referral was not found to influence mortality outcomes although the 
numbers may have been insufficient to demonstrate a difference. In the AKI group 
having had a referral was strongly associated with an increased risk of a fall in eGFR of 
10mls/min or a fall of 25% from baseline after 6 months follow up. This was 
unaffected by adjustment for age, sex, and comorbidities. In the case of a fall in eGFR 
of 25% the odds in those who had a referral was 5.362 (95% C.I. 1.656 – 17.359, 
p=.005) This is likely to reflect AKI severity and the severity of the underlying illness. 
  
These findings highlight key issues concerning referral practices. A significantly larger 
proportion of the AKI/CKD group was referred to nephrology. This study has 
demonstrated that functional recovery is actually worse in the AKI group. The 
increased referral rate may be because there is a greater awareness of renal disease in 
the CKD population. Some of these CKD patients were already known to the renal 
service and this may have prompted earlier referral. Regardless, it is concerning that 
over three quarters of AKIN stage 3 in the AKI group did not receive a nephrology 
review. This appears to contravene the National Service Framework for Renal Services 
in the UK which states that patients experiencing an AKI are entitled to clinically 
appropriate care in partnership with specialised renal teams 
417.  
 
8.7.3 AKI coding practices 
 
International Classification of Diseases codes are used in many countries to record and 
classify patient diagnoses at the time of death or discharge from hospital. Their use 
has formed the basis of numerous contemporary retrospective AKI studies in the 
literature. The accuracy of this coding system is dependent on the teams managing the 
patients and it is known to under-report certain diagnoses. Waikar et al conducted a 
study of coding practices in relation to AKI in a US hospital and found that ICD-9 codes 
failed to identify a large proportion of clinically significant changes in serum 
creatinine. Patients who had a rise in creatinine of at least 100% from baseline during 
their hospital stay were identified. The authors found that the sensitivity of the codes 
for this definition was only 35.4% while the specificity was 97.7% 
418. However, the 
accuracy of coding will clearly be dependent on local practices.  
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In this study patient records were reviewed after death or discharge from hospital to 
ascertain what coding if any was used in relation to the AKI episode. During the course 
of this study ICD-9 codes were in use in Queen Alexandra Hospital. In the case of the 
AKI group only 38.9% had an AKI related code while 50.8% of the AKI/CKD group had 
one (p=.021). When the AKI group is divided by AKIN stage 8.7%, 35.2%, and 61.6% 
were coded for AKIN stages 1,2, and 3 respectively. In the AKI/CKD group these 
figures were 38.4%, 50.9% and 87.9% respectively. The code used in the vast majority 
of cases was ICD-9:N17.9 – ARF unspecified.  
 
These findings have important implications. A large proportion of patients who had an 
AKI during their hospital admission do not have this recorded at discharge. The most 
worrying finding is that nearly 40% of the more severe AKIN stage 3 in the AKI group 
are not recorded. In the majority of cases the discharge summary from which these 
codes are derived is the sole communication with the patients general practitioner 
after discharge. The findings indicate that general practitioners are not being made 
aware of a large proportion of patients with a severe AKI. This raises questions 
regarding the quality of the follow up these patients receive at least in relation to the 
hospital in which this study took place. However, there is no reason to believe that this 
is not the case at a national level. Another important implication is that the codes used 
in the hospital discharge summaries are used to determine the tariff for that hospital 
episode. While many of these AKI episodes will be bundled with the primary diagnosis 
and not influence the tariff, it is still possible that the tariffs may be incorrect and 
therefore the hospital may not be remunerated appropriately for the episode. Finally, 
routine discharge data have been used to identify AKI in many studies and so are likely 
to underestimate AKI.  
 
8.7.4 Use of RAS-blockers 
 
The use of RAS blockers is generally considered in clinical practice to contribute to the 
causes of AKI. This is based on their effect of reducing GFR. As a result it is now 
common practice to discontinue their use in those at risk of or experiencing an AKI. 
Several studies have demonstrated an increased risk of AKI in those taking RAS 
blockers in different settings to support this practice 
116,220,419,420. Thakar et al reported 
an increased risk in a cohort that had undergone gastric bypass surgery while Akram 
et al reported an increased risk in those with community – acquired pneumonia 
116,220. 
However, in the setting of cardiac surgery the findings have been conflicting. Arora et 
al demonstrated an increased risk of AKI after cardiac surgery while Yoo et al showed 
no increase in the risk 
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AKI after on-pump bypass surgery in the RAS blockade group 
422. The reason for the 
differences in these studies is unclear.  
 
While RAS blockers may be associated with an increased risk of AKI, their influence on 
outcomes have not been studied in detail. In the study by Akram et al the use of RAS-
blockers was found to have no effect on adverse outcomes 
220.  
 
This study gives an insight into current practices in the use of RAS blockers at the time 
of an AKI episode and reviews their influence on outcomes. At baseline the use of RAS 
blockers was considerable in both groups. 52% of the AKI Group and 74% of the 
AKI/CKD group were on a RAS-blocker (p<.001). It is notable that when the AKI/CKD 
group was compared to the non-AKI CKD controls there was a significant difference in 
their use with only 46% of controls taking them (p=.003).  
 
At the time of the AKI episode over 90% of patients had their RAS blocker 
discontinued. However, an important finding is that of those who were taking them at 
baseline only 73% of the AKI group and 66% of the AKI/CKD group were taking them 
after 6 months of follow up. The reason why the drugs were not restarted is unclear. It 
is likely that in some cases they were not deemed to be clinically necessary. In 50% of 
the AKI group and 71% of the AKI/CKD group the original indication for the RAS 
blocker was hypertension. However it is also possible that they were not restarted as 
an oversight on the part of the admitting team. This could have an impact on long-
term outcomes particularly in those with cardiac failure or diabetics with proteinuria.  
 
The use of RAS blockers at the time of the AKI had no influence on mortality after 6 
months in the AKI group. However in the AKI/CKD group in univariate analysis RAS 
blocker use was found to be associated with a reduced 6 month mortality (OR .468, 
95% C.I. .227 to .965, p=.040). This protective influence was lost with adjustment for 
age, sex, and comorbidities in the multivariate analysis. In the AKI group RAS blocker 
use was found to be associated with an increased risk of having a fall in eGFR by 25% 
after 6 months in univariate analysis. This effect was lost in the multivariate models. 
RAS blockers were not found to influence functional outcomes in the AKI/CKD group 
after 6 months.  
 
The finding that RAS blockers may reduce mortality in the AKI/CKD group is a weak 
association at best. There are many potential confounding issues not least of which is 
the fact that the RAS blockers were not restarted in some patients. Nevertheless it 
highlights some important issues. This study has demonstrated that a large proportion 
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there is the potential for a protective effect in terms of mortality in the AKI/CKD group 
then this practice needs to be reviewed. This is an area that clearly needs further 
study.  
 
8.8 Methodological issues 
 
Chapters 2 and 3 highlighted several methodological issues hampering current AKI 
research. These included the definitions of baseline kidney function, that of AKI itself, 
and of recovery of function. This study adds to the current literature as it has further 
examined these areas and may aid in the design of future studies. 
 
 
8.8.1 Definition of baseline kidney function 
 
Up to 30 different definitions of baseline function have been used in AKI research. The 
definition of baseline kidney function is important because it effectively anchors the 
definition of AKI and provides a longitudinal reference point 
423. This is crucial in any 
study of the functional outcomes of AKI. The lack of a consensus definition of baseline 
function contributes to study heterogeneity and potentially confounds the reports of 
long-term functional outcomes after AKI 
424.  
 
In the design of this study close attention was paid to the identification of baseline 
function resulting in one of the most rigorous definitions used to date. Despite the 
rigorous approach taken in defining baseline potential problems were identified. 
During the retrospective review of biochemistry records it was found that 14.7% of 
patients selected for the AKI Group had at least one eGFR measured as an outpatient < 
60mls/min when the search was extended back over a three year period from the 
chosen baseline. In addition 8.4% of patients were found to have evidence of 
microalbuminuria prior to their admission. It therefore could not be said with certainty 
that these patients did not already have underlying CKD. Sensitivity analysis in this 
study revealed no differences in outcomes in this group of patients however it remains 
a potential source of confounding.  
 
Siew et al examined several different methods of estimating baseline kidney function. 
This included the mean outpatient value, the most recent outpatient value, the nadir 
outpatient value, and the most recent inpatient value. They concluded that using the 
mean outpatient serum creatinine from values taken during the previous 7 – 365 days 
most closely approximated a nephrologist-adjudicated estimation of baseline function. 
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standard.  This was an unusual study because the authors suspected that the 
nephrologists had used a similar averaging method themselves and therefore the 
study was essentially comparing like with like. They found that by extending the 
search for outpatient values back to 2 years the numbers available for assessment 
increased but the accuracy of the estimation was reduced. They did not report if the 
fall in accuracy was due to under- or overestimation of baseline 
424. 
 
Choosing the average value within the previous 12 months would seem to be a 
reasonable approach. However, based on the findings in this study care should be 
exercised to ensure that there is no evidence of renal dysfunction in those who are 
being classified as not having CKD. In addition previous evidence of microalbuminuria 
may need to be taken into account.  
 
Finally, it is important to note that while it is necessary to define baseline function this 
will inevitably result in missing cases of AKI where no baseline can be defined which 
was approximately 15% in this study. As a result any conclusions drawn from AKI 
research cannot be generalised to the entire population.  
 
8.8.2 Definition of AKI 
 
Overall the AKIN staging system was found in this study to be a poor predictor of key 
outcomes. There were also clear differences in its performance between the AKI and 
AKI/CKD groups.  
 
In regression analysis AKIN staging did not predict mortality in the AKI group. In 
addition, AKIN stage did not predict failure to recover function when the original study 
definition of a fall in eGFR of at least 5mls/min was used. For a fall of 10mls/min or 
25% from baseline AKIN stage 3 appeared to predict this outcome and this became 
stronger with adjustment for age, sex and comorbidities. But as AKIN stage 2 
remained unclear within the regression modelling the staging system as a whole was 
unsatisfactory. 
 
The system performed slightly better in the AKI/CKD group. At 6 months it appeared 
to predict mortality however the highest odds on regression analysis were associated 
with AKIN stage 2 and this was unaffected by adjustment in any of the models used in 
multivariate analysis. Where failure to recover function was concerned the findings 
were mixed. For a fall in eGFR of 5mls/min AKIN appeared predictive of this outcome 
however it was strongest in AKIN stage 2. It performed well when the definition of a 
fall of 10mls/min was used with the odds increasing with increasing stage.  Mark Uniacke    Chapter 8     
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The performance of AKIN was therefore disappointing. The study may have lacked 
sufficient power to demonstrate any clear differences between the stages. However 
several studies in the literature have also failed to demonstrate a strong association 
between staging and outcomes. In an intensive care validation study Ostermann et al 
showed that only AKIN stage 3 predicted mortality (Ostermann 2008). Kwon et al 
reported a similar result in a cohort of general hospitalised patients (Kwon 2010). 
While it has been demonstrated in at least one study that AKI severity influences 
functional outcomes no study to date has looked specifically at the ability of AKIN 
staging to predict these outcomes 
369.  
 
One possibility for the poor performance of the AKIN system is that it is entirely reliant 
on changes in serum creatinine. It was discussed at length in Chapter 2 that creatinine 
is an imperfect marker of renal dysfunction and it is possible that as a result the AKIN 
stages do not reflect the true underlying injury. This highlights the need to develop 
better biomarkers of renal injury.  
 
Finally, it is worth noting that in this study the urine output criteria specified by the 
AKIN definition were not used. There are many potential problems associated with the 
use of urine output as discussed in Chapter 2. Chief among these are concerns about 
the accuracy of output measurement on wards where often patients will not have a 
urinary catheter in situ. It was decided from the outset that urine output would not be 
relied upon in the definition of AKI in this study. Nevertheless an effort was made to 
record urine output at the time of the AKI where possible. In 18.4% of cases in the AKI 
group no records had been kept of urine output. In the AKI/CKD group this figure 
reached 27.6%. Many of the cases where an output chart was maintained relied upon 
periodic measurement of urine collections provided by the patient. Therefore the 
accuracy of these results could be drawn into question. Overall, based on the findings 
in this study it is unlikely that urine output will ever play a significant role in AKI 
research in the non-critically ill where it would not be routine or appropriate to insert a 
urinary catheter.  
 
8.8.3 Defining recovery of function 
 
It was highlighted in Chapter 3 that the recovery that occurs after an episode of AKI 
remains poorly characterised in the literature. To date the methodological issues 
surrounding this aspect of AKI research have not been addressed in any detail. In this 
respect the work carried out in this study adds to the literature in terms of AKI 
research design.  
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Two key issues are relevant to the assessment of recovery after an AKI episode. The 
first is the appropriate timeframe after which patients should be followed up and the 
second is the definition of recovery itself. In addition to these issues there is also the 
problem of repeat AKI episodes that may occur during the follow up period. 
 
The timeframe of follow up was discussed in Chapter 3. Based on the evidence 
available recovery appears to peak between 3 and 6 months after the AKI and then 
plateaus. For this reason a 6 month follow up point was chosen in this study. In 
addition to straight-forward recovery of function this study identified another group of 
patients who appear to have recovered at the time of discharge from hospital but show 
a decline in function during follow up. This phenomenon may be explained by several 
factors including the loss of muscle mass during the acute illness or vigorous 
rehydration. These may reduce serum creatinine and mask any sustained kidney injury 
in hospital. One thing that has been made clear from this study is that while renal 
function is measured using serum creatinine as a marker, recovery at the point of 
discharge from hospital should not be used as an endpoint in any study. This practice 
continues in contemporary literature 
426.   
 
The question of how to define recovery after an episode of AKI has not been addressed 
in the literature. There are currently 19 different approaches to defining the recovery 
of function and progression of CKD in the literature. These widely differing definitions 
have the potential to report very different outcomes. Consequently, there is marked 
heterogeneity in the literature rendering cross-validation of studies difficult 
352. It has 
already been mentioned that the recent NIDDK reports on AKI study design suggested 
that recovery could be used as a suitable endpoint in AKI clinical trials. However, no 
recommendations were given on how to define recovery 
408.  
 
This study explored several different definitions of recovery. The outcome of a fall in 
eGFR of at least 5mls/min was reached in over 50% of the AKI group and 34% of the 
AKI/CKD group after 6 months. When the definition is extended to 10mls/min the 
proportions reaching this endpoint are reduced to 41% and 20% respectively and these 
fall further if a fall of 25% from baseline is used. This impact of broadening the 
definition might be expected. However, in doing so, this study has identified how this 
variation can result in very different findings when data is analysed. For example, in 
the AKI/CKD group when the AKIN staging system was explored in regression analysis, 
broadening the definition from a fall of 5mls/min to a fall of 25% from baseline had 
the effect of completely reversing the findings in relation to the AKIN stages.  
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The question then arises as to which definition should be used. The definition should 
be clinically meaningful and ideally should be shown to influence outcomes such as 
mortality. At present no data exists which might help solve this problem. During the 
analysis in this study the effect of the different definitions of recovery at 6 months on 
12 month mortality was explored, however the event rates were too low to show any 
differences. Therefore at present the decision on which definition is best needs to be 
made based on what is known about CKD and CKD progression. 
 
The NICE CKD Guidelines define rapid progression of CKD as a fall of more than 
5mls/min/year 
74. Stevens et al defined ‘rapid progressors’ as having a fall of > 
4mls/min/year which was also the definition used by KDOQI in the 2002 CKD clinical 
practice guidelines 
314,410. James et al used this latter definition in a recent study 
exploring outcomes following an AKI episode after coronary angiography 
230. These 
definitions are likely to be appropriate only when follow up is carried out over a 
prolonged period of time with multiple measurements. In addition, intra-individual 
variation in eGFR measurement is more than 5mls/min and therefore a fall in eGFR of 
5mls/min or less at a single time point is unlikely to be accurate or clinically 
meaningful. It is clear from this argument that a fall of 25% from baseline would be the 
most robust and least likely to give false positives. However, it is more likely to miss 
clinically significant changes in function. Therefore if it is applied in a clinical trial, 
patients who may benefit from an intervention may be missed. In both groups in this 
study a fall of 10mls/min correlated well with AKIN staging. This definition is above 
intra-individual variation if follow up is taken at a single time point and therefore may 
be the most appropriate. In the case of multicentre studies intra-laboratory analytical 
variation will also need to be considered and therefore the argument may lean toward 
using the most robust definition such as a fall of 25% in eGFR from baseline. This is 
open to debate and is an area that needs further work. 
 
The ASSESS AKI study group are currently exploring the natural history of AKI 
404. In 
this study the authors opted for the more robust definition of recovery. They require a 
fall in eGFR of 25% from baseline and progression to at least CKD stage 3 in the AKI 
group and a fall of at least 50% from baseline in the AKI/CKD group. In this study there 
was little difference between a fall of 25% from baseline and this outcome if the 
definition also required reaching a least CKD stage 3 (20.8% v 19.6%). In the case of a 
fall of 50% in the AKI/CKD group only 3.7% reached this. The event rates in the ASSESS 
AKI study are therefore going to be low in the AKI/CKD group and will arguably under-
report the phenomenon and the study will lack power.  
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8.8.4 Recruitment of controls for the AKI/CKD group 
 
During this study it became apparent that the study design made recruitment of 
adequate numbers in the CKD control group extremely difficult if not impossible. The 
reasons for this were discussed in Chapter 4. In summary, there was an inevitable time 
delay between recruitment of the AKI/CKD patient and efforts to recruit a matched 
control. Consequently, many of the intended controls had been discharged from 
hospital. This may have been influenced by the fact that these patients were less ill 
than their AKI counterparts. In addition patients who were recruited as controls may 
have then gone on to have an AKI themselves and so switched arms in the study. An 
attempt was made to overcome this by waiting a few days to ensure that patients 
remained stable, however many were discharged in the interim. This aspect of the 
study was not anticipated but it is information for the design of future AKI research.  
The only reasonable way around these problems would be to recruit every patient with 
CKD as they came into hospital and direct them into either a stable CKD arm or an 
AKI/CKD arm. However, this would require vastly more resources than were available 
for this study. Personal communication with one of the investigators involved in the US 
ASSESS AKI study revealed that they are having similar problems with the recruitment 
of controls.  
 
8.9 Strengths and weaknesses of this study 
 
This study has much strength over and above the work that has been previously 
published in this area. To date no prospective study in general hospitalised patients 
that has been specifically designed to explore recovery of renal function after an 
episode of AKI has been published.  
 
The prospective nature of this study allowed for the systematic follow up of patients. 
This removes concerns about ascertainment bias that have been raised about the 
retrospective studies carried out to date 
357. A nephrologist reviewed each case 
recruited into this study and this removes some uncertainty about the clinical 
diagnosis. In addition, the prospective nature of the study allowed for the real–time 
collection of extensive clinical data. This ability has been lacking in recent AKI 
research. All creatinine measurements were carried out in the same laboratory using 
the same analyser. This will have considerably reduced the influence of analytical 
variation. This study also had a relatively low attrition rate. Unlike many studies that 
were confined to the critical care environment, this study covers the broader hospital 
population and therefore the findings are more generalisable from a clinical viewpoint. 
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The extensive baseline and clinical data allows for a more thorough understanding of 
the natural history of the syndrome. Examples include the distinction between 
community and hospital-acquired AKI, any influence of the causes of AKI on outcomes, 
and recovery patterns following the AKI episode including repeat AKI episodes. Above 
all else, the detail in this study has helped draw a clear distinction between those with 
and without pre-existing CKD who sustain an AKI. This was recently highlighted by 
KDIGO as a research priority 
48. An additional strength of this study is that it has 
facilitated the exploration of AKI research methodology. To date this has not been 
studied in detail in a prospective manner. 
 
As with any study there are also weaknesses. This is a single centre study in a largely 
Caucasian UK population and therefore the results may not be generalisable to every 
population. The sample size was also limited. Queen Alexandra Hospital is a large 
district general hospital and does not have a number of specialist services onsite. In 
particular there is no cardiothoracic service and it does not offer trauma services. This 
could have influenced the case mix and the outcomes reported. The AKI group in this 
study lacked a control group. However this study was designed to explore the natural 
history of recovery of function and the factors influencing this and so a control group 
was not necessary per se.  
 
The definition of AKI relied on the measurement of serum creatinine which is an 
imperfect marker of renal function. However, there is currently no better alternative. 
The definition of baseline kidney function has been highlighted as an important aspect 
of AKI research design however this inevitably results in missing patients who have no 
baseline available. These patients are likely to be younger and fitter. This also limits 
the generalisability of the results. Patients in this study were followed up at a single 
time point and it may be argued that it cannot be proven that any failure to recover 
found was sustained. In addition, a single follow up measurement may be confounded 
by intra-individual variation. To address the problem that intra-individual variation may 
have affected the findings, this study explored several different definitions of recovery. 
Intra-individual variation is unlikely to have influenced the extended definition using a 
fall in eGFR of 10mls/min and even less so when a fall in eGFR of 25% was used.  
 
In order to prevent the study cohort being saturated with milder AKIN stage 1, random 
sampling of this group was undertaken. This will not have influenced the primary aim 
of this study to explore the recovery of function. However it does mean that some of 
the findings in this study need to be interpreted with caution. For example, the overall 
mortality for each group is likely to overestimate the true mortality figure associated 
with AKI because the milder cases have been removed. In addition there were Mark Uniacke    Chapter 8     
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considerable losses during the recruitment phase of this study. It was shown in 
Chapter 5 that close to a third of patients in each group were discharged and so could 
not be assessed. It is therefore uncertain what happens to this group in terms of 
mortality or recovery of function. Finally, the design of this study allowed only for 
recruitment of patients who had an AKI that resulted in an eGFR < 60. It is possible 
that some patients may have had an AKI above this threshold. For example, a fall in 
eGFR from 90 to 65 may also be clinically significant but will not have been recorded in 
this study.  
 
8.9 Future Research Directions 
 
The field of AKI is rapidly evolving and numerous areas requiring further investigation 
and research have been identified during the course of this study. Some of the more 
important areas are summarised here: 
1.  The use of RAS blockers in this population needs to be further explored. It 
appears from the literature that RAS blockers increase the risk of AKI. However 
this study has raised several important questions. Do RAS blockers influence 
long-term outcomes in this group? Should they be restarted after an AKI 
episode and in whom? This study identified a possible protective effect in terms 
of mortality in the AKI/CKD group and yet it was found that RAS blockers were 
not restarted in a large proportion of patients. In addition a possible adverse 
effect on functional recovery was identified in the AKI group. What if any is the 
meaning of this?  
2.  This study identified the possible important influence of repeat AKI episodes in 
this population. This area needs further exploration as it may be a key aspect 
of CKD progression in the general population.  
3.  The definition of recovery of function needs further work. Most importantly 
work needs to be done to identify what levels of failure to recover are clinically 
meaningful in order to be applied in AKI clinical trials. This could involve 
looking longer term in those who have not recovered function to assess 
mortality outcomes.  
4.  The influence of different relative changes in serum creatinine in those with 
CKD need to be explored further. In this study recovery of function was 
significantly better in the AKI/CKD group. Is this because there are different 
pathological processes in play or is it because the relative changes in function 
expressed by creatinine reflect injury differently in those with and without CKD?  
5.  This study has highlighted the need for a better marker of renal injury than 
serum creatinine alone. This work is ongoing in many centres.  Mark Uniacke    Chapter 8     
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6.  This study clearly demonstrated an increased length of hospital stay in the 
AKI/CKD group compared to controls. This raises several questions. Are 
patients remaining in hospital simply to wait for their creatinine to fall and 
could this be modifiable? Would a nephrology review facilitate earlier 
discharge? Could patients be discharged earlier before the creatinine has 
settled and leave follow up for primary care? This area needs to be explored 
further as it may reduce the burden of AKI on the healthcare system.  
 
8.11 Final Summary 
 
This study has demonstrated that recovery of function is incomplete after 6 months 
follow up in a substantial portion of hospitalised patients who have sustained an AKI. 
In those without pre-existing CKD stage 3-5 21% experienced a fall in eGFR of at least 
25% while in those with CKD stages 3-5 15% experienced a fall of at least 25% in eGFR. 
AKI is therefore contributing to the incident CKD population and to the progression of 
CKD. In addition this study has demonstrated a pattern of repeat admissions and 
repeat AKI episodes in these patients. There may be a cumulative effect in terms of 
loss of function and it lends some support to the theory of Bedford et al that 
progression of CKD at least in some may be due to step-downs in function as a result 
of repeated AKI episodes. AKI may be an important marker of CKD progression in 
much the same way as proteinuria. This has important practice implications. It 
highlights the importance of AKI prevention and management not only in hospital but 
also in the community. In addition, it raises important questions regarding the follow 
up of these patients in the aftermath of their AKI episode.  
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Appendix 1 
 
The strategy used to carry out a broad search of the Medline and Embase databases 
for studies relevant to the natural history of AKI.  
 
1)  incidence.tw 
2)  cause$.tw 
3)  aetiology.tw 
4)  (risk adj factor$).tw 
5)  definition.tw 
6)  classification.tw 
7)  progression.tw 
8)  survival.tw 
9)  (follow adj up).tw 
10) outcome$.tw 
11) (recovery adj3 function).tw 
12) mortality.tw 
13) or/1-12 
14) kidney failure, chronic/ 
15) chronic kidney disease.mp 
16) 14 or 15 
17) 13 or 16 
18) 18 exp Acute kidney injury/ 
19) 19 exp Kidney tubular necrosis, acute/ 
20) 18 or 19 
21) 17 and 20 
22)  limit 21 to (humans and yr=”1990-2011” and “all adult(19 plus years) and 
journal article) 
 
 
 
!Mark Uniacke    Appendix 2     
        266 
Appendix 2 
 
42 different definitions of AKI found in observational research between 1990 and 
2011. Creatinine (Creat.) expressed in  mol/l or mg/dl. Some of these were unique to 
the particular study while others have been used in more than one study. 
 
 
Author (Year) 
 
 
Definition of AKI 
Gentric et al (1991)
19  Rise in Creat. to > 120  
Tran et al (1993)
100  Rise in Creat. to > 280 or twofold rise if 
history of CKD present 
Feest et al (1993)
101  Rise in Creat. to > 500 
Bhandari et al (1996)
102  Rise in Creat. to > 600 or RRT 
Neveu et al (1996)
103  Rise in Creat. to > 310 or 100% increase if 
CKD present 
Khan et al (1997)
104  Rise in Creat. to > 300 
Barreti et al (1997)
2  Rise in Creat. by > 30% 
Baraldi et al (1998)
21  Rise in Creat. to > 2.0 or twofold rise if 
history CKD present 
Behrend et al (1999)
105  Rise by at least 0.9 to at least 2.0 if 
baseline < 2.0 or rise by 1.5 if baseline > 
2.0 
Kohli et al (2000)
106  Rise in Creat. to > 178 or if CKD present a 
rise > 132.6 
Obialo et al (2000)
107  Rise in Creat. by 0.5 to at least 2.0 
Guerin et al (2000)
108  Rise in Creat. to > 300 or urine output < 
500mls/24hrs or need for RRT 
Stevens et al (2001)
35  Rise in Creat. to > 300 and/or a rise in urea 
to > 40 or a 50% rise in Creat. if CKD 
present and baseline < 250 
Nash et al (2002)
8  Stratified starting from a rise of 0.5 if 
baseline < 1.9 
Koreny et al (2002)
109  Urine output < 20mls/hr and 50% rise in 
Creat. 
Sesso et al (2004)
110  Rise in Creat. by > 0.5 
Mehta et al (2004)
43  Rise in Creat. > 0.5 if baseline < 1.5 or a 
rise > 1.0 if baseline 1.5 to 5.0 Mark Uniacke    Appendix 2     
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Author (Year) 
 
 
Definition of AKI 
Yegenaga et al (2004)
25  Rise in Creat. to > 2.0 
Loef et al (2005)
111  Rise in Creat. by > 25% 
Uchino et al (2005)
112  RRT or a rise in Urea to > 30 
Franceschini et al (2005)
113  Rise in Creat. by 0.5 if baseline < 2.0, by 
1.0 if baseline 2 to 4.9 or by 1.5 if baseline 
> 5.0 
Thakar et al (2005)
114  30% decline in GFR 
Thakar et al (2007)
14  > 50% fall in GFR 
Kheterpal et al (2007)
115  At least a 37.5% fall in Cr/Cl to < 
50mls/min 
Thakar et al (2007)
116  A rise in Creat. > 50% 
Bagshaw et al (2007)
16  A rise in Creat. to > 133 or urine output < 
410mls/24hrs 
Weisbord et al (2008)
117  Stratified by % rise in Creat. from 25 to 
100% 
Welten et al (2008)
118  > 10% fall in Cr/Cl 
Oppert et al (2008)
119  Rise in Creat. by 100% 
Lo et al (2009)
120  RRT and at least a 50% rise in Creat. 
Khosla et al (2009)
121  Rise in Creat. > 0.5 if baseline < 1.5 or by > 
1.0 if baseline > 1.5 
Tian et al (2009)
22  Rise in Creat. > 0.3 
Mehta et al (2010)
122  Risein Creat. by > 50% or by 0.7 
Engleberger et al (2010)
123  Rise in Creat. by > 2.0 and at least twofold 
from baseline 
Van Kuijk et al (2010)
124  Decline in CKD-EPI eGFR by > 10% 
La France et al (2010)
125  Fall in GFR of 25% or by > 5mls/min 
Ali et al (2011)
126  25% rise in Urea or Creat. or Creat. rise to > 
1.5 or Urea rise to > 55 in 24 hrs 
Broce et al (2011)
23  Rise in Creat. by increments of 0.1 
Ishani et al (2011)
127  Stratified by % rise in Creat. 
Multiple studies  RRT requirement 
Multiple studies  RIFLE definition 
Multiple Studies  AKIN definition 
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Appendix 3 
 
Summary of publications with comparison of the RIFLE Classification and AKIN 
definition of AKI. The table includes the numbers of patients in each study together 
with the percentage with AKI as defined by each definition. In addition the AuROC for 
predicting mortality for each definition is included where available. 
 
 
Author 
(Year) 
 
Country 
 
Setting 
 
Number of 
patients 
 
AKI – 
RIFLE (%) 
 
AKI-AKIN 
(%) 
 
Mortality 
ROC-RIFLE 
 
Mortality 
ROC-AKIN 
 
Bagshaw 
(2008)
138 
 
Australia/New 
Zealand 
 
General ITU 
 
120,123 
 
36.1 
 
37.1 
 
0.66 
 
0.67 
Lopes  
(2008)
139 
Portugal  General ITU  662  43.8  50.4  0.93  0.97 
Joannidis 
(2009)
140 
International 
(SAPS 3) 
General ITU  14,356  35.5  28.5  _  _ 
Jiang  
(2011)
141 
China  General ITU  524  18.1  25.8  0.73  0.78 
Kim  
(2012)
142 
Korea  Sepsis/Septic 
Shock ITU 
291  62.9  65.6  _  _ 
Haase  
(2009)
143 
Australia  Post Cardiac 
Surgery 
282  45.8  44.7  0.91  0.94 
Robert 
(2010)
144 
USA  Post Cardiac 
Surgery 
24747  31  30  0.78  0.79 
Yan  
(2010)
145 
China  Post Cardiac 
Surgery 
67  81  85  0.74  0.80 
Engleberger 
(2011)
146 
USA  Post Cardiac 
Surgery 
4836  18.9  26.3  0.80  0.82 
Ando  
(2010)
147 
Japan  Post HSCT  249  52.6  46.6  0.65  0.64 
Han  
(2011)
148 
China  Haemorrhagic 
Fever 
120  79.2  82.5  _  _ 
Garner 
(2012)
149 
UK  General 
Hospital 
1315  7.1  9.5  _  _ Mark Uniacke    Appendix 4     
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Appendix 4 
 
Observational studies using the AKIN definition since its introduction in 2007. Study 
type is given as retrospective or prospective. Studies using variants of the AKIN 
definition are noted as ‘adapted’ or unclear.  
 
 
Author (Year) 
 
Study Type 
 
Setting 
 
AKIN Criteria 
Used 
 
Stable 
Baseline 
Reference 
Y/N 
 
 
Urine Output 
Y/N 
 
Volume Status 
Assessed Y/N 
Massoudy 
(2008)
151 
Retrospective  Cardiac Surgery  AKIN  Y  N  N 
Arora 
(2008)
152 
Retrospective  Cardiac Surgery  Adapted  Y  N  N 
Ostermann 
(2008)
137 
Retrospective  ITU  AKIN  N  N  N 
Parikh  
(2008)
153 
Retrospective  Acute M.I.  Adapted  N  N  N 
Abelha  
(2009)
154 
Retrospective  Post surgery  AKIN  Y  Y  N 
Barrantes 
(2009)
24 
Retrospective  General 
Hospital 
AKIN  N  N  N 
Thakar  
(2009)
155 
Retrospective  ITU  Adapted  N  N  N 
Machado 
(2009)
156 
Retrospective  ITU  AKIN  N  N  N 
Zhu  
(2010)
157 
Retrospective  Post Liver 
Transplant 
Unclear  N  N  N 
James  
(2010)
158 
Retrospective  Post 
angiography 
Adapted  Y  N  N 
Gude  
(2010)
159 
Retrospective  Post Heart 
Transplant 
Adapted  Y  N  N 
Brown 
(2010)
160 
Retrospective  Cardiac Surgery  Adapted  Y  N  N 
Kramer 
 (2010)
161 
Retrospective  Cardiac Surgery  Adapted  Unclear  N  N 
Swaminathan 
(2010)
162 
Retrospective  Cardiac Surgery  Adapted  Y  N  N 
Coca  
(2010)
163 
Retrospective  Post surgery  Adapted  Y  N  N 
Anzai  
(2010)
164 
Prospective  Acute M.I.  Adapted  N  N  N 
La France 
(2010)
9 
Retrospective  VA hospital 
admissions 
Adapted  N  N  N Mark Uniacke    Appendix 4     
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Author (Year) 
 
Study Type 
 
Setting 
 
AKIN Criteria 
Used 
 
Stable 
Baseline 
Reference 
Y/N 
 
 
Urine Output 
Y/N 
 
Volume Status 
Assessed Y/N 
Choi  
(2010)
165 
Retrospective  HIV Register  Adapted  Y  N  N 
Fonseca 
(2011)
166 
Retrospective  ITU  AKIN  N  Y  N 
Li  
(2011)
167 
Retrospective  Cardiac Surgery  AKIN  Y  N  N 
Pannu  
(2011)
168 
Retrospective  General 
Hospital 
Adapted  Y  N  N 
Mithani 
(2011)
169 
Retrospective  Cardiac Surgery  AKIN  Unclear  N  N 
Mandelbaum 
(2011)
170 
Retrospective  ITU  AKIN  N  Y  N 
Thakar  
(2011)
34 
Retrospective  US VA 
Diabetics 
Adapted  N  N  N 
Lombardi 
(2011)
171 
Retrospective  ITU ventilated 
patients 
AKIN  N  N  N 
Medve 
 (2011)
172 
Prospective  ITU  AKIN  N  Unclear  N 
Mori  
(2011)
173 
Retrospective  Aortic Arch 
Surgery 
AKIN  Y  N  N 
Meier  
(2011)
174 
Retrospective  General 
Hospital 
AKIN but 
unclear 
Y  Unclear  N 
Lakhal 
 (2011)
175 
Retrospective  ITU contrast  AKIN  Y  N  N 
Minejima 
(2011)
176 
Prospective  Vancomycin 
patients 
AKIN  Y  N  Y 
Bucovi  
(2011)
177 
Retrospective  ATN cases  AKIN but 
unclear 
N  Y  N 
Martin-Loech 
(2011)
178 
Prospective  ITU  AKIN  N  N  N 
Li  
(2011)
179 
Retrospective  Neuro ITU  AKIN  N  Unclear  N 
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Appendix 5 
 
Table illustrating the 30 different definitions of baseline renal function in use in the 
AKI literature over the past decade. Some of these definitions were used in more than 
one study. 
 
 
Author (Year) 
 
 
Definition of baseline kidney function. 
Obialo (2000)
107  Any serum creatinine < 150μmol/l in the previous 12 months 
defined as normal. 
 
Nash (2002)
8  Lowest in hospital serum creatinine. 
 
Sesso (2004)
110  Any previously normal serum creatinine with no timeframe 
specified. 
 
Yegenaga (2004)
25  The creatinine on the first day of sepsis in septic patients if < 
2mg/dl. 
 
Abosaif (2005)
181  Lowest in hospital serum creatinine or from records up to three 
months before admission. 
 
Hoste (2006)
182  A back estimate using eGFR 75mls/min if no history of CKD or the 
lowest of the hospital admission creatinine or ITU admission 
creatinine. 
 
Uchino (2006)
183  The last hospital discharge serum creatinine or a back estimate 
using an eGFR of 75mls/min. 
 
Kheterpal (2007)
115  A pre-operative serum creatinine within 30 days of surgery. 
 
Coca (2007)
185  The lowest serum creatinine within 5 days of hospital admission. 
 
Cruz (2007)
186  Any pre-morbid serum creatinine without specified timeframe or a 
back estimate using an eGFR of 75mls/min. 
 
Ali (2007)
187  A serum creatinine in the previous 6 months or the recovery level. Mark Uniacke    Appendix 5     
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Author (Year) 
 
 
Definition of baseline kidney function. 
Weisbord (2008)
117  The most recent outpatient serum creatinine within 60 days of 
admission. 
 
Lopes (2008)
139  A back estimate using an eGFR of 75mls/min for all patients. 
 
Hsu (2009)
188  The last outpatient eGFR before admission with no specified 
timeframe. 
 
Kheterpal (2009)
184  A pre-operative serum creatinine within 90 days of surgery. 
 
Bihorac (2009)
189  The lowest of either the lowest measured serum creatinine at 
hospital admission or a back estimate using an eGFR of 
75mls/min. 
 
Kwon (2010)
190  Either the last hospital discharge serum creatinine, the last 
outpatient serum creatinine or the lowest in hospital serum 
creatinine. 
 
Hata (2010)
191  With a history of CKD the lowest in hospital value otherwise a back 
estimate using an eGFR of 75mls/min. 
 
Bennet (2010)
192  The discharge serum creatinine level. 
 
Anzai (2010)
164  The admission serum creatinine level. 
 
La France (2010)
9  The lowest serum creatinine between 3 months before the index 
admission and hospital discharge. 
 
Choi (2010)
165  The most recent outpatient serum creatinine with no timeframe 
specified or the first creatinine on admission. 
 
James (2010)
158  The last outpatient serum creatinine within 6 months of 
admission. 
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Author (Year) 
 
 
Definition of baseline kidney function. 
Murugan (2010)
31  A known pre-morbid serum creatinine with no specified timeframe 
or the lower of either a back estimate using eGFR 75mls/min or 
the lowest creatinine during admission. 
 
 
Palmieiri (2010)
193  The earliest available creatinine available on admission. If this was 
elevevated with no preadmission level then a back estimate using 
eGFR 75mls/min was used. 
 
Engleberger 
(2010)
124 
The last serum creatinine before surgery. 
 
Pannu (2011)
168  The mean eGFR from all outpatient serum creatinines within 6 
months of admission. 
 
Meier (2011)
174  The last outpatient value more than 30 days before the index 
admission or the average of all values between 30 and 365 days 
before admission. 
 
Bucaloiu (2012)
194  The lowest serum creatinine between three months before 
admission and 30 days after discharge. 
 
Plataki (2011)
195  A value within the last three months of admission or a back 
estimate using eGFR 75mls/min. 
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Appendix 6 
 
Summary of the observational studies reviewed from 1990 onwards which contain 
figures for the risk/incidence of AKI in various populations and where available the % 
requiring renal replacement therapy. Study type is single center, multicenter (Multi) or 
derived from a database (Data). Mean age and % male is included where available. A 
basic summary of the definition used is provided. In addition, where the information is 
available, there is confirmation if patients with CKD were fully included in the cohort 
and their proportion of the total. Missing data was either not provided in the 
publication or was unclear. 
 
Author 
(Year) 
Country  Study 
Type 
Setting  Patient 
Number 
Mean 
Age 
% 
Male 
Definition 
summary 
CKD 
Y/N 
Incidence 
/Risk 
RRT 
Kaufman 
(1991)
206 
USA  Single  Community  100      Cr. rise > 
177 
Y  1% of 
admissions 
 
Metha 
(2010)
122 
USA  Single  Cardiac 
Surgery 
10415  68  70  Cr. Rise > 
50% 
N  20%   
Elhmidi 
(2011)
207 
Germany  Single  AV valve 
implants 
234  82  33  RIFLE  Y  19.6%  10.3% 
Nash  
(2002)
8 
USA  Single  Hospital  4622    54  Cr. rise by 
0.5 
Y  
45% 
7.2%   
Yegenaga 
(2004)
25 
Belgium  Single  ITU sepsis  217  65  72  Cr. Rise > 
177 
N  13%  45% of AKI 
Thakar 
(2007)
14 
USA  Single  Cardiac 
Surgery 
31677      50% fall in 
eGFR 
Y  
42% 
5.9%  1.8% 
Coca 
(2007)
185 
USA  Single  Burns  304  45  68  RIFLE  N  26.6%   
Engleberger 
(2010)
123 
USA  Single  Cardiac 
Surgery 
12096  68  71  RRT or 
rise x 2 
N  6%  2.1% 
Pannu 
(2011)
168 
Canada  Data  Community 
+ Hospital 
43008      AKIN  Y 33%  18.3%   
Koreny 
(2002)
109 
Austria  Single  Cardiogenic 
shock 
118    67  Cr. Rise > 
50% 
Y  33%   
Cole  
(2000)
208 
Australia  Multi  ITU  135  63  66  Need for 
RRT 
Y    13.4/ 
100,000/yr 
Guerin 
(2000)
108 
France  Multi  ITU  14116  64  65  Cr. Rise to 
> 300 
Y  7.7%   Mark Uniacke    Appendix 6     
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Author 
(Year) 
Country  Study 
Type 
Setting  Patient 
Number 
Mean 
Age 
% 
Male 
Definition 
summary 
CKD 
Y/N 
Incidence 
/Risk 
RRT 
Falvo 
(2008)
209 
USA  Single  Cardiac 
Surgery 
1085        Y  37%  2% 
Kheterpal 
(2007)
115 
USA  Single  Surgery  15102  59  56  CrCl < 50  N  0.8%  0.1% 
Kheterpal 
(2009)
184 
USA  Data  Surgery  75952  65  57  Rise > 
2mg/dl 
Y  1%   
Bihorac 
(2009)
189 
USA  Single  ITU Surgery  10518  62  56  RIFLE  N  32%  6% 
Gaudino 
(2005)
210 
Italy  Single  Cardiac 
Surgery 
6542  75  42  RRT  Y 
44.9% 
  1.1% 
Brown 
(2010)
160 
USA  Single  Cardiac 
Surgery 
4837  67  71      39%   
Kramer 
(2010)
161 
USA  Single  Cardiac 
Surgery 
668      AKIN    45%  1.5% 
Swaminathan 
(2010)
162 
USA  Single  Cardiac 
Surgery 
1113  72  66  AKIN  N  10.8%   
Licker  
(2011)
211 
Swiss  Single  Lung 
Surgery 
1345  67  80  RIFLE    6.8%   
Mithani 
(2011)
169 
USA  Single  Cardiac 
Surgery 
2104      AKIN  N  24%   
Kagoya 
(2011)
212 
Japan  Single  Stem cell 
transplants 
207      RIFLE    76.3%   
Obialo 
(2000)
107 
USA  Single  Community 
+ Hospital 
100      Cr. rise by 
0.5 
N  0.69%   
Weisbord 
(2008)
117 
USA  Single  Contrast 
AKI 
421  69  96 
VA 
% rise  Y  7.7%  0.2% 
Parikh 
(2008)
153 
USA  Data  Acute MI  147007      AKIN  Y  19.4%   
Ishani  
(2011)
127 
USA  Data  Cardiac 
Surgery 
29388      % Rise  Y  32%   
Machado 
(2009)
156 
Brasil  Data  Cardiac 
Surgery 
817  61  65  AKIN  Y  48.5%  7.8% 
Fang 
(2010)
213 
China  Single  Community 
+ Hospital 
176155      AKIN    3.19%   
Garzotto 
(2011)
214 
Italy  Multi  ITU  576  66  59  RIFLE  Y  65.7%  8,3% Mark Uniacke    Appendix 6     
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Author 
(Year) 
Country  Study 
Type 
Setting  Patient 
Number 
Mean 
Age 
% 
Male 
Definition 
summary 
CKD 
Y/N 
Incidence 
/Risk 
RRT 
Swaminathan 
(2007)
17 
USA  Data  Cardiac 
Surgery 
10275      Coded  N  3.95%   
Ostermann 
(2007)
11 
UK/ 
Germany 
Data  ITU  41972      RIFLE  Y  35.8%   
Barrantes 
(2008)
136 
USA  Single  ITU  471  69  50  AKIN    31.5%   
Thakar 
(2009)
155 
USA  Data  ITU  325395      AKIN  Y  
38% 
22%  0.9% 
Marenzi 
(2010)
215 
Italy  Single  Cardiogenic 
Shock 
97  69  71  RIFLE  Y  55%  13.4% 
Mandelbaum 
(2011)
170 
USA  Single  ITU  14524      AKIN  Y  57%   
Li  
(2011)
167 
Taiwan  Single  Cardiac 
Surgery 
964      AKIN  Y  19.8%  7% 
Hata  
(2010)
191 
Japan  Single  ITU Heart 
Failure 
376  73  57  RIFLE  Y  
18% 
73%   
Tallgren 
(2007)
216 
Finland  Single  AAA 
Surgery 
69  72  87  RIFLE  N  22%   
Bennet 
(2010)
192 
UK 
Scotland 
Data  Fractured 
Femur 
177  85  48  RIFLE  Y  16%   
Loef  
(2005)
111 
Holland  Single  Cardiac 
Surgery 
843  65  74  Cr. Rise of 
25% 
Y  17.2%   
Uchino 
(2005)
112 
Inter-
national 
Multi  ITU  29269  67  64  RRT or 
urea > 30 
Y  5.7%  4.2% 
Anzai  
(2010)
164 
Japan  Single  Acute MI  195  69  77  AKIN  Y  22%   
Li  
(2010)
217 
China  Single  Pancreatitis  228  57  60  Cr. rise > 
177 
Y  18.4%   
Fonseca 
(2011)
166 
Colombia  Single  ITU  794      AKIN  Y  39.8%  12.4% 
Hoste  
(2003)
218 
Belgium  Single  ITU Surgical  185  62  66  Cr. Rise > 
2.0 
Y  16.2%   
Ali  
(2007)
187 
UK 
Scotland 
Multi  Community 
+ Hospital 
562  76  54  RIFLE  Y  
16% 
2147 pmp  8% of AKI 
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Author 
(Year) 
Country  Study 
Type 
Setting  Patient 
Number 
Mean 
Age 
% 
Male 
Definition 
summary 
CKD 
Y/N 
Incidence 
/Risk 
RRT 
Ishani  
(2009)
42 
USA  Data  Community 
+ Hospital 
233803  80  48  Code  Y 
34.3% 
3.1%    
Grams 
(2010)
30 
USA  Data  Community 
+ Hospital 
11,200  65  52  Code  Y  
28% 
4/1000 pt 
years 
 
La France 
(2010)
9 
USA  Data  Community 
+ Hospital 
82711  66  97 
VA 
AKIN  Y  9.6%   
Liano  
(1996)
20 
Spain  Multi  Community 
+ Hospital 
748      Cr. rise > 
177 
N  209pmp/yr   
Behrend 
(1999)
105 
USA  Single  Coronary 
Care 
106  69  53  Cr. Rise > 
2.0 
Y  
21% 
4%   
Clermont 
(2002)
219 
USA  Single  ITU  254  59    Cr. rise by 
0.5 
Y  17.2%  11% 
Franceschini 
(2005)
113 
USA  Single  HIV  754    80  Cr. rise by 
0.5 
Y  5.9/1000 
person yrs 
 
Thakar 
(2005)
114 
USA  Single  Cardiac 
Surgery 
31677      Fall in GFR 
by 30% 
Y  17.4%  1.7% 
Feest  
(1993)
101 
UK  Multi  Community 
+ Hospital 
125    72  Cr. Rise > 
500 
  140.5pmp   
Palmieri 
(2010)
193 
USA  Single  ITU  
Burns 
60  46  82  RIFLE    53.3%   
Akram 
(2010)
220 
UK 
Scotland 
Single  Community 
Pneumonia 
1241      RIFLE  Y  18%  2.4% 
Hobson 
(2009)
221 
USA  Single  Cardiac 
Surgery 
2973  64  63  RIFLE  N  43%  6% 
Karkouti 
(2009)
222 
Canada  Multi  Cardiac 
Surgery 
3460      RIFLE  Y  34%   
James  
(2011)
33 
Canada  Data  Coronary 
angio 
14782      AKIN  Y  9.6%   
Chertow 
(1997)
223 
USA  Multi  Cardiac 
Surgery 
43642      RRT  N    1.1% 
Thakar 
(2011)
34 
USA  Single  Diabetes  3679      AKIN  N  29%   
Liangos 
(2006)
224 
USA  Data  Community 
+ Hospital 
29 
million 
73  52  Codes  Y  1.9%  7.5% of AKI 
Thakar 
(2007)
116 
USA  Single  Gastric 
Surgery 
491  43  17  Cr. Rise > 
50% 
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Author 
(Year) 
Country  Study 
Type 
Setting  Patient 
Number 
Mean 
Age 
% 
Male 
Definition 
summary 
CKD 
Y/N 
Incidence 
/Risk 
RRT 
Cruz  
(2007)
186 
Italy  Multi  ITU  2164      RIFLE  Y  10.8%  30.3% of 
AKI 
Arora  
(2008)
152 
USA  Multi  Cardiac 
Surgery 
1358  69  79  AKIN    40.2%   
Mittalhenkle 
(2008)
225 
USA  Data  Elderly  5731  75  63  Codes  N  3.9% over 
10 years 
 
Hsu  
(2009)
188 
USA  Data  Community 
+ Hospital 
39805  67  57  RRT  Y    2.7% 
Van Kuijk 
(2010)
124 
Holland  Single  Vascualr 
Surgery 
1308  64  72  > 10%fall 
in CKD-EPI 
N  38%   
Plataki 
(2011)
195 
USA  Single  ITU 
Septic 
390  68  54  RIFLE  N  61%   
Broce  
(2011)
23 
USA  Single  Hospital 
only 
29645      AKIN  Y  15.3%   
Lombardi 
(2011)
171 
Multi-
national 
Data  ITU 
Ventilation 
2783  61  64  AKIN  Y  28.8%   
Gude  
(2010)
159 
Norway  Single  Heart 
Transplants 
585  52    AKIN  Y  25%  12% 
Bagshaw 
(2005)
226 
Canada  Multi  ITU  5693  67  60  RRT  Y  11/100000 
/yr or 4.2% 
 
Hoste  
(2006)
182 
USA  Single  ITU  5383  63  56  RIFLE  Y  67%  4.1% 
Ostermann 
(2008)
137 
UK/ 
Germany 
Data  ITU  7898  62    AKIN  Y  35.4%   
Lopes  
(2008)
139 
Portugal  Single  ITU  662  64  66  AKIN  Y  50.4%   
Bagshaw 
(2008)
227 
AusNZ  Data  ITU 
Septic 
14039  67  55  RIFLE  Y  42.1%   
Clec’h 
(2011)
12 
France  Data  ITU  8639  66  59  RIFLE  Y  32.9%  19% 
Silvester 
(2001)
228 
Australia  Multi  ITU  299  61  70  RRT  Y 
34.1% 
  8/100000/ 
year 
Metnitz 
(2002)
229 
Austria  Data  ITU  17126  63    RRT  N    4.9% 
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Author 
(Year) 
Country  Study 
Type 
Setting  Patient 
Number 
Mean 
Age 
% 
Male 
Definition 
summary 
CKD 
Y/N 
Incidence 
/Risk 
RRT 
Choi  
(2010)
165 
USA  Data  HIV  17325      AKIN  Y  18%   
James  
(2010)
230 
USA  Data  Coronary 
angio 
11249    67  AKIN  Y  7.6%   
Coca  
(2010)
163 
USA  Data  Surgery 
Diabetic 
35302      AKIN  Y  17.8%   
Murugan 
(2010)
31 
USA  Multi  Community 
Pneumonia 
1836  73  51  RIFLE  Y  34%   
James  
(2010)
231 
Canada  Data  Community 
+ Hospital 
920985      Code  Y  0.7%  <0.01% 
Tran  
(1993)
100 
Holland  Single  Pancreatitis  267  60  57  Cr. Rise to 
> 280 
Y  16%   
Kolli  
(2010)
232 
USA  Multi  Cardiac 
Surgery 
1359      AKIN  Y 
20.4% 
40.2%  15.2% 
vanNoorgate 
(2003)
233 
Belgium  Single  Cardiac 
Surgery 
82      RRT  Y    2.3% 
Lin  
(2006)
234 
Taiwan  Single  ITU 
ECMO 
46      RIFLE  Y  78%  34.8% 
Prescott 
(2007)
44 
UK 
Scotland 
Multi  Hospital 
RRT 
809      RRT  Y  
25% 
  286pmp/ 
year 
Welten 
(2008)
118 
Holland  Single  Surgery  1944  68  78  Fall in 
CrCl >10% 
Y  34%  2.4% 
Bagshaw 
(2008)
10 
AusNz  Data  ITU  120123      RIFLE  Y  36.1%   
Oppert 
(2008)
119 
Germany  Multi  ITU 
Sepsis 
401  71  63  Cr. Rise 
by 100% 
Y  41.4%  4.2% of AKI 
La France 
(2010)
125 
Canada  Data  CKD  6862  68  55  Fall in GFR 
by 
5mls/min 
Y all  44.9% over 
19mts 
 
Uchino 
(2010)
180 
Australia  Single  Community 
+ Hospital 
3641  74  55  RIFLE  Y  18.1%  1% 
Kwon  
(2010)
190 
Korea  Single  Hospital  96  63  60  AKIN  Y  1.2%   
Hegarty 
(2005)
235 
UK  Multi  Community 
+ Hospital 
28  65  68  Cr. > 500 
Single org 
Y  
36% 
125pmp/ 
year 
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Author 
(Year) 
Country  Study 
Type 
Setting  Patient 
Number 
Mean 
Age 
% 
Male 
Definition 
summary 
CKD 
Y/N 
Incidence 
/Risk 
RRT 
Khan  
(1997)
104 
UK 
Scotland 
Single  Community 
+ Hospita 
310      Cr. Rise 
>300 
N  620pmp/ 
year 
 
Stevens 
(2001)
35 
UK  Multi  Community 
+ Hospital 
288  73  64  Cr. Rise 
>300 
N  545pmp/ 
year 
 
Metcalfe 
(2002)
236 
UK 
Scotland 
Multi  Hospital 
RRT 
89  71    RRT  Y    203pmp/ 
year 
Barretti 
(1997)
2 
Brasil  Single  Hospital  200  51  64  Cr. Rise 
by 30% 
  4.9/1000 
admissions 
51% 
Bagshaw 
(2008)
237 
AusNZ  Multi  ITU 
Trauma 
1711      RIFLE  Y  18.1%   
Abelha 
(2009)
154 
Portugal  Single  Surgery  1166  68  64  AKIN  N  7.5%   
Meier  
(2011)
174 
Swiss  Single  Hospital 
Non-critical 
4296  61  55  AKIN  Y  4.12%   Mark Uniacke    Appendix 7     
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Appendix 7 
 
Table A7. 1  Summary of contemporary AKI observational studies reporting incidences 
for the general hospital population. These studies used consensus definitions AKIN 
and RIFLE or Codes from hospital discharge summaries. 
 
 
Author 
(Year) 
 
 
Country 
 
Patient 
Number 
 
Definition 
 
CKD Incl. 
Y/N 
 
Incidence 
/Risk 
 
Incidence 
Rate 
 
RRT 
James 
(2010)
231 
 
Canada  920985  Coded  Y  0.7%  -  <0.01% 
Uchino 
(2010)
180 
 
Australia  3641  RIFLE  Y  18.1%  -  1% 
Liangos 
(2006)
224 
 
USA  29 million  Coded  Y  1.9%  -  - 
Ali 
(2007)
187 
 
UK 
Scotland 
562  RIFLE  Y 
16% 
-  2147pmp  8% of AKI 
Ishani 
(2009)
42 
 
USA  233803  Coded  Y 
34.3% 
3.1%  -  - 
LaFrance 
(2010)
9 
 
USA  82711  AKIN  Y  9.6%  -  - 
Pannu 
(2011)
168 
 
Canada  43008  AKIN  Y 
33% 
18.3%  -  - 
Fang 
(2010)
213 
 
China  176155  AKIN  -  3.19%  -  - 
Bedford 
(2011)
238 
UK  44266  AKIN  Y  5.7%  7007pmp  - 
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Table A7.2  Summary of contemporary AKI studies from the critical care setting that 
reported incidences. These studies applied the RIFLE or AKIN criteria.  
 
 
Author (Year) 
 
 
Country 
 
Patient 
Number 
 
Definition 
 
CKD Incl. 
Y/N 
 
 
Incidence 
/Risk 
 
Incidence 
Rate 
 
RRT 
Garzotto 
(2011)
214 
 
Italy  576  RIFLE  Y  65.7%  -  8.3% 
Ostermann 
(2007)
11 
 
UK/ 
Germany 
41972  RIFLE  Y  35.8%  -  - 
Barrantes 
(2008)
136 
 
USA  471  AKIN  -  31.5%  -  - 
Thakar (2009)
155 
 
USA  325395  AKIN  Y  22%  -  0.9% 
Mandelbaum 
(2011)
170 
 
USA  14524  AKIN  Y  57%  -  - 
Fonseca (2011)
166 
 
Colombia  794  AKIN  Y  39.8%  -  - 
Cruz 
(2007)
186 
 
Italy  2164  RIFLE  Y  10.8%  -  30.3% of 
AKI 
Hoste  
(2006)
182 
 
USA  5383  RIFLE  Y  67%  -  4.1% 
Ostermann 
(2008)
137 
 
UK/ 
Germany 
7898  AKIN  Y  35.4%  -  - 
Lopes  
(2008)
139 
 
Portugal  662  AKIN  Y  50.4%  -  - 
Clec’h  
(2011)
12 
 
France  8639  RIFLE  Y  32.9%  -  19% 
Bagshaw (2008)
10  AusNZ  120123  RIFLE  Y  36.1%  -  - 
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Table A7.3  Summary of contemporary studies focusing on AKI in specific patient 
groups in critical care. 
 
 
Author 
(Year) 
 
 
Country 
 
Patient 
Number 
 
Patient Type 
 
Definition 
 
 
CKD Incl. 
Y/N 
 
 
Incidence 
/Risk 
 
RRT 
Bihorac 
(2009)
189 
USA  10518  General 
Surgical 
RIFLE  N  32%  6% 
Licker 
(2011)
211 
Swiss  1345  Lung Surgery  RIFLE  -  6.8%  - 
Hata 
(2010)
191 
Japan  376  Heart Failure  RIFLE  Y  73%  - 
Palmieri 
(2010)
193 
USA  60  Burns  RIFLE  -  53.3%  - 
Plataki 
(2011)
195 
USA  390  Septic  RIFLE  N  61%  - 
Lombardi 
(2011)
171 
Multi-
national 
2783  Mechanical 
Ventilation 
AKIN  Y  28.8%  - 
Bagshaw 
(2008)
227 
AusNZ  14039  Septic  RIFLE  Y  42.1%  - 
Lin (2006)
234  Taiwan  46  On ECMO  RIFLE  Y  78%  34.8% 
Bagshaw 
(2008)
237 
AusNZ  1711  Trauma  RIFLE  Y  18.1%  - 
 
!
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Appendix 8 
 
Illustration of the division of the causes of AKI into prerenal, intrinsic and postrenal 
causes with examples. This list is by no means exhaustive (Sharfuddin 2011, KDIGO 
2012) 
 
 
     Prerenal causes of AKI 
 
 
   
Intravascular volume depletion  - haemorrhage 
  - burns  
  - gastrointestinal fluid losses e.g diarrhoea 
  - salt-wasting renal disease 
  - diuretics 
  - nephrotic syndrome 
  -  advanced liver disease 
-   
Reduced Cardiac Output  Any cause of myocardial dysfunction 
  - ischaemic heart disease and myocardial infarction 
  - arrhythmias 
  - valvular heart disease 
  - pulmonary disease e.g pulmonary embolism 
  - sepsis 
 
Systemic vasodilation  - drugs 
  - anaphylaxis 
  - sepsis 
  - advanced liver disease 
 
Renal Vasoconstriction  - Drugs eg. NSAIDS, Calcineurin inhibitors, ACE 
inhibitors, noradrenaline 
  - sepsis 
  - hepatorenal syndrome 
  - radiocontrast agents 
 
Mechanical occlusion of renal arteries  - thrombotic occlusion 
  - trauma 
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 Intrinsic causes of AKI 
 
   
Acute tubular necrosis (ATN)  e.g. prolonged prerenal ischaemia, toxins such as 
radiocontrast and aminoglycosides, pigmenturia 
with rabdomylosis 
 
Glomerulonephritis  e.g rapidly progressive glomerulonephritis due to 
vasculitis 
 
Interstitial nephritis  e.g drugs such as NSAIDS, Omeprazole or 
idiopathic such as TINU syndrome 
 
Infiltration  e.g sarcoidosis 
 
Infections  e.g malaria 
 
Intratubular Causes  e.g light chains 
   
    Postrenal causes of AKI   
   
Intrinsic obstruction of pelviureters  e.g. stones, tumours 
 
Extrinsic obstruction of pelviureters  e.g pelvic malignancy, retroperitoneal fibrosis 
 
Bladder obstruction  e.g. prostatic hypertrophy, bladder tumours 
 
Urethral obstruction  e.g. urethral stricture 
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Appendix 9 
 
Summary of thirteen prospective studies reviewed from the period 2000 - 2011 that 
reported causes contributing to the aetiology of AKI. The summary illustrates the 
diverse and overlapping reporting of aetiology in each cohort that makes it impossible 
to conduct any reasonable comparisons. 
 
 
Author 
(Year) 
 
 
Population 
 
AKI Definition 
 
Aetiology of AKI as reported 
       
Kwon  
(2010)
190 
Hospital 
acquired AKI 
 
AKIN 
 
Infection                                  30.2% 
      Reduced circulating volume       2.1% 
      Diuretics                                   31% 
      SIRS                                          24% 
      Sepsis                                        9.3% 
      ARB/ACEi                                   4.2% 
      Chemotherapy                           7.3% 
      Contrast                                    6.2% 
      Operation                               20.8% 
       
Guerin  
(2000)
108 
 
ITU 
Creat. > 300 or 
RRT 
 
Pre-renal                                    12% 
      Renal Artery Thrombosis             1% 
      Obstructive                                  2% 
      ATN            - Ischaemic              54% 
                         - Endogenous toxic   4% 
                         - Exogenous toxic    4% Mark Uniacke    Appendix 9     
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Author 
(Year) 
 
 
Population 
 
AKI Definition 
 
Aetiology of AKI as reported 
                         -  Mixed                  21% 
      Undetermined                              3% 
       
Cruz 
 (2007)
186 
 
ITU 
 
RIFLE 
 
Prerenal                                     38% 
      Sepsis                                      25.6% 
      Ischaemic   ATN                       14.5% 
      Contrast                                    0.4% 
      Nephrotoxic ATN                       5.6% 
      Other                                         5.1% 
       
Bagshaw 
(2005)
226 
 
ITU 
 
RRT 
 
Prerenal                                      15% 
      Intra-renal   85%     -   ATN          75%    
                                    -  Glomerular  5% 
                                    -  Interstitial   4% 
                                    -  Vascular    14% 
      Post-renal                                   0.4% 
       
Cole  
(2000)
208 
 
ITU   
 
RRT 
 
Ischaemia/Low BP                    40.6% 
      Sepsis                                        5.1% 
      Septic Shock                            45.8% 
      Rhabdomyolysis                         5.1% 
      Other                                         3.4% Mark Uniacke    Appendix 9     
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Author 
(Year) 
 
 
Population 
 
AKI Definition 
 
Aetiology of AKI as reported 
Kholi   
(2000)
106 
 
Elderly 
Creat.rise > 
176.8 
 
Drugs                                         66% 
      Sepsis                                      45.7% 
      Reduced renal perfusion          45.7% 
      Septic shock                              8.5% 
      Surgery                                   25.4% 
      Radiocontrast                          16.9% 
       
Prescott 
(2007)
44 
 
Hospital 
 
RRT 
 
Sepsis                                         48% 
      Hypotension                               25% 
      Post-surgical                            21.5% 
      Hypovolaemia                          22.6% 
      Toxins and drugs                     12.5% 
      Hepato-renal syndrome              7.5% 
      Myocardial infarction                 6.3% 
      Rhabdomyolysis                        5.6% 
      Glomerulonephritis                      3% 
      Obstruction                               5.2% 
       
Albright 
(2000)
250 
 
Hospital 
 
RRT 
 
Post-operative                             39% 
      Radiocontrast                             26% 
      Sepsis                                         18% 
      Atheroembolic                              8% Mark Uniacke    Appendix 9     
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Author 
(Year) 
 
 
Population 
 
AKI Definition 
 
Aetiology of AKI as reported 
      Prerenal                                      71% 
      Hepatorenal syndrome                12% 
      Multiorgan failure                    25.7% 
      Drug toxicity                               21% 
      Obtstructive                                  3% 
      Rhabdomyolysis                            3% 
       
Metcalfe 
(2002)
236 
 
Hospital 
 
RRT 
 
Sepsis                                         69% 
      Surgery                                       25% 
      Obstruction/hypotension         13.5% 
      Hypovolaemia                            9.6% 
      Pancreatitis/nephrotoxins             6% 
      Gastrointestinal haemorrhage       4% 
       
Nash  
(2002)
8 
 
Hospital 
 
Creat. Rise > 0.5 
 
Reduced renal perfusion          38.7% 
      Medications                                16% 
      Contrast                                   11.3% 
      Post-operative                            9.2% 
      Sepsis                                        6.6% 
      Liver-transplant                          3.7% 
      Heart – transplant                      2.1% 
      Obstruction                                1.8% 
      Hepato-renal syndrome              1.8% Mark Uniacke    Appendix 9     
        290 
 
Author 
(Year) 
 
 
Population 
 
AKI Definition 
 
Aetiology of AKI as reported 
      Rhabdomyolysis                            1% 
      Glomerulonephritis                    0.8% 
      Artifactual                                  0.8% 
      Nephrectomy                             0.8% 
      Interstitial nephritis                   0.5% 
      Atheroembolic                           0.5% 
      Hypercalcaemia                          0.5% 
       
Van 
Berendoncks 
(2010)
252 
 
ITU 
 
Creat. Rise > 2.0 
 
 
Pre-renal                                  49.7% 
      Renal (42.4%) :  ATN                 84.4% 
                               Acute GN          5.9% 
                               AIN                   4.7% 
                               Systemic Dis.    3.9% 
      Post-renal                                  0.8% 
      Acute on Chronic                          7% 
       
Piccinni  
(2011)
251 
 
ITU 
 
RIFLE 
 
Hypovolaemia                          29.5% 
      Sepstic shock                           13.5% 
      Surgery                                    12.1% 
      Cardiogenic shock                   11.8% 
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Author 
(Year) 
 
 
Population 
 
AKI Definition 
 
Aetiology of AKI as reported 
Liano   
(1996)
20 
General 
Hospital 
Creat. Rise to > 
177 
 
ATN                                            45% 
      Prerenal                                      21% 
      Obtructive                                  10% 
      Acute on Chronic                     12.7% 
      Interstitial nephritis                       2% 
      Vasculitis                                   1.5% 
      Vascular                                        1% 
      Primary glomerulonephritis        1.5% 
      Secondary glomerulonephritis    1.6% 
      Other                                         3.5% Mark Uniacke    Appendix 10     
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Appendix 10 
Summary of the risk factors for AKI provided by studies that have carried out adjusted 
analysis from the past decade. 
 
 
Author 
(Year) 
 
 
Setting and AKI definition 
 
Risk Factors for AKI 
 
Hoste 
(2003)
218 
ITU Septic Patients 
Creat. Rise to > 2.0mg/dl  
 
PH < 7.3 
 
Creatinine > 1.0mg/dl 
 
 
Bagshaw  
(2005)
226 
ITU 
Need for RRT 
Age ! 65 
Male Sex if ! 65 years 
Heart Disease 
Stroke 
COPD 
Diabetes 
Cancer 
Connective Tissue Disease 
CKD 
Alcohol abuse 
 
Gaudino 
(2005)
210 
Cardiac Surgery 
Need for RRT 
Age > 70 
Type of surgery 
Hypertension 
Vasculopathy 
 
Emergency surgery 
CPB time > 120 mins 
Preop. Creat > 2.1mg/dl 
Hoste  
(2006)
182 
ITU 
RIFLE 
Age 
CKD 
Medical admission 
Trauma 
GI Disease 
 
Malignancy 
SOFA Score 
Blacks for RIFLE Class Failure 
Kheterpal 
(2007)
115 
Surgery 
CrCl " 50mls/min 
Age 
Emergency surgery 
BMI 
Liver Disease 
 
High risk surgery 
Peripheral vascular Disease 
COPD 
Coca  
(2007)
185 
Burns 
RIFLE 
Inhalational Injury 
Catheter infection 
Sepsis 
 
Note: Age and female sex by 
univariate  analysis only 
Mittalhenkle 
(2008)
225 
Elderly > 65 years 
Cardiovascular  
Health Study 
ICD – 9 Codes 
CKD 
Age 
Male Sex 
Nonwhite Race 
 
Hypertension 
Diabetes 
Smoking 
Bagshaw 
(2008)
237 
 
ITU 
RIFLE 
Age > 65 
Female Sex 
Comorbid Disease 
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Author 
(Year) 
 
 
Setting and AKI definition 
 
   Risk Factors for AKI 
 
Hsu  
(2008)
271 
Hospitalised with history  
of CKD 
RRT 
 
Lower baseline GFR 
Diabetes 
Hypertension 
Proteinuria 
Kheterpal 
(2009)
184 
Surgery 
 
Age > 56 years 
Male Sex 
Emergency Surgery 
Type of surgery 
Diabetes 
 
CCF 
Ascites 
Hypertension 
CKD 
Karkouti 
(2009)
222 
Cardiac Surgery 
RIFLE 
Age 
BSA 
Diabetes 
Hypertension 
Atrial Fibrillation 
LV dysfunction 
 
Preop IABP 
CKD 
Anaemia 
Thrombocytopenia 
Blood Transfusion 
Marenzi 
(2010)
215 
Cardiogenic Shock post 
infarction 
Rise > 25% from baseline 
 
Age > 75 years 
LVEF < 40% 
Use of ventilation 
SOFA score 
Li 
 (2010)
217 
Severe Pancreatitis 
Creat. Rise > 177 
CKD 
hypoxaemia 
Acute coronary syndrome 
 
Elhmidi (2011)
207  Aortic valve implants 
RIFLE 
Preoperative serum 
creatinine level 
 
 
Fonseca 
(2011)
166 
ITU 
AKIN 
Age 
Sepsis 
Heart Failure 
Vasopressor use Mark Uniacke    Appendix 11     
        294 
Appendix 11 
 
Summary of the outcome data from the AKI observational studies reviewed that 
possessed a control group. Outcomes are expressed in terms of length of hospital stay 
(or ITU stay where stated) as well as in hospital mortality and follow up mortality. 
Where the information was provided the adjusted mortality risk for AKI is also given. 
 
 
Author (Year) 
 
 
Population 
Setting 
 
AKI 
Definition 
 
Length of Stay 
days 
 
Inhospital 
Mortality % 
AKI v Control 
 
Follow up 
mortality 
Yegenaga 
(2004)
25 
ITU 
Sepsis 
Rise > 
2.0mg/dl 
23 v 15  72 v 24  - 
Elhmidi 
(2011)
207 
AV Implants  RIFLE  11.7 v 8.7  15.2 v 7.7  35.6 v 14.3 at 
6mts 
Thakar (2007)
14  Cardiac Surgery  > 50% fall in 
GFR 
-  27.1 v 2.2  - 
Tian 
(2009)
22 
Medical 
Admissions 
AKIN  14 v 5  14.8 v 1.3  - 
Pannu (2011)
168  Hospital with 
CKD 
AKIN  -  24 v 4  - 
Koreny (2002)
109  Cardiogenic 
Shock 
50% rise in 
Creat. 
-  87 v 53 
Adjusted OR 6.5 
- 
Guerin (2000)
108  ITU  Cr. Rise > 
300 
-  66 v 15  - 
Falvo 
(2008)
283 
Cardio-thoracic 
ITU 
Used 6 
definitions 
21 v 8.6 in ITU  18 v 2  - 
Gaudino 
(2005)
210 
Cardiac Surgery  RRT  -  40.5 v 6.4  - 
Brown (2010)
160  Cardiac Surgery  AKIN  -  15.3 v 2.3  - 
Fang 
(2010)
213 
General 
hospital 
AKIN  -  19.68 v 2.84  - 
Garzotto 
(2011)
214 
ITU  RIFLE  7 v 3  in ITU  28.8 v 8.1 in ITU  - 
Palmieri 
(2010)
193 
Burns ITU  RIFLE  42 v 25  34.4 v 0 Adjusted 
OR for RIFLE F = 
3.21 
- Mark Uniacke    Appendix 11     
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Author (Year) 
 
 
Population 
Setting 
 
AKI 
Definition 
 
Length of Stay 
days 
 
Inhospital 
Mortality % 
AKI v Control 
 
Follow up 
mortality 
Liangos 
(2006)
224 
General 
hospital 
ICD -9 codes  7 v 3  21.3 v 2.3  - 
Cruz 
(2007)
186 
ITU  RIFLE  -  36.3 v 13.4 
Adjusted OR for 
RIFLE F = 4.9 
- 
Plataki (2011)
195  Septic 
Shock 
RIFLE  9 v 8.5  49 v 34  - 
Broce 
(2011)
23 
Hospital AKI  Rise from 
0.1 
8 v 4  14.8 v 1.7  - 
Lombardi 
(2011)
171 
ITU ventilated  AKIN  19 v 20  55 v 38 
Adjusted OR 1.65 
- 
Hoste (2006)
182  ITU  RIFLE 
 
9 v 6 
 
13.3 v 5.5 
Adjusted HR 1.7 
- 
Bagshaw 
(2007)
16 
ITU  Rise > 133  14 v 11  42.7 v 13.4 
Adjusted OR 1.23 
- 
Osterman 
(2008)
137 
ITU  AKIN  7 v 2 in ITU  40.4 v 16.9  - 
Lopes (2008)
139  ITU  AKIN 
 
-  39.8 v 8.5 Adjusted 
OR 3.59 
- 
Bagshaw 
(2008)
227 
ITU 
Septic 
RIFLE  17 v 12  29.7 v 12.6 
Adjusted OR 1.54 
- 
Clec’h (2011)
12  ITU  RIFLE  -  27.6 v 8.7  - 
Metnitz 
(2002)
229 
ITU  RRT  -  62.8 v 15.6  - 
Osterman 
(2007)
11 
ITU 
 
RIFLE 
 
- 
 
56.8 v 8.4 
Adjusted OR 
increased by RIFLE 
class 
- 
Barrantes 
(2008)
136 
ITU  AKIN  14 v 9  45.8 v 16.4 
Adjusted OR 3.7 
- 
Marenzi 
(2010)
215 
MI with shock  RIFLE  11 v 8  50 v 2.2 Adjusted 
RR 17.0 
- 
Mandel-baum 
(2011)
170 
ITU  AKIN  -  16 v 6.7 Adjusted 
OR increased by 
AKIN stage 
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Author (Year) 
 
 
Population 
Setting 
 
AKI 
Definition 
 
Length of Stay 
days 
 
Inhospital 
Mortality % 
AKI v Control 
 
Follow up 
mortality 
Hata 
(2010)
191 
Heart Failure  RIFLE  48 v 25  10 v 1  - 
Bennet (2010)
192  Fractured 
Femur 
RIFLE  -  19 v 0  41 v 13 at 120 
days 
Loef  
(2005)
111 
Cardiac Surgery  Rise in Creat. 
By 25% 
5.4 v 1.4  14.5 v 1.1 Adjusted 
HR 
1.6 
- 
Li 
(2010)
217 
Pancreatitis  Rise > 177  57 v 49  66.6 v 14.5  - 
Fonseca 
(2011)
166 
ITU  AKIN  -  32.1 v 7.3  - 
Hoste (2003)
218  ITU 
Septic 
Rise in Creat. 
to > 
2.0mg/dl 
-  56.7 v 28.4  - 
Behrend 
(1999)
105 
Coronary Care 
Unit 
Rise in Creat. 
to > 
2.0mg/dl 
-  50 v 8  - 
Clermont 
(2002)
219 
ITU  Rise in Creat 
> 0.5mg/dl 
11 v 4 in ITU  34 v 9  - 
Thakar (2005)
114  Cardiac Surgery  Fall in GFR 
by 30% 
- 
 
5.9% v 0.4% for non 
– RRT patients 
- 
Murugan 
(2010)
31 
Pneumonia  RIFLE  8 v 5  11 v 1.3  24 v 9.8 at 90 
days 
Barrantes 
(2009)
24 
Hospital  Rise > 
0.3mg/dl 
7.9 v 3.7  14.8 v 1.5  - 
Tran 
(1993)
100 
Pancreatitis  Rise > 280  -  81% v *5  - 
Kohli 
(2000)
106 
Hospital Elderly  Rise > 178  -  25.4 v 12.7  - 
Van den 
Noorgate 
(2003)
233 
Cardiac Surgery  RRT  -  56 v 3.7  - 
Bagshaw 
(2008)
138 
ITU  RIFLE 
AKIN 
-  24.2 v 8.9 
24.5 v 8.5 
- 
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Author (Year) 
 
 
Population 
Setting 
 
AKI 
Definition 
 
Length of Stay 
days 
 
Inhospital 
Mortality % 
AKI v Control 
 
Follow up 
mortality 
Oppert (2008)
119  ITU 
Septic Shock 
Rise in Creat. 
By 100% 
38 v 30 
 
67.3 v 42.8  - 
Bagshaw 
(2008)
237 
ITU 
Trauma 
RIFLE  -  16.7 v 7.8 Adjusted 
OR 1.8 
- 
Abelha (2009)
154  General 
Surgery 
AKIN  16 v 13  26.4 v 2.5  35.6 v 9.5 at 
6mts 
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Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Abosaif 
(2005)
181 
UK  ITU 
Admission 
Retro  183  Y  Y  Two used 
Preadmission 
or lowest 
during adm. 
RIFLE  none  -  6 
months 
Expressed 
as Mean 
Creat.. 
Overall fell 
by 
0.5mg/dl 
Apparent 
improvement 
Albright 
(2000)
250 
USA  ITU  
 
Trial  66  N excluded 
Cr. > 3.0 
N  Two used 
Preadmission 
or baseline 
during adm. 
RRT  7 days off 
dialysis 
-  30 days  59% off 
RRT at 30 
days 
Only 18% of 
deaths had 
recovered 
Ali 
(2011)
126 
Pakistan  Obstetric  Retro  100  Unclear  N  Unclear. 
Normal = 
Creat< 1.5l 
25% rise or 
Creat. rise 
> 1.5mg/dl 
Normal < 
1.5mg/dl 
23% 
normal on 
d/c 
-  -  No link to 
baseline 
function 
Ali 
(2007)
187 
UK  Hospital  Retro  562  Y  N  Preadmission 
< 150 !mol/l 
 
RIFLE  Full, partial, 
or failure 
relative to 
150!mol/l 
threshold 
-  90 days  AKI group 
– 93% full, 
7% partial, 
0.6% none 
CKD group 
– 65% full, 
29% 
partial, 6% 
none 
AKI group 
likely 
contained 
CKD stage 3. 
Recovery 
defined by 
threshold so 
inaccurate 300 
 
Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Alric 
(2003)
364 
France  EVR 
AAA Repair 
Retro  315  Y  Y  Preoperative  > 20% rise 
in 
creatinine 
from 
baseline 
Creat. > 
103 
defined 
CKD 
Return to 
‘normal’ 
Not defined 
-  3 
months  
then 3 
years 
and 5 
years 
At 3 mts 
20.3% of 
CKD group 
with 
persistent 
decline 
and 6.1% 
of normal 
group 
At 3 years 6% 
of normal 
group had 
persistent 
decline and 
16% at 5 
years. For 
CKD group 
44%  for each 
time point. 
Amdur 
(2009)
365 
USA  VA 
Hospital 
Retro  113,272  Y  Y  Preadmission  ICD-9 
Codes for 
AKI and 
ARF 
Entry to 
CKD-4 
-  75 
months 
Hazard 
Ratio 
ATN – 6.64 
ARF – 4.03 
97.8% men 
 
Ando 
(2010)
147 
Japan  Hemato. Cell 
Transplant 
Retro  158  N  Y  Pre- transplant  > 2 fold 
increase in 
serum 
creatinine 
CKD  -  3  
years 
Adjusted 
OR of CKD 
9.91 
- 
Bagshaw 
(2005)
226 
Canada  ITU  Retro  240  Y 
If Creat > 
150!mol/l 
N  unclear  RRT  Off RRT  68% off 
RRT at d/c 
1 year  78% off 
RRT 
63% of those 
on RRT at 
follow up had 
history of CKD  
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Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Bagshaw 
(2006)
366 
Canada  ITU  Retro  240  Y 
If Creat > 
150!mol/l 
N  unlcear  RRT  Off RRT  -  90 days  72% off 
RRT 
Adjusted odds 
of recovery 
increased if 
Male or septic 
shock. 
Reduced with 
higher 
Charlson 
score  
 
Bahar 
(2005)
367 
Turkey  Cardiac 
Surgery 
Retro  116  Y  N  Preoperatvie  RRT  Not defined 
Return to 
‘normal’ 
87.5% had 
not 
recovered 
4.7% on 
dialysis 
6  
years 
15% not 
recovered 
with CKD 
24% on 
RRT 
 
 
Barratt 
(2000)
368 
UK  Surgical AAA 
Repair 
Retro  65  Y  N  Admission  Creat. Rise 
> 600 or 
RRT 
Not defined 
clearly 
16 
survivors 
69% failed 
to recover 
6% on RRT 
 
-  -   302 
 
Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Bhandari 
(1996)
102 
UK  Hospital  Prosp  1095  N  N  Unclear  RRT  Off RRT  16.7% on 
RRT 
-  -  Outcome 
influenced by 
cause 
Baraldi 
(1998)
21 
Italy  Hospitalised 
Medical Pts 
Retro  109  Y  N  Preadmission 
when available 
Rise > 
2.0mg/dl 
or doubling 
if CKD 
Not defined  -  ? 1 
month 
32% full 
recovery 
49% partial 
19% RRT 
Elderly 
appeared at 
greater risk of 
no recovery. 
Bihorac 
(2009)
189 
USA  ITU 
Major 
Surgery 
Retro  10518  N  Y  Lowest in 
hospital or 
estimated 
RIFLE  Complete < 
50% above 
baseline 
56% 
complete, 
41% 
partial,  3% 
on HD 
-  -  - 
Bucaloiu 
(2012)
194 
USA  Hospital 
Reversible 
AKI 
Retro  1610  N 
All excluded 
including 
history of 
proteinuria 
 
Y 
Matched 
Lowest from 3 
months before 
to 30 days 
after 
admission 
50% rise in 
Creat. 
relative to 
baseline 
eGFR within 
at least 90% 
of baseline 
within 90 
days of AKI 
-  3.3 
years 
De novo 
CKD  
Hazard 
Ratio 1.91 
Risk factors: 
Older age, 
CCF, 
AKI stage,  
albumin 
preadmission 
Bucuvic 
(2011)
177 
Brazil  Hospital ATN  Retro  477  Y  N  Unclear  AKIN  Not defined  96.9% 
complete 
or partial 
-  -  -  
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Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Chawla 
(2011)
369 
USA  VA 
Hospital 
Retro  5351  N  Y  Preadmission  
otherwise 
excluded 
ICD-9 
Codes 
+ 
RIFLE 
Entry to 
CKD-4 
-  Mean 
2.4 
years 
CKD-4 
AKI – 14% 
Con – 9% 
Predictors: 
Older age, 
Low albumin, 
Diabetes, 
AKI severity. 
Chertow 
(1995)
370 
USA  ITU  Retro  132  Y  N  unlcear  RRT  Off RRT  67% off 
RRT 
-  -  - 
Choi 
(2010)
165 
USA  VA 
HIV registry 
Retro  17325  Y  Y  Preadmission 
or first 
inpatient 
AKIN  Decrase in 
Creat. 
below AKIN 
1 
-  5.7 
years 
Adjusted 
Hazard 
Ratio for 
ESRD by 
AKIN stage 
1: 1.37 
2: 3.8 
3: 20.36 
No increased 
risk in Stage 1 
who have 
recovered at 
discharge 
Chugh 
(1994)
371 
India  Hospital  Retro  113  Unclear  N  Unclear  RRT  Off RRT  -  3 
months 
44% off 
RRT 
 
Coca 
(2010)
163 
USA  VA Surgical 
Diabetics 
Retro  35302  Y  Y  Preoperative  AKIN  Within 
0.2mg/dl of 
baseline 
71% 
recovered 
at 
discharge 
-  -   304 
 
Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Cosentin 
(1994)
372 
USA  ITU  Retro  363  Y  N  unclear  RRT  Off RRT  34% on 
RRT at d/c 
 
-  -  - 
Cruz 
(2007)
186 
Italy  ITU  Prosp.  2164  Y  Y  Preadmission 
or estimated 
RIFLE  Creat. < 
1.5mg/dl or 
return to 
baseline 
36% 
recovered 
at time of 
ITU d/c 
 
-  -  Recovery 
linked to AKI 
severity 
Fonseca 
(2011)
166 
Colombia  ITU  Retro  794  Y  Y  Unclear  AKIN  Full = Creat. 
Returns to 
normal 
67.9% full 
3.5% 
partial 
22.9% no 
recovery 
-  -  - 
Gentric 
(1991)
19 
France  Elderly > 65  Retro  46  Unclear  N  Unclear  Creat. Rise 
> 120 
Total = 
Creat. < 
100 
20% total 
recovery at 
discharge 
39 
months 
56% 
normal 
37% CKD 
7% RRT 
No reference 
to baseline 
 
 
Gonwa 
(2001)
373 
USA  Liver 
Transplants 
Retro  1535  Y  Y  Preoperative  RRT  Off RRT  -  1  
year 
16% on 
RRT 
 
 
-  
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Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Gruberg 
(2000)
374 
USA  Coronary 
angio 
Retro  439  All CKD Cr. 
> 1.8mg/dl 
Y  Preoperative  Creat. Rise 
> 25% 
Off RRT  -  1  
year 
18% of RRT 
group 
- 
Gude 
(2010)
159 
Norway  Heart 
Transplants 
Retro  585  Y  Y  Preoperative  AKIN  Need for 
RRT 
-  6.6 
years 
AKI did not 
predict 
ESRD 
By 2 years 
there was no 
difference in 
Creat. 
between 
groups 
Hingoran  
(2007)
375 
USA  Hemato. Cell 
Transplant 
Retro  1635  N  Y  Pretransplant 
normal 
Creat. Rise 
> 2.0mg/dl 
De novo 
CKD 
-  Max 
540 
days 
CKD in 
23% of AKI 
group and 
17% of no 
AKI group 
HR 1.7 
Increased risk 
with AKI but 
many shared 
risk factors 
between 
groups 
Hobson 
(2009)
221 
USA  Cardiac 
Surgery 
Retro  2973  N  Y  Lowest on 
admission or 
estimated 
RIFLE  Complete = 
return to 
<50% above 
baseline 
None = RRT 
60% 
complete, 
37% 
partial, 
3% non 
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Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Hsu 
(2009)
188 
USA  Hospital  Retro  39805  All with 
eGFR < 45 
Y  Taken from > 
30 days from 
admission to 
365 days 
RRT  ESRD  -  7 years  Adjusted 
HR of ESRD 
1.47 
 
Ishani 
(2009)
42 
USA  Hospital  
Medicare 
Retro  233,803  Y  Y  Coded for 
CKD 
ICD-9 
Codes 
ESRD  -  2 years  Adjusted 
HR: 
AKI – 13.0 
AKI/CKD – 
41.2 
CKD only – 
8.4 
Without a 
history of 
recognized 
CKD 72% had 
CKD within 2 
years after AKI 
 
Ishani 
(2011)
127 
USA  Cardiac 
Surgery 
Retro  29388  Y  Y  Preoperative 
within 30 days 
Stratified in 
rises from 
0% to > 
100% 
Progress to 
next CKD 
stage or 
reaching 
CKD 
staging if 
previously 
normal 
-  5  
years 
Graded 
increased 
risk of 
incident 
CKD 
(adjusted 
HR 2.33) 
and 
progress-
ion 
 
Risk persisted 
over 5 years  
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Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
James 
(2010)
231 
Canada  Hospital  Retro  920985  Y  Y  Mean of 
previous 6 
months 
Coded  ESRD or 
doubling of 
serum 
creatinine 
-  35 
months 
Increased 
risk of 
composite 
outcome of 
ESRD or 
doubling 
of creat. 
- 
James 
(2010)
230 
Canada  Coronary 
Angiogram 
Retro  14782  Y  Y  Preangio 
Within 6 
months 
Mild = rise 
in Creat > 
0.3mg/dl 
or 50-99% 
 
Mod/sev = 
Rise > 
100% 
Sustained 
loss of 
function = 
Creat > 50% 
or 0.3mg/dl 
above 
baseline up 
to 3 months 
Prog. = 
decline > 
4mls/min 
In GFR /yr 
-  2.5 
years 
Odds of 
decline at 
3 months 
Mild – 4.74 
Mod/Sev  - 
17.31. 
 
Adjusted 
rate of 
decline 
increased 
in AKI 
group 
Severity 
predicted 
decline 
 
Rate of 
decline in Mild 
group no 
different to 
year pre AKI 
but increased 
for 
Mod/Severe 
Jones 
(1998)
376 
UK  ITU 
ventilated 
Retro  408  Y  Y  unclear  RRT  Off RRT  -  6 
months 
8% on RRT 
 
- 308 
 
Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Kholi 
(2000)
106 
India  Hospital  
Acquired 
Elderly 
Prosp  4176  Y  Y  Admission 
Creat. If stable 
Creat. Rise 
> 178 
Not defined  86.3% 
complete, 
13.6% 
deranged 
 
-  -  - 
Korkeila 
(2000)
377 
Finland  ITU  Retro  62  Unclear  N  Unclear  RRT  Off RRT at 6 
months 
82% off 
RRT 
6 
months 
85% off 
RRT 
Follow up 
continued to 5 
years 
 
Kwon 
(2010)
190 
Korea  Hosptial 
acquired 
Prosp  96  Y  N  Preadmission 
or lowest in 
hospital 
AKIN  Return to 
baseline 
50% 
recovered 
-  -  AKIN stage 
predicted 
recovery 
 
La France 
(2010)
125 
USA  CKD Register 
GFR < 30 
Retro  6562  All  Y  Lowest 
between 3 
months before 
and discharge 
AKIN 
 
RRT 
excluded 
eGFR 
decrease < 
10% 
follow up 
from 90 
days 
-  19 
months 
Adjusted 
RR of ESRD 
2.33 in AKI 
group 
No account of 
readmissions 
or reaki 
 
 
Landoni 
(2006)
378 
Italy  Cardiac 
Surgery 
Retro  7846  Y  Y  preoperative  RRT  Off RRT  -  3.5 
years 
91% off 
RRT 
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Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Liano 
(2007)
46 
Spain  Hospital ATN  Retro  187 
 
Y but Cr > 
3mg/dl 
excluded 
N  Amission but 
poorly defined 
Rise in 
Creat. > 
2mg/dl 
Total= 
Creat < 
1.4mg/dl 
Partial= 
Creat > 1.4 
but lower 
than peak 
-  12 
years 
19% with 
CKD 
2% on RRT 
58 survivors 
evaluated 
 
Lin 
(2009)
379 
Taiwan  ITU  
Post-op 
Retro  342  Y  N  Unclear  RRT  Off RRT  -  90 days  84.7% off 
RRT at 90 
days 
50% had come 
off RRT by 14 
days 
Recovery 
predicted by 
lower baseline 
Creat., lower 
SAPS ii score 
and use of 
CRRT 
Lines 
(2011)
380 
UK  ITU  Retro  821  Y  N  Within 3 
months of 
admission 52% 
RRT  Need for 
RRT and 
mean 
increase in 
Creat. 
6.5% on 
RRT 
Mean 
increase in 
Creat from 
111 to 127 
1 year  Mean 
increase 
from 127 
at 
discharge 
to 134 
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Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Lins 
(2006)
381 
Belgium  ITU  Retro  145   N   N  Unclear  Creat. Rise 
to > 
2mg/dl 
-  31.7% had 
eGFR > 60 
1 year  No change 
in mean 
serum 
creatinine 
 
Lo 
(2009)
120 
USA  Hospital 
RRT 
survivors 
from 30days 
after d/c 
Retro  703  N 
Excluded 
GFR < 45 
Y  Outpatient 
eGFR 
RRT with 
Creat. Rise 
of > 50% 
Progress to 
CKD 4 or 
beyond 
9% on RRT 
at d/c 
33 
months 
Adjusted 
hazard for 
progress 
CKD 28.1 
Higher risk for 
those with 
baseline GFR 
> 60 
 RR 54.0 
But lower 
absolute risk 
Loef 
(2005) 
Holland  Cardiac 
Surgery 
Retro  843  Y  Y  Preoperative  Creat. Rise 
> 25% 
Return to 
baseline 
68% 
returned to 
baselin 
-  -  - 
Mccarthy 
(1996)
382 
USA  ITU 
Two eras 
1970’s 
versus 
1990’s 
 
 
Retro 
 
142  N excluded 
Cr. > 
5.0mg/dl 
N  Unclear  RRT  Off RRT  45% in 
1970s 
35% in 
1990s 
1 year  96% in 
1970’s 
78% in 
1990’s 
 
 
 
  
311 
Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Mehta 
(2010)
122 
USA  Cardiac 
Surgery 
Retro  2083  N 
Excluded 
Creat. > 
2mg/dl 
Y  Preoperative  Creat. Rise 
> 50% or > 
0.7mg/dl 
from 
baseline 
Complte = 
return to 
baseline 
33.7% 
returned to 
baseline at 
d/c 
-  -  Predictors of 
failure to 
recover: 
Age, CVD, 
CCF. 
Morgera 
(2002)
292 
Germany  ITU  Retro  979  Unclear  N  Unclear  RRT  -  -  938 
days 
Missing 
data 
10% on 
RRT 
46% with 
CKD 
 
Nash 
(2002)
8 
USA  Hospital  Prosp  332  Y  Y  Lowest in 
hospital 
Creat. Rise 
from 
0.5mg/dl 
Complete or 
partial not 
defined 
39% 
complete 
recovery. 
22.6% 
partial 
recovery. 
2.7% on 
dialysis 
-  -  - 
Newsom 
(2008)
383 
USA  Elderly 
Myocardial 
Infarction 
Retro  87094  Y  Y  First on 
admission 
Stratified 
increases in 
creat. 
ESRD  -  4  
years 
Adjusted 
HR 3.26 
Hazard 
graded by 
severity of AKI 312 
 
Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Ojo 
(2003)
384 
USA  Organ 
Transplants 
Retro    Y  Y  Preoperative  50% 
reduction 
from 
baseline 
GFR or RRT 
CKD 
defined as 
eGFR < 29 
or ESRD 
-  36 
months 
Relative 
risk of CKD 
post AKI 
2.13 
Risk of CKD 
increased if 
older, female, 
HTN, DM, 
postop AKI 
Pannu 
(2011)
168 
Canada  Hospital  Retro  7856  Y  Y  Outpatient 
within 6 
months 
AKIN  ESRD  -  2  
years 
Graded 
increased 
hazard of 
death or 
ESRD 
ESRD was very 
uncommon 
Parames 
(2004)
385 
USA  Liver 
Transplant 
Retro  1602  N  Y  preoperative  RRT  Off RRT or 
CKD  
-  6  
years 
23% on 
RRT 
46% with 
CKD 
Baseline CKD 
not defined 
Risk for 
ESRD= Creat > 
1.7mg/dl at 1 
year, use of 
Cyclosporin, 
diabetes 
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Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Picinni 
(2011)
251 
Italy  ITU  Prosp  576  Y  Y  Lowest in 
previous 3 
months or 
estimate 
RIFLE  Complete= 
Creat at ITU 
d/c < 120% 
of baseline 
59.4% 
complete 
at death or 
d/c, 13.5% 
partial 
-  -  Sepsis 
patients less 
likely to 
recover 
function 
Ponte 
(2008)
386 
Spain  Hospital ATN  Retro  187  Excluded Cr 
> 1.4mg/dl 
but 25% 
CKD 3 
N  Unclear  Creat rise > 
2mg/dl 
Return to 
baseline 
38.4% 
recovered 
to baseline 
8 years  61.1% had 
some 
degree of 
renal 
failure 
1.1% on 
RRT 
 
 
Multivariate 
Model 
predictors of 
CKD: 
Age, 
Comorbidity 
GFR at d/c 
Follow up 
time 
Prescott 
(2007)
44 
UK 
Scotland 
National RRT 
sample 
Prosp  809  Y  N  Cr. > 150 = 
CKD otherwise 
normal 
Not all had 
baseline 
RRT  Off RRT  -  90 days  Of CKD 
group 53% 
on RRT 
Of 
previous 
normal 
group 13% 
on RRT 
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Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Salmanul 
(2003)
387 
USA  VA Hospital  Retro  916  Y  N  Pre-AKI but 
unclear 
Stratified 
by % rise in 
Creat. 
Return to 
baseline 
-  Up to 9 
years 
Prior 
normal 
function 
with mild 
AKI 
recovered 
60% 
recovered 
in mod/sev 
group 
 
Schiffl 
(2006)
45 
Germany  ITU 
ATN only 
Prosp  425  N 
Excluded 
Creat. > 
1.3mg/dl 
N  Preadmission 
but unclear 
RRT  Complete= 
return to 
baseline 
57% had 
complete 
recovery. 
33% 
mild/mod 
renal 
failure Cr. 
> 1.3 but < 
3.0. 
10% severe 
Cr. 3-6 but 
no RRT 
I year  1 patient 
on RRT = 
<1% of 
survivors 
No info. on 
function 
No adjusted 
predictors of 
complete or 
partial 
recovery  
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Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Schiffl 
(2008)
388 
Germany  ITU 
ATN only 
Prosp  425  N 
Excluded 
Creat. > 
1.3mg/dl 
N  Preadmission 
but unclear 
RRT  Complete= 
return to 
baseline ! 
10% 
-  5 years  86% 
normal 
9% CKD 
5% RRT 
!%of total 
cohort 
needed 
RRT at 5 
years 
No patient 
discharged 
with recovery 
showed a 
decline in 
function over 
the 5 years of 
follow up 
Siew 
(2011)
389 
USA  VA Hospital 
AKI survivors 
Retro  32929  Y  N  7 – 365 days 
before AKI 
AKIN  At 1 year 
improved= 
eGFR > 60 
All had 
eGFR <60 
at 30 days 
1 year  With 
baseline > 
60 50.2% 
had 
improved 
to > 60 
< 1% of 
cohort 
needed 
RRT 
- 
Silvester 
(2001)
228 
Australia  ITU  Prosp  299  Y  N  Preadmission  RRT  Off RRT  8.7% on 
RRT at d/c 
- 
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Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Soares 
(2006)
390 
Brazil  ITU 
Oncology 
Prosp  309  Y  N  unclear  Bellomo 
Criteria 
Rise in 
Creat from 
> 
1.44mg/dl 
Failure to 
recover = 
ESRD or 
CKD 
-  6 
months 
8% on RRT 
26% with 
CKD 
Baseline 
function 
unclear 
Thakar 
(2009)
155 
USA  VA ITU  Retro  325395  Y  Y  Lowest in ITU  AKIN  Complete= 
< 25% 
above 
baseline 
 
 
56,5% 
complete 
-  -  Recovery 
graded by 
severity of AKI 
Thakar 
(2011)
34 
USA  VA 
Diabetics 
Retro  3679  N 
Excluded 
GFR < 30 
Y  Last 
outpatient 
AKIN  Developing 
CKD  
Stage 4 
CKD 
-  3.8 
years 
Adjusted 
HR 3.56 of 
outcome 
Risk 
cumulative 
Risk factors: 
Proteinuria, 
HTN, 
Female, 
Higher 
baseline 
creatine 
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Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Touzot 
(2010)
391 
France  Hemato. Cell 
Transplant 
Retro  123  unclear  Y  unclear  RIFLE  Reaching 
CKD eGFR 
<60 
-  2  
years 
40% had 
CKD at 
follow up 
AKI odds 
ratio 4.54 
Age > 45, 
AKI, 
GFR<90 
predicted CKD 
Triverio 
(2009)
392 
Swiss  ITU  RCT  206  Y  N  Creat. one 
month prior to 
AKI 
RRT  Complete= 
!10% of 
baseline 
GFR 
Partial =not 
on RRT 
36% 
complete 
at d/c. 
60% 
partial, 
4.4% RRT 
3  
years 
50% with 
normal 
function 
had CKD at 
f/u 
 
Uchino 
(2005)
112 
Multi- 
national 
ITU  Prosp  29269  Y  Y  unclear  RRT or Urea 
rise > 30 
Off RRT  13% on 
RRT at 
discharge 
-  -  - 
Van 
Beren-
doncks 
(2010)
252 
Belgium  ITU 
AKI survivors 
Prosp  595  Y  N  unclear  Creat rise > 
2.0mg/dl 
Off RRT  16% on 
RRT aat 
d/c 
3  
years 
Function 
expressed 
as mean 
Creat. With 
no change 
from disch. 
to follow 
up 
- 318 
 
 
Author 
(Year) 
Country  Setting  Study 
Type 
Patient 
Number 
CKD 
Included 
Controls 
without 
AKI 
Y/N 
Baseline 
Definition 
AKI 
Definition 
Recovery 
Definition 
or failure 
to recover 
Hospital 
Outcome 
% 
survivors 
Follow 
up 
Follow up 
Outcome 
% 
survivors 
Notes 
Wald 
(2009)
393 
Canada   ITU 
survivors 
Retro  3769  Y  Y  none  RRT 
coded 
Off RRT  -  3  
years 
HR fo ESRD 
3.26 
- 
Weiss 
(2006)
394 
USA  Hemato. Cell 
Transplant 
Retro  122  N  Y  Pre-transplant  Graded by 
rise in 
Creat. And 
% fall in 
GFR 
Decrease in 
GFR 25% 
-  1 year  Adjusted 
OR 32.8 
- 
Wu 
(2011)
395 
Taiwan  ITU Major 
Surgery 
Prosp  9425  Y  Y  First on 
admission or 
nadir in 
hospital 
RIFLE  < 50 % 
above 
baseline 
AKI 
86.7% 
recovered 
AKI/CKD 
72.3% 
recovered 
RRT 2% 
5  
years 
HR for 
ESRD 
AKI/CKD 
123 
HR 
increased 
with AKI 
severity 
CKD patients 
without 
recovery at 
discharge had 
highest risk of 
ESRD 
Van 
Kuijk 
(2010)
124 
Holland  Vascular 
Surgery 
Retro  1308  N  Y  Preoperative  > 10% fall 
in CKD-Epi 
eGFR 
 
Within 10% 
of baseline 
GFR 
-  5  
years 
Adjusted 
RR of CKD 
with temp. 
decline in 
function 
3.4 
RR 3.6 with 
Functional 
decline 
predicted by 
RIFLE stage Mark Uniacke    Appendix 13     
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Appendix 13 
 
19 different definitions of recovery of renal function found in the literature for the 
period 1990-2012. 
 
 
Author (Year) 
 
 
Definition of Recovery/Progression 
Abosaif (2005)
181  Expressed as change in mean serum 
creatinine. 
 
Albright (2000)
250  7 days off renal replacement therapy 
 
Ali (2011)
126  Normal function = creatinine < 1.5mg/dl 
 
Ali (2007)
187  Full recovery if creatinine < 150μmol/l 
 
Amdur (2009)
365  Progression to CKD stage 4 
 
Bagshaw (2005)
226  Off renal replacement therapy 
 
Bihorac (2009)
189  Recovered if creatinine < 50% above 
baseline 
 
Bucaloiu (2012)
194  eGFR ±10% of baseline 
 
Choi (2010)
165  Fall in creatinine to below threshold of 
AKIN stage 1 
 
Coca (2010)
163  Creatinine within 0.2mg/dl of baseline 
 
Gentric (1991)
19  Total recovery = creatinine < 100μmol/l 
 
Hingorani (2007)
375  Lack of recovery = de novo CKD with eGFR 
< 60mls/min 
 
Ishani (2011)
127  Lack of recovery = progression to next CKD 
stage Mark Uniacke    Appendix 13     
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Author (Year) 
 
 
Definition of Recovery/Progression 
James (2010)
231  Rapid progression = fall in eGFR > 
4mls/min/year 
 
Korkeila (2000)
377  Recovery = off renal replacement therapy at 
6 months 
 
Liano (2007)
46  Total recovery = creatinine < 1.4mg/dl 
 
Piccini (2008)
251  Total recovery = creatinine < 120% of 
baseline 
 
Thakar (2009)
155  Creatinine < 25% above baseline 
 
Weiss (2006)
394  Failure to recover = decrease in GFR by 25% 
 
 
 
 
!
 
 
 
 
 
 
 
!
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Appendix 14 
 
Information sheets used in the study: 
 
  1. AKI Group 
  2. AKI/CKD Group 
  3. Control Group 
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Study:    Natural  history  of  Acute  Kidney  Injury  and  its  relationship  to  Chronic 
kidney Disease. 
 
Patient Information Sheet 
 
Introduction 
 
We would like to invite you to take part in our research study which is explained in this 
information sheet. Before you decide to take part we would like you to understand why 
the  research  is  being  done  and  what  it  will  involve  for  you  if  you  take  part.  Our 
researcher who is a medical doctor and a member of the kidney team will go through 
the information sheet with you and answer any questions you may have. This should 
not  take  any  more  than  twenty  minutes.  You  do  not  need  to  make  a  decision 
immediately but can think about it for 24 hours if you wish. You can also talk to others 
about the study if you wish. 
 
Part 1 of this information sheet will tell you the purpose of this study and what will 
happen to you if you take part.  Part 2 gives you more detailed information about the 
conduct of the study.  
 
We would encourage you to ask any questions you may have especially if something is 
not clear.  
 
Part 1. 
 
1. What is the purpose of this study? 
 
The purpose of this study is to improve our knowledge of kidney disease and how it 
behaves. Kidney disease is very common. Many people have some kidney impairment 
which  is  often  simply  watched  by  their  doctors.  Sometimes  when  people  become 
unwell for other reasons their kidney impairment can deteriorate. It generally appears 
to get better but we do not know if this will result in more impairment in the future. 
This study hopes to answer this question by comparing your kidney function now with 
its future values. 
 
In  this  study  we  will  be  looking  at  three  different  groups  of  patients.  The  first  are 
people who experience some impairment in their kidney function for the first time 
during  their  hospital  stay.  We  want  to  observe  these  people  to  see  if  their  kidney Mark Uniacke    Appendix 14     
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function recovers fully after their illness has settled. The second group are people who 
have  existing  kidney  impairment  who  experience  a  further  decline  in  their  kidney 
function during their illness. We will observe these to see if the further impairment of 
their kidney function results in any permanent decline in their function. We will then 
have a third group who have existing impairment but do not have a further decline 
during their illness. This group is called a control group and we will compare these 
with group two to see if there are differences. 
 
This study will involve monitoring only and will not mean any changes in your usual 
treatment or affect the treatment you currently need.  
 
2. Why have you been invited to take part?  
 
During this stay in hospital your doctors have done some blood tests to help monitor 
your  condition.  It  has  been  noted  in  these  blood  tests  that  you  have  some  kidney 
impairment. The doctors are watching this closely. We can see from some of your older 
blood tests that this kidney impairment has not been present before. This places you 
in the first group mentioned above. We would like to observe your kidney function to 
see how it changes in the future.   
 
3. Do I have to take part? 
 
It is up to you to decide if you wish to take part in this study. Whatever you decide will 
have no effect on the standard of care you receive. We will describe the study and go 
through this information sheet with you. If you agree to take part, we will ask you to 
sign a consent form. You are free to withdraw at any time, without giving a reason. 
 
4. What will happen to me if I take part? 
 
This  type  of  study  will  involve  monitoring  only.  It  will  involve  the  recording  of 
information and will not affect the standard treatment you need in any way. In the 
beginning, we will record your previous kidney function and how it has been affected 
by your current illness. We will also record from your medical records your medical 
history which will include previous illnesses to see how these have influenced your 
kidney  condition.  When  you  are  discharged  from  hospital  we  will  record  your  final 
blood test results. After you are discharged we will write to your GP and tell them you 
are part of this study.  
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We  will  then  wish  to  record  your  kidney  function  again  after  six  months  and  after 
twelve months. We will write to you in the future when it is time to check your kidney 
function again and invite you to attend a clinic appointment in the renal outpatients 
department of this hospital. At these appointments we will take a blood sample to 
check your kidney function and also a urine sample. In addition we will check your 
blood pressure and record the medications you are taking at that time. You will be part 
of this study for a total of one year. When the study is complete we will write to your 
GP to let them know the study is over and outline your condition at that time. All of 
your results will be recorded anonymously and will be identified by number only. 
 
5. Will there be any expenses or payments? 
 
You will not be paid for taking part in this study and it is purely voluntary. If you have 
any difficulty getting transport for the follow up appointments we will be happy to pay 
for a taxi to bring you to the hospital.  
 
6. What will I have to do? 
 
The good news is that you will have to do very little. You will not be receiving any 
additional treatments and we will not expect you to change your lifestyle in any way. 
Our only request is that you attend for the two follow up appointments at six months 
and twelve months. Your GP may wish to see you more frequently than this but that 
would not be part of this study. 
 
7. Are there any risks to me by taking part? 
 
We do not see any risks to you as a result of taking part in this study. It is possible that 
during follow up we may identify a significant decline in your kidney function. In the 
event of this happening we will inform your GP in writing. 
 
8. Are there any possible benefits from taking part? 
 
This study will involve monitoring only and will not involve any treatment. It is not 
designed to have any affect on your condition. The information gathered from this 
study  will  improve  our  knowledge  of  kidney  disease  which  may  help  improve  the 
treatment of the condition in the future. 
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9. What happens when the study ends? 
 
You participation in the study will end after the second follow up appointment in one 
year. The information recorded during the study will be stored anonymously in our 
confidential database and will not be linked to you by name. We may use your NHS 
number to link to NHS hospital records for statistics purposes. All information will be 
analysed to produce reports on the subject. We will be happy to provide you with a 
brief report on the results of the study if you request this. 
 
If the information in Part 1 interests you and you are considering taking part please 
read the additional information in Part 2 before making a decision. 
 
Part 2 
 
1. What will happen if I do not want to carry on with the study? 
 
You can withdraw from this study at any time if you wish. If you withdraw we will need 
to  let  your  GP  know.  We  will  need  to  record  your  withdrawal  but  all  information 
gathered on you will be removed from our database. 
 
2. What if there is a problem? 
 
If you have a concern about any aspect of this study our principal researcher will do 
their best to answer your questions and can be contacted at the address and number 
given at the end of this document. If you wish to complain or have any concerns about 
any  aspect  of  the  way  you  have  been  approached  or  treated  during  this  study  the 
normal NHS complaints mechanisms are available to you. 
 
3. Will the information recorded on me be kept confidential? 
 
All information collected about you during the course of this study will be kept strictly 
confidential. It will be stored by number only and will not be identifiable to you. We will 
record your personal contact details separately and this will include your hospital and 
NHS numbers, name, date of birth, contact address and telephone number as well as 
your GP contact details. We will ask you to sign a consent form to allow us access to 
this information.  
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4. What will happen to any samples that I give? 
During the follow up you will have routine blood and urine testing performed. These 
samples will be performed in our hospital laboratory in a standard manner. We will not 
be storing samples for the purposes of this study. 
 
5. What will happen to the results of this study? 
 
Once the results of this study have been gathered and analysed, we will publish them 
in medical journals in order to add to the knowledge of kidney disease so that others 
can learn from it.  
 
6. Who is organising and funding the research? 
 
This research is being organised by a team from the Wessex Renal and Transplant Unit 
with help form the Health Care Research Unit of the University of Southampton School 
of Medicine. It is funded by the local Renal Research Fund. The researcher conducting 
this study is paid a fixed salary which is independent of whether you take part in the 
study or not. 
 
7. Who has reviewed the study? 
 
All research in the NHS is looked at by an independent group of people called an ethics 
committee,  to  protect  your  interests.  This  study  has  been  reviewed  and  given 
favourable opinion by Milton Keynes Research Ethics Committee. Mark Uniacke    Appendix 14     
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Study:    Natural  history  of  Acute  Kidney  Injury  and  its  relationship  to  Chronic 
kidney Disease. 
 
Patient Information Sheet 
 
Introduction 
 
We would like to invite you to take part in our research study which is explained in this 
information sheet. Before you decide to take part we would like you to understand why 
the  research  is  being  done  and  what  it  will  involve  for  you  if  you  take  part.  Our 
researcher who is a medical doctor and a member of the kidney team will go through 
the information sheet with you and answer any questions you may have. This should 
not  take  any  more  than  twenty  minutes.  You  do  not  need  to  make  a  decision 
immediately but can think about it for 24 hours if you wish. You can also talk to others 
about the study if you wish. 
 
Part 1 of this information sheet will tell you the purpose of this study and what will 
happen to you if you take part.  Part 2 gives you more detailed information about the 
conduct of the study.  
 
We would encourage you to ask any questions you may have especially if something is 
not clear.  
 
Part 1. 
 
1. What is the purpose of this study? 
 
The purpose of this study is to improve our knowledge of kidney disease and how it 
behaves. Kidney disease is very common. Many people have some kidney impairment 
which  is  often  simply  watched  by  their  doctors.  Sometimes  when  people  become 
unwell for other reasons their kidney impairment can deteriorate. It generally appears 
to get better but we do not know if this will result in more impairment in the future. 
This study hopes to answer this question by comparing your kidney function now with 
its future values. 
 
In  this  study  we  will  be  looking  at  three  different  groups  of  patients.  The  first  are 
people  who  experience  some  impairment  in  their  kidney  function  for  the  first  time 
during  their  hospital  stay.  We  want  to  observe  these  people  to  see  if  their  kidney 
function recovers fully after their illness has settled. The second group are people who Mark Uniacke    Appendix 14     
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have  existing  kidney  impairment  who  experience  a  further  decline  in  their  kidney 
function during their illness. We will observe these to see if the further impairment of 
their kidney function results in any permanent decline in their function. We will then 
have a third group who have existing impairment but do not have a further decline 
during their illness. This group is called a control group and we will compare these 
with group two to see if there are differences. 
 
This study will involve monitoring only and will not mean any changes in your usual 
treatment or affect the treatment you currently need.  
 
2. Why have you been invited to take part?  
 
During this stay in hospital your doctors have done some blood tests to help monitor 
your  condition.  It  has  been  noted  in  these  blood  tests  that  your  kidneys  are  not 
working as well as they normally do. The doctors are watching this closely. We can see 
from some of your older blood tests that your kidneys have been impaired before this 
illness. This places you in the second group mentioned above and we would like to 
observe your kidney function to see what affect this illness will have on it in the future.   
 
3. Do I have to take part? 
 
It is up to you to decide if you wish to take part in this study. Whatever you decide will 
have no effect on the standard of care you receive. We will describe the study and go 
through this information sheet with you. If you agree to take part, we will ask you to 
sign a consent form. You are free to withdraw at any time, without giving a reason. 
 
4. What will happen to me if I take part? 
 
This  type  of  study  will  involve  monitoring  only.  It  will  involve  the  recording  of 
information and will not affect the standard treatment you need in any way. In the 
beginning, we will record your previous kidney function and how it has been affected 
by your current illness. We will also record from your medical records your medical 
history which will include previous illnesses to see how these have influenced your 
kidney  condition.  When  you  are  discharged  from  hospital  we  will  record  your  final 
blood test results. After you are discharged we will write to your GP and tell them you 
are part of this study.  
 
We  will  then  wish  to  record  your  kidney  function  again  after  six  months  and  after 
twelve months. Your GP will review you at these times and take a blood sample and a Mark Uniacke    Appendix 14     
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urine sample. We will also need a measure of your blood pressure at these times as 
well as a list of your medications. These visits should not take any longer than fifteen 
minutes  and  in  most  cases  would  be  expected  as  routine  in  somebody  with  some 
kidney impairment. 
 
You will be part of this study for a total of one year. When the study is complete we will 
write to your GP to let them know the study is over and outline your condition at that 
time. All of your results will be recorded anonymously and will be identified by number 
only. 
 
5. Will there be any expenses or payments? 
 
You will not be paid for taking part in this study and it is purely voluntary. 
 
6. What will I have to do? 
 
The good news is that you will have to do very little. You will not be receiving any 
additional treatments and we will not expect you to change your lifestyle in any way. 
Our only request is that you attend for the two follow up appointments with your GP at 
six months and twelve months. Your GP may wish to see you more frequently than this 
but that would not be part of this study. 
 
7. Are there any risks to me by taking part? 
 
We do not see any risks to you as a result of taking part in this study. It is possible that 
during follow up we may identify a significant decline in your kidney function. In the 
event of this happening we will inform your GP in writing and recommend appropriate 
action. 
 
8. Are there any possible benefits from taking part? 
 
This study will involve monitoring only and will not involve any treatment. It is not 
designed to have any affect on your condition. The information gathered from this 
study  will  improve  our  knowledge  of  kidney  disease  which  may  help  improve  the 
treatment of the condition in the future. 
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9. What happens when the study ends? 
 
You participation in the study will end after the second follow up appointment in one 
year. The information recorded during the study will be stored anonymously in our 
confidential database and will not be linked to you by name. We may use your NHS 
number to link to NHS hospital records for statistics purposes. The information will be 
analysed to produce reports on the subject. We will be happy to provide you with a 
brief report on the results of the study if you request this. 
 
If the information in Part 1 interests you and you are considering taking part please 
read the additional information in Part 2 before making a decision. 
 
Part 2 
 
1. What will happen if I do not want to carry on with the study? 
 
You can withdraw from this study at any time if you wish. If you withdraw we will need 
to let your GP know that we will not be requiring your follow up information. We will 
need to record your withdrawal but all information gathered on you will be removed 
from our database. 
 
2. What if there is a problem? 
 
If you have a concern about any aspect of this study our principal researcher will do 
their best to answer your questions and can be contacted at the address and number 
given at the end of this document. If you wish to complain or have any concerns about 
any  aspect  of  the  way  you  have  been  approached  or  treated  during  this  study  the 
normal NHS complaints mechanisms are available to you. 
 
3. Will the information recorded on me be kept confidential? 
 
All information collected about you during the course of this study will be kept strictly 
confidential. It will be stored by number only and will not be identifiable to you. We will 
record your personal contact details separately and this will include your hospital and 
NHS numbers, name, date of birth, contact address and telephone number as well as 
your GP contact details. 
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4. What will happen to any samples that I give? 
 
During the follow up you will have routine blood and urine testing performed. These 
samples will be performed in our hospital laboratory in a standard manner. We will not 
be storing samples for the purposes of this study. 
 
5. What will happen to the results of this study? 
 
Once the results of this study have been gathered and analysed, we will publish them 
in medical journals in order to add to the knowledge of kidney disease so that others 
can learn from it.  
 
6. Who is organising and funding the research? 
 
This research is being organised by a team from the Wessex Renal and Transplant Unit 
with help form the Health Care Research Unit of the University of Southampton School 
of Medicine. It is funded by the local Renal Research Fund. The researcher conducting 
this study is paid a fixed salary which is independent of whether you take part in the 
study or not. 
 
7. Who has reviewed the study? 
 
All research in the NHS is looked at by an independent group of people called an ethics 
committee,  to  protect  your  interests.  This  study  has  been  reviewed  and  given 
favourable opinion by Milton Keynes Research Ethics Committee. 
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Study:    Natural  history  of  Acute  Kidney  Injury  and  its  relationship  to  Chronic 
kidney Disease. 
 
Patient Information Sheet 
 
Introduction 
 
We would like to invite you to take part in our research study which is explained in this 
information sheet. Before you decide to take part we would like you to understand why 
the  research  is  being  done  and  what  it  will  involve  for  you  if  you  take  part.  Our 
researcher who is a medical doctor and a member of the kidney team will go through 
the information sheet with you and answer any questions you may have. This should 
not  take  any  more  than  twenty  minutes.  You  do  not  need  to  make  a  decision 
immediately but can think about it for 24 hours if you wish. You can also talk to others 
about the study if you wish. 
 
Part 1 of this information sheet will tell you the purpose of this study and what will 
happen to you if you take part.  Part 2 gives you more detailed information about the 
conduct of the study.  
 
We would encourage you to ask any questions you may have especially if something is 
not clear.  
 
Part 1. 
 
1. What is the purpose of this study? 
 
The purpose of this study is to improve our knowledge of kidney disease and how it 
behaves. Kidney disease is very common. Many people have some kidney impairment 
which  is  often  simply  watched  by  their  doctors.  Sometimes  when  people  become 
unwell for other reasons their kidney impairment can deteriorate. It generally appears 
to get better but we do not know if this will result in more impairment in the future. 
This study hopes to answer this question by comparing your kidney function now with 
its future values. 
 
In  this  study  we  will  be  looking  at  three  different  groups  of  patients.  The  first  are 
people  who  experience  some  impairment  in  their  kidney  function  for  the  first  time 
during  their  hospital  stay.  We  want  to  observe  these  people  to  see  if  their  kidney 
function recovers fully after their illness has settled. The second group are people who Mark Uniacke    Appendix 14     
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have  existing  kidney  impairment  who  experience  a  further  decline  in  their  kidney 
function during their illness. We will observe these to see if the further impairment of 
their kidney function results in any permanent decline in their function. We will then 
have a third group who have existing impairment but do not have a further decline 
during their illness. This group is called a control group and we will compare these 
with group two to see if there are differences. 
 
This study will involve monitoring only and will not mean any changes in your usual 
treatment or affect the treatment you currently need.  
 
2. Why have you been invited to take part?  
 
During this stay in hospital your doctors have done some blood tests to help monitor 
your condition. It has been noted from these blood tests that you have some kidney 
impairment. The doctors are watching this closely. We can see from some of your older 
blood  tests  that  your  kidneys  have  been  impaired  like  this  before  but  it  has  not 
changed. Your kidney impairment has not been affected by your current illness. This 
places you in the third group mentioned above, the control group, and we would like 
to observe your kidney function to see what will happen to it in the future.   
 
3. Do I have to take part? 
 
It is up to you to decide if you wish to take part in this study. Whatever you decide will 
have no effect on the standard of care you receive. We will describe the study and go 
through this information sheet with you. If you agree to take part, we will ask you to 
sign a consent form. You are free to withdraw at any time, without giving a reason. 
 
4. What will happen to me if I take part? 
 
This  type  of  study  will  involve  monitoring  only.  It  will  involve  the  recording  of 
information only and will not affect the standard treatment you need in any way. In the 
beginning, we will record your previous kidney function and how it has been affected 
by your current illness. We will also record from your medical records your medical 
history which will include previous illnesses to see how these have influenced your 
kidney  condition.  When  you  are  discharged  from  hospital  we  will  record  your  final 
blood test results. After you are discharged we will write to your GP and tell them you 
are part of this study.  
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We  will  then  wish  to  record  your  kidney  function  again  after  six  months  and  after 
twelve months. Your GP will review you at these times and take a blood sample and a 
urine sample. We will also need a measure of your blood pressure at these times as 
well as a list of your medications. These visits should not take any longer than fifteen 
minutes  and  in  most  cases  would  be  expected  as  routine  in  somebody  with  some 
kidney impairment. 
 
You will be part of this study for a total of one year. When the study is complete we will 
write to your GP to let them know the study is over and outline your condition at that 
time. All of your results will be recorded anonymously and will be identified by number 
only. 
 
5. Will there be any expenses or payments? 
 
You will not be paid for taking part in this study and it is purely voluntary. 
 
6. What will I have to do? 
 
The good news is that you will have to do very little. You will not be receiving any 
additional treatments and we will not expect you to change your lifestyle in any way. 
Our only request is that you attend for the two follow up appointments with your GP at 
six months and twelve months. Your GP may wish to see you more frequently than this 
but that would not be part of this study. 
 
7. Are there any risks to me by taking part? 
 
We do not see any risks to you as a result of taking part in this study. It is possible that 
during follow up we may identify a significant decline in your kidney function. In the 
event of this happening we will inform your GP in writing and recommend appropriate 
action. 
 
8. Are there any possible benefits from taking part? 
 
This study will involve monitoring only and will not involve any treatment. It is not 
designed to have any affect on your condition. The information gathered from this 
study  will  improve  our  knowledge  of  kidney  disease  which  may  help  improve  the 
treatment of the condition in the future. 
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9. What happens when the study ends? 
 
You participation in the study will end after the second follow up appointment in one 
year. The information recorded during the study will be stored anonymously in our 
confidential database and will not be linked to you by name. We may use your NHS 
number to link to NHS hospital records for statistics purposes. All information will be 
analysed to produce reports on the subject. We will be happy to provide you with a 
brief report on the results of the study if you request this. 
 
If the information in Part 1 interests you and you are considering taking part please 
read the additional information in Part 2 before making a decision. 
 
Part 2 
 
1. What will happen if I do not want to carry on with the study? 
 
You can withdraw from this study at any time if you wish. If you withdraw we will need 
to let your GP know that we will not be requiring your follow up information. We will 
need to record your withdrawal but all information gathered on you will be removed 
from our database. 
 
2. What if there is a problem? 
 
If you have a concern about any aspect of this study our principal researcher will do 
their best to answer your questions and can be contacted at the address and number 
given at the end of this document. If you wish to complain or have any concerns about 
any  aspect  of  the  way  you  have  been  approached  or  treated  during  this  study  the 
normal NHS complaints mechanisms are available to you. 
 
 
3. Will the information recorded on me be kept confidential? 
 
All information collected about you during the course of this study will be kept strictly  
confidential. It will be stored by number only and will not be identifiable to you. We will 
record  your  personal  contact  details  separately  and  this  will  include  your  hospital 
number and NHS number, name, date of birth, contact address and telephone number 
as well as your GP contact details. 
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4. What will happen to any samples that I give? 
 
During the follow up you will have routine blood and urine testing performed. These 
samples will be performed in our hospital laboratory in a standard manner. We will not 
be storing samples for the purposes of this study. 
 
5. What will happen to the results of this study? 
 
Once the results of this study have been gathered and analysed, we will publish them 
in medical journals in order to add to the knowledge of kidney disease so that others 
can learn from it.  
 
6. Who is organising and funding the research? 
 
This research is being organised by a team from the Wessex Renal and Transplant Unit 
with help form the Health Care Research Unit of the University of Southampton School 
of Medicine. It is funded by the local Renal Research Fund. The researcher conducting 
this study is paid a fixed salary which is independent of whether you take part in the 
study or not. 
 
7. Who has reviewed the study? 
 
All research in the NHS is looked at by an independent group of people called an ethics 
committee,  to  protect  your  interests.  This  study  has  been  reviewed  and  given 
favourable opinion by Milton Keynes Research Ethics Committee. 
 
 
 
 
 
 
 
 
 
 
 
 
 Mark Uniacke    Appendix 15     
  337 
Appendix 15 
 
Copy of the patient consent form used in the study. Mark Uniacke    Appendix 15     
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Patient Identification Number: !!!!!!!! 
 
 
Consent Form 
 
Study: Natural History of Acute Kidney Injury and its relationship to Chronic Kidney 
             Disease. 
 
 
Chief Investigator: Dr. Mark Uniacke             Please Initial  
                          Box 
   
1. I confirm that I have read and understand the information sheet  
    dated !!!!. ( version !!) for the above study. I have had 
    the opportunity to consider the information, ask questions and  
    have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free                        
    to withdraw at any time without giving any reason, without my 
    medical care or legal rights being affected. 
 
3. I understand that the researcher will have access to my medical  
    notes and that data collected during the study will be stored  
    confidentially. I understand that relevant sections of my medical                
    notes and data collected during the study, may be looked at by  
    individuals from regulatory authorities or from the NHS Trust 
    where it is relevant to my taking part in this research. I give 
    permission for these individuals to have access to my records. 
 
4. I agree to my GP being informed of my participation in this study.            
 
 
 
5. I agree to take part in the above study.           
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____________________    __________    __________________ 
Name of patient      Date      Signature 
 
 
 
____________________    __________    ___________________ 
Name of person taking consent  Date      Signature 
 
 
When completed the original will be kept in the medical notes and two copies should be 
made, one for the participant and one for the research file. 
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Appendix 16 
 
Study Review Forms: 
  1. Original version used in research proposal (Version 2) 
  2. Final Version used in the study (Version 11) 
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AKI  Study review form 
 
 
1. Patient Details 
 
Patient Study ID number!!!!!!!.  Admission Date : !!!!!.. 
 
Age!!!!!! 
Sex!!!!!!. 
 
2. Pre - Admission     
 
Comorbidities ( Based on Charlson Index ) 
 
Tick if the patient has a history or active disease 
 
Myocardial Infarction   
 
Congestive Heart Failure 
 
Peripheral Vascular Disease 
 
Cerebral Vascular Disease 
 
Dementia 
 
Chronic Lung Disease 
 
Rheumatological Disease 
 
Peptic Ulcer Disease 
 
Mild Liver Disease 
 
Inflammatory bowel disease 
 
Diabetes without complications Mark Uniacke    Appendix 16 
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Hemiplegia 
 
Diabetes with complications 
 
Neoplasia 
 
Moderate / severe liver disease 
 
Metastatic Disease 
 
Leukemia 
 
Lymphoma 
 
Human Immunodeficiency Virus 
 
Additional backround information  
 
Any previous known renal or urological problems 
 
 
Smoking History  Current   Ex-smoker  Never    No data 
 
Alcohol/ Illicit drug History............................................................................ 
 
Herbal / Alternative therapies 
 
 
 
Regular medications pre-admission 
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Previous blood results available 
 
  Date    Date   
Urea 
 
       
Creat.         
Na         
K         
Ca.         
Albumin         
Urate         
Chol.         
CRP         
Hb.         
 
Previous Urine Dipstick/ PCR / ACR  Date!!!!. Values!!!! 
                    !!!!.    !!!! 
                    !!!!.    !!!! 
 
 
If previously known to have CKD what was the diagnosis/ presumed diagnosis 
of the cause ( indicate which) !!!!!!!!!!!!!!!!!!!!!!.. 
 
3. Admission Details 
 
Specialty –  
 
Initial Diagnosis –  
 
Final Diagnosis –  
 
 
Notes: 
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4. AKI Details 
 
Date noted: !!!!!!!!!    In Hospital!!!!! 
                                                           On admission!!!!. 
 
 
Treatment given prior to AKI 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!.. 
 
Was team aware of problem? 
.......................................................................................... 
 
Bloods at the time the AKI was noted 
 
Urea      Ca.      pH 
Creat.      Alb      HCO3 
Na      CRP 
K      WCC 
Fluid status !!!!!!!!!!!!!!!!!!!!!!!!!!!!!.. 
 
Input / Output records   Yes    No 
 
Blood pressure  !!!!!....................................................................... 
      !!!!!!!!!!!!!!!!!!!!!!. 
      !!!!!!!!!!!!!!!!!!!!!!.. 
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Urine    Dipstick        PCR/ACR (specify) 
    Microscopy 
 
Action taken if any 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 
 
Ultrasound    Yes  No    Result!!!!!!!!!!!!!! 
                      !!!!!!!!!!!!!! 
                      !!!!!!!!!!!!!! 
      Renal Size  Right    Left 
 
Other investigations if any !!!!!!!!!!!!!!!!!!!!!!!. 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 
 
Outcome/Notes 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.. 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.. 
 
5. Hospital Discharge 
 
Bloods at time of discharge 
 
Urea      Ca. 
Creat.      Alb. 
Na 
K 
 
Discharge blood pressure 
 
 
Discharge urine dipstick / ACR 
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Discharge Medications 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!..........................................
......................................................................................... 
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AKI Study Review Form 
 
1. Patient Details 
 
Study I.D.          Admission Date :   / /
 
                 
 
Age       Sex  Male      Female     
 
Group:  New  AKI1        AKI1 C3A      AKI2 C3A      AKI3 C3A      
                     AKI2                  C3B              C3B               C3B  
 
                         AKI3                   C4                C4                 C4    
 
                               C5          C5             C5      
               CKD Control    
 
2. Pre - Admission     
 
Comorbidities  
 
Myocardial Infarction                   Congestive Heart Failure        
 
         
   
Peripheral Vascular Disease        Cerebral Vascular Disease        
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Dementia                                     Chronic Lung Disease       
   
           
Rheumatological Disease                    Peptic Ulcer Disease          
 
 
Mild Liver Disease                      Diabetes without complications      
 
 
Hemiplegia                                  Diabetes with complications       
 
 
Neoplasia                                      Moderate / severe liver disease       
 
 
Metastatic Disease            Leukemia             
 
 
Lymphoma               AIDS                    
 
Additional backround information  
 
Obesity:      Weight        Height      
 
Smoking:  Current/ Ex.      Never      
 
Hypertension:   Yes           No      
 
Number of antihypertensives:    1.     2.     3.     4. or more   Mark Uniacke    Appendix 16 
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Previous known renal or urological problems    Yes         No      
Comment: 
                  coding  
 
 
Age at which they left full time education?     
 
 
Do they live alone?         Yes       No           Do carers call?    
 
Katz Index (Tick if independent and score 1) 
 
Bathing        Dressing             Toileting      
 
Transfer       Continence         Feeding        
 
Score      
 
Regular medications pre-admission 
 
_______________________________ _______________________  
_______________________________ _______________________  
_______________________________ _______________________  
_______________________________ _______________________  
_______________________________ _______________________  
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What was the indication for the ACE/ARB  :   
    
    Previous M.I.      CCF      DM/Alb.       
               
    Hypertension      Unknown   
 
3. AKI Details 
 
Specialty :  Medical          Surgical        Obstetric      
                     __________   ___________     
 
 
Working Diagnosis on Admission after Consultant review:    
____________________________________________________________________________________
______________________   
 
 
When AKI was noted:    On Admission        In hospital        Date ____________ 
 
Urine Dipstick:  Yes         No     
 
      Blood         Protein      
 
Most recent pre-admission PCR/ACR (Specify):      ………. 
 
Ultrasound performed:   Yes       No     
 
Clinical impression of fluid status at time of AKI 
Dry    Euvolaemic    Overloaded    Mark Uniacke    Appendix 16 
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Documented Hypotension within 72hrs of AKI/@ad:   Yes       No      N/A       
 
Urine Output in previous 24hrs     mls    Not measured     N/A 
  
                          
  mls/hr    Peri – AKI documented     Anuria     Oliguria    No      
 
Highest MEWS score in previous 72 hours/ On Admission 
 
Systolic BP         Heart Rate         Resp. Rate      
 
Temperature        AVPU               Sats            O2 therapy    
 
 
 
Total               
 
 
4. AKI Type 
 
Pre-renal       Intrinsic        Post- renal      
 
Pre-renal ( loss of effective circulating volume) 
 
1. Sepsis         Features:   Pyrexial         Rigors            Hypotension    
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                                      WCC>12     Neutropenic     Clear focus     
   
                    _______ 
               Culture Positive 
                                             Urine     Blood     Sputum     Swab    
 
2.  other causes of ECV loss 
 
     Diarrhoea         Vomiting        Cardiac      ____________  
 
     Blood Loss          Other           _____________ 
 
Was subject within 48hrs of a surgical procedure   Yes        No     
                    ______________  
 
Relevant drugs taken within 48hrs of AKI 
 
ACEi             ARB             NSAID      
 
Diuretic      __________________other       ________________  
 
 Management of AKI:    ACE/ARB stopped           NSAID stopped     
                                        Diuretic stopped                 other_________________  
 
Intrinsic 
 
Biopsy Proven        ___________________________________________ 
 
High Clinical Suspicion        _____________________________________ Mark Uniacke    Appendix 16 
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Post-renal  detail 
________________________________________________________________ 
 
Renal Review Obtained         Yes     No    
 
ITU admission     Yes                No     
Filtered / HD        Yes      No     
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Appendix 17 
 
Outline of the Charlson Comorbidity Score with the weights attached to each 
condition. The total score is calculated from the sum of the weights for each 
condition a patient has. For example a history of congestive heart failure and 
diabetes with end organ damage carries a score of 3.  
 
 
Assigned weights for diseases 
 
Conditions 
   
1  Myocardial infarction 
Congestive heart failure 
Peripheral vascular disease 
Cerebrovascualr disease 
Dementia 
Chronic pulmonary disease 
Connective tissue disease 
Peptic ulcer disease 
Mild liver disease 
Diabetes without complications 
 
2  Hemiplegia 
Moderate or severe renal disease 
Diabetes with end organ damage 
Any tumor 
Leukaemia 
Lymphoma 
 
3  Moderate or severe liver disease 
 
6  Metastatic solid tumor 
AIDS 
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Appendix 18 
 
Example of letter sent to a patients General Practitioner in the event that there were 
concerns regarding ongoing care. 
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Study: Natural history of Acute Kidney Injury and its relationship to Chronic Kidney 
Disease. 
 
 
Re  
Study I.D.         NHS No. 
 
Recruitment date: February 2011.         
 
 
Dear Dr. , 
 
  During an admission to Queen Alexandra Hospital in February of last year 
your patient !!!!. was kind enough to consent to be enrolled in the above major 
research  study  which  has  been  conducted  by  the  regional  renal  unit  at  Queen 
Alexandra Hospital. The purpose of this study is to assess the impact of acute kidney 
injury on chronic kidney disease.  
  In  this  case  !!sustained  a  significant  Stage  3  AKI  at  the  time  of  his 
admission. Prior to admission his baseline kidney function on record showed a serum 
creatinine of 83"mol/l (eGFR 79) on the 29/07/2010. His AKI peaked at a creatinine 
of 512"mol/l during his February admission whilst under the endocrinology team. It 
was at that point he was recruited into this study. At that time he had a normal renal 
ultrasound  and  the  usual  screening  tests  for  AKI  were  negative.  This  included  a 
negative  autoimmune  screen  and  negative  screening  for  myeloma.  His  working 
diagnosis  was  a  pre-renal  type  AKI  due  to  an  underlying  urinary  tract  infection 
combined with the use of an ACE inhibitor. The ACE inhibitor was put on hold during 
the admission. 
  !!! r e t u r n e d  t o  m e  f o r  f o l l o w  u p  i n  t h e  s t u d y  i n  S e p t e m b e r  w h e n  h e  
showed  evidence  of  sustained  loss  of  renal  function  with  a  serum  creatinine  of 
159"mol/l and eGFR 37. In hindsight he had evidence of microalbuminuria on record 
in  2010  and  I  suspect  the  AKI  has  unmasked  a  degree  of  underlying  diabetic 
nephropathy. I note that he had further blood tests in November when his creatinine 
was 183"mol/l (eGFR 31) and a urine ACR of 25.1. 
  This study has been purely observational and participation has now ended. 
The purpose of this letter is to draw your attention to the renal issues outlined above 
which I am sure you are already monitoring. !!. ACE inhibitor was discontinued in Mark Uniacke    Appendix 18 
  357 
the context of the AKI however I can see no reason why this cannot be restarted. He 
has microalbuminuria and renal impairment and ACE inhibition would be beneficial in 
this setting. It would obviously have to be restarted with care and a repeat blood test 
should be performed a week after restarting it. I think that this renal disease is likely 
to progress in the longer term and would recommend a formal renal referral when he 
reaches CKD stage 4. 
 
   
     
 Yours Sincerely 
 
 
 
__________________ 
Dr. Mark Uniacke 
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Appendix 19 
 
Multivariate logistic regression models used to explore a priori factors of interest in 
the AKI and AKI/CKD Groups with 6 month and 12 month mortality as the dependent 
variables. 
 
A19.1 : AKI Group and 6 month mortality. 
 
A19.2 : AKI/CKD Group and 6 month mortality. 
 
A19.3 : AKI Group and 12 month mortality. 
 
A19.4 : AKI/CKD Group and 12 month mortality. 
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Appendix 20 
 
Multivariate logistic regression models used to explore a priori factors of interest in 
the AKI and AKI/CKD Groups using failure to recover function after 6 months as the 
dependent variable. Modeling is presented for the three definitions of faiure to 
recover explored in the study – a fall in eGFR by 5mls/min, a fall of 10mls/min, and 
a fall of 25% from baseline.  
 
 
A20.1 : AKI Group for a fall in eGFR of 5mls/min after 6 months. 
 
A20.2 : AKI/CKD Group for a fall in eGFR of 5mls/min after 6 months. 
 
A20.3 : AKI Group for a fall in eGFR of 10mls/min after 6 months. 
 
A20.4 : AKI/CKD Group for a fall in eGFR of 10mls/min after 6 months. 
 
A20.5 : AKI Group for a fall in eGFR of 25% from baseline after 6 months. 
 
A20.6 : AKI/CKD Group for a fall in eGFR of 25% from baseline after 6 months. 
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Appendix 21 
 
Multivariate logistic regression models used to explore a priori factors of interest in 
the AKI and AKI/CKD Groups using the combined outcome of mortalty and a fall in 
eGFR of 5mls/min or more from baseline as the dependent variable.  
 
 
A21.1 : AKI Group models for the combined outcome. 
 
A21.2 : AKI/CKD Group models for the combined outcome. 
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Appendix 22 
 
Multivariate logistic regression models used to explore the influence of recovery at 
discharge, readmission and repeat AKI in the AKI and AKI/CKD Groups using 
mortality at 6 months as the dependent variable. 
 
 
A22.1 : AKI Group models. 
 
A22.2 : AKI/CKD Group models. 
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Appendix 23 
 
Multivariate logistic regression models used to explore the influence of recovery at 
discharge, readmission and repeat AKI in the AKI and AKI/CKD Groups using failure 
to recover function after 6 months according to the three definitions explored in the 
study as the dependent variables 
 
A23.1 : AKI Group models for a fall in eGFR of 5mls/min or more after 6 months. 
 
A23.2 : AKI/CKD Group models for a fall in eGFR of 5mls/min or more after 6 
months. 
 
A23.3 : AKI Group models for a fall in eGFR of 10mls/min or more after 6 months. 
 
A23.4 : AKI/CKD Group models for a fall in eGFR of 10mls/min or more after 6 
months. 
 
A23.5 : AKI Group models for a fall in eGFR of 25% or more after 6 months. 
 
A23.6 : AKI/CKD Group models for a fall in eGFR of 25% or more after 6 months. 
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